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Abstract 
 
N-myristoylation is the irreversible attachment of myristate, a C14-lipid, to the N-terminal glycine of 
a protein. This modification is catalysed by myristoyl CoA: protein N-myristoyltransferase (NMT). 
N-myristoylation has been shown to be essential for the viability and survival of many organisms, 
including plants, parasites and humans. In humans, two isoforms of NMT, HsNMT1 and HsNMT2, 
were identified and it was suggested that they possess overlapping substrate specificities. NMT was 
identified as a potential chemotherapeutic target for cancer 18 years ago and subsequent studies 
showed that NMT was up-regulated in several cancers. However, no study demonstrated that NMT 
could be a therapeutic target in cancer therapy.  
In this study, chemically-tagged analogues of myristic acid were synthesised and applied to cancer 
cell lines to study protein N-myristoylation. The analogues can be incorporated on the N-terminal 
glycine of NMT substrates. The tag in this system enables a second extremely selective and high-
yielding chemical ligation to any reporter of choice, for instance a dye label. Visualisation of the 
tagged proteins was carried out by in-gel fluorescence. Tagged-proteins could also be enriched and 
analysed by mass spectrometry-based proteomics. The combination of chemical proteomics with a 
potent NMT inhibitor is described in this thesis as a new method to identify with high confidence a 
large number of NMT substrates. 
In search for novel and potent human NMT inhibitors, various compounds were tested using an 
in vitro assay and a cell cytotoxicity assay. On-target inhibition of NMT in cells was assessed by in-gel 
fluorescence using analogues of myristic acid. 
The best inhibitors were employed as tools to study NMT inhibition in cancer cells. Western blot 
analysis and flow cytometry were used to assess the phenotype of NMT inhibition. 
Finally, the substrate specificity of the two isoforms was studied in cells using siRNAs against 
HsNMT1 or HsNMT2, and in vitro by screening for activity libraries of peptides against NMT1 or 
NMT2. 
 
3 
 
Acknowledgements 
 
I would like to thank everyone who has helped me over the past few years. 
First, I would like to thank my supervisors, Ed Tate and David Mann for giving me the opportunity to 
work on such an interesting and varied project. I have learnt so much in their presence and they 
have provided me with countless encouragements, guidance, advice, availability and enthusiasm 
over the past four years. 
I would like to thank current and past members of the Tate and Mann groups for creating such an 
enjoyable and productive working environment and for all their help during my PhD project. I am 
grateful to Will and Megan for teaching me the basics of chemical biology and Victor for all his help 
with the enzyme assay. I am thankful to Jenny, Victor, Will and Jone for their good advice on organic 
synthesis and their patience when answering my questions. I am also grateful to Neki for all his help 
with the peptide synthesiser, Ute for teaching me everything I know about cell culture, Antonio for 
his help with the ELISA assay and Chris for his help with the E. coli work. Special thanks go to Remi 
for his advice and time spent on the proteomics experiments.  
I would like to thank everyone who provided with compounds, which were used in this study, or 
helped me run some experiments. I thank Megan, Goska and Kalesh for giving me some capture 
reagents and all the people from the medicinal chemistry project who provided me with inhibitors. I 
would also like to acknowledge Goska, Remi, James and Tom for running my samples on the 
Q-exactive. I am grateful to Jane Srivastava, for her kindness and patience when teaching me how to 
use the flow cytometer and answering all my questions. I also thank Jim Brannigan and Tony 
Wilkinson (University of York) for the determination of the protein crystallography and the provision 
of the recombinant enzymes for the assay. I would like to acknowledge Andrew Bottrill (University of 
Leicester) for running some of my proteomic samples. 
Special thanks go to my proof-readers for their time and valuable comments: Jennie, Lisa, Mark, 
Megan, Remi, and Jenny. 
I would like to thank current and past residents of the 5th floor office for the nice chats and their 
support in stressful times. Thanks to Jenny, Jennie, Megan, Yunyun, Lisa for the well-deserved lunch 
breaks!  
 
4 
 
I am grateful to CRUK for funding and for providing me with the opportunity to attend scientific 
conferences and other meetings with other CRUK students. I am also grateful to Imperial College for 
allowing me to go to the research summer school in Singapore and to Prof. Yao Shao Q. for giving me 
the chance to visit his lab for a few weeks. It was a fruitful experience and great networking 
opportunity.  
I would like to thank my parents for their endless love, trust and support. Thank you for always 
letting my sisters and I choose what we wanted to do with our life and doing everything you could to 
make it happen. 
And last but not least, Flo, thank you for all your support, especially over the past few months. 
Thanks for trying to keep me sane and getting me out of the lab when I needed it, especially on 
Friday nights when you dragged me to the Holland club or Union. Now, I promise, I will stop talking 
about NMT and try to relax. 
 
5 
 
Table of contents 
Abstract......................................................................................................................................................................2 
Acknowledgements....................................................................................................................................................3 
Table of contents.......................................................................................................................................................5 
Publications and presentations arising from this thesis...........................................................................................13 
Abbreviations...........................................................................................................................................................15 
 
Chapter 1 Introduction .............................................................................................................................. 20 
1.1 N-Myristoylation ................................................................................................................................. 21 
1.2 Human NMT: two isozymes ................................................................................................................ 23 
1.2.1 HsNMT1 structure........................................................................................................................... 23 
1.2.2 Homology of HsNMT1 and HsNMT2 sequences ............................................................................. 24 
1.2.3 Sequence similarity and identity across species ............................................................................. 26 
1.3 NMT catalytic reaction ........................................................................................................................ 27 
1.4 Substrate specificity ............................................................................................................................ 28 
1.4.1 Myristoyl CoA .................................................................................................................................. 28 
1.4.2 Protein substrate: prediction and consensus ................................................................................. 30 
1.5 N-myristoylated proteins ..................................................................................................................... 31 
1.5.1 Co-translationally myristoylated proteins ...................................................................................... 31 
1.5.2 Post-translationally myristoylated proteins ................................................................................... 31 
1.5.3 Biological function and regulation of myristoylation ...................................................................... 33 
1.6 Regulation of NMT activity.................................................................................................................. 35 
1.6.1 NMT phosphorylation ..................................................................................................................... 35 
1.6.2 NMT localisation ............................................................................................................................. 36 
1.7 Relevance to cancer ............................................................................................................................ 36 
1.8 HsNMT inhibitors ................................................................................................................................. 38 
1.8.1 Lipidic inhibitors .............................................................................................................................. 38 
1.8.2 Other NMT inhibitors ...................................................................................................................... 39 
1.8.3 NMT Assays ..................................................................................................................................... 42 
1.9 Selective HsNMT inhibitors as tools to study isoform substrate specificities ...................................... 42 
1.9.1 Possible strategies .......................................................................................................................... 42 
1.9.2 SPOTTM synthesis............................................................................................................................. 43 
1.10 Detection of myristoylation using bioorthogonal reactions ................................................................ 44 
1.10.1 Traditional methods to study protein N-myristoylation ............................................................ 44 
1.10.2 Metabolic chemical tagging and bioorthogonal ligation ............................................................ 45 
1.10.3 Analogues of MyrCoA used as chemical reporters ..................................................................... 47 
1.11 Mass spectrometry for chemical proteomics ...................................................................................... 50 
1.11.1 Introduction to mass spectrometry-based proteomics .............................................................. 50 
1.11.2 Quantification ............................................................................................................................. 53 
1.12 Project objectives ................................................................................................................................ 55 
Chapter 2 Tools to study N-myristoylation ................................................................................................ 56 
2.1 Synthesis of analogues ........................................................................................................................ 57 
2.1.1 YnC12 16 ......................................................................................................................................... 57 
2.1.2 AzC12 15 ......................................................................................................................................... 58 
2.1.3 YnC15 24 ......................................................................................................................................... 58 
2.1.4 Coenzyme A thioesters ................................................................................................................... 62 
2.2 Kinetic studies of analogues and peptide substrates .......................................................................... 64 
2.2.1 Enzyme kinetics .............................................................................................................................. 64 
2.2.2 CPM assay ....................................................................................................................................... 65 
2.2.3 KM of peptide substrates ................................................................................................................ 66 
2.2.4 KM determination of MyrCoA and analogues ................................................................................. 69 
2.3 Validation of YnC12 as a tool to study N-myristoylated proteins in cells ............................................ 71 
2.3.1 Lysis buffer ...................................................................................................................................... 71 
2.3.2 Optimisation of labelling concentration and time .......................................................................... 73 
2.3.3 Competition experiment................................................................................................................. 73 
2.3.4 Enrichment of known NMT substrates ........................................................................................... 74 
2.3.5 Assessment of the toxicity of YnC12 and Myr in HeLa ................................................................... 75 
2.4 YnC12 as a tool to study post-translational myristoylation ................................................................ 78 
2.5 Conclusions .......................................................................................................................................... 82 
Chapter 3 HsNMT inhibitors ...................................................................................................................... 83 
3.1 Inhibitor evaluation ............................................................................................................................. 84 
3.2 HsNMT inhibitors previously reported in the literature....................................................................... 85 
3.2.1 2-Hydroxymyristic acid ................................................................................................................... 85 
3.2.2 Tris DBA ........................................................................................................................................... 85 
3.3 Characterisation of IMP366 (DDU85646, compound 4) and analogues: ............................................ 88 
3.3.1 Evaluation of IMP366 (DDU85646, compound 4) as an HsNMT inhibitor ...................................... 88 
7 
 
3.3.2 Analogues within a series: correlations of IC50, TC50 and EC50. ...................................................... 94 
3.3.3 Further validation of IMP366 as a tool inhibitor............................................................................. 96 
3.4 Screening of in-house NMT inhibitors ............................................................................................... 102 
3.4.1 Non selective ................................................................................................................................ 103 
3.4.2 Selective compound...................................................................................................................... 107 
3.4.3 Promising inhibitors with no off-target effect .............................................................................. 111 
3.5 Conclusions ........................................................................................................................................ 113 
Chapter 4 Detection of co-translational NMT substrates by mass spectrometry-based proteomics ........ 115 
4.1 Previously reported NMT substrates and predictions of N-myristoylation ....................................... 116 
4.1.1 Previously reported co-translationally N-myristoylated proteins ................................................ 116 
4.1.2 Prediction of N-myristoylation...................................................................................................... 117 
4.1.3 Post-translational N-myristoylation .............................................................................................. 119 
4.2 First experiment: YnC12/DMSO ......................................................................................................... 119 
4.2.1 Experimental design ..................................................................................................................... 120 
4.2.2 Modified peptides ......................................................................................................................... 125 
4.2.3 Conclusions ................................................................................................................................... 126 
4.3 Gel-based proteomics ........................................................................................................................ 126 
4.4 Label-free quantification: DMSO/YnC12 (4 replicates) ..................................................................... 128 
4.4.1 Experimental design ..................................................................................................................... 128 
4.4.2 Results and discussions ................................................................................................................. 129 
4.5 Double SILAC YnC12 +/- NMT inhibitor.............................................................................................. 132 
4.5.1 Experimental design ..................................................................................................................... 132 
4.5.2 Results and discussion .................................................................................................................. 133 
4.5.3 Conclusions ................................................................................................................................... 135 
4.6 Spike-in SILAC with inhibitor .............................................................................................................. 137 
4.6.1 Experimental design ..................................................................................................................... 137 
4.6.2 Data processing ............................................................................................................................ 138 
4.6.3 Results: proteins with a N-terminal MG motif .............................................................................. 140 
4.6.4 Conclusions ................................................................................................................................... 143 
4.7 Proteins tagged with YnC12 but not NMT substrates ....................................................................... 143 
4.7.1 S-Palmitoylated proteins and GPI-anchored proteins .................................................................. 143 
4.7.2 Proteins with no N-terminal MG motif but dose-dependently sensitive to NMT inhibition ........ 150 
4.7.3 Lysine side-chain myristoylation ................................................................................................... 152 
4.8 74 N-myristoylated proteins identified with high confidence in HeLa ............................................... 153 
8 
 
4.8.1 30 newly identified N-myristoylated proteins .............................................................................. 153 
4.8.2 N-myristoylated proteins function and localisation ..................................................................... 154 
4.8.3 Consensus ..................................................................................................................................... 154 
4.8.4 Significance of the newly identified NMT substrates ................................................................... 155 
4.8.5 Comments on previously known and putative NMT substrates not identified in the present study
 159 
4.9 Conclusions ........................................................................................................................................ 161 
Chapter 5 NMT inhibition: mode of action studies .................................................................................. 162 
5.1 Cell cycle arrest and cell death .......................................................................................................... 163 
5.1.1 HeLa cells ...................................................................................................................................... 163 
5.1.2 Other cell lines .............................................................................................................................. 170 
5.2 Apoptosis ........................................................................................................................................... 174 
5.2.1 Introduction to apoptosis ............................................................................................................. 174 
5.2.2 Detection of caspase activation or cleaved substrates by Western blotting ................................ 176 
5.2.3 Flow cytometry (Annexin V/PI) ..................................................................................................... 179 
5.2.4 Comments on other possible mechanisms ................................................................................... 181 
5.2.5 Does NMT inhibition delay apoptosis? ......................................................................................... 181 
5.3 N-myristoylated proteins turnover .................................................................................................... 184 
5.3.1 Introduction to protein turnover .................................................................................................. 184 
5.3.2 Is it possible to predict protein turnover? .................................................................................... 185 
5.3.3 Methods to study protein turnover .............................................................................................. 185 
5.3.4 Experimental design and results ................................................................................................... 187 
5.3.5 Conclusions ................................................................................................................................... 190 
5.4 Effect of NMT inhibition on NMT substrates ..................................................................................... 191 
5.4.1 Hypothesis on key targets............................................................................................................. 191 
5.4.2 Tumour suppressors ..................................................................................................................... 194 
5.5 Conclusions ........................................................................................................................................ 195 
Chapter 6 HsNMT1 and HsNMT2 selectivity ............................................................................................ 196 
6.1 In vitro studies using recombinant HsNMT1/2 .................................................................................. 197 
6.1.1 In vitro myristoylation in cell lysate .............................................................................................. 197 
6.1.2 Spot synthesis ............................................................................................................................... 202 
6.1.3 ELISA assay .................................................................................................................................... 216 
6.1.4 Conclusions on in vitro HsNMT1/2 selectivity .............................................................................. 220 
6.2 In-cell studies using siRNA ................................................................................................................. 221 
9 
 
6.3 Conclusions ........................................................................................................................................ 224 
Chapter 7 Conclusions and future work .................................................................................................. 226 
7.1 Conclusions ........................................................................................................................................ 226 
7.1.1 Chemical tools to study N-myristoylation..................................................................................... 226 
7.1.2 Identification of N-myristoylated proteins in HeLa cells............................................................... 227 
7.1.3 NMT inhibition in cancer cells....................................................................................................... 227 
7.2 Future work ....................................................................................................................................... 229 
7.2.1 N-myristoylation ........................................................................................................................... 229 
7.2.2 NMT as an anti-cancer drug target ............................................................................................... 230 
Chapter 8 Materials and methods ........................................................................................................... 232 
8.1 Chemical synthesis ............................................................................................................................ 232 
8.1.1 General methods .......................................................................................................................... 232 
8.1.2 YnC12 synthesis ............................................................................................................................ 233 
8.1.3 AzC12 synthesis ............................................................................................................................ 235 
8.1.4 YnC15 synthesis ............................................................................................................................ 236 
8.1.5 YnC12CoA synthesis (19) .............................................................................................................. 242 
8.1.6 MyrCoA synthesis (17) .................................................................................................................. 243 
8.1.7 AzC12CoA (18) .............................................................................................................................. 243 
8.1.8 Prodrug synthesis ......................................................................................................................... 244 
8.1.9 4-azidobutyric acid ........................................................................................................................ 246 
8.1.10 Linker for the spot synthesis .................................................................................................... 247 
8.1.11 Peptide synthesis ...................................................................................................................... 249 
8.1.12 Manual acetylation at the peptide N-terminus ........................................................................ 252 
8.1.13 Peptide characterisation .......................................................................................................... 252 
8.2 Biological and biochemical methods ................................................................................................. 254 
8.2.1 General methods .......................................................................................................................... 254 
8.2.2 Enzymatic assay ............................................................................................................................ 254 
8.2.3 NMT ELISA assay ........................................................................................................................... 254 
8.2.4 Mammalian cancer cell culture..................................................................................................... 255 
8.2.5 Gel electrophoresis ....................................................................................................................... 257 
8.2.6 CuAAC and in-gel fluorescence ..................................................................................................... 257 
8.2.7 Enrichment of myristoylated proteins .......................................................................................... 258 
8.2.8 Western blot analysis ................................................................................................................... 258 
8.2.9 Immunoprecipitation and capture of myristoylated proteins ...................................................... 260 
8.2.10 Metabolic activity assay (MTS assay) ....................................................................................... 260 
10 
 
8.2.11 Cell cycle analysis ..................................................................................................................... 261 
8.2.12 Annexin V / PI analysis .............................................................................................................. 261 
8.2.13 SiRNA transfection .................................................................................................................... 261 
8.2.14 Assays on cellulose membrane ................................................................................................ 262 
8.2.15 Protein expression in E. coli ...................................................................................................... 263 
8.2.16 In vitro-myristoylation .............................................................................................................. 265 
8.3 Chemical Proteomics ......................................................................................................................... 266 
8.3.1 General methods .......................................................................................................................... 266 
8.3.2 Lysate preparation ........................................................................................................................ 266 
8.3.3 Base treatment of the lysate before CuAAC ................................................................................. 266 
8.3.4 Capture and enrichment for MS-based proteomics ..................................................................... 266 
8.3.5 On-bead reduction, alkylation and digest..................................................................................... 267 
8.3.6 Gel-based proteomics: sample preparation, in-gel reduction, alkylation and digest ................... 268 
8.3.7 LC-MS/MS runs. ............................................................................................................................ 268 
8.3.8 LC-MS/MS data analysis. ............................................................................................................... 269 
8.3.9 Bioinformatics ............................................................................................................................... 271 
Chapter 9 References .............................................................................................................................. 272 
 
 
Appendix A: List of electronic files.....................................................................................................................286 
Appendix B: Sequences of short NMT1 and NMT2............................................................................................287 
Appendix C: TC50 curves-inhibitor IMP-653/654/655.........................................................................................288 
Appendix D: YnC12 labelling assay-Non specific HsNMT inhibitor.....................................................................289 
Appendix E: Best in-house HsNMT inhibitors.....................................................................................................291 
Appendix F: Previous studies of co-translationally N-myristoylated proteins....................................................294 
Appendix G: Previous studies of post-translationally N-myristoylated proteins...............................................297 
Appendix H: Proteomics results.........................................................................................................................298 
Appendix I: Turnover proteomics results...........................................................................................................328 
Appendix J: Membrane peptide sequences.......................................................................................................330 
Appendix K: Kinetic studies of HIV Gag and HIV Nef..........................................................................................340 
  
11 
 
Publications and presentations arising from this thesis 
 
Publications 
W. P. Heal, M. H. Wright, E. Thinon, E. W. Tate, “Multifunctional protein labeling via enzymatic 
N-terminal tagging and elaboration by click chemistry”, Nat. Protoc. 2012, 7, 105-117. 
V. Goncalves, J. A. Brannigan, E. Thinon, T. O. Olaleye, R. Serwa, S. Lanzarone, A. J. Wilkinson, E. W. 
Tate, R. J. Leatherbarrow, “A fluorescence-based assay for N-myristoyltransferase activity”, Anal. 
Biochem. 2012, 421, 342-344. 
D. Alibhai, D. J. Kelly, S. Warren, S. Kumar, A. Margineau, R. A. Serwa, E. Thinon, Y. Alexandrov, E. J. 
Murray, F. Stuhmeier, E. W. Tate, M. A. Neil, C. Dunsby, P. M. French, “Automated fluorescence 
lifetime imaging plate reader and its application to Förster resonant energy transfer readout of Gag 
protein aggregation”, J. Biophotonics. 2013,6(5):398-408 
Conference paper: E. Thinon, D. J. Mann, E. W. Tate, “Targeting N-myristoyl transferase in cancer 
using peptide arrays”, J. pep. sc., 2012: 18, S75-S75 
 
 
Oral presentations 
E. Thinon et al. “Using chemical tools to validate a new target in cancer therapy”, VIPCA Chemical 
Biology: Methods, Progress, Perspectives, Vienna, Austria, February 2013. 
E. Thinon et al. “Using chemical tools and proteomics to validate a new target in cancer therapy”, 
34th EORTC-PAMM-BACR Meeting, Section new cancer drug targets, Cardiff, UK, January 2013. 
E. Thinon et al. “Using chemical tools and proteomics to validate a new target in cancer therapy”, 
RSC PPSG Early Stage Researcher Meeting, London, November 2012. 
E. Thinon et al. “Targeting N-myristoyltransferase in cancer”, Imperial College Chemistry Department 
Postgraduate Symposium, July 2012. 
 
12 
 
Poster presentations 
E. Thinon et al. “Using chemical tools to validate N-myristoyl transferase as a new therapeutic target 
in cancer”, RSC Organic Division Poster Symposium, London, UK, December 2012. 
E. Thinon et al. “Targeting N-myristoyl transferase in cancer using peptide arrays”, 32nd European 
peptide symposium, Athens, Greece, September 2012.* 
E. Thinon et al. “Targeting N-myristoyl transferase in cancer”, Cancer Research UK-Students' Meeting 
2012, London, UK, May 2012. 
E. Thinon et al. “Targeting N-myristoyl transferase in cancer”, RSC-BMCS Chemical Biology for Drug 
Discovery, Alderley Park, March 2012. 
E. Thinon et al. “Targeting N-myristoyl transferase-1 in cancer”, RSC PPSG Early Stage Researcher 
Meeting, London, November 2011.  
E. Thinon et al. “Targeting N-myristoyl transferase-1 in cancer”, FASEB meeting on Protein Lipidation, 
Signaling and Membrane Domains, Vermont, USA, July 2011. 
E. Thinon et al. “Targeting N-myristoyl transferase-1 in cancer”, Imperial College Chemistry 
Department Postgraduate Symposium, London, UK, July 2011. 
E. Thinon et al. “Targeting N-myristoyl transferase-1 in cancer”, Peptide arrays as tools for study of 
protein interactions, February 2010.* 
 
 
* Awarded a prize for best poster based on content and delivery. 
13 
 
Abbreviations 
 
°C Degrees Celcius  
AA amnio acid 
ABP activity-based probes  
Ac acetyl  
AcN acetonitrile  
AHA azidohomoalanine  
AMBIC ammonium bicarbonate  
AMC 7-amino-4-methylcoumarin 
ARF adenosine diphosphate ribosylation factor  
Az probe containing an azide functional group  
AzC12 ω-azido dodecanoic acid  
AzC15 ω-azido pentadecanoic acid  
AzTB azido-TAMRA-biotin capture reagent  
AzKTB azido-lysine-TAMRA-biotin capture reagent  
BASP1 brain acid soluble protein 1 
BPD before pull down 
Boc tert-Butoxycarbonyl  
BSA bovine serum albumin  
cAMP cyclic adenosine monophosphate  
CaNMT Candida albicans N-myristoyltransferase  
c-SRC cellular SRC 
Cat. no. catalogue number 
CDI  carbonyldiimidazole 
CF cell free 
CHX  cycloheximide  
CP chemical proteomics 
CPM  7-diethylamino-3-(4'- maleimidylphenyl)-4- methylcoumarin)  
CoA coenzyme A  
CuAAC copper-catalysed azide-alkyne [3+2] cycloaddition  
Da Dalton  
DCC N,N'-dicyclohexylcarbodiimide 
14 
 
DCM dichloromethane  
DIC N,N’-diisopropylcarbodiimide  
DIPEA N,N-diisopropylethylamine  
DMAP 4-dimethylaminopyridine 
DMF N,N-dimethylformamide  
DMEM Dulbecco’s modified eagle’s medium  
DMSO dimethylsulfoxide  
DNA deoxyribonucleic acid  
DTT dithiothreitol  
EC50 half maximal effective concentration  
EDI Ettan Dige imager 
EDTA thylenediaminetetraacetic acid  
ELISA enzyme-linked immunosorbent assay  
ER endoplasmic reticulum 
ESI electrospray ionisation  
Et ethyl  
EtOAc  ethyl acetate 
FA  formic acid  
FASP filter-aided sample preparation  
FBS foetal bovine serum  
FDA food and drugs administration  
FDR false discovery rate 
FTLD frontotemporal lobar degeneration  
Fmoc  9-fluorenylmethoxycarbonyl  
FSC forward scatter pulse 
GDP guanosine diphosphate  
GEMM genetically engineered mouse tumor models  
GNAT Gcn5-related N-acetyltransferases 
GO  gene ontology  
GPI glycosylphosphatidylinositol  
GTP guanosine triphosphate 
H/L ratio heavy other light 
HA hydroxylamine  
HATU N,N,N′,N′-Tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate  
15 
 
HBTU N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate  
HIV Human immunodeficiency virus 
HMA 2-hydroxymyristic acid 
HMB 4-hydroxymethylbenzoic acid  
HMPA hexamethylphosphoramide 
HOAt N-hydroxy-9-azabenzotriazole  
HPLC high performance liquid chromatography  
HRMS high resolution mass spectrometry  
HRP horse radish peroxidase  
HsNMT Homo sapiens N-myristoyltransferase  
Hz Hertz  
IC50 concentration of inhibitor required to inhibit 50% of enzyme activity  
IMP366 DDD85646, compound 4 
IP Intellectual Property  
Kcat  catalytic constant or turnover number 
KM Michaelis-Menten constant  
LFQ label-free quantification  
LB media Lauria-Bertani broth media 
LC liquid chromatography  
LC-MS/MS liquid chromatography with tandem mass spectrometry  
LmNMT Leishmania major N-myristoyltransferase 
M  Molar  
[M + ...]  molecular ion plus ...  
MALDI  matrix-assisted laser desorption/ionisation  
MARCKS myristoylated alanine-rich C kinase substrate  
Me methyl  
MeOH methanol  
MetAP methionine aminopeptidase  
min minute  
mol moles  
MOPS 3-(N-morpholino)propanesulfonic acid  
MP MYR predictor 
mRNA messenger ribonucleic acid  
MS mass spectrometry  
16 
 
MTS 3-(4,5-Dimethylthiazol-2-yl)- 5-(3-carboxymethoxyphenyl)- 2-(4-sulfophenyl)-2H- 
tetrazolium, inner salt  
iTRAQ isobaric tags for relative and absolute quantification 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 
MW molecular weight  
Myr myristic acid 
MyrCoA myristoyl-coenzyme A  
Myrist Myristoylator 
m/z mass to charge ratio  
n/a not available 
Nat native 
nd not determined  
NMP N-Methyl-2-pyrrolidinone 
NMR nuclear magnetic resonance  
NMT N-Myristoyltransferase  
NN non native 
p p-value, inverse probability of statistically significant result  
PalmCoA palmitoyl-CoA 
PARP procyclic acidic repeats protein  
PAT palmitoyl acyl transferase  
PBS phosphate buffered saline  
PD pull-down  
PDB Protein Data Bank  
PEG polyethyleneglycol  
PfNMT Plasmodium falciparum N-myristoyltransferase  
PI propidium iodide 
ppm parts per million  
PMS phenazine methosulfate  
PTM post-translational modification  
PVDF polyvinylidene difluoride  
PvNMT Plasmodium vivax N-myristoyltransferase  
R2 Coefficient of Determination  
Rf retention factor  
RFU relative fluorescence unit 
17 
 
RIA (L) relative abundance of the light isotope. 
RING finger Really Interesting New Gene 
Rt retention time 
RSMD root-mean-square deviation 
RNA ribonucleic acid  
RNAi RNA interference  
Rpm revolutions per minute  
RT room temperature  
ScNMT Saccharomyces cerevisiae N-myristoyltransferase  
sd standard deviation 
SDS sodium dodecyl sulfate  
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SILAC Stable isotope labelling with amino acids in cell culture  
siRNA small interfering ribonucleic acid  
SLB sample loading buffer  
SMM small molecule microarrays  
SPPS solid phase peptide synthesis  
SSC Side-scatter pulse 
STS Staurosporine 
TAMRA carboxy-tetramethylrhodamine  
TbNMT Trypanosoma brucei N-myristoyltransferase  
TBME tert-butyl methyl ether  
TBS tris buffered saline  
TBS-T TBS-Tween buffer 
TBTA Tris[(1-benzyl-1H-1,2,3- triazol-4-yl)methyl]amine  
TC50 tagging inhibitory concentration  
TCEP Tris(2- carboxyethyl)phosphine  
TEAB triethylammonium bicarbonate  
TFA trifluoroacetic acid  
THF tetrahydrofuran  
TIRF total internal reflection fluorescence 
TIS triisopropylsilane  
TLC Thin layer chromatography 
TMB 3,3’, 5,5’ tetramethyl benzidine 
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TMS trimethylsilyl  
TRAIL TNF-related apoptosis-inducing ligand 
TUNEL Terminal dUTP Nick End-Labeling 
Tris tris(hydroxymethyl)aminomethane  
Tris DBA Tris (dibenzylideneacetone) dipalladium  
Ts toluenesulfonyl  
UV ultraviolet  
v-SRC virus SRC 
Vmax maximum velocity  
Wt weight 
Yn probe containing an alkyne functional group  
YnC12 tetradec-13-ynoic acid  
YnC15 heptadec-16-ynoic acid  
YnTB alkynyl-TAMRA-biotin capture reagent 
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Chapter 1 Introduction 
 
In recent years, target drug discovery has been preferred over cytotoxic chemotherapy drug 
discovery to generate small molecule cancer drugs.1 This strategy was made possible by the 
sequencing of cancer genomes and the better understanding of abnormal biology and genetics of 
cancer cells. Target drug discovery, which has already proven beneficial for numerous cancer 
patients, is a giant step towards the establishment of a personalised medicine strategy. 
However, new cancer drug targets are still needed for the development of new strategies to trigger 
additional cancer types.1 Target validation is a fundamental step in the target-based drug discovery 
pipeline. Failure to identify effective targets has been suggested to be the main cause for failure in 
drug discovery campaigns.1 In order to validate a new target, it is important to first show that the 
target is druggable and that the modulation of the target of interest would give the desired 
therapeutic effect. Additionally, the functional role of the molecular target must be clearly defined in 
the disease of interest.1 
N-Myristoyltransferase (NMT) has been shown to be implicated in cancer 2 and the current study 
evaluates the potential of NMT as an anti-cancer drug target. 
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1.1? N-Myristoylation 
Protein N-myristoylation is the irreversible N-terminal glycine acylation of a target protein with a C14 
saturated fatty acid (myristate) via formation of an amide bond (Figure 1).3-5 This protein 
modification is catalysed by myristoyl Coenzyme A (MyrCoA) : protein N-myristoyltransferase (NMT).  
N-Myristoylation usually occurs co-translationally after the excision of the terminal methionine by 
methionine aminopeptidase (MetAP) to expose a N-terminal glycine,6,7 when the growing protein 
chain is less than 100 amino acids long.6 It can also occur post-translationally, as for instance for the 
protein BID implicated in the apoptotic pathway, where cleavage by caspase 8 leads to the exposure 
of an internal glycine residue.8  
NMT is a monomeric enzyme and a member of the Gcn5-related N-acetyltransferases (GNAT) 
superfamily of proteins.9 It has been purified and characterised in many organisms such as plants 
(Arabidopsis thaliana),10 fungi (Candida albicans,11 Saccharomyces cerevisiae,12,13 Cryptococcus 
neoformans,11 Aspergillus nidulans,14 and Triticum aestivum 15), parasites,15 protozoa (Leishmania 
major,16 Trypanosoma brucei,16 Plasmodium falciparum 17), insects (Drosophila melanogaster),18and 
mammals (rat,19 cow 20 and human 21). The extensive distribution of NMT across species indicates 
that N-myristoylation is a ubiquitous protein modification.6,22,23 NMT was shown to be essential for 
 
Figure 1: Co-translational (a) and post-translational (b) N-myristoylation. 
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cell survival and for the viability in several organisms (Saccharomyces cerevisiae,24 Candida 
albicans,25 Cryptococcus neoformans 26 and mouse 27). NMT in lower eukaryotes is encoded by a 
single copy gene, whereas in higher organisms including plants, mice and humans, two distinct NMT 
genes, NMT1 and NMT2 have been identified.27-29 In Homo sapiens, NMT1 and NMT2 diverge in the 
protein-binding region, and they might possess distinct but overlapping substrate specificity and 
function.27,28,30-33  
N-Myristoylation of a protein can have various effects. In isolation it can direct relatively weak and 
reversible attachment of proteins to a lipid bilayer membrane, and plays a role in subcellular 
localisation and protein-protein interaction.34 Not all N-myristoylated proteins have been 
experimentally determined but it has been suggested that 1% of eukaryotic proteins are 
myristoylated.35,36 Known myristoylated proteins include the pro-apoptotic protein BID, guanosine 
triphosphate (GTP)-binding proteins such as Gα and ARF (ADP-Ribosylation Factor) proteins, 
oncogene products such as SRC family tyrosine kinases and viral proteins, such as HIV-Gag protein.5 
These proteins have diverse biological functions in signal transduction and oncogenesis.2 
In humans, there is evidence showing the connection of mis-regulated myristoylation to several 
diseases including epilepsy,31 Alzheimer's disease,37 Noonan-like syndrome 38 and HIV infection.39 
NMT has been suggested as a new therapeutic target to treat cancer 2 (Section  1.7) inflammatory 
diseases 40 and viral or bacterial infection.35 Interestingly, certain viruses and intracellular bacteria 
exploit host NMT to myristoylate their own proteins and to complete their life cycle. NMT is also a 
therapeutic target for protozoan parasites and fungi as N-myristoylation is essential for the viability 
and survival of these human pathogens.41 By selectively targeting the pathogen NMT, it would be 
possible to kill the parasite and prevent any toxicity to humans.42 Small molecule inhibitors have 
been developed for NMT from Leishmania major,19 Trypanosoma brucei,16,43 Plasmodium 
falciparum,16,43,44 and Candida albicans.45  
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1.2? Human NMT: two isozymes  
In the 1990s, several groups isolated and characterised a single human cDNA encoding for NMT.21 As 
there was biochemical evidence of multiple distinct NMTs in vivo, i.e. different molecular weights 
and subcellular distribution, the enzyme was termed HsNMT1.5 A second distinct NMT cDNA was 
later isolated by Giang and Cravatt and labelled HsNMT2.29 HsNMT2 has been identified as a single 
65 kDa protein whereas HsNMT1 appears to have several splice isoforms.29 The biological 
significance of these multiple HsNMT1 isoforms remains unknown. Giang and Cravat identified four 
distinct forms of HsNMT1 in transfected COS-7 cells, ranging in size from 49 to 68 kDa, and they 
suggested that these several forms may arise from in vivo processing events. Later, McIlhinney et al. 
showed that several forms of HsNMT1 were likely the result from alternative splicing of the mRNA.46 
HsNMT2 is comprised of 496 AA while HsNMT1 is comprised of 498 AA. HsNMT1 and HsNMT2 share 
only 76-77% sequence identity. Distinct roles have been suggested for the two isozymes in vivo as 
there is evidence of distinct substrate specificity. They may have a different role in protein 
N-myristoylation, cell proliferation and apoptosis (see Section ?1.7, Relevance to cancer).27-29,47 
1.2.1? HsNMT1 structure 
No crystallographic analysis of the apo-enzyme HsNMT2 has been published to date. However, four 
structures of HsNMT1 with MyrCoA and /or inhibitors are deposited in the Protein Data Bank (PDB). 
The overall structure of HsNMT1 comprises several ?-sheets and ?-helices (Figure 2). The enzyme 
has a MyrCoA binding pocket and a deep peptide binding pocket (see Section?1.4). 
Figure 2: Crystal structure of HsNMT1 with bound MyrCoA. The figure was generated in PyMOL and using the 
PDB ID: 3IU1. a) The enzyme is shaded in white, red and blue, showing the calculated electrostatic surface (red 
= negative; white = neutral; blue = positive). b) The enzyme is shaded in red, yellow and green showing the 
secondary and tertiary structure of the enzyme. 
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1.2.2 Homology of HsNMT1 and HsNMT2 sequences 
As previously mentioned, all mammals studied to date appear to have two NMT isozymes. Multiple 
sequence alignment showed that each isomer has a high degree of similarity to the same isomer of 
other species.48 For instance, HsNMT1 and mouse NMT1 share 97% identity in their amino acid 
sequence, and HsNMT2 and  mouse NMT2 share 96% identity.29 
Comparison of the amino acid sequences of the two human NMT isozymes showed 76-77% identity 
(Figure 3). Sequence divergence is greatest in the N-terminal domain of the enzyme and corresponds 
to missing amino acids (AA), replacement of an AA by a similar one such as isoleucine (I) by valine 
(V), or replacement by an AA having different properties. The N-terminal domain is not important for 
NMT catalytic activity,50 but these differences may influence the recognition or interactions with 
substrates,22,29 by varying the geometry of the enzyme, its localisation in the cell, or modifying the 
substrate binding interactions (hydrogen bonds and/or the hydrophobicity of the peptide-binding 
site). The MyrCoA binding pocket is highly conserved across species and between isoforms.51 
NMT1_HUMAN   MADESETAVKPPAPPLPQMMEGNGNGHEHCSD-CENEEDNSYNRGGLSPANDTGAKKKKK 59 
NMT2_HUMAN   MAEDSESAASQQSLEL--------DDQDTCGIDGDNEEET--EHAKGSPGGYLGAKKKKK 50 
  **::**:*..  :  *        : :: *.   :***:.  ::.  **.   ******* 
 
NMT1_HUMAN   KQKKKKEKG----SETDS-------AQDQPVKMNSLPAERIQEIQKAIELFSVGQGPAKT 108 
NMT2_HUMAN   KQKRKKEKPNSGGTKSDSASDSQEIKIQQPSKNPSVPMQKLQDIQRAMELLSACQGPARN 110 
  ***:****     :::**         :** *  *:* :::*:**:*:**:*. ****:. 
 
NMT1_HUMAN   MEEASKRSYQFWDTQPVPKLGEVVNTHGPVEPDKDNIRQEPYTLPQGFTWDALDLGDRGV 168 
NMT2_HUMAN   IDEAAKHRYQFWDTQPVPKLDEVITSHGAIEPDKDNVRQEPYSLPQGFMWDTLDLSDAEV 170 
  ::**:*: ************ **:.:** :******:*****:***** **:***.*  * 
 
NMT1_HUMAN   LKELYTLLNENYVEDDDNMFRFDYSPEFLLWALRPPGWLPQWHCGVRVVSSRKLVGFISA 228 
NMT2_HUMAN   LKELYTLLNENYVEDDDNMFRFDYSPEFLLWALRPPGWLLQWHCGVRVSSNKKLVGFISA 230 
  *************************************** ******** *.:******** 
 
NMT1_HUMAN   IPANIHIYDTEKKMVEINFLCVHKKLRSKRVAPVLIREITRRVHLEGIFQAVYTAGVVLP 288 
NMT2_HUMAN   IPANIRIYDSVKKMVEINFLCVHKKLRSKRVAPVLIREITRRVNLEGIFQAVYTAGVVLP 290 
  *****:***: ********************************.**************** 
 
NMT1_HUMAN   KPVGTCRYWHRSLNPRKLIEVKFSHLSRNMTMQRTMKLYRLPETPKTAGLRPMETKDIPV 348 
NMT2_HUMAN   KPIATCRYWHRSLNPRKLVEVKFSHLSRNMTLQRTMKLYRLPDVTKTSGLRPMEPKDIKS 350 
  **:.**************:************:**********:. **:****** *** 
 
NMT1_HUMAN   VHQLLTRYLKQFHLTPVMSQEEVEHWFYPQENIIDTFVVENANGEVTDFLSFYTLPSTIM 408 
NMT2_HUMAN   VRELINTYLKQFHLAPVMDEEEVAHWFLPREHIIDTFVVESPNGKLTDFLSFYTLPSTVM 410 
  *::*:. *******:***.:*** *** *:*.********. **::************:* 
 
NMT1_HUMAN   NHPTHKSLKAAYSFYNVHTQTPLLDLMSDALVLAKMKGFDVFNALDLMENKTFLEKLKFG 468 
NMT2_HUMAN   HHPAHKSLKAAYSFYNIHTETPLLDLMSDALILAKSKGFDVFNALDLMENKTFLEKLKFG 470 
  .**:************:**:***********:*** ************************ 
 
NMT1_HUMAN   IGDGNLQYYLYNWKCPSMGAEKVGLVLQ 496 
NMT2_HUMAN   IGDGNLQYYLYNWRCPGTDSEKVGLVLQ 498 
  *************:**.  :******** 
 
Figure 3: Sequence alignments of HsNMT1 and HsNMT2 using the program ClustalOmega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/).49 
The consensus is the following: * identical residues; : conserved substitutions; . semi-conserved 
substitutions; no sign : no match. The residues Phe-258, Leu-259 are written in green (see Section  1.3, NMT 
catalytic reaction). 
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Glover et al. also proposed that the N-terminal domain of HsNMT1 may target the enzyme to the 
ribosome in vivo,21 and HsNMT2 might also be localised at the ribosome. However, it was suggested 
that the two NMT isozymes may have different intracellular locations: one might be ribosome-based 
and act co-translationally while the other could be cytosol-based and operate post-translationally.22 
Figure 4 shows the crystal structure of HsNMT1 with bound MyrCoA. The divergences in sequence 
with HsNMT2 are shown in red. The N-terminal part of HsNMT1 is missing in the crystal structure 
and many differences in the sequence are in this region.29 At the amino acid level, there does not 
appear to be any divergence in the peptide-binding pocket. However, it has been suggested that the 
two isoforms have a different peptide affinity in vitro and in vivo.29,52 
 
 
Figure 4: Co-Crystal structure of HsNMT1 with bound MyrCoA (Yellow). The figure was generated in PyMOL 
using the PDB ID: 3IU1. The similarities in the AA sequence with HsNMT2 are shown in blue and the 
divergences are shown in red. The two pictures represent the same structure but rotated by 180° about the 
vertical axis.  
 
Interestingly, in the context of HIV infection, knock down of NMT1 but not NMT2 resulted in a 
decrease in HIV-1 production and mislocalisation of Gag, a myristoylated protein known to be 
essential for the progression of the virus infection.53 However, these results contradict a previous 
report as they suggested that Gag mostly associates with NMT2 in cells while Nef, another 
N-myristoylated viral protein, can immunoprecipitate NMT1.47 
Recently, Toska et al. also noticed that the two isoforms might have different substrate specificity in 
vivo.54 The brain acid soluble protein 1, BASP1, is known to be myristoylated and function as a WT1 
transcriptional corepressor in cells only when it is myristoylated. Interestingly, knockdown of NMT1, 
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but not NMT2, decreased the transcriptional repression activity compared to the wild-type cells, 
suggesting that BASP1 is preferentially lipidated by NMT1. 
1.2.3? Sequence similarity and identity across species  
NMT is a drug target against different protozoa parasites, Leishmania major (Lm), 16 the causative 
agent of Leishmaniasis, Trypanosoma brucei (Tb),16 responsible for the sleeping sickness and  
Plasmodium falciparum (Pf),17 the parasite causing malaria. While the MyrCoA binding pocket is 
usually well conserved across species, the peptide binding pocket is more diverse. Drugs inhibiting 
the parasite NMT should be specific for the parasite enzyme over the human isoforms to avoid 
undesirable toxicity. Table 1 compares NMT protein identity and similarity for the different 
organisms’ isoforms described in this PhD thesis. 
 
Table 1. Percentages of sequence identity (blue) and percentages of sequence similarity (grey) of the 
catalytic domain of NMT from different species. The values were defined by BLAST 55 between the catalytic 
domains of Human NMT isoforms HsNMT1 (Swiss-Prot P30419) and HsNMT2 (Swiss-Prot O60551) and NMTs 
from L. donovani (LdNMT, EMBL accession number FN555136), P. falciparum (PfNMT, Swiss-Prot Q81LW6), T. 
brucei (TbNMT, EMBL FN554973). The table was adapted from Bell et al.56 
As discussed in Section ?1.2.2, NMT1 and NMT2 active sites seem to be well conserved as the 
sequences mostly diverge in the N-terminal domain of the enzymes. Interestingly, the active site of 
human and Pf NMTs are relatively similar, suggesting it might be possible to use PfNMT inhibitors as 
tools to study NMT inhibition in human cells. 
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1.3 NMT catalytic reaction 
The structure and the catalytic mechanism of NMT have been well studied for Saccharomyces 
cerevisiae (Sc).13,22,57,58 Using kinetic studies, Rocque et al. have shown that the catalytic mechanism 
of NMT established for Sc was also valid for human NMT.59 Considering that NMT (role, structure, 
substrate specificity) is well conserved across species from different kingdoms, it can be supposed 
that the mechanism is conserved across all eukaryotes. 
Rudnick et al. have established that NMT follows an ordered Bi-Bi mechanism where two products 
and two substrates are involved in the reaction (Figure 5).58 
 
 
Figure 5: NMT catalytic cycle, adapted from Bhatnagar et al. 57 
 
MyrCoA binds to NMT prior to the peptide and induces a conformational change of the Ab loop (a 
loop connecting helix A and strand b) in the peptide-binding site. The thioester carbonyl of MyrCoA 
interacts with an oxyanion hole formed by two amides (Phe-170, Leu-171 for ScNMT and Phe-258, 
Leu-259 for HsNMT) of the enzymatic backbone via hydrogen bonding. This interaction creates a 
partial positive charge on the carbonyl and activates it for nucleophilic substitution.57 
Secondly, the peptide substrate binds to the enzyme in the C-terminal domain of NMT, in a deep and 
narrow pocket. Residues in the Ab loop contribute to peptide recognition and binding. The 
N-terminal Glycine of the peptide substrate, which is positively charged in the physiological 
environment, is deprotonated by the C-terminal carboxylate of NMT, producing a nucleophilic 
amine. This amine attacks the carbonyl of the thioester to form a tetrahedral intermediate, which is 
stabilised by interaction with the oxyanion hole. The Coenzyme A (CoA) by-product is released first, 
leading to a relaxed structure and elimination of the myristoylated peptide. The C-terminal 
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carboxylic acid is then deprotonated, most likely by solvent interactions, leaving the enzyme ready 
for another round of catalysis.57,58 
 
1.4? Substrate specificity 
NMT is specific to MyrCoA and to proteins or peptides bearing an N-terminal glycine.13 
1.4.1? Myristoyl CoA 
MyrCoA is a C14 fatty acid which accounts for 1-3% of the total cellular fatty acid in cells.5,34 The 
synthesis of MyrCoA in cells, from free CoA and myristic acid, is catalysed by acyl CoA synthetase.34 
This enzyme is ubiquitous in prokaryotes and eukaryotes.61 Kinetic studies of fatty acid analogues 
have provided some understanding of the MyrCoA specificity of NMT. In general, these experiments 
were carried out using ScNMT, and the MyrCoA analogues investigated include fatty acids with 
different chain lengths and compounds with various modifications such as double bonds, sulfur or 
oxygen atoms or aromatic groups.58,62-67  
NMT-Bound MyrCoA shows four bends (relative to a fully extended chain) and its conformation is 
similar to a question mark (Figure 7).22 Several features are essential for MyrCoA recognition and 
specificity:  1) fatty acid length;62 2) the interaction with the oxyanion hole (see Section ?1.3);57 3) the 
conformation of MyrCoA with bends at C1 and C6;22 4) the distance between C1 and the first bend;68 
5) the distance between C1 and the C-terminus of the fatty acid;64 6) the floor of the MyrCoA binding 
 
Figure 6: Co-crystal structure of HsNMT1 with bound MyrCoA (Multicolour) and an inhibitor (orange).    
((2R)-2-(4-hydroxy-5-methoxy-2-[3-(4-methylpiperazin-1-yl)propyl]phenyl)-3-pyridin-3-yl-1,3-thiazolidin-4-one) 
(Orange). The figure was generated in PYMOL with the PDB ID: 3IU2. The enzyme is shaded in blue, the 
C-terminus of the enzyme is shown is red and the key residues Phe-258 and Leu-259 are shaded in yellow.60 
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site. 22 Kinetic studies have also shown that the fatty acyl chain length is more important than the 
hydrophobicity for binding.62?
It was suggested that the fatty acyl binding pocket acts as a measuring tool which measures and 
recognises the distance from the thioester carbonyl to the omega terminus of the chain.63,64,69 This 
pocket also specifically recognises the steric bulk at the omega terminus. Towler and Glover showed 
that other available fatty acids in vivo, such as C10 and C12 fatty acyl CoA, are low-affinity substrates 
of NMT. Longer acyl chains, such as the abundant palmitoyl-CoA (PalmCoA), are not transferred to 
proteins.67,70 However, PalmCoA can bind to NMT in vitro, but this binding is less thermodynamically 
favoured.71 There is no evidence that PalmCoA compete with MyrCoA in vivo.  
 
The acyl-CoA binding site is highly conserved across species studied to date (yeast,62 plant,73 rat,70 
human 65). Rundle et al. have compared the KM of MyrCoA in the presence of v-SRC and recombinant 
HsNMT1 or HsNMT2. The KM is the substrate concentration at which the rate of reaction is half its 
maximum value. They found that the KM of MyrCoA was four fold higher for HsNMT2 (6.6 μM) than 
for HsNMT1 (1.6 μM).50 These results are surprising as the acyl-CoA binding pocket is well-
conserved.62,65,70 However, this difference between KM values might not be significant and might be 
attributed to experimental errors. 
 
Figure 7: Zoom of a co-crystal structure of HsNMT1 with bound MyrCoA (multicolour). The figure was 
generated in PyMOL with the PDB ID: 3IU1.72 
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1.4.2? Protein substrate: prediction and consensus
Not all proteins bearing an N-terminal glycine can be N-myristoylated 74. Extensive studies of both 
peptide 67,70 and protein 75,76 substrates of ScNMT established a consensus regarding the substrate 
sequence. The first eight residues were shown to be essential for enzyme specificity.70,77 However, 
this consensus cannot be applied to HsNMT as the substrate specificity has been shown to be 
different.59 
Maurer-Stroh et al. used a bioinformatic approach to establish a consensus for HsNMT (Figure 8). 
They found that, as for other organisms, an N-terminal glycine residue is critical. NMT has a 
preference for small polar residues at position 3, polar residues at position 4, large hydrophobic AA 
at position 5, small, polar residues such as serine at position 6 and finally lysine or threonine at 
position 7.78 Bulky residues are not favoured at position 8, 10 and 11, basic and hydrophilic residues 
are preferred at position 9 and small polar residues are favoured at positions 11 and 12. 
Maurer-Stroh et al. have also proposed that the 17 first amino acids are needed to determine 
whether or not a protein is myristoylated.78 They identified three regions in the peptide substrate: in 
region 1 (position 2-7), the residues bind to the active site; in region 2 (position 8-12), the residues 
interact with the enzyme surface at the entrance of the narrow peptide binding pocket; in region 3 
(position 13-18), the residues act as a hydrophilic linker.78 The third region is mainly composed of 
hydrophilic residues, probably to prevent the N-terminal chain from folding and inhibiting the 
recognition by the enzyme.  
 
 
Figure 8: HsNMT peptide substrate specificity. Residue 1 is the leader methionine removed by MetAP prior to 
N-myristoylation.78 
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Based on these observations, two predictors of myristoylation are available online: the Myr 
predictor 79,80 and Myristoylator.81,82 Giglione et al. also prepared a predictor able to predict 
N-terminal methionine removal, N-terminal acylation such as N-myristoylation, and N-palmitoylation 
in various organism and plants.83,84 Another model of prediction was developed recently but is not 
accessible online.85 
However, these predictors are not always reliable even at the peptide level, and it is unknown to 
what extent they apply in live cells or in vivo.86,87 More work is therefore required in order to 
understand the protein substrate specificity of HsNMT. Proteomics studies in live cells are required 
to identify more NMT substrates in a native context. Furthermore, little is known about the peptide 
specificity of HsNMT1 and HsNMT2, although experiments to date suggest that they possess similar 
but distinguishable specificity with recombinant enzymes or in live cells.29,47,52 
1.5 N-myristoylated proteins 
1.5.1 Co-translationally myristoylated proteins 
Co-translational myristoylation is more prevalent than post-translational myristoylation. Known 
co-translationally myristoylated proteins have diverse biological functions in signal transduction and 
oncogenesis.2 Examples of myristoylated proteins include protein kinases such as the oncogenes SRC 
and LYN, phosphatases, Gα proteins, ADP ribosylation factor (ARF) GTP-binding proteins, the 
myristoylated alanine-rich C kinase substrate (MARCKS).51  
Many of these co-translationally myristoylated proteins have been implicated in diseases such as 
cancer (Section  1.7). Interestingly, it has been shown that a genetic disease, the Noonan-like 
syndrome, depends on the myristoylation of the protein SHOC2.38 SHOC2 is normally not 
myristoylated but the genetic disease induces a mutation of SHOC2 and introduces an 
N-myristoylation site in SHOC2. The myristoylated SHOC2 is relocated to the plasma membrane, 
resulting in aberrant signalling.38 
Methods to identify and study N-myristoylated proteins will be discussed in Section  1.10 and 
co-translationally myristoylated proteins will be discussed more in detail in Chapter 4.  
1.5.2 Post-translationally myristoylated proteins 
Post-translational myristoylation of proteins is involved in the regulation of programmed cell death, 
known as apoptosis 88. The apoptosis process involves cysteine-aspartic proteases called caspases, 
which cleave several proteins in the cell. One apoptotic pathway corresponds to the cleavage of the 
protein p22 BID by Caspase-8 (Figure 9). The p15 Bid fragment released is myristoylated post-
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translationally during the apoptotic process 8 and is relocated to the mitochondrial membrane 
where it can trigger cytochrome c release leading to further caspase activation. Other proteins have 
been shown to be myristoylated post-translationally, such as the p21-activated protein kinase-2 
(PAK-2) or ?-actin and gelsolin (an actin-binding protein).89  
Recently, Martin et al. developed a method to identify post-translational N-myristoylation proteins 
in the context of apoptosis.90 They designed a caspase-cleavable tandem fluorescent reporter 
protein for each protein they wanted to assess and expressed the reporter protein in COS7 cells. The 
reporter proteins were composed of several fluorescent moieties as well as a caspase cleavage site 
(four amino acids: DEVD) followed by a putative N-myristoylation sequence of 10 amino acids. After 
induction of apoptosis, the reporter proteins were cleaved by caspases and revealed the new 
N-terminal sequence which could be tagged by myristic acid analogues and detected in fluorescence 
(see Section ?1.10).  
Five proteins were identified: cell division control protein 6 homolog (Cdc6), induced myeloid 
leukemia cell differentiation protein (Mcl-1), microtubule-actin cross-linking factor 1 (MACF1), YTH 
domain family protein 1 (YTHFD2) as well as the protein involved in Huntingtin disease (HTT).89 The 
role of N-myristoylation of these proteins has yet to be studied. For instance, the importance of HTT 
N-myristoylation for the progression of the Huntingtin disease remains unclear. Many proteins 
cleaved during apoptosis have an N-terminal glycine after the protease cleavage site,91,92 suggesting 
that new post translationally myristoylated proteins remain to be identified.  
 
Figure 9. Post-translational myristoylation of BID upon apoptosis induction with a death receptor ligand. 
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However, the method developed Martin et al.90 presents several limitations. The caspase cleavage 
site of these proteins was not always known and was thus predicted. This method does not provide 
any strong evidence that the cleavage site is correct since the putative caspase cleavage sequence 
was replaced by the DEVD sequence. Additionally, the five novel substrates were not identified in 
the native context. 
1.5.3 Biological function and regulation of myristoylation 
Protein myristoylation increases the protein hydrophobicity and affinity for membranes.93 
Localisation to membranes is thought to be essential for the function and regulation of 
N-myristoylated proteins and to trigger cellular transformations. The addition of myristate can also 
stabilise the tertiary structure of a protein 94 or be part of a protein-protein interaction site.95 
1.5.3.1 Two signal membrane binding model 
N-Myristoylation allows localisation of a protein to the membrane. It has been estimated that 10 
carbons, out of 14 of myristate, incorporate into the lipid bilayer.96 Peitzsch and McLaughlin 
estimated the Gibbs free energy of binding of a myristoylated peptide to membrane lipids to be 
around 8 kcal/mol, corresponding to an apparent dissociation constant of 10-4 M. This binding 
energy is relatively weak and the hydrophobicity increase is not enough to provide a stable 
association to membranes implying that another interaction is often required to localise a protein to 
the membrane.97 The membrane affinity can be increased by the addition of a second lipid such as 
palmitate, close to the protein N-terminus. Palmitate is a C16 fatty acid, typically added to one or 
several cysteine residues of a protein. This protein modification is often reversible.98 Many 
N-myristoylated proteins are dual-lipidated, such as SRC-family tyrosine kinases FYN and LCK.99 It has 
been noticed that for these proteins, myristoylation is required for palmitoylation. 100 
Membrane affinity of an N-myristoylated protein can also be enhanced by the presence of an 
electrostatic interaction at the protein N-terminus. A cluster of basic amino acids at the N-terminus 
of the protein can interact with membrane acidic phospholipid head groups. MARCKS 101 and HIV 
Gag 96 use the combination of hydrophobic (myristate) and electrostatic (basic residues) interactions 
to associate to membranes. Finally, Resh suggested that membrane localisation could be promoted 
by a protein-protein interaction with another membrane-bound protein.93 
1.5.3.2 Molecular switches 
N-Myristoylated proteins are usually partitioned between cytosolic and membrane compartments. 
They undergo regulated and reversible membrane binding, modulated by ‘‘switches’’ occurring in 
response to additional covalent or non-covalent modifications.93,102  
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Four different mechanisms have been proposed for the myristoyl-switch and are shown in Figure 
10.51,93,102 When myristate is exposed, it can trigger membrane binding. In scenario A, upon ligand 
binding, the protein undergoes a conformational change. Myristate is buried in a hydrophobic 
pocket in the N-myristoylated protein and cannot interact with the membrane bilayer. In B and C, 
membrane binding of the N-myristoylated protein is achieved by an electrostatic switch. Binding of a 
negatively charged ligand or phosphorylation, decreases the charge of the polybasic cluster reducing 
membrane binding (Section ?1.5.3.1). Scenario D describes the myristoylated switch of ARF-GTPases. 
GTP is hydrolysed by Guanine nucleotide exchange factors (GEFs) into guanosine diphosphate (GDP) 
and contributes to regulation of ARFs. GTP-bound ARF can associate to membrane but upon 
hydrolysis of GTP to GDP, a conformational change occurs and, similar to scenario A, myristate is 
buried into the protein.  
Many proteins, including HIV-Gag, the tyrosine kinase ABL, MARCKS and ARF proteins, undergo a 
myristoyl-switch.93,102,103 The only exception known to date is the tyrosine kinase c-SRC.104 Myristate 
is not buried in a hydrophobic pocket and as a consequence, nearly 90% of c-SRC present in cells is 
membrane bound.104 
 
Figure 10. Reversible membrane association of N-myristoylated proteins. The figure was adapted from 
Wright et al. 51 
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1.5.3.3 Reversible myristoylation 
For a long time, N-myristoylation was thought to be an irreversible protein modification as there was 
little evidence of the presence of de-myristoylated substrates in vivo. The only protein reported to 
be de-myristoylated was MARCKS, the myristoylated alanine-rich C kinase substrate as non lipidated 
MARCKS was found in synaptosomes from rat and bovine brain.105,106 The biological relevance of 
de-myristoylation in eukaryotic cells is unclear but it’s been suggested that de-myristoylation might 
regulate MARCKS’ membrane association.106,107 N-myristoylated MARCKS associates with 
membranes, while non-myristoylated MARCKS is mainly found in cytosolic fractions (see 
Section  1.5.3.2). It’s also been suggested that NMT could de-myristoylate a substrate in the absence 
of a CoA pool in cells but the hypothesis has yet to be validated in vivo.108 
Recently, cleavage of the myristoyl moiety has been shown to be possible by a bacterial effector 
protein with cysteine protease activity, the Shighella virulence factor IpaJ, in the context of human 
infection.109 This process is irreversible as the N-myristoylated glycine is cleaved from the protein. 
Several substrates, such as ARF1, c-SRC or MARCKS were shown to be cleaved by IpaJ. This process 
might allow Shigella to exploit host cell signalling pathways and is one of the events triggering 
bacterial infection.  
1.6 Regulation of NMT activity 
Regulation of NMT activity in vivo is not well understood. It was suggested that NMT activity in cells 
might be limited to the amount of available MyrCoA.110,111 It was also proposed that levels of NMT 
might be optimal to myristoylate endogenous proteins but, in this context it is difficult to understand 
why NMT levels would be higher in many tumour tissues (Section  1.7).48  It has also been proposed 
that NMT has several biological inhibitors in cells, such as the NMT inhibitor protein 71 (NIP71) 
isolated from bovine brain and these could play a role in NMT regulation. However, this possibility 
has yet to be validated in vivo.48 
NMT could also be regulated via a phosphorylation/dephosphorylation mechanism and NMT 
localisation in cells could be an important feature for regulation of NMT activity.112 
1.6.1 NMT phosphorylation 
Sharma et al. suggested that NMT could be regulated by phosphorylation.112 HsNMT1 was 
phosphorylated in vitro by non-tyrosine kinases FYN, LYN, and LCK.113 They proposed that 
phosphorylated NMT could associate with other proteins and be relocated within cells. As they 
noticed that an NMT mutant missing the N-terminal region (149 first AA) was only poorly 
phosphorylated by LYN in vitro, they suggested that the phosphorylation site was located in the 
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N-terminal region of NMT. Site-directed mutagenesis experiments suggested that Tyr 100 could be 
the phosphorylation site.113 Sharma et al. have also shown that NMT could be dephosphorylated 
in vitro by calcineurin, a Ca2+/ calmodulin-dependant protein phosphatase.112 Phosphorylation 
decreased NMT activity, and could possibly reduce ribosome association. Regulation of NMT by 
phosphorylation/dephosphorylation has yet to be validated in vivo. 
1.6.2 NMT localisation 
The N-terminus of NMT is not essential for catalytic activity but functions as a targeting signal.114 It 
enables the localisation of NMTs, possibly both at the ribosome (Section  1.2.2) and it was suggested 
that it could provide access to myristoyl-CoA pools in cells.114 
Subcellular fractionation of different human cancer cell lines showed that HsNMT1 was mostly 
present in cells as a 60 kDa protein localised to the ribosome.21 Full length HsNMT1 and HsNMT2 
possess a poly-lysine cluster at their N-terminus, often referred as the “K box motif”. This region is 
known to be a ribosomal targeting signal.21 As expected, NMT is mainly localised at the ribosome, 
where it can myristoylate proteins co-translationally.  
Glover et al. noticed the presence of NMT in other subcellular fractions which was explained by the 
existence of a shorter isoform of NMT (Section  1.2). This shorter isoform might arise from proteolytic 
degradation and was truncated at the N-terminus, thus missing the required K box motif to bind to 
the ribosome. However, the function of this shorter isoform was not well understood.21 Recently, 
HsNMT1 and HsNMT2 have been shown to be cleaved at the N-terminus during apoptosis, removing 
the K box motif and allowing the enzymes to relocate from the ribosome to the cytosol.115  
Interestingly, Sharma et al. observed that NMT localisation could change in cancerous cells. In bone 
marrow mononuclear cells, NMT was localised in the nucleus, while it was found in the cytoplasm of 
control samples.116 They proposed that abnormal NMT localisation could be used as a biomarker to 
detect early stage colon cancer. 
1.7 Relevance to cancer 
Considering that NMT is a critical cellular enzyme and that some N-myristoylated proteins are 
involved in proliferative signalling pathways, Felsted et al.  suggested in 1995 that NMT could be a 
chemotherapeutic target for cancer.2 They proposed that further investigations were necessary 1) to 
understand the relationship between N-myristoylation and cancer by establishing if N-myristoylation 
is a cause or a consequence of cancer; 2) to understand how protein N-myristoylation is regulated in 
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mammalian cells; 3) to find strategies to selectively target N-myristoylation in tumour cells to avoid 
toxicity in healthy cells.  
Extensive studies by Sharma et al. later showed that NMT is up-regulated in colorectal cancer,33,48,117-
119 brain cancer,30 gallbladder carcinoma,117,120 and breast cancer,121 and in many clinical cases 
increased NMT expression correlates with increased invasiveness.122 
Furthermore, RNA interference (RNAi) experiments on a mouse xenograft model of mammary 
adenocarcinoma suggested that knockdown of NMT1 inhibits tumour growth, whereas knockdown 
of NMT2 had no effect.28 These results provided the first direct evidence that isoform-specific 
inhibitors against NMT1 might be effective anti-cancer agents. If residual NMT2 activity can 
compensate for loss of NMT function in healthy cells, potential toxicity may also be minimised.28 
However, these experiments were poorly controlled, and the results have yet to be confirmed by 
other groups; work is on-going in our lab to investigate this hypothesis.  
Previous studies have established that c-SRC and LCK, both tyrosine kinases of the SRC family are 
oncogenes that require myristoylation for activity.104,123,124 c-SRC is activated after being 
autophosphorylated in trans at Tyr416 via an intermolecular mechanism.125 Patwardhan et al. 
suggested that the tyrosine kinase activity of myristoylated c-SRC might be increased due to the 
optimal conformation of membrane bound N-myristoylated c-SRC  as the proteins might be oriented 
and in close packing.104 Elevated activity of c-SRC was reported in some human cancers such as colon 
cancer, and c-SRC was shown to be a critical regulator of several human cancers.126 Inhibition of 
SRC-family tyrosine kinases is now an established therapeutic strategy for cancer therapy as a 
selective inhibitor, dasatinib, has recently been FDA-approved (Food and Drugs Administration-
approved). Inhibition of myristoylation might have the same effect on cancer cells as 
non-myristoylated SRC family members have reduced activity. 
Interestingly, activation of the tyrosine kinase ABL is not associated with cancer progression but has 
instead been shown to inhibit tumorigenesis, metastasis and invasion of breast cancer cells.127,128 
Association of the myristoyl moiety of ABL with a hydrophobic pocket in its kinase domain was 
shown to be essential for the formation of an autoinhibitory complex of ABL (Section  1.5.3.2). Yang 
et al. developed an inhibitor to block the myristoyl binding pocket, leading to a change in the 
structure of ABL and activation of ABL as seen by the phosphorylation of the two key tyrosine 
residues (Tyr 245 and Tyr 412).129 However, it is unclear if NMT inhibition could have the same effect 
on ABL. Upon NMT inhibition ABL would not adopt an autoinhibited conformation and might thus be 
activated. However, it is possible that myristoylation might be needed to phosphorylate the two 
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tyrosine residues, as required for full activation, given that the tyrosine kinase SRC requires 
myristoylation to be phosphorylated and fully activated.125  
N-Myristoylation of the tumour suppressor Fus1 is required for its proper activity in cells. A 
tumour-suppressor gene, or anti-oncogene, tends to enhance the apoptosis of cells that appear to 
be mutated, therefore preventing it becoming a cancer cell. The tumour-suppressor gene Fus1 is 
located in the critical 3p21.3 chromosomal region often mutated in human cancers. When Fus1 
protein is not myristoylated in human lung cancer cells, it loses its tumour suppressor activity.130 Ji et 
al. suggested that Fus1 is not myristoylated efficiently in cancer cells but the reason is not 
understood. The myristoylation process might be down regulated and non-myristoylated Fus1 might 
be degraded by proteases in human lung cancer cells, but if this is the case the cause is nevertheless 
not well understood.131 These latter results are in contradiction to the concept that inhibition of 
NMT could be an effective anticancer agent. However, no study has replicated these results to date.  
1.8 HsNMT inhibitors 
Several compounds have been reported in the literature to inhibit HsNMT activity but they are 
almost exclusively tested against HsNMT1 and any selectivity over HsNMT2 has not been 
established. HsNMT1 or HsNMT2 selective inhibitors could be valuable tools to study the isoforms 
substrate specificity in cells. They could also be used as chemical genetic tools to confirm the results 
from the RNAi experiments described in Section  1.7. Inhibitors of HsNMT1 include myristic acid 
analogues, non-hydrolysable MyrCoA analogues, peptidomimetic compounds and synthetic organic 
compounds targeting the fatty acyl or peptide-binding pocket.48 
1.8.1 Lipidic inhibitors 
Myristic acid analogues such as 2-hydroxymyristic acid (HMA) or non-hydrolysable MyrCoA 
analogues (e.g. S-(2-oxopentadecyl)-CoA) have been designed as alternative substrates for NMT. 
They showed inhibition of mouse NMT,132,133 bovine NMT,134 and yeast NMT 135 with IC50 values up to 
the micromolar range. Myristic acid analogues have been used to demonstrate that NMT could be a 
therapeutic target against HIV-1 136 137 and Hepatitis B.138 
One lipidic inhibitor of particular interest is HMA. It is commercially available and was shown to 
decrease [3H]myristate labelling in cells,139 suggesting that it inhibits NMT activity. HMA is 
metabolically activated in cells to yield 2-hydroxymyristoyl-CoA, which is responsible for NMT 
inhibition.133 HMA will be discussed in Section  3.2.1. 
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Myristic acid analogues and non-hydrolysable MyrCoA target the MyrCoA binding pocket of the 
enzyme. This pocket is thought to be well-conserved across isoforms and species. However, if this is 
the case and if an HsNMt1 or HsNMT2 selective inhibitor is required, it would  be difficult to target 
one isoform selectively using these compounds. It has been suggested that selective inhibitors 
should target the peptide binding pocket, which is known to be less conserved.65 
1.8.2 Other NMT inhibitors 
Bhandarkar et al. found that a palladium complex generally used as a catalyst in organic synthesis, 
Tris (dibenzylideneacetone) dipalladium (Tris DBA), had an antitumor activity against A375 
melanoma. Treating the cells with 10 µg/mL (~11 µM) of Tris DBA resulted in a 96% decrease of cell 
count.140 Using Western blot and gene array analyses, they found that HsNMT1 expression 
decreased upon treatment with Tris DBA. However, expression of many other genes was also 
affected and some experiments are missing to prove that Tris DBA targets NMT in cells. The authors 
have not for instance shown that Tris DBA was a competitive inhibitor of the peptide substrates of 
NMT or that an overexpression of NMT rescues the cells from inhibition.  
James et al. reported several selective peptidic and peptidomimetic inhibitors of Candida albicans 
NMT.45 In their study, they also found potent HsNMT1 inhibitors in vitro (Figure 11). However, the 
potency against HsNMT1 has not been tested in live cells or in vivo. 
French et al. discovered a novel class of HsNMT inhibitors based on cyclohexyl-octahydro-
pyrrolo[1,2-α]pyrazin.141 They showed by kinetic studies that the compounds were competitive 
inhibitors with respect to the peptide substrate. The best inhibitor, COPP-24, is shown in Figure 12.  
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Figure 11: Peptidomimetic inhibitors of HsNMT1. 1 and 2 were the more potent inhibitors against 
recombinant HsNMT1identified by James et al. 45 
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COPP-24 inhibited the proliferation of various tumour cell lines (DU145: prostate; HepG2: liver; 
HT29: colon; MCF-7: breast; MCF-10A B: breast non–transformed; MDA-MB-231: breast; Panc-1: 
pancreas, SKOV3: Ovary, A-498: kidney) in a concentration-dependent manner. However, the IC50 
and EC50 values were in the micromolar range (0.9–14.8 µM), suggesting that these compounds have 
a low affinity for NMT in vitro and in cells.  
Two analogues of L-histidine, L-histidinol and histamine, have been shown to inhibit HsNMT1 activity 
in vitro as non-competitive inhibitors. They inhibited HsNMT1 in a concentration-dependent manner 
with 50% inhibition at 18 and 1.5 nM respectively. These results have not been confirmed in vivo or 
in live cells.48 
Recently, Wyatt et al. have identified a series of N-heterocyclic sulphonamide analogues that inhibit 
HsNMT1 with an IC50 in the micro- to nanomolar range.142 The best of these inhibitors were tested in 
a variety of cancer cell lines (Figure 13, Table 2). The EC50, which is the concentration of inhibitor 
that induces a response halfway between the minimum and the maximum was determined.  
All inhibitors showed a high potency for recombinant HsNMT1 but the selectivity over HsNMT2 has 
not been reported. These inhibitors also have high potency in various cancer cell lines. The reason 
why the EC50 is significantly different in several cell lines for a given inhibitor is currently unclear. 
However, the cytotoxicity assay used might be misleading and will be discussed in Chapter 3. 
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Figure 12: HsNMT1 inhibitor COPP-24.141 
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Table 2: Activity of HsNMT1 inhibitors 4-13 determined in vitro using recombinant HsNMT1 (SPA assay) and 
several human cancer cell lines. HT29 : Human colon adenocarcinoma grade II cell line; HCT 116: Human 
colorectal carcinoma cell line; SkBr3: Human breast adenocarcinoma cell line; RT112: Human urinary bladder 
carcinoma (epithelial); C6: human glioma cell line; H460: Human lung carcinoma cell line; MRC5: Human lung 
cancer cell line; HT1080: Human connective tissue fibrosarcoma cell line; A549: adenocarcinomic human 
alveolar basal epithelial line; NCI-H1299 human non-small cell lung carcinoma cell line derived from the lymph 
node; MDA-MB-231: human breast adenocarcinoma cell line; OE19: human adenocarcinoma of gastric 
cardia/esophageal gastric junction cell line; OE21: human squamous carcinoma of mid oesophagus. 
IC50 
(µM) EC50 (µM) 
 SPA 
assay 
HT29 HCT116 SkBr3 RT112 C6 H460 MRC5 HT1080 A549 NCI-
H1299 
MDA-MB-
231 
OE19 OE21 
4 
 
0.003 0.112 0.234 0.108 0.33 1.16 1.32 0.123 0.123 0.157 0.57 0.23 0.66 0.29 
5 0.003 0.154 0.422 0.141 0.425 1.89 2.53 0.209 0.209 0.213     
6 0.02          1.08 0.64 4.37 1.39 
7 0.008          3.71 0.89 4.57 1.20 
8 0.001          0.096 0.047 0.132 0.057 
9 0.006 0.176 0.629         0.448   
10 0.004 0.281 0.921         0.537   
11 0.002 >10 1.91         2.23   
12 0.006  0.282         0.218   
13 0.005  0.419         0.249   
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Figure 13.HsNMT1 inhibitors.142 
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1.8.3 NMT Assays  
Several assays have been reported in the literature. A scintillation proximity assay (SPA), which uses 
detection based on radioactivity, has become widely used, including in our lab.44 However, this assay 
is complex to implement, suffers from the inherent hazards associated with radioactive assays and 
the high cost of reagents, and is discontinuous. Recently, a fluorescence-based assay143 and an ELISA 
assay 144 have been published to study the enzymatic activity of NMT while another has been 
developed in our lab using CPM (N-[4-(7-diethylamino-4-methyl-3-coumarinyl)phenyl]maleimide) 
(see Section  2.2.2 for more details). 145 This latter assay can be used for kinetic studies as well as for 
high-throughput screening of NMT inhibitors.  
1.9 Selective HsNMT inhibitors as tools to study isoform substrate specificities 
1.9.1 Possible strategies 
As explained in Section  1.7, it may be possible to develop novel anticancer drugs by selectively 
targeting HsNMT1 over HsNMT2. A selective inhibitor could also be used as a tool to study isozyme 
substrate specificities in cells. The acyl-CoA pocket is thought to be well conserved and several 
authors have suggested that selective inhibitors of NMT should target the peptide binding 
pocket.65,141 The divergence in peptide substrate specificity for the two HsNMT isoforms might 
therefore be exploited for drug development but this will require a better understanding of the 
isozyme substrate specificity. 
Several methods are widely used to generate starting points for developing drug-like inhibitors, 
including high-throughput screening,146 fragment based approaches,147 in silico screening,148 or a 
substrate mimetic approach.149 The first method is usually expensive, while using docking studies 
would be problematic for designing a selective HsNMT1 inhibitor as the crystal structure of HsNMT2 
has not been determined to date. The last method, using a substrate mimicking approach would be 
advantageous to determine the isozyme substrate specificity as large libraries of peptides can be 
prepared relatively easily and quickly compared to libraries of synthetic organic compounds. In order 
to design a peptide inhibitor or substrate, the proposed consensus of myristoylated proteins should 
be respected (see Section  1.4.2). Farazi et al. have also suggested that the selectivity and potency of 
an inhibitor may be improved by adding features that modify the conformation and dynamics of the 
Ab loop of NMT (see Section  1.3) 22.  
Each isozyme could, in principle, be screened for activity using peptide libraries prepared using 
techniques including peptide macroarrays (also known as SPOTTM technology),150 peptide 
microarrays151, one-bead one-peptide (OBOP) libraries,152 or phage display 153 combined with a 
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method to select or detect sequences that are myristoylated, for example using a chemical labelling 
technology developed for the detection of myristoylation.154 The SPOTTM technology appeared 
advantageous as it allows rapid preparation and screening for activity a large number of peptides.150 
1.9.2 SPOTTM synthesis 
SPOTTM synthesis is a high throughput and miniaturised screening tool which was first introduced by 
Frank in 1992.150 It allows highly parallel synthesis of peptides up to the microgram range.150,155,156 
On the equipment available in our lab up to 1200 peptides can be prepared at the same time (on 
two membranes of 600 sequences each), with purities that are expected to be sufficient for a 
screening assay on cellulose membrane. The cellulose-bound peptide arrays were shown to be well 
suited for the rapid investigation of molecular recognition events such as protein–protein 
interactions.157 The membranes are constructed via optimised solid-phase synthesis methods.157 The 
cellulose membrane is first functionalized with an amino moiety to allow the attachment of the 
growing molecules (Figure 14).  
A cleavable linker or a spacer can be added. A spacer, such as PEG, would enhance the accessibility 
of membrane-bound molecules for ensuing reactions and for on-support screening. In the next step, 
peptides are assembled from the C- to the N-terminus, using Fmoc/tBu chemistry.158 After side chain 
deprotection, peptide arrays are ready to be used for biological assays. Depending on the linker 
chemistry used, peptides may be cleaved from the cellulose membrane in the dry state (e.g. using 
 
Figure 14: General schematic of SPOTTM synthesis. 
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gaseous reagents or light) or in solution in order to do solution phase assays. However, on-support 
assays are more attractive as they require minimal peptide processing relative to off-support 
assays.159 The quality of SPOT-synthesised peptides can be investigated by cleaving the peptide and 
analysing them by LC-MS or MALDI. The main disadvantage of this technique is that it is impossible 
to quantify absolutely the binding activities. Hits would need to be re-synthesised and tested using 
solution-phase assays. 
1.10 Detection of myristoylation using bioorthogonal reactions 
1.10.1 Traditional methods to study protein N-myristoylation 
Before the democratisation of bioorthogonal reactions such as “click chemistry”, several techniques 
have been used to demonstrate that a protein was N-myristoylated in cells. Radiolabelling with [3H] 
myristate followed by detection by fluorography was one of the two main techniques used for 
studying protein acylation. However, the exposure time required was long (weeks to months) and to 
improve this, an analogue of myristate containing [125I] was developed more recently. The sensitivity 
was greatly improved and the exposure time was much faster. However, both techniques require 
the use of hazardous material and unambiguous detection of the protein myristoylation often 
necessitates the purification or immunoprecipitation of the protein. Immunoprecipitation is a 
laborious technique and one antibody, often expensive or difficult to produce, is required for each 
protein of interest. As NMT is thought to have up to 100 targets in cells, new methods were needed 
to study myristoylation. 
Myristate is only attached to the N-terminal glycine of NMT substrates and allows them to localise to 
the membrane (see Section  1.5.3). Overexpression of a G2A mutant of the protein in cells often 
leads to mislocalisation of the protein and can be seen by fluorescence microscopy in the presence 
of a fluorescent antibody for the molecule of interest. Several proteins have been shown to be 
myristoylated using this technique such as the neuron-specific calcium-binding protein hippocalcin, 
HPCA,160 but it has several drawbacks. The proteins are not strictly shown to be N-myristoylated at 
the endogenous level as the protein is overexpressed in cells, greatly increasing the effective 
substrate concentration. Moreover, similarly to the radiolabelling experiments, this technique also 
requires expensive antibodies for each protein substrate. 
Mass spectrometry can also be used to identify post-translational modifications (PTM) such as 
N-myristoylation, but this method also usually requires the enrichment or purification of the 
proteins of interest. The whole protein can be purified, digested with trypsin and analysed by MALDI 
or LC-MS/MS. The site of modification and the nature of the PTM can be identified and a few 
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proteins, such as BASP1,161 were shown to be myristoylated using this technique. Alternatively, the 
whole cell lysate can be digested with trypsin. Recently, Bienvenut et al. analysed the modification 
of the N-terminal peptides of proteins in A2780 cells.86 They managed to identify three N-
myristoylated proteins, GNAI2, SLC44A1 and PSMC1 by identification of the N-terminal 
myristoylated peptide. However, such analysis of complex mixtures is extremely difficult, as 
suggested by the fact that only three NMT substrates were identified. This analysis is also limited by 
the need of a unique peptide and a tryptic site in the right place. 
All this suggests that a simple, cheap and reliable method is needed to label as well as enrich 
N-myristoylated proteins.  
1.10.2 Metabolic chemical tagging and bioorthogonal ligation 
 Chemical labelling technologies have recently been developed to detect N-myristoylation based on 
an enzymatic tagging strategy combined with bioorthogonal reactions, such as Copper-catalysed 
azide-alkyne cycloaddition (CuAAC).154,163 The metabolic tagging strategy involves the incorporation 
of a unique functionality, a chemical reporter, into targets of interest, followed by chemical labelling 
with a small molecule probe (Figure 15).162  
The term ‘bioorthogonal ligation reaction’ has been coined to encapsulate the concept of reactions 
that can couple two molecules bearing particular functional groups with complete specificity against 
the background of a complex biological system. Some authors extend this to reactions that are 
strictly non-toxic to cells or animals.164 Bioorthogonal ligation is mainly used for in vitro and cell-free 
applications, although some have been used ex vivo and in vivo.162 An ideal bioorthogonal reaction 
should be specific, fast and irreversible, producing no by-products (or only non-toxic by-products) 
and take place readily in buffers or in vivo. Reactions of particular interest are those with azide or 
alkyne as chemical reporters because of their small size and their absence in natural systems.162 
 
Figure 15: The metabolic tagging strategy (also referred to as the bioorthogonal chemical reporter strategy. 
A probe, which comprises a chemical reporter unit (black) and a reactive group or warhead (green triangle), is 
introduced into a target biomolecule or peptide through cellular metabolism. The probe covalently reacts with 
the biomolecule or peptide. In a second step, the reporter is chemically labelled with an imaging moiety 
(yellow). 162 
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Several bioorthogonal reactions have been studied to date including Staudinger ligation, Copper-
catalysed azide-alkyne cycloaddition (CuAAC) and Strain-promoted azide-alkyne cycloaddition 
(SPAAC) (Scheme 1).  
1.10.2.1 The Staudinger ligation  
The Staudinger ligation is a reaction between an azide and an ester-derivatised phosphine, 
producing an amide.165 Although this reaction is highly specific and reagents are easily prepared, the 
reaction is slow and suffers from competing oxidation of the phosphine reagents.166 
1.10.2.2 Copper-catalysed azide-alkyne cycloaddition (CuAAC)  
The Cu-catalysed azide–alkyne cycloaddition (CuAAC), also known as the most widely recognised 
“click reaction”, was first developed by Sharpless et al. 167 and Meldal et al..168 This reaction, 
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Scheme 1. Commonly used bioorthogonal reactions. a) Staudinger ligation; b) Copper-catalysed azide-alkyne 
cycloaddition (CuAAC); c) Copper-free cycloaddition (EWG= electron widrawing group). 
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between an azide and a terminal alkyne, activated by a Cu catalyst and provides a 1,4-disubstituted 
triazole with a high reaction rate . The reaction is highly specific and has been used in Dr Tate’s 
group to perform chemical labelling and tag-mediated proteomics.154 However, this reaction 
requires the use of several reagents including either copper (I) or copper (II) and a reducing agent, 
and a ligand in addition to the azide and alkyne moieties. The reaction conditions need to be 
optimised for a given application.  
1.10.2.3 Strain-promoted azide-alkyne cycloaddition (SPAAC) 
An alternative reaction is catalyst-free [3 + 2] cycloaddition with azides activated by ring strain. This 
strain-promoted cycloaddition is a reaction between an azide and an alkyne affording a bicyclic 
triazole, and was discovered by Wittig and Krebs in 1961.169 They noted that cyclooctyne, the 
smallest of the stable cyclooctynes, reacted spontaneously with phenyl azide to give a triazole. The 
bond angle of the acetylene in an 8-member ring is 163° ,170 whereas the normal bond angle of 
acetylene is 180°. This considerable bond angle deformation of the acetylene represents 18 kcal/mol 
of ring strain.170 This destabilisation of the ground state of the reaction decreases the activation 
energy and provides a significant rate acceleration compared to unstrained alkynes.170 The reaction 
can also be promoted by appending electron-withdrawing groups (fluorine or aromatics) to the 
octyne ring in order to lower the energy of the LUMO of the alkyne. This allows a greater overlap 
with the azide HOMO and favours the reaction. A number of compounds have been developed to 
date, but they usually suffer from demanding synthesis (many steps, low yield), low stability and 
slower reaction kinetics compared to the copper catalysed reaction.166 Several reagents have been 
reported in the literature that when used in cell lysates or in vivo suffer from high background.171 
1.10.3 Analogues of MyrCoA used as chemical reporters 
In order to study myristoylation, our group has developed two myristic acid analogues, adding an 
azide or alkyne at the terminal position (Figure 16). The two analogues, azido dodecanoic acid (15, 
AzC12) and tetradec-13-ynoic acid (16, YnC12), mimic myristic acid as they respect the chain length 
and flexibility. Importantly, they have been shown to be transferred with equal efficiency in vivo.154 
The fatty acid chain acts as the reactive group (warhead) and binds covalently to a protein or peptide 
substrate in the presence of NMT. The alkyne and azide moieties act as a chemical reporter, which is 
needed to perform bioorthogonal ligation in the second step (Figure 15).  
The myristic acid analogues can be directly fed to the cells as they are converted into the CoA 
thioester in cells by CoA transferase.154 However, to carry out in vitro experiments, the two myristic 
acid analogues need to be converted into the CoA thioesters: AzC12CoA (18) and YnC12CoA (19) 
(Figure 16).154 
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Figure 16: Myristic acid (Myr) and analogues (AzC12 and YnC12) and MyrCoA and MyrCoA analogues 
(AzC12CoA and YnC12CoA). 
 
Imaging probes using click chemistry have also been developed in our lab.163 Probes 20 (referred to 
as AzTB) and 21 (referred to as YnTB) comprise a fluorescent moiety (TAMRA), biotin, a linker and a 
chemical reporter moiety (azide and or alkyne respectively) (Figure 16). The fluorescent moiety 
allows direct visualisation of the myristoylated proteins by fluorescence while the biotin moiety 
allows enrichment of the myristoylated proteins on streptavidin beads or detection of the proteins 
by chemiluminescence (using a horseradish peroxidase (HRP) anti-biotin antibody conjugate) when 
fluorescence detection is not appropriate. Probe 22 is composed of a fluorescent moiety 
(fluorescein) and an alkyne tag. These probes are used to carry out tag-mediated proteomics 
experiments, also referred as chemical proteomics (see Section 1.11). A typical workflow applied to 
study N-myristoylation in cells or in vivo is presented in Figure 18. 
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Figure 17: Imaging probes AzTB 20, YnTB 21 and fluorescein-alkyne22. 
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It was suggested that the enzymes mediating protein palmitoylation are less specific and transfer 
probes of different length,172,173 implying that YnC12 could label palmitoylated proteins.163 Protein 
palmitoylation, catalysed by palmitoyl acyltransferases, predominantly corresponds to the reversible 
attachment of a C16-fatty acid to side-chain cysteine residues (S-palmitoylation), but irreversible 
attachments have also been reported (N-palmitoylation, through S-N rearrangement forming amide 
bond).  
Alkyne-tagged probes have been reported to study protein palmitoylation, such as YnC15 (24) 174 
and YnC16 (25)172,175 (Figure 19). YnC16 (also referred to as 17-ODYA or 17-octadeynoic acid)172,173,175, 
is widely used to study protein palmitoylation but it has also been shown to label N-myristoylated 
proteins, possibly in place of myristate.175 
 
Figure 18. In vitro and in-cell chemical labelling of N-myristoylated proteins by YnC12. 
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Figure 19. Structure of palmitic acid (Palm) and analogues compared to Myr and YnC12, and structure of human 
glycosylphosphatidylinositol (GPI) anchor. Palmitate is shown in red in the GPI-anchor.176 
 
YnC12 could also incorporate into glycosylphosphatidylinositol (GPI)-anchored proteins (Figure 19). 
GPIs are glycolipids attached post-translationally to the C-terminus of a protein, and are composed 
of lipids, carbohydrates, and inositol phosphoester groups.177 In some species, such as Plasmodium, 
GPIs incorporate myristic acid via an ester linkage and YnC12 was shown to label GPI-anchored 
proteins.163 Whilst GPIs in humans are not enriched in myristate, they do incorporate palmitic acid. It 
is probable that YnC12 also labels GPI-anchored proteins in humans, in the same way that YnC12 can 
replace palmitate in S-palmitoylation. 
1.11 Mass spectrometry for chemical proteomics 
1.11.1 Introduction to mass spectrometry-based proteomics 
Mass spectrometry (MS)-based proteomics is now widely used to answer biological questions.178 It 
relies on the accurate measurement of the mass-to-charge ratio (m/z) of a protein or peptides 
originating from proteins, which can then be identified using various databases and software. 
Equipment and computational software are rapidly improving and many sample preparation 
protocols are now available for a wide-range of needs and applications. MS-based proteomics can 
for example allow identification of the protein composition of a cell or an interacting protein from a 
purified protein complex, as well identifying PTMs of proteins in a lysate.  
Two approaches have been developed for sample preparation and analysis. A protein can be purified 
and characterised directly by analysis of its mass (“top-down proteomics”). This technique presents 
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many drawbacks; large proteins are sometimes difficult to identify as the mass differences between 
proteins with similar composition is small and complex mixtures cannot be analysed using this 
approach.179 
Bottom-up proteomics relies on the analysis of peptides derived from the enzymatic cleavage of 
proteins.178 The proteins can be separated prior to the digest, enriched on beads (see 
Section  1.10.3), separated on a SDS-PAGE gel, or complex mixtures can be digested and analysed 
(“Shotgun”) (Figure 20). Proteins are usually cleaved into small peptides by the addition of a 
proteolytic enzyme, such as trypsin, which cleaves the protein backbone after each lysine and 
arginine residue. Peptides mixtures are analysed by liquid chromatography coupled to a tandem 
mass spectrometer (LC-MS/MS). Peptides are separated by liquid chromatography (LC), ionised and 
the mass of the peptide analysed by MS. A first MS-spectrum (MS1) shows the ion current versus the 
mass-to-charge ratio (m/z). The most abundant peptides are selected and fragmented by collision 
with an inert gas at low pressure (“collision induced dissociation”). A second MS-spectrum (MS2) 
presents the list of m/z ratios for different fragments, which will allow the identification of the 
peptide sequence by calculating the mass difference between the various fragments and correlating 
it to the mass of an amino acid. The whole data recorded (Retention time (Rt), MS1 and MS2) is 
automatically recorded and saved as a .raw file. Using software, the data is searched against 
genome-specific protein databases to identify proteins via their “peptide mass fingerprint”.180 A 
peptide is referred as a “unique peptide” when its sequence can only be found in one protein in the 
protein database. One unique peptide can be sufficient to identify a protein, but two or more 
peptides provide higher confidence identification. 
The most widely used peptide search engines, Mascot 181 and SEQUEST 182 are commercially 
available but free program such as X!Tandem are also available.183 Each MS2 is compared to model 
MS2 spectra of all candidate peptides in a protein database. Once the peptides have been identified, 
a second software, such as Scaffold, is required to identify the proteins.184 
For quantitative proteomics, MaxQuant was used in the current study as it was available free of 
charge and provided with its own research engine, Andromeda.185 A typical proteomics workflow is 
presented in Figure 20. 
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One of the key challenges in MS-based proteomics is to separate and detect peptides in very 
complex mixtures. LC methods can be optimised to allow better resolution of the peptides but 
sample fractionation or protein enrichment is often require to reduce complexity. Sample 
fractionation can be achieved by eluting proteins on a 1D or 2D SDS-PAGE gel. The gel can be cut in 
several portions, proteins in-gel digested and peptides extracted.186 Alternatively, whole cell lysates 
can be subjected to a subcellular fractionation. A detergent such as sodium dodecyl sulphate (SDS) 
may be required for cell lysis but this is not always compatible with in-solution digestion of the 
sample and MS analysis. To overcome this problem, a new method was recently reported, filter-
aided sample preparation (FASP).187 
Another strategy to reduce sample complexity relies on digest of a complex mixture of proteins into 
peptides which can then be separated and fractionated according to their polarity (using a reverse 
phase column) or according to their charge (using a strong cation exchange column). 
Finally, proteins of interest can also be tagged using activity-based probes (ABP) 188or a metabolic 
chemical tagging approach (Section ?1.10.2), subjected to CuAAC with a capture reagent bearing a 
biotin moiety and enriched on streptavidin beads, before being subjected to on-bead digestion. The 
latter method is highly advantageous to enrich and detect N-myristoylated proteins tagged with an 
analogue of MyrCoA and captured as described in Section ?1.10.3. In theory, only tagged proteins 
should be enriched on beads and detected. Moreover, this approach dramatically reduces the 
 
Figure 20. Typical proteomics workflow. 
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sample complexity and should allow the identification of a large number of N-myristoylated 
proteins, including proteins poorly abundant in cells. 
1.11.2 Quantification 
In the last ten years, many methods have been developed to allow relative quantification between 
samples. Absolute quantification is also possible by using an internal standard, but is often not 
required as relative quantification is often sufficient to answer biological questions.189,190 The choice 
of the method depends on the cost, number of samples to be compared, simplicity of sample 
preparation and the accuracy required. Most techniques are based on the introduction of an isotopic 
label at different stages of the sample preparation, which can then be differentiated by mass 
spectrometry. When the isotope is introduced at the beginning of the sample preparation, the 
samples to be compared are mixed, prepared (digested/fractionated/enriched) and analysed 
together. This approach is advantageous as there is a low risk of experimental bias arising from 
sample loss during enrichment/fractionation, from the sample digest or with the LC-MS/MS analysis. 
Isotopic label can be incorporated directly in the biological sample, such as for SILAC (Stable isotope 
labelling with amino acids in cell culture) or can also be added just prior to the LC-MS/MS analysis as 
for the isobaric labelling method iTRAQ (isobaric tags for relative and absolute quantification)191 or 
dimethyl labelling method.192 Label-free quantification is also possible and has the advantage of an 
easy and inexpensive sample preparation.189,193 Protein quantification is then possible using either 
spectral counting or ion peak intensity. However, as unlabelled samples are individually analysed, 
the workflow must be tightly controlled to avoid bias. An overview of the principles, advantages and 
disadvantages of the most commonly used methods is presented in Table 3.  
Table 3. Most commonly used methods for MS-based quantitative proteomics:189,190 label-free 
quantification,193 SILAC,194 spike-in SILAC,195 dimethyl labelling 192 and iTRAQ.191 n/a = not available.  
53 
 
Method Example of technique Principle 
Introduction 
of label 
Number 
of 
samples  
Main advantages Main disadvantages 
Label-free 
quantification n/a No label no label  ∞ 
Easy sample preparation, easy 
and cheap sample preparation 
Experimental bias, careful 
processing required, 
samples need to be 
processed at the same time 
and analyse one after the 
other to decrease 
experimental bias 
Metabolic 
labelling SILAC  
Arginine and lysine 
replaced by isotopically 
labelled Arg and Lys in the 
culture media 
At lysate 
level, before 
sample 
processing  
3 
No experimental bias, can 
compare 2 or 3 samples in one 
LC/MS/MS run, Heavy Lys and 
Arg allow most peptides to 
potentially be quantified. 
Typically a large isotope shift 
(> 6Da). 
Requires dialysed serum or 
a defined media to introduce 
the label, heavy amino acids 
are expensive, labelled Arg 
might convert to Pro, in vivo 
labelling is difficult as 
proteome turnover is 
required for complete 
labelling 
Spike-in 
SILAC n/a 
Preparation of a standard 
containing heavy labelled 
Arg and Lys. Other 
samples / tissue are 
prepared as usual 
At lysate 
level, before 
sample 
processing  
∞ 
No experimental bias, no limit 
of the number of samples, the 
experiment and heavy control 
can be in different cell lines 
including tissues that cannot 
be SILAC labelled, samples 
prepared at different times can 
still be compared if they have 
the same heavy standard 
Overlap is required between 
the SILAC and the non-
labelled samples. 
Isotopic tags Dimethyl labelling 
Stable isotope 
incorporation into primary 
amines at the peptide level 
by addition of isotopically 
labelled formaledhyde and 
sodium cyanoborohydride  
At peptide 
level, before 
LC-MS/MS 
analysis  
3 
Cheap reagents, quick and 
reliable reaction, applicable to 
any samples 
Experimental bias due to the 
introduction of the label at 
the peptide level, small 
isotopic effect during the LC 
separation of peptides. 
Isobaric tags 
Isobaric tags for 
relative and 
absolute 
quantification 
(iTRAQ) 
Stable  incorporation of an 
isobaric reagent into 
primary amines at the 
peptide level 
At peptide 
level,  before 
LC-MS/MS 
analysis  
8 
Applicable to any samples, 
can compare up to 8 samples 
in one LC-MS/MS run 
Experimental bias due to the 
introduction of the label at 
the peptide level, reagents 
are expensive and not highly 
stable. Analysis is not well 
suited for Orbitraps. 
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1.12 Project objectives 
The aim of this PhD project is to validate a set of chemical tools to study the role of NMT in cancer 
and provide further validation of NMT (and perhaps NMT1) as a cancer drug target. As explained in 
Section  1.7, NMT has been suggested as a potential therapeutic target in cancer, but to date no 
study has shown that NMT inhibition could kill cancer cells. Several NMT inhibitors have been 
reported in the literature (Section  1.8), but cell toxicity has not been correlated with on-target 
inhibition of NMT. It was also proposed that selective inhibition of NMT1 could be sufficient to kill 
cancer cells and could have reduced toxicity in healthy cells. 
The main objectives of this PhD thesis were to: 
1) Optimise the synthesis of myristic acid analogues and demonstrate that these analogues 
can be applied in cancer cells to label N-myristoylated proteins. 
2) Identify NMT substrates in a cancer cell line using a chemical proteomics approach. 
3) Identify potent inhibitors of HsNMT that could be used as tools to manipulate 
myristoylation in cancer cell lines.  
4) Study the effects of NMT inhibition in cancer cells. 
5) Explore the substrate specificity of the HsNMT isoforms. 
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Chapter 2 Tools to study N-myristoylation 
 
Previous work in the Tate group showed that myristate analogues YnC12 and AzC12 (Figure 16) can 
be used in combination with trifunctional capture reagents AzTB and YnTB (Figure 17) to label 
proteins in HeLa, a mammalian cancer cell line.163 This chapter describes an optimised synthesis of 
both myristate analogues YnC12 and AzC12 and a novel synthesis of the palmitate analogue YnC15 
(Figure 19). Myristate analogues might also incorporate into palmitoylated proteins (Section  1.10.3) 
and YnC15 would be a valuable tool to identify crosstalk between labelling of myristoylated and 
palmitoylated proteins.174  
A fluorescent assay to study N-myristoylation, referred to here as the CPM assay, will be described. 
Kinetic studies were used to define kinetic parameters of MyrCoA and a peptide corresponding to 
the N-terminus of known NMT substrates. These parameters have been used to set up conditions for 
the inhibition assay; the latter was employed to screen for new HsNMT inhibitors (Chapter 3). The 
kinetic parameters of MyrCoA were compared to YnC12CoA and AzC12CoA in order to show that 
myristate analogues mimic the natural lipid substrate and are good substrates of both HsNMT 
isoforms. 
Initial experiments with the myristate analogues in cells will be described, including optimisation of 
the labelling conditions and subsequent experiments that show that the probe YnC12 can be used to 
label and enrich NMT substrates in HeLa cells. While the main focus of the current Chapter is on co-
translational myristoylation, experiments were also carried out to optimise the labelling conditions 
to detect post-translational NMT substrates in cells undergoing apoptosis (Section  1.5.2). 
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2.1 Synthesis of analogues 
Synthetic routes to prepare myristate analogues as well as a palmitate analogue are reported but 
modification of the reported procedures was required to achieve good yields. Myristate analogues 
could be directly fed to the cells but could not be used for in vitro studies (Section  1.10.3). As a 
consequence, MyrCoA analogues were also synthesised to assess NMT activity in an in vitro assay 
(Section  2.2) or to carry out in vitro reactions (Chapter 6). 
2.1.1 YnC12 16 
YnC12 synthesis was initially achieved in two steps from commercially-available 
12-bromododecanoic acid 27, according to a procedure previously published by our group.154 The 
first step involved displacement of the bromide by an organolithium reagent generated in situ using 
n-butyl lithium and TMS-acetylene (Scheme 2). Ensuing deprotection with potassium carbonate was 
quantitative and the product 16, YnC12, did not require further purification. 
However, the first step suffered from low yields (typically 10-20 %) due to the poor conversion of the 
bromo- starting material 27 to product 28 and the difficulty separating the starting material and the 
product by column chromatography. This yield was comparable to a previously reported yield of 
25%.154 To overcome this problem, 12-bromododecanoic acid 27 was converted to 12-
iodododecanoic acid 29 (Scheme 2). The yield of the reaction to form the TMS-acetylene product 26 
proved to be higher (48%) using the iodo- starting material as Iodine is a better leaving group than 
bromine. After this second step, the crude product 30 still contained 2 % intermediate 29 (by 
1H NMR) and purification was difficult. However, this impurity could easily be removed following the 
deprotection step by heating the product in the presence of ethanolamine in DMSO. The iodo- 
intermediate reacts with ethanolamine, and the polar product formed could then be removed by 
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Scheme 2. Synthesis of YnC12. Reagents and conditions: i) TMS-acetylene, n-Buli (2.5 M in hexanes), dry THF, 
HMPA, -78 °C, 14%; ii) K2CO3, MeOH, RT, quantitative; iii) KI, dry acetone, 89%; iv) TMS-acetylene, n-Buli (2.5 
M in hexanes),  hexanes, dry THF, HMPA, -78 °C, 48%; v) 1) K2CO3, MeOH, RT; 2) Ethanolamine, DMSO, 120 °C; 
84%. 
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washing the crude product dissolved in Et2O with water. The product 16 did not require further 
purification. The overall yield of YnC12 16 was significantly higher using this new synthetic route 
(36% versus 14%). The new synthesis required two additional steps, but following the last step no 
further purification was required. The yield of the second step could still be improved by decreasing 
the excess of n-butyl lithium used and the time of the reaction as a large excess of n-butyl lithium 
might lead to the degradation of the product. It was noticed that for similar reaction, to prepare a 
alkyne-tagged fatty acid of different length, using 2 eq of n-butyl lithium instead of 3 eq and leaving 
the reaction to stir at room temperature for 4 h instead of overnight, could dramatically improve the 
yield of the reaction up to 60-70% (observation made by Tom Charlton, Tate group, Imperial College 
London). This improved protocol will be used to prepare a new batch of YnC12, when required. 
2.1.2 AzC12 15 
AzC12 was also prepared from 12-bromododecanoic acid according to a procedure previously 
established in our lab.154 However, this procedure, which involved the synthesis of AzC12 15 in one 
step, via SN2 displacement of the bromide by sodium azide, suffered from low conversion and the 
product was difficult to separate from the starting material.  
To overcome this problem, 12-bromododecanoic acid 27 was first esterified in the presence of 
catalytic amounts of sulphuric acid and methanol (Scheme 3). The ester 31 was then allowed to react 
with sodium azide to yield methyl-12-azidododecanoate in a good yield. 1H NMR of the product 32 
showed that there was no starting material left. Saponification of ester 32 gave 12-azidododecanoic 
acid 15, AzC12, in high yield.  
2.1.3 YnC15 24 
YnC15 is an analogue of palmitic acid and has been used in the Tate group to study palmitoylated 
proteins (Section  1.5.3.1). A procedure to prepare YnC15 was previously established in our lab from 
the commercially available 15-bromopentadecanoic acid. However, this starting material was no 
longer readily available commercially and therefore another strategy was developed to prepare 
YnC15.  
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Scheme 3. Synthesis of AzC12. Reagents and conditions: i) MeOH, H2SO4, reflux, 93%; ii) NaN3, DMSO, RT, 89%; 
iii) NaOH 2N, MeOH, 83%. 
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Two methods were envisaged (Scheme 4). The first method comprised the conversion of the 
hydroxyl group of 15-hydroxypentadecanoic acid 34 into a better leaving group such as bromine, 
tosylate or iodine, followed by the nucleophilic substitution of this leaving group by TMS-acetylene. 
Deprotection would then provide YnC15 24.  
The second method involved the formation of a C17-fatty acid chain, bearing a terminal alcohol and 
an alkyne function anywhere along the chain (36), followed by the displacement of the triple bond to 
the terminal position opposite to the alcohol using to the zipper reaction (35).196 The alcohol could 
then be oxidised to yield the expected product 24. This strategy was applied in the literature to 
prepare another analogue of palmitic acid, YnC16 from the commercially available 7-hexadecyn-1-
ol.197 No suitable starting material was commercially available to prepare YnC15 using this method 
but 36 could be easily synthesised in one step from 11-bromoundecanol 8 and 1-hexyne 37. 
2.1.3.1 First strategy 
Several reactions were attempted to convert the terminal alcohol into a better leaving group 
(Scheme 5).  
First, synthesis of 15-bromopentadecanoic acid 39 was attempted by heating a solution of 
15-hydroxypentadecanoic acid 34 in HBr 33 % wt in AcOH under reflux.198 The yield was fairly low 
(38%) but might have been improved by the addition of more HBr 33 % wt in AcOH. Another attempt 
to prepare compound 39 was carried out by adding CBr4 and PPh3 in acetonitrile to 
15-hydroxypentadecanoic acid 34.199 39 was afforded with moderate yield but an unknown impurity 
was present with the product and proved difficult to separate by column chromatography as the two 
compounds had the same retention factor (Rf) on TLC. Mass analysis did not help assign the 
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Scheme 4. Strategies to prepare YnC15 24. 
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structure of the by-product but it appeared that an atom other than bromine was substituted at the 
hydroxy group as the protons adjacent to the terminal position were shifted on the NMR (Section 
 8.1.4). Protecting the carboxylic acid as a methyl ester and bromating the ester did not improve the 
reaction as a similar impurity was present. 
Attempts to tosylate the hydroxyl group (compound 40) or to iodinate (compound 41) in this 
position were unsuccessful, and the starting material was recovered. Therefore, it was decided to 
protect the acid as the methyl ester. Methyl 15-hydroxypentadecanoate 42 was converted to methyl 
15-iodopentadecanoate 44 in presence of imidazole, I2, PPh3 and DCM.200 Ester cleavage proved 
difficult in aqueous solution of NaOH 2N due to the poor solubility of compound 44. Addition of THF 
improved the solubility and compound 45 was afforded with good yield (70%).  
Another method had been used in the literature to prepare compound 45.201 The commercially 
available pentadecanoline 46 was heated under reflux in a solution of HI in AcOH. This method 
afforded compound 45 in one step, with moderate yield and was preferred to prepare 
15-iodopentadecanoic acid 45. The later was then converted to YnC15 24 in two steps, using the 
same method as for YnC12 (Scheme 6 and Section  2.1.1).  
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Scheme 5. Attempts to replace the hydroxyl group of 15-hydroxypentadecanoic acid 34 with a better leaving 
group. Reagents and conditions: i) HBr, AcOH, 80 °C, 38 %;  ii) CBr4, PPh3, MeCN, RT, 44%;  iii) TsCl, pyridine, 
DMAP; iv) imidazole, I2, PPh3, DCM; v) MeOH, H2SO4, Reflux, 91%; vi) CBr4, PPh3, AcN, RT, 44%; vii) imidazole, 
I2, PPh3, DCM, 64%; viii) 4N NaOH, THF, RT, 70 %; ix) HI, AcOH, reflux, 77 %. 
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2.1.3.2 Second strategy: zipper reaction 
As described in Scheme 4, a C17 fatty alcohol bearing an alkyne in the middle of the chain could be 
prepared from 11-bromoundecanol 38 and 1-hexyne 37 via a SN2 reaction and converted to a 
terminal alkyne using the zipper reaction. Attempts to couple these two reagents in the presence of 
n-BuLi and DMPU in THF were unsuccessful. The hydroxyl group was therefore THP-protected and 
the intermediate 48 was coupled to 1-hexyne 37 using the same conditions. 
The zipper reaction relies on the migration of an alkyne to the end of an alkyl chain upon exposure 
to strong base. The strong base is generated in situ by adding 1,3-diaminopropane to sodium hydride 
or potassium hydride, to give 1,3-diaminopropanide.196 The reaction involves a series of 
alkyne/allene interconversions (Scheme 8). This process repeats itself until a stable terminal alkyne 
anion is formed.  
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Scheme 6. Synthesis of YnC15 using the first strategy. Reagents and conditions: i) TMS-acetylene, n-Buli (2.5 M in 
hexanes), DMPU, dry THF, -78 °C then RT, 37 %; ii) K2CO3, MeOH, RT, 94 %. 
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Scheme 7. Second strategy to synthesise YnC15. Regents and conditions: i) 1-hexyne 37, n-BuLi, DMPU, THF; 
ii) DHP, p-TsOH, DCM, RT, 81%; iii) 1-hexyne, n-BuLi, DMPU, THF, -78 °C then RT; 66 %; iv) NaH, 
1,3-diaminopropane; 70 °C then 50 °C,  v) p-TsOH, MeOH, reflux, 83%; vi) NaH, 1,3-diaminopropane, 70 °C then 
50 °C, 35%; vii) Jones reagent, acetone, 0 °C then RT, 67%.  
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Attempts to displace the alkyne of the THP-protected intermediate 49 were unsuccessful as only the 
starting material was recovered; the reason for this is unclear. In the literature, the reaction was 
carried out on the deprotected alcohol similar to 36; thus compound 49 was deprotected.197 The 
zipper reaction was carried out in anhydrous conditions and afforded 36 in low yield after 
purification by silica-gel chromatography.  
The last step comprised the oxidation of 35 to carboxylic acid 24 using Jones reagent. Using this 
strategy, YnC15 24 was synthesised in five steps, with an overall yield of 10%.  
As the first strategy gave higher overall yield (27%), it is the preferred route to YnC15. However, the 
second strategy with the zipper reaction might be advantageous to prepare a alkyne-tagged fatty 
acid of different chain length if an alcohol of the correct chain length and with an internal alkyne is 
commercially available. The number of steps would be reduced to two and the overall yield could be 
improved. 
2.1.4 Coenzyme A thioesters 
Coenzyme A thioesters were first prepared according to Heal et l..154 The corresponding acid, AzC12 
15 or YnC12 16, was coupled to the commercially available but expensive Coenzyme A 50 (CoASH) 
via a CDI-mediated coupling (Scheme 9). The products, 18 and 19, were isolated in low yields, 15 and 
13% respectively, using preparative RP-HPLC and a gradient of methanol and 10 mM ammonium 
acetate buffer pH 5.2 (Table 4). 
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Scheme 8. Zipper reaction mechanism, adapted from Brown et al. 196 R represents a bulky group at one end of 
the alkyne chain.  
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The yields were similar to those reported in the literature.154 The poor isolated yields were due to a 
low conversion and loss of product during the purification process. Some product could have been 
lost during the several washes with acetone and also using preparative RP-HPLC as re-suspension of 
the crude product in the acidic buffer for the purification was quite difficult. The crude product was 
easier to solubilise in weak basic buffer, such as 25 mM ammonium carbonate pH 8 and the use of 
this buffer should improve the yields. Importantly, no hydrolysis of the coenzyme A thioester was 
noticed in the basic buffer.  
During this PhD project, Gaffarogullari et al.202 reported a synthesis of myristoyl CoA according to 
Heal et al.154 with modifications. The main difference was the use of 2 eq of CDI and myristic acid, 
instead of 1 eq, compared to the limiting reagent, CoASH. Unfortunately, no yield was reported and 
the fact that the product was not purified might suggest that the conversion was high or that the 
purification was difficult. 
AzC12CoA 18, YnC12CoA 19 and MyrCoA 17 were prepared according to these new conditions: the 
use of the basic buffer for the purification and 2 eq of CDI and the appropriate acid. The yields were 
noticeably increased, possibly due to the formation of acid anhydride as the reactive species (Table 
4). AzC12CoA 18 and YnC12CoA 19 stock solutions were prepared as 20 mM stock in a 1:1 ratio 
10 mM NaOAc pH 5.0:EtOH, while MyrCoA 17 was dissolved in DMSO as required for the in vitro 
enzyme assay (Section  2.2).  
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Scheme 9. Synthesis of Coenzyme A analogues and structure of the Coenzyme A trilithium salt used for the 
synthesis. Reagents and conditions: i) 1) CDI, THF, DCM, 2) CoASH, NaHCO3 (aq) 0.5 M. Yields are reported in 
Table 4. 
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Table 4: Yields for the preparation of Coenzyme A thioesters using various conditions. 
Heal et al.154 Same conditions as Heal et al.154 After optimisation 
AzC12CoA 18 17% 13% 30% 
YnC12CoA 19 19% 15% 66% 
MyrCoA 17 n/a n/a 32% 
2.2? Kinetic studies of analogues and peptide substrates 
To evaluate the specificity of NMT1 and NMT2 for MyrCoA or analogues and also for some known 
peptide substrate, kinetic studies were carried out.  
2.2.1? Enzyme kinetics 
Kinetic parameters (KM and Vmax) can be determined using an in vitro enzyme assay. The KM is the 
substrate concentration at which the rate of reaction is half its maximum value and is therefore a 
measure of the affinity of the substrate for the binding pocket. A low KM value indicates a tight 
binding of a substrate to the enzyme binding pocket. Vmax is the maximal rate of the reaction. These 
two parameters can be derived according to the Michaelis Menten equations (Figure 21, Equation 1) 
using GraFit 7.0. 
 
Figure 21. Graph used for the determination of the kinetic parameters, KM and Vmax. a) Enzyme saturation 
curve with plotted data of rate of reaction versus substrate concentration. [S] is the concentration of substrate 
and V is the rate of the reaction. b) Lineweaver-Burk plot from which kinetic constants can easily be 
determined. 
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2.2.2 CPM assay 
A fluorescence assay was recently developed in our group to study N-myristoylation.145 The assay 
relies on the reaction of the nucleophilic Coenzyme A 50, by-product of the myristoylation reaction, 
with a Michael acceptor, 7-diethylamino-3-(4-maleimido-phenyl)-4-methylcoumarin 51 (CPM). The 
CPM-CoA adduct 52 is fluorescent at 490 nm, while CPM alone has no fluorescence at this 
wavelength (Figure 22).  
The concentrations of HsNMT1 and HsNMT2 were set to 300 ng/mL in the assay. Recombinant 
enzymes used in the present study were prepared by Dr James Brannigan (University of York). Full 
length HsNMT1 and HsNMT2 (Section  1.2.2) as well as truncated HsNMT1 and HsNMT2 were used 
(Appendix B). The truncated proteins, referred as ∆HsNMT1 and ∆HsNMT2 correspond to the 
catalytic domains of both human NMT isoforms. These proteins lack the N-terminus involved in NMT 
subcellular localisation (Section  1.6.2).  
As myristoylation operates via a Bi-Bi mechanism (Section  1.3) and two substrates are involved, the 
KM of the substrate of interest cannot be determined in the absence of the other. To acknowledge 
the requirement for a second substrate, an apparent KM value (KMapp) can be measured in the 
presence of a saturating amount of peptide, to reduce the reaction to the one-substrate situation. 
Once the second KM is determined, it is necessary to check that the first KM was measured under a 
saturating amount of the second substrate. 
To carry out the assay, certain precautions need to be taken. The substrates, enzymes and buffers 
should be of high purity and stable under the conditions of the assay. Peptides or inhibitors tested 
should not contain any strong nucleophile such as thiols as they could react with CPM, leading to an 
increase of the background fluorescence.  
 a)  E + S ES E + P b)  𝑉 =  𝑉max[𝑆]
𝐾M + [𝑆] 
 
 c)  𝐾M = 𝑘2+ 𝑘−1𝑘1  d)  1𝑉 =  𝐾M 𝑉max 1[𝑆] +  1𝑉max 
Equation 1: Michaelis Menten enzyme kinetic equation. a) Enzymatic reaction. k1, k-1 and k2 are the rate 
constants. b) Correlation between KM, the Michaelis constant, and the rate constants. c) Equation connecting V 
(the rate of the reaction where all enzymes are unbound) with Vmax (the maximum rate where the enzyme is 
completely saturated with substrate), [S] (the substrate concentration) and KM. d) Correlation between 1/V 
and 1/[S] required for the (Lineweaver-Burk) plot. 
 
k1 
k-1 
k2 
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The assay was used in this study to evaluate the kinetic parameters of peptide substrates and 
MyrCoA analogues, and also to study the potency of HsNMT inhibitors (Chapter 3).  
2.2.3? KM of peptide substrates 
CPM assays were carried out to evaluate the specificity of HsNMT1 and 2 for a peptide substrate in 
the presence of HsNMT1 or HsNMT2, CPM and MyrCoA or analogues (YnC12CoA or AzC12CoA).  
As explained in Section ?2.2.2, MyrCoA should be present at a concentration that saturates the 
enzyme binding site. By analogy with the KM values of MyrCoA reported in the literature, the KM was 
expected to be in the low micromolar range. Indeed, three values have been reported in the 
literature, using different assays, in the presence of the 8 amino acid (AA) v-SRC peptide 
(GSSKSKPKR): 15 ± 2 65 , 2.6 59 and 7.6203 μM. For peptide studies the concentration of MyrCoA was 
set to 30 μM, and MyrCoA KM is explored further in Section ?2.2.4.  
The kinetic parameters of peptide substrates were usually determined by varying the concentration 
of peptide from 40 μM to 0 μM or from 10 μM to 0 μM when the KM was lower than 1 μM. 
Fluorescence was recorded (excitation at 390 nm, emission at 470 nm, cut-off at 435 nm) every 
minute. For each solution, a no-enzyme control was carried out with the peptide substrate, CPM, 
 
Figure 22: CPM assay. a) N-Myristoylation of the protein substrate releases Coenzyme A (CoASH). 
b) Nucleophilic attack of CoASH on CPM yields a stable CPM-CoA-adduct which can be seen by fluorescence. c) 
Fluorescence profile of the CPM and CPM-CoA versus the wavelength. Adapted from Goncalves et al.145 
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and various concentrations of MyrCoA (or analogue). Initial rate of reactions were determined by 
calculating the initial slope of the curve plotting the fluorescence intensity versus time. The value 
obtained in the negative control (no peptide) was subtracted from the other values. Background 
signal presumably arises from spontaneous hydrolysis of CoA thioester in Coenzyme A. 
KM and Vmax were calculated using GraFit 7.0 for each enzyme for MyrCoA, AzC12CoA and YnC12CoA 
(Table 5). Typical graphs obtained with GraFit are presented in Figure 23.   
The KM values of a peptide corresponding to the 15 AA at the N-terminus of v-SRC were first 
determined in the presence of MyrCoA, as values had been previously reported in the literature for 
the 8AA peptide.59,65,203 v-SRC is a protein found in Rous sarcoma virus, similar to the human 
oncogene c-SRC, which has been well studied in the literature in the context of 
myristoylation.104,123,204 15 AA v-SRC was prepared by Victor Goncalves (Tate group, Imperial College 
London). The values reported in the literature (44,205 30,59 44.2203 μM) were different from the 
values measured using the CPM assay (Table 5), probably due to the different peptide length. It 
should also be noted that the conditions (enzyme concentration, concentration of MyrCoA) used for 
the assay in the literature were not the same as in the CPM assay and we should not expect to find 
exactly the same values. Interestingly, the KM values for 15 AA c-SRC and 15 AA v-SRC, both 
evaluated with MyrCoA, are comparable for both HsNMT isoforms.  
 
Figure 23: KM determination of 8AA c-SRC using a) HsNMT1 or b) HsNMT2 and saturating amount of MyrCoA 
(30 μM). The figure was generated in GraFit 7.0.  
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The KM of 15AA c-SRC was lower than the KM of 8 AA c-SRC (both evaluated with MyrCoA) suggesting 
a tighter binding to the enzyme. However, 8AA c-SRC can still be considered an NMT substrate, and 
8 amino acids are enough for protein substrate recognition by the enzyme (Section  1.4.2). 
Table 5: KM and Vmax values of various peptides in the presence of saturating amount of MyrCoA. KM values 
are given in µM and Vmax in RFU/min (RFU: relative fluorescence unit). nd indicates that the values have not 
been determined. 
Peptide Parameters HsNMT1 ∆HsNMT1 HsNMT2 ∆HsNMT2 
15 AA   
v-SRC 
KM 0.67 ±0.20 nd 1.24 ±0.27 nd 
Vmax 14311 ±1361 nd 14817 ±1249 nd 
15 AA   
c-SRC 
KM 0.25 ±0.05 0.84 ±0.11 0.18 ±0.04 0.18 ±0.07 
Vmax 38496 ±1772 101442 ±3624 28952 ±1236 29421 ±2295 
8 AA     
c-SRC 
KM 2.67 ±0.28 2.76 ±0.21 2.64 ±0.17 2.77 ±0.14 
Vmax 15679 ±437 22895 ±487 14715 ±255 17280 ±249 
 
Comparable KM values were obtained in the presence of HsNMT1 and HsNMT2, suggesting that the 
peptide binding pocket might be well conserved between the two isoforms. Full length enzymes and 
truncated enzymes gave similar results for c-SRC; suggesting that in the truncated enzyme, the 
active site is conserved. However, when the CPM assay was used to evaluate the potency of 
inhibitors, the full length was preferred to ensure we would not lose any HsNMT1/HsNMT2 
selectivity by removing the N-terminus of the enzymes (Section  1.2.2).  
For the inhibitor assay, it was decided to use 8AA c-SRC as the peptide substrate, at a concentration 
close to the KM value (4 µM). It would be difficult for an inhibitor to compete with 15AA c-SRC as it 
binds too tightly to the enzyme.  
Another assay was performed to test if a protein or peptide substrate could still be lipidated in the 
presence of the MyrCoA analogues. Comparable KM and Vmax were obtained for 8AA c-SRC, though 
the KM values were slightly higher with YnC12CoA or AzC12CoA than with MyrCoA (Table 6).  
 
Table 6: KM of 8AA c-SRC in the presence of saturating amount of MyrCoA analogues. KM values are given in 
µM and Vmax in RFU/min (RFU: relative fluorescence unit).   
Peptide Co-substrate Parameters HsNMT1 HsNMT2 
8 AA  
c-SRC 
YnC12CoA 
KM 9.8 ± 1.6 2.0 ± 0.6 
Vmax 22953 ± 1480 17586 ± 1319 
AzC12CoA 
KM 5.9 ± 0.6 1.5 ± 0.2 
Vmax 17405 ± 1320 13927± 351 
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During the work described in this thesis, different batches of enzymes or substrates were used. 
Every time a new batch was used, the KM of c-SRC 8 AA and MyrCoA were compared with the 
original values to check the quality of the new batch. 
2.2.4? KM determination of MyrCoA and analogues 
Similar experiments were carried out by varying the concentration of MyrCoA or analogue and 
keeping the concentration of peptide substrate constant. The parameters KM and Vmax were 
determined using GraFit 7.0 in order to characterise the specificity of HsNMT1 and 2 for MyrCoA and 
analogues (Figure 24). The concentration of c-SRC was set to 30 μM (~ 10x KM). 
KM values of MyrCoA were first determined in the presence of a peptide corresponding to the N-
terminus of v-SRC, as these values had been reported in the literature for the 8AA peptide.59,65,203 
The values shown in Figure 24 were similar to the reported values: 15 ± 2,65 2.6,59 7.6,203 even though 
the peptide length was different.  
Different studies were carried out in the presence of peptide of various lengths corresponding to the 
N-terminal sequence of the known NMT substrate c-SRC (Table 7).204 
  
 
Figure 24 KM determination of MyrCoA using a) HsNMT1 or b) HsNMT2 and saturating amount of v-SRC 
(30 μM). The rate is the initial rate of the reaction measured for a given concentration of substrate. The figure 
was generated from GraFit (7.0.).  
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Table 7: KM and Vmax values of MyrCoA and analogues using 15AA v-SRC, 8 AA c-SRC or 15AA c-SRC. KM  
values are given in µM and Vmax in RFU/min (RFU: relative fluorescence unit). 
  HsNMT1 HsNMT2 
Peptide Co-substrate KM Vmax KM Vmax 
15 AA v-
SRC 
MyrCoA 3.37 ± 0.8 148887 ± 14508 2.83 ± 0.30 112495 ± 4810 
15 AA  
c-SRC 
MyrCoA 4.43 ± 0.62 76696 ± 3593 4.70 ± 0.60 58596 ± 2524 
YnC12CoA 0.14 ± 0.05 6400 ± 243 0.48 ± 0.11 12640 ± 509 
AzC12CoA 0.76 ± 0.30 9970 ± 828 0.51 ± 0.23 13016 ± 7629 
8 AA 
c-SRC 
MyrCoA 4.07 ± 1.09 30795 ± 2537 2.86 ± 0.90 19487± 1735 
YnC12CoA 0.65 ± 0.26 17383 ± 1210 1.19 ± 0.13 15888 ± 373 
 
Importantly, the KM values of the MyrCoA and analogues were in the low micromolar range and 
30 µM should be sufficient to saturate the MyrCoA binding pocket of the enzyme during the KM 
determination of peptides (Section  2.2.3).  
Surprisingly, the KM values obtained for MyrCoA were higher than the values obtained for the 
analogues. However, Vmax appeared to be an important characteristic. The Vmax obtained with both 
analogues were lower than the Vmax obtained with MyrCoA. This result suggests that the enzyme 
adopts a less efficient catalytic conformation with the analogues. KM values between the two 
HsNMT isomers, for a given co-substrate, were similar. These results verify that the myristoylation 
reaction is not strongly affected by these small structural modifications of MyrCoA and that the 
analogues could be transferred to the N-terminal glycine of substrate equally by both NMT isoforms. 
The kinetic parameters were similar for YnC12CoA and AzC12CoA in the presence of 15AA c-SRC, 
suggesting that both analogues would be suitable to study N-myristoylation. 
Importantly, KM values of MyrCoA determined in the presence of a saturating amount of various 
peptide lengths gave similar results, suggesting that the peptide binding pocket was saturated and 
the KM of MyrCoA was thus independent of the peptide substrate.  
For the inhibitor assay, it was decided to use MyrCoA at a concentration similar to the KM value 
(4 µM).  
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2.3 Validation of YnC12 as a tool to study N-myristoylated proteins in cells 
In this study, the cervical cancer HeLa cell line was used as a model system in view of the potential of 
NMT as a target for cancer therapy (Section  1.7). HeLa cells are rapidly dividing, easy to work with, 
and have been well studied in the literature. The HeLa genome, transcriptome 206 and proteome 207 
have recently been characterised.  
Previous work in the Tate group has shown that YnC12 can be used as a tool to analyse N-
myristoylated proteins in HeLa cells using in-gel fluorescence or chemical proteomics.163 
Optimisation work established that sufficient labelling could be achieved after treating the cells for 
6 h with 20 µM YnC12. Preliminary proteomics experiments allowed the identification of eight 
known NMT substrates as well as 9 putative NMT substrates. The labelling experiments were 
repeated a few times to ensure a similar labelling pattern could be observed by in-gel fluorescence. 
A higher labelling efficiency could increase the number of NMT substrates identified by chemical 
proteomics. 
2.3.1 Lysis buffer  
Previous work in the group to identify N-myristoylated proteins consisted in treating the cells for 6 h 
with 20 µM YnC12, washing the plates with PBS (2x) to remove any excess of culture media and 
YnC12, followed by cell lysis.163 A Tris-based lysis buffer was added to the plate and the cells were 
scraped off the plate (Table 8). Lysates were kept on ice, the insoluble materials were removed by 
centrifugation and the protein concentration was determined. Capture of the N-myristoylated 
proteins with AzTB (Figure 17) allowed visualisation of the proteins using in-gel fluorescence (Section 
 1.10). The experiment was repeated using the two analogues of myristic acid (Myr), YnC12 and 
AzC12, prepared in Section  2.1 (Figure 25a). 
 
Table 8: The table shows the components of the two lysis buffer used for the labelling experiments in HeLa. 
 
Lysis Buffer Components 
Tris 50 mM Tris pH 7.4, 1 % NP40, 1 % sodium deoxycholate, 0.1 % SDS, 150 
mM NaCl, EDTA-free protease inhibitor 
PBS PBS pH 7.4, 1% Triton, 0.1 % SDS, EDTA-free protease inhibitor 
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As previously observed, YnC12 and AzC12 give similar labelling in HeLa cells (Figure 25a).163 However, 
the background in fluorescence, as seen when the cells were treated with Myr, is higher when the 
lysate was captured with YnTB instead of AzTB. Similar observations have been made by Charron et 
al. using similar capture reagents.172 They noticed that an alkyne-capture reagent (to detect azide-
tagged proteins) often produces higher background than the use of an azido-capture reagent (to 
detect alkyne-tagged proteins). The decision was made to only use YnC12 for the in-cell study of 
N-myristoylated proteins, although AzC12 and AzC12CoA were used later for the in vitro study of 
N-myristoylated proteins (Chapter 6). 
As the background fluorescence seen with lysate treated with Myr and AzTB was sometimes high, 
depending on the experiment (data not shown), another lysis buffer was tested. A PBS-based lysis 
buffer was used by other members of the group and did not seem to raise any background issues 
(Table 8). This lysis buffer still contained 0.1 % SDS, a detergent that breaks the plasma membrane 
for cell lysis, but the other detergents were modified. Detergents are also required in order to 
solubilise proteins, especially membrane-bound proteins such as N-myristoylated proteins. As shown 
in Figure 25b, a very similar labelling pattern was obtained with this new lysis buffer but no band 
could be seen in fluorescence in the Myr control. This PBS lysis buffer was thus used in all the further 
experiments described in the present study, except where otherwise indicated. 
 
Figure 25: YnC12 and AzC12 labelling in HeLa cells using different lysis buffer. HeLa cells were treated for 24 h 
with YnC12 (20 μM), AzC12 (20 μM) or Myr (20 μM). After cell lysis with a) a Tris-based buffer or b) a PBS-
based buffer; samples were captured ( a) The capture reagent is indicated in brackets; b) AzTB was used) and 
analysed by in-gel fluorescence (left). Colloidal coomassie (right) staining shows equal protein loading across all 
lanes. Proteins molecular weight (Mw) markers were loaded on the gel (first lane). 
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2.3.2? Optimisation of labelling concentration and time 
In order to determine the optimal conditions for metabolic incorporation of YnC12 in HeLa cells, a 
concentration and time course study was performed (Figure 26). In-gel fluorescence analysis showed 
that maximum labelling was obtained after treating the cells for 24 h with 20 μM of YnC12.  
By increasing the labelling time from 6 h to 24 h, poorly abundant NMT substrates, and those with 
slower turnover in cells should be more enriched and may be easier to detect by proteomics. 
2.3.3? Competition experiment 
A competition experiment was performed to confirm that YnC12 mimics Myr in cells in which HeLa 
cells were treated with YnC12 (20 μM) in combination with increasing concentration of Myr. As 
expected, the natural substrate outcompeted YnC12 labelling; a concentration of Myr as low as 
10 μM leads to a significant decrease in YnC12 labelling, as evidenced by the reduction in fluorescent 
signal (Figure 27). If both substrates had equal affinity for the enzyme, the fluorescence signal would 
decrease by half compared to the positive control (0 μM Myr) when the cells are treated with the 
same concentration of Myr and YnC12 (20 μM). It is possible that YnC12 concentration might be 
lower than expected in cells as YnC12 could have a lower uptake, stability, or conversion to the 
coenzyme A thioester. 
 
Figure 26: Optimisation of the YnC12 labelling in HeLa cells. a) Time course labelling with YnC12 (20 μM). 
b) Concentration series of YnC12. HeLa cells were labelled for 24 h. 
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2.3.4? Enrichment of known NMT substrates 
An experiment was carried out to assess whether N-myristoylated proteins could be tagged by 
YnC12, captured with AzTB (bearing a fluorescent moiety and a biotin moiety, (Figure 17) and 
enriched on streptavidin beads (Figure 28). Western blot analysis of three known NMT substrates, 
MARCKS,105 PSMC1 208 and PRKACA 209 was performed for the samples before pull down (BPD, total 
lysate), the supernatant from the pull down (S) and the pull down sample (PD). In-gel fluorescence 
analysis showed a similar labelling pattern for both YnC12 labelled samples BPD and PD. Importantly, 
no signal in the supernatant was observed, indicating that alkyne-tagged proteins were immobilised 
quantitatively on streptavidin beads. Western blot analysis showed that the three known substrates 
could be tagged with YnC12 and enriched, and the proteins were still present in the supernatant 
suggesting they are not 100% tagged with YnC12 after 24 h treatment in HeLa cells. The equivalent 
of 4-fold more protein was loaded in the PD samples compared to the BDP and S to be able to detect 
a band by western blot analysis. Quantification of bands BPD and of the supernatant using ImageJ 
allowed quantification of the relative incorporation of YnC12 for MARCKS, PSMC1, and PRKACA, 
giving 66%, 35% and 18%, respectively. This percentage may depend strongly on the protein 
turnover rate, since proteins with a higher turnover rate will be more quickly degraded and 
synthesised in cells and will thus incorporate more YnC12. Turnover of N-myristoylated proteins is 
discussed in Chapter 5.  
The incorporation of YnC12 is relatively low for PRKACA (18% of the protein was tagged). However, 
from earlier optimisation of labelling concentration and time (Section 1.3.2) there is no suggestion 
that this incorporation can be improved (Figure 26). Moreover, it has been observed by Dr. Remi 
Serwa (Tate group, Imperial College London) that incubating the cells with YnC12 for 7 days does not 
significantly improve labelling by in-gel fluorescence (data not shown).  
 
Figure 27: Competition experiment?showing that YnC12 can compete with the natural lipid substrate (Myr). 
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It is important to note that no study has investigated the stability of YnC12 in cells over prolonged 
time-periods. Other alkyne lipids analogues can be metabolised in cells or used for the synthesis of 
longer fatty acid chains or fatty acid analogues.210 If YnC12 is in fact metabolised after a long 
incubation time, it could label other proteins than N-myristoylated proteins, and lead to aberrant 
signal for the gel-based analysis or false identification of NMT substrates by proteomics. It could also 
reduce the competition against Myr, resulting in a lower YnC12 incorporation. It is unclear how 
incorporation of YnC12 could be further increased, however the enrichment level was expected to 
be sufficient to carry out proteomics experiments. 
2.3.5? Assessment of the toxicity of YnC12 and Myr in HeLa 
A cell cytotoxicity assay was carried out to confirm that Myr and YnC12 were not toxic to HeLa cells. 
As these compounds were later used in combination with NMT inhibitors in cells (Chapter 3), it was 
important to ensure that they do not add to the toxicity of NMT inhibition. 
2.3.5.1? Cell viability assay: MTS assay 
A large variety of assays are available to assess cytotoxicity or cell viability in a 96-well plate format. 
They rely on the measure of: 
 
Figure 28: Enrichment of known NMT substrates. HeLa cells were treated for 24 h with YnC12 (20 μM) or Myr 
(20 μM). After cell lysis, samples were captured with AzTB and enriched on streptavidin beads. Samples were 
analyzed by in-gel fluorescence (top) and Western blotting (bottom). The samples before pull-down (BPD), 
pull-down samples (PD) and the supernatants from the pull-down (S) were analysed. MARCKS, PSMC1 and 
PRKACA are enriched in the pull-down samples. The small MW band shift of the proteins in the PD can be 
explained by the presence of the capture reagent. Tubulin was used as the loading control. The equivalent of 
4-fold more protein was loaded in the PD samples compared to the BPD and S. 
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 The activity of esterase substrates present in living cells. Typically, the reagent added to the cells 
penetrates the cell membrane and is cleaved by cytoplasmic esterase enzymes. A fluorophore is 
released, and the fluorescent signal is proportional to the amount of living cells. 
 The amount of nucleic acid released from dead cells using a non-cell permeable nucleic acid 
stain. The reagent can intercalate into nucleic acids present outside the cells which leads to a 
large fluorescence enhancement. As living cells have an intact cell membrane, the assay only 
measures the amount of dead cells. This type of assay is often used in combination with the first 
type to concurrently measure the amount of living and dead cells. 
 Oxidation or reduction occurring in metabolically active cells. A redox dye is added to the cells 
and converted to a fluorescent or coloured product after oxidation or reduction by viable cells. 
The absorbance or fluorescence is proportional to the amount of viable or metabolically active 
cells. Dead cells lose their membrane integrity and the metabolic processes are inactivated. 
Commonly used reagents are resazurin, and (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT). 
It was decided to use a cell viability assay based on a redox reagent: 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 53 (MTS). The MTS assay (Promega) is 
similar to the MTT assay but the procedure requires fewer steps as the reagent is water soluble 
(Figure 29). MTS 53 is added in combination with an electron coupling reagent, phenazine 
methosulfate (PMS). The MTS reagent is reduced by metabolically active cells, presumably by 
NADPH or NADH released by dehydrogenase enzymes.211 The product 54 is coloured and can be 
detected by measuring absorbance at 490 nm. The absorbance is proportional to the amount of 
formazan 52 produced and consequently to the number of living cells in the well. A negative control 
(cells not treated with compound) and a positive control (cells treated with puromycin, a compound 
toxic to eukaryotic cells) are required (Figure 29). The protocol from the supplier (Promega) was 
slightly modified (Optimisation work performed by Dr. Will Heal, Tate group, Imperial College 
London). The culture media was not aspirated before adding the cytotoxic compound to be tested as 
it seems to perturb the cells and high error bars were obtained, even with six replicates per 
concentration. The cells were seeded using a smaller volume of media (50 µL) and the solution of 
cytotoxic compound (50 µL) was added directly to the well to give a final volume of 100 µL, as 
required for the assay. 
This assay was also used later to assess the toxicity of NMT inhibitors in HeLa cells (Chapter 3). 
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2.3.5.2? YnC12 and Myr are not toxic to HeLa cells 
It has been suggested that fatty acids might be toxic to cells at high concentrations by activating 
c-SRC and altering its membrane distribution.212 A cell cytotoxicity assay was thus carried out in HeLa 
cells for 3 days to check that the addition of YnC12 up to 160 μM (8 x the maximal concentration 
used in cells) was not toxic (Figure 30). No apparent toxicity could be seen after 1 day for Myr and up 
to 3 days for YnC12. 
 
 
Figure 29: MTS assay. a) In living cells, MTS 53 is converted to formazan 54. The change in absorbance can be 
detected at 490 nM and is proportional to the number of living cell in the plate. b) Picture of the 96-well plate 
after the MTS assay. The outer wells contain only the culture media. Cells are treated with various 
concentrations of compound (6 replicates; 1 concentration per column). The wells circled in black are used as a 
negative control (no inhibitor) and the one in blue are the positive control, where the cells have been treated 
with puromycin.  
Figure 30: Non-toxicity of YnC12 and Myr in HeLa cells determined using the MTS assay (Promega). Each 
point corresponded to the average value of a triplicate experiment and the error bars show the standard 
deviation between replicates. 
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2.4 YnC12 as a tool to study post-translational myristoylation 
As explained in Section  1.5.2, proteins have also been shown to be post-translationally 
N-myristoylated, in the context of apoptosis.89  
As described in Section  2.3 for co-translational NMT substrates, YnC12 labelling followed by capture 
by AzTB and enrichment, could be used to identify the N-myristoylated proteins in apoptotic cells. 
Post-translationally myristoylated proteins have been successfully labelled with AzC12 213 or 
YnC12 115 in Jurkat T-cells. However, induction of apoptosis was always used in combination with 
cycloheximide, an inhibitor of protein synthesis. To date, no mass spectrometry-based proteomics 
experiments have been reported in the literature to identify post-translationally N-myristoylated 
proteins. 
Further optimisations were required to ensure that sufficient labelling could be obtained after brief 
treatment with YnC12. Low abundance proteins are sometimes difficult to detect by proteomics, and 
it was decided not to use cycloheximide as it could possibly have other effects in cells and lead to 
more rapid cell death as cycloheximide is toxic.214 However, apoptosis rapidly stops protein 
synthesis [39] and cycloheximide should not be needed to stop co-translational labelling. 
Staurosporine (STS) was employed to induce apoptosis in HeLa cells (see Section  5.2.2.1 for more 
details and control for the induction of apoptosis). A preliminary experiment (data not shown) 
showed that the YnC12 labelling was weak after 4 h in HeLa cells treated with STS (1 µM), and so 
cells were therefore pre-treated for 1 h with YnC12 before the induction of apoptosis with STS 
(Figure 31). Cells were lysed after 4 and 8 h after the induction of apoptosis. Cells were treated with 
20 µM of YnC12 as usual, or with a higher concentration, 50 µM, to determine whether labelling 
intensity could be improved by increasing the concentration of YnC12. 
After induction of apoptosis and 8 h labelling with YnC12, with or without pre-feeding for 1 h with 
YnC12 (lanes 5, 8, 10, 12), several new bands appeared on the gel compared to the lane showing the 
co-translational labelling (lane 2). The labelling intensity was similar with 20 or 50 µM YnC12. 
However, labelling for 8 h significantly improved the labelling.  
Pre-feeding the cells with YnC12 seemed to enhance the co-translational labelling over post-
translational labelling of myristoylated proteins. For example, the labelling patterns in lanes 3 (1 h 
YnC12 tagging) and 4 (1 h YnC12 tagging followed by 4h YnC12 tagging in the presence of STS) were 
highly similar. 
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Another experiment was carried out to confirm that pre-feeding with YnC12 was not required. 
Another time point, 16 h, was added to see if the labelling intensity could be further improved 
(Figure 32a). However, extensive cell death started to occur after 8 h and cells were mostly dead by 
16 h, and so even if labelling intensity is slightly improved from 8 to 16 h, it would be preferable to 
run the experiment for the shorter period. As observed in Figure 31, pre-feeding the cells for 1 h 
increased co-translational labelling. 
Finally, we envisaged that pre-treating the cells with STS for 1 h should decrease the contribution of 
co-translational labelling even further (Figure 32b). As the optimal labelling time appeared to be 8 h 
(Figure 32a), HeLa cells were treated for 8 h with YnC12 and STS. They were pre-treated with YnC12, 
STS or not pre-treated. Bands that can be attributed to co-translational myristoylated proteins are 
indicated with a blue arrow; pre-treatment with STS for 1 h seemed to be optimal in order to 
decrease co-translational labelling. 
 
Figure 31. Post-translational N-myristoylation. HeLa cells were treated with DMSO (lane 1), or YnC12 (lane 2) 
as a control. Co-translationally myristoylated proteins are seen in lane 2. Cells in lanes 3-8 were pre-treated 
with YnC12 for 1 h and treated with STS (1 μM) + YnC12 for 0, 4 or 8 h. Two concentrations or YnC12 were 
used (20 and 50 μM). In lanes 9-12, cells were treated at the same time with STS (1 μM) + YnC12 (20 and 
50 μM), and lysed after 4 or 8 h. Post translationally N-myristoylated proteins, as seen with the appearance of 
new bands by in-gel fluorescence, are indicated with a blue arrow. 
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A band around 15 kDa could be seen by in-gel fluorescence that might correspond to the p15 BID 
fragment known to be post-translationally myristoylated.8 As a relatively low amount of BID is 
present in cells, it would be difficult to capture BID with AzTB, enrich it and detect it by Western Blot 
analysis (Section 2.3.4). BID was therefore immuno-precipitated from whole cell lysate with 
Sepharose A beads using BID antibody, captured by AzTB on beads, released from the beads and 
analysed by in-gel fluorescence and Western blotting.215 As expected, a band corresponding to BID 
could be seen at 15 kDa when the cells where tagged with YnC12. This method could potentially be 
used to validate other substrates, and proteomics experiments are currently carried out within the 
Tate group to identify novel post-translational NMT substrates. 
 
Figure 32. Optimisation of the labelling of post-translationally N-myristoylated proteins. a) HeLa cells were 
treated with DMSO (lane 1), or YnC12 (lane 2) as a control. Co-translationally myristoylated proteins should be 
seen in lane 2. Samples in lanes 3-5 were treated with STS for 4 ; samples in lanes 6-8 were treated with STS 
for 8 h and samples in lanes 9-11 were treated with STS for 16 h. Samples in lanes 3-11 were not treated with 
YnC12 or were treated with YnC12 at the same time as STS (with or without pre-feeding for 1 h). b) Cells were 
treated with only YnC12 (first lane) or with STS and YnC12 for 1 h. Samples were pre-fed with STS (1 μM, 1 h) 
or YnC12 (1 h). Bands which can be attributed to co-translationally N-myristoylated proteins are indicated with 
a blue arrow. 
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 Figure 33. BID post-translational N-myristoylation. M = MW markers, IP = immunoprecipitation and L = whole 
lysate. HeLa cells were treated with STS (1 μM) and YnC12 (20 μM) for 8 h. Cells were pre-treated for 30 min 
with NMT inhibitor IMP366 (1 μM) (see Chapter 3). Lysate were either immunoprecipitated using BID 
antibody, and captured with AzTB on beads or lysates were directly captured with AzTB. The samples were 
analysed by in-gel fluorescence (top) and by Western blot (bottom). On the in-gel fluorescence, molecular 
weight (MW) can be seen in red while the TAMRA-captured N-myristoylated proteins can be seen in green. 
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2.5 Conclusions 
This chapter has introduced the chemical tools and assays used to study protein N-myristoylation in 
the work described in Chapters 3, 4 and 6.  
Issues with the synthesis of the probes YnC12, AzC12 and YnC15 were addressed, and the probes can 
now be prepared reliably and in good yields (Section  2.1). The synthesis of the MyrCoA analogues 
was also optimised as they originally suffered from low yields.  
Kinetic studies using the CPM assay developed in our group showed that tagged analogues of 
MyrCoA could be transferred to the N-terminal glycine of substrate proteins with similar efficiency 
to the natural substrate. The kinetic parameters of a peptide substrate, c-SRC, and of MyrCoA were 
determined and were used to set up the conditions for the inhibitor assay (Chapter 3). This inhibitor 
assay is based on the increase of the fluorescent signal upon release of CoA during myristoylation of 
the peptide substrate by NMT. The concentrations of enzyme, CPM, peptide, MyrCoA are held 
constant while the concentration of inhibitor varies, and this inhibitor assay will be used in Chapter 3 
to study the potency of known and novel inhibitors of HsNMT1/2. 
Chemically-tagged analogues of myristic acid were then applied to cancer cells to demonstrate that 
NMT substrates could be labelled by these probes. The tag introduced to NMT substrates enabled a 
second extremely selective and high-yielding chemical ligation to a capture reagent, AzTB or YnTB. 
These reagents are multifunctional and possess a dye label and a biotin moiety. The dye label can be 
used to visualise the tagged proteins by in-gel fluorescence while the biotin moiety allows the 
enrichment of the tagged proteins on streptavidin beads and their further analysis by mass 
spectrometry-based proteomics. The labelling conditions were optimised and the lysis buffer was 
modified to ensure that NMT substrates were tagged without increasing the background labelling. 
YnC12 was preferred to AzC12 as it gave no detectable background by in-gel fluorescence. Western 
blot analysis showed that YnC12 was a useful probe to selectively enrich known NMT substrates and 
a cell metabolic assay demonstrated that this probe was not toxic to the cells up to three days. 
Taken together, these experiments confirmed that YnC12 could be used to study N-myristoylation in 
cancer cells and to identify novel N-myristoylated proteins. 
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Chapter 3 HsNMT inhibitors  
 
This chapter describes the search for HsNMT inhibitors. The best inhibitors are used as tools to study 
the phenotype of NMT inhibition in cancer cells. The selectivity of the inhibitors for the two HsNMT 
isoforms is also studied, but not prioritised.   
Several features will be discussed for inhibitors, including enzyme affinity and cell cytotoxicity. On-
target activity of the inhibitors was assessed using YnC12 tagging in cells. YnC12 was shown to label 
NMT substrates (Chapter 2) and YnC12-tagged proteins can subsequently be captured by AzTB and 
analysed by in-gel fluorescence. Upon NMT inhibition, NMT substrates are not tagged by YnC12 in 
cells, hence decreasing the fluorescence on the gel.  
Compounds reported as HsNMT inhibitors in the literature before the beginning of this study 
(Section  1.8.2) were evaluated. NMT is also under investigation as a potential therapeutic target in 
diseases caused by various protozoan parasites, such African sleeping sickness (T. brucei), malaria 
(Plasmodium falciparum and Plasmodium vivax) or leishmaniasis (Leishmania spp.). Recently, potent 
inhibitors of T-brucei (Tb) NMT were reported and also shown to inhibit HsNMT ex vivo (Section 
 1.8.2). The potential of these inhibitors to target recombinant NMT and NMT in cancer cells will be 
assessed. Additionally, inhibitors developed in-house by co-workers as part of a medicinal chemistry 
program at Imperial College London will also be tested. These compounds were predominantly 
designed as Plasmodium falciparum (Pf) NMT and Plasmodium vivax (Pv) NMT, but some of these 
compounds also had a high affinity for HsNMT ex vivo.  
At the beginning of this project, there was no strong evidence that NMT inhibition would have a 
cytotoxic effect on cancer cells. Several inhibitors had been tested (Section  1.8) and shown to kill 
cancer cells but the correlation between NMT inhibition and cell death was never demonstrated. 
The cytotoxicity could only arise from off-target effects and this possibility will be discussed in this 
Chapter. 
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3.1 Inhibitor evaluation 
In this Chapter, several inhibitors are evaluated. Their potential to be used as tools to study the 
phenotype of NMT inhibition in cells will be discussed. A good HsNMT inhibitor has to fulfil several 
criteria. It should: 
 Have a high enzyme affinity (IC50 <1 µM). The CPM assay, described in Section  2.2.2, will be used 
to assess the affinity of the compounds against both recombinant HsNMT1 and HsNMT2. For an 
accurate IC50 (half maximal inhibitory concentration) determination, it is preferable to use a 
minimum of 10 inhibitor concentrations, equally spaced (typically 3-fold dilutions were used).216 
Half the data points on the dose dependent response should be higher than the IC50 value and 
half should be below the IC50 value. As discussed in Section  2.2, 8AA c-SRC peptide will be used 
to evaluate the potency of the inhibitors as this peptide was a modest substrate for the enzyme 
(KM~ 3 µM) (Chapter 2). If the peptide binds too tightly to the enzyme, such as the 15AA c-SRC 
peptide, a weak competitive inhibitor would not be able to displace the peptide and no IC50 
value would be determined. The lower limit for the assay corresponds to half of the enzyme 
concentration (~5 nM).  
 Selectively toxic to cancer cells. Cytotoxicity of anticancer reagents is typically measured after 1-
3 days in cells. Toxicity of the compounds tested is assessed here in HeLa cells treated for 3 days 
with a concentration range of the inhibitor using the MTS assay described in Section  2.3.5.1. The 
concentration that gives half maximal response (EC50) is determined. 
 Act on-target through inhibition of NMT in cells. The ability of compounds to inhibit HsNMT in 
cells will be assessed using the metabolic labelling technology described in Sections  1.10.2 and 
 2.3. If a compound inhibits NMT in live cells, the efficiency of YnC12 transfer to the N-terminal 
glycine of substrate proteins will be impaired, resulting in an observable decrease in the 
fluorescence signal on the gel 
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3.2 HsNMT inhibitors previously reported in the literature 
Before starting this PhD project, many inhibitors of HsNMT had been described in the literature.217 
However, only two inhibitors had been employed in cancer cells to inhibit NMT (Section  1.8.2). We 
thus decided to evaluate these inhibitors as described in Section  3.1. 
3.2.1 2-Hydroxymyristic acid 
2-Hydroxymyristic acid (HMA) was first reported as a selective inhibitor of myristoylation in 1990 133 
and has been since widely used.218-220 However, this compound is poorly soluble in the cell media at 
the concentration required to inhibit HsNMT in cells (typically between 0.5 mM and 1 mM). When 
this compound was tested in MDA-MD-231 cells, a precipitate was formed as soon as the compound 
(from a stock solution in DMSO) was added to the culture media and no decrease of labelling was 
observed by in-gel fluorescence when the cells were treated at the same time with YnC12 (data not 
shown). To increase the solubility, a protocol described in the literature was tested.220 HMA was 
saponified using potassium hydroxide and the fatty acid salt was dissolved in warm serum-free 
culture media containing 20% fatty acid-free BSA before being added to the cells. The solubility 
improved but the fatty acid still precipitated in the culture media and no decrease of labelling was 
observed by in-gel fluorescence (data not shown).  
All these experiments suggested that a more reliable, soluble and potent HsNMT inhibitor was 
needed to study NMT inhibition in cancer cells. It should be noted that even though this compound 
had several issues, it was shown to dose-dependently decrease [3H]myristate labelling in cells.139 
Furthermore, it was successfully used to show that NMT inhibition could be a new therapeutic 
strategy in the context of viral infections such as varicella-zoster virus139 and HIV.138,221 
3.2.2 Tris DBA 
The second inhibitor reported in the literature before the beginning of this PhD project was Tris DBA, 
an organometallic complex used as a palladium-based catalyst in organic chemistry.140,144 The activity 
of this compound is quite surprising and by inspection of the chemical structure, was predicted to be 
poorly soluble in aqueous media such as the cell culture media. 
It was reported that this compound could inhibit HsNMT1 activity in vitro and in cells.140 More 
recently, Tris DBA was suggested to be more selective for HsNMT1 than HsNMT2 144 with IC50 values 
of 0.5 ± 0.1 µM and 1.3 ± 0.1 µM respectively. A CPM assay was carried out to confirm these results. 
The IC50 values for HsNMT1 and HsNMT2 were in the same order of magnitude as previously 
reported but we found that the IC50 values were very similar for both HsNMT isoforms (Figure 34). 
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We then evaluated the cytotoxicity of this compound in HeLa using a MTS assay. No metabolically 
active cells remained in wells treated with a concentration of Tris DBA higher than 1 μM. Bhandarkar 
et al. similarly found that Tris DBA had a cytotoxic effect against B16 murine and A375 human 
melanoma after one day treatment with a concentration of 1 μM.140 However, we noticed that 
Tris DBA precipitated in the media containing the cells treated with the highest concentrations of 
inhibitor (>1 μM). In these wells, cells seemed dead after only a few hours, as suggested by the 
rounded up shape. 
A YnC12 tagging experiment was carried out to see if the toxicity could be credited to NMT 
inhibition. If NMT is inhibited in cells, YnC12 labelling should drop dose-dependently with an 
increasing amount of inhibitor. At 50 μM, only one band could be seen using in-gel fluorescence and 
the cells seemed to be rapidly killed by the inhibitor. The proteins in this remaining band, which are 
still apparently labelled by NMT, are unknown but proteomics experiments could be carried out to 
 
Figure 34.Evaluation of Tris DBA as an NMT inhibitor in vitro and in cells. a) Dose dependant response of the 
inhibitor determined using the CPM assay. b) Cell metabolic assay (MTS assay) carried out for 3 days in HeLa. 
c) In-gel fluorescence showing the YnC12 labelling in HeLa cells treated with various concentrations of 
Tris DBA. Cells were dead after 7 h treatment at 50 μM.  
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identify the nature of the proteins. This result could suggest that NMT is inhibited and hence the 
inhibitor is acting on target. However, at 10 μM cells were almost killed after three days (Figure 34b) 
while NMT substrates were still being tagged with YnC12 (Figure 34c), suggesting the enzyme is not 
completely inhibited. Tris DBA is thus not toxic due to NMT inhibition but probably due to an 
off-target effect. It is unclear if the loss of labelling at 10 μM could be credited to NMT inhibition or 
is just an artefact of the off-target effect of Tris DBA. If the compound partly inhibits protein 
synthesis or kills the cells, it could result in a decrease of YnC12 labelling. Bhandarkar et al. 
suggested that NMT is not inhibited by Tris DBA in cells; they proposed that Tris DBA could decrease 
HsNMT1 expression in cells.140 Indeed, gene array analysis revealed that HsNMT1 gene was highly 
down-regulated upon inhibition with Tris DBA. However, other genes were also down-regulated, 
suggesting that toxicity was not only the result of a decrease of NMT activity. 
A competition experiment was carried out to confirm whether Tris DBA was a competitive inhibitor 
of the peptide substrate. As expected, the compound is not a competitive inhibitor of the peptide 
binding pocket as the Vmax values were different when the KM of c-SRC was determined in the 
presence of different amount of Tris DBA (Figure 35a). If Tris DBA was a competitive inhibitor, the 
curves in Figure 35a should reach the same maximum at the highest concentration of peptide 
substrate and the linear fits in Figure 35b should cross the y axis at the same position.222  
 
 
Figure 35. Competition experiment: Tris DBA does not compete with the peptide substrate. a) Shows the 
relative fluorescent intensity (RFU) versus the concentration of peptide substrate, 8AA c-SRC. Increasing the 
amount of substrate cannot overcome the inhibition, and Vmax are different, suggesting that Tris DBA is a non-
competitive inhibitor. b) Shows the 1/V value versus the reverse value of the peptide concentration. The 
y-intercept is equivalent to the inverse of Vmax and this plot confirms that the Vmax values are different. The 
data were linearly fitted in Excel. The R-squared value and equation are indicated. 
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These results showed that Tris DBA was not a competitive inhibitor of NMT but most probably NMT 
activity was reduced due to enzyme aggregation. While the compound was toxic to HeLa, the toxicity 
could not be correlated to NMT inhibition. This compound was thus not used to study NMT 
inhibition in cancer cells in this work, and these results suggested that a better inhibitor was needed. 
3.3? Characterisation of IMP366 (DDU85646, compound 4) and analogues: 
Recently, potent inhibitors of Trypanosoma brucei NMT (TbNMT) have been reported.43,142,223 The 
protein binding pocket of the enzyme is highly conserved across species and TbNMT share 83% 
identity and 90% similarity with human NMT1 and NMT2.  
3.3.1? Evaluation of IMP366 (DDU85646, compound 4) as an HsNMT inhibitor 
Inhibitor DDU85646, referred to here as IMP366, was synthesised (kind gift from Dr. Remi Serwa and 
Dr. Will Heal, Tate group, Imperial College London) and its potency was assessed against 
recombinant HsNMT1 and HsNMT2 by determining the IC50 values (Figure 36). Compound IMP366 
was a potent inhibitor of both HsNMT isoforms with an IC50 in the low nM range (17 and 22 nM 
respectively). A comparable IC50 was found in the original paper against HsNMT1 (3 nM) using a 
different assay.142 The slope factors were close to 1, suggesting that the inhibitor might be a 
competitive inhibitor. Several experiments were carried out by Dr. Victor Goncalves (Tate group, 
Imperial College London ) to confirm that the inhibitor was a competitive inhibitor of the protein 
binding pocket of HsNMT1. 
 
Figure 36. Enzyme affinity of IMP366. a) Structure of IMP366. b) Inhibition profile of IMP366 against HsNMT1 
and HsNMT2. The response is the% remaining activity. The figure was generated from GraFit using the 
background corrected IC50 function.  
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The inhibition of HsNMT in HeLa cells was assessed. HeLa cells were treated with a concentration 
range of inhibitor IMP366, starting from 10 µM and using 3-fold dilutions, in the presence of YnC12 
for 24 h. We envisioned that pre-feeding the cells for 1 h with the inhibitor would be sufficient to 
allow the compound to penetrate inside the cells and inhibit NMT. The pre-feeding time was 
optimised later (Section  3.3.3.3). Following cell lysis, proteins were captured with AzTB, separated 
on a SDS-PAGE gel and the captured proteins visualised by fluorescence (Figure 37a). The 
fluorescence signal decreases with increasing concentration of inhibitor in a dose dependant 
manner. The disappearance of the fluorescence signal at the highest concentration of inhibitor 
suggests that NMT is fully inhibited at this concentration.  
The fluorescence of individual bands on the gel was quantified using ImageJ and plotted against the 
concentration of inhibitor. The error in quantification was determined through two biological 
replicates. The fluorescence of individual bands was normalised to the protein loading using the 
coomassie-stained gel, which could be quantified. The fluorescence could also have been normalised 
according to the relative amount of HsNMT1 and HsNMT2 in the samples. However, this 
quantification was subject to experimental bias (protein transfer on the membrane for example) and 
this method was thought to be less reliable than the coomassie stain.  
The concentration, at which metabolic tagging is inhibited by 50%, referred here as the TC50, was 
calculated for the three major bands (Figure 37b), by fitting the data to an IC50 function in GraFit. 
The slope factor of the dose-dependent response ranged from 0.96 to 1.32, similar to values 
observed for the determination of the IC50 values using the in-vitro assay. The TC50 values ranged 
from 90 nM to 253 nM, with an average value of 160 nM. These differences between bands 
probably reflect the specificity for NMT for each individual protein at the enzyme level. Assessing the 
TC50 on only the three major bands might not reflect perfectly the enzyme inhibition in cells. Many 
bands observed in fluorescence cannot be quantified, especially bands between 25 kDa and 37 kDa. 
Protein N-myristoylation on these bands might be differently affected by the concentration range of 
inhibitor IMP366. The fluorescence of the whole band was thus quantified using ImageJ and fitted as 
before to an IC50 function in GraFit (Figure 37c). The new TC50 value, 169 nM, was similar to the 
average TC50 value of the three major bands. However, this second method was more efficient, and 
was preferred to measure the TC50 values of other NMT inhibitors. 
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The toxicity of the inhibitor IMP366 was then assessed in HeLa cells using the MTS assay (Figure 38). 
The percentage of metabolic activity for cells treated with various concentrations of the inhibitor 
compared to the control (no inhibitor) was measured. This response gives an indication of the 
relative amount of viable cells in culture compared to the control. It is interesting to notice that 
IMP366 has an atypical dose-dependent response in HeLa after 3 days (Figure 38a). The cells have no 
remaining metabolic activity at the highest concentrations of inhibitor (100 μM), and are thus 
Figure 37. Effect of inhibitor IMP366 on YnC12 labelling. a) In-gel fluorescence showing that the fluorescence 
intensity in bands 1-3 decreases dose dependently with increasing amounts of inhibitor IMP366. Protein 
loading on the gel was checked by coomassie and with the Western blot against HsNMT1. b) Tagging IC50 
(referred as TC50) determination for the 3 major fluorescent bands. The fluorescent signal of bands 1-3 was 
quantified (ImageJ) and the average dose-dependent response of two biological replicates was plotted in 
GraFit. The error bars correspond to the standard deviation between replicates. c) Similar to b), the 
fluorescent signal for each whole lane was quantified and used to determine the tagging IC50 (TC50).  
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probably killed. However, the response (percentage residual metabolic activity) seems to show a 
plateau at 20%.  
This result was correlated to the YnC12 labelling experiment (Figure 37a). As seen by in-gel 
fluorescence, NMT seems to be nearly completely inhibited (<10% remaining fluorescence) from 
concentrations higher than 1 μM, which correspond to the start of the plateau observed on the MTS 
assay curve. In other words, NMT inhibition for 3 days does not kill HeLa cells but leaves ca. 20% 
residual metabolism compared to the control (no inhibitor). We hypothesised that the cells either 
stop dividing or it is also possible that only a portion of the cells is sensitive to NMT inhibition, due to 
the presence of different colonies of HeLa cells. These hypotheses will be studied in Chapter 5. 
However, these experiments showed for the first time that on-target inhibition of NMT in cells could 
decrease the metabolic activity and thus cell viability of cancer cells. 
When HeLa cells were treated with an excessive concentration of inhibitor (100 μM), no metabolic 
activity was observed and we hypothesised that cells were probably killed due to off-target effect 
(Figure 38a). At 10 μM, NMT seems completely inhibited in cells, but the metabolic activity was the 
same as at 1 μM. 
 
Figure 38. Evaluation of the cytotoxicity of IMP366 using the MTS assay. The assay was carried out for 3 days 
in HeLa cells. The error bars display the standard deviation between six biological replicates. a) 
Dose-dependent response showing the% of remaining activity versus the concentration of inhibitor. Seven 
concentrations of inhibitor were tested, starting from 100 μM, and using 3-fold dilutions. b) The 
dose-dependent response was plotted in GraFit. The highest concentration of inhibitor (100 μM) was 
discarded to allow the data points to fit the IC50 function in GraFit.  
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The EC50 value of this inhibitor was evaluated by fitting the data to the IC50 function in GraFit. The 
highest concentration of inhibitor was discarded as it probably does not correspond to on-target 
NMT inhibition and could prevent the data from fitting to the dose-dependent function in GraFit 
(Figure 38b).The EC50 value correlated well with the TC50 values, suggesting that the cell toxicity is 
predominantly, if not exclusively, due to NMT inhibition and that there is no significant off-target 
effect. However, to confirm this correlation, inhibitors from the same series were evaluated later 
(see Section  3.3.2).  
IMP366 was crystallised in the presence of MyrCoA with HsNMT1 by Dr. Jim Brannigan (University of 
York). As expected, the inhibitor binds to the protein binding pocket of HsNMT1 (Figure 39a). It has 
some key interactions with the enzyme, including a salt bridge with the C-terminal carboxylate of the 
enzyme, a hydrogen-bonding interaction with Ser405 and a π-π interaction with Tyr 296. 
The electron density map of the inhibitor IMP366 is presented in Figure 39b-c. HsNMT1 crystal 
structure with bound-inhibitor was superimposed with the crystal structures of the inhibitor-free 
HsNMT1 and inhibitor-free HsNMT2 (in each case the enzyme was bound to MyrCoA or a non-
hydrolysable analogue). These structures show a very similar arrangement of key residues in the 
human HsNMT1 and HsNMT2 active sites. The two inhibitor-free enzymes superimpose well to the 
inhibitor-bound HsNMT1 structure and this feature can be characterised by the measure of the root-
mean-square deviation (RMSD). The RSMD corresponds to the average distance between the 
backbone atoms of superimposed proteins. The RMSD value between inhibitor-free NMT1 and 
inhibitor-free NMT2 was 0.390 (325 to 325 atoms) and between inhibitor-bound NMT1 with 
inhibitor-free NMT1 was 0.117 (290 to 290 atoms).Regarding this last number, it seems that the 
enzyme undergoes limited rearrangement upon inhibitor binding. It suggests that the inhibitor  
binds tightly to a pocket that is probably pre-organized by binding of MyrCoA.58 
The crystal structure of inhibitor-bound HsNMT1 was also superimposed with a structure of LmNMT 
bound with the same inhibitor as this structure had been previously published and well-described.223  
Several interactions are conserved, including the salt bridge to the NMT1 C-terminus and a hydrogen 
bond to Ser405, although an additional hydrogen interaction can be observed in the LmNMT 
structure between the oxygen of the sulfonamide moiety and several surrounding amino acids. 
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 Figure 39. Crystal structure of IMP366. a) Crystal structure of IMP366 (grey) bound to NMT1 in the presence of 
MyrCoA. Key water molecules are shown as red spheres. Polar interactions are shown as black dashes. NMT1 
key residues are shown is green and non-hydrolysable MyrCoA in black. The C-terminus is labelled C (Q496). 
The structure was overlayed with the apo forms of NMT1 (blue) and NMT2 (pink) bound with MyrCoA (dark 
grey) and non–hydrolysable MyrCoA (light grey) respectively. The figure was generated in PyMOL using PDB ID: 
4C2Z (NMT1 bound to IMP366 and MyrCoA), PDB ID 4C2Y (apo NMT1) and PDB ID 4C2X (apo NMT2). b) and c) 
Electron density of IMP366 bound to HsNMT1 (PDB 4C2Z). d) Overlay of HsNMT1 and LmNMT, both bound 
with IMP366. Key water molecules are shown as grey spheres for HsNMT1 and pink spheres for LmNMT. Key 
residues are shown in green for HsNMT1 and blue for LmNMT. IMP366, MyrCoA, polar interaction and key 
molecules are shown in grey for HsNMT1 and in pink for LmNMT. Key amino acids are labelled for clarity in 
green for HsNMT1 and blue for LmNMT. The figure was generated in PyMOL using PDB ID 4C2Z. (NMT1 bound 
to IMP366 and Myr CoA), PDB ID 2WSA (LmNMT). 
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3.3.2 Analogues within a series: correlations of IC50, TC50 and EC50. 
Three analogues of IMP366 were prepared by Dr. William Heal (Tate group, Imperial College London) 
(Figure 40a), and their enzyme affinity assessed using the CPM assay. Compounds IMPP366, IMP653 
and IMP655 had similar enzyme affinities. However, compound IMP654 was a much less potent 
inhibitor of HsNMT1 and HsNMT2 with an IC50 in the low micromolar range (1684 and 2096 nM 
respectively). 
These similarities and differences in potency could be rationalised using the crystal structure of 
HsNMT1 bound to IMP366. For the less potent inhibitor IMP654, the N-O bond might disrupt the 
hydrogen bond between the nitrogen and the carboxyl group of Ser405, which could explain the low 
affinity for the enzyme. Surprisingly, an extra methyl group in position R3 (inhibitor IMP653) did not 
disrupt the salt bridge interaction with the C-terminal carboxylate of the enzyme. The presence of a 
difluoromethyl moiety also did not dramatically change the affinity for the enzyme, as there is 
probably sufficient space to accommodate it in the enzyme binding pocket. 
EC50 values were determined using the MTS assay (Figure 40b). Inhibitor IMP654 was not toxic to the 
cells up to 10 µM. The other two compounds, IMP653 and IMP655 showed a similar response as 
IMP366, with a plateau of residual activity between 3.3 and 10 µM.  
Enzyme inhibition in HeLa cells was assessed using YnC12 tagging (Figure 40c). For compounds 
IMP653 and IMP655, as previously seen with 366 (Figure 37a), the fluorescence labelling was dose-
dependently affected by the increasing amount of inhibitor, but the fluorescent signal at 0.2 and 
1 uM was greater than for IMP366, confirming that the IC50 and EC50 values are higher for these 
compounds than for IMP366. The TC50 values were evaluated by quantifying the fluorescence 
intensity of the whole lane and normalising to the protein loading using ImageJ (Figure 40b). For a 
more accurate evaluation of the TC50 values, another inhibition experiment was carried out with a 
larger concentration range (7 concentrations starting from 10 µM, tripling dilutions). The gels are 
presented in Appendix C and the TC50 values in Figure 40b. 
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Compound IMP654 was not potent against the recombinant enzyme and the labelling experiment in 
cells showed no dose-dependent response. The structure of IMP654 is highly similar to IMP366 but 
did not show any toxicity in HeLa cells up to 10 μM. This result strongly supports the hypothesis that 
366 does not have any off-target effect leading to toxicity in cells (at least up to 10 μM).  
For these four analogues, there is an excellent correlation between IC50, EC50 and NMT inhibition in 
HeLa cells (Figure 40d). The TC50 was measured based on a 24 h labelling experiment while the EC50 
values were measured after 3 days. The TC50 values are slightly lower than the EC50 values, probably 
due to an experimental error that shifts everything equally.  
Figure 40. Assessment of IMP366/653/654/655 for on-target activity using YnC12 tagging. a) Structures of 
the four inhibitors. b) Enzyme and cellular data for the four inhibitors. The EC50 is the average value of three 
replicates and the TC50 value was calculated from in-gel fluorescence of two biological replicates c) In-gel 
fluorescence analysis. The cells were pre-treated with the inhibitor for 1 h and were tagged with YnC12 in the 
presence of the inhibitor for 24 h. d) Correlation between IC50 or TC50 with EC50. The IC50 value shown here is 
the average value of IC50 against HsNMT1 and the IC50 against HsNMT2.  
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All these results give us high confidence that IMP366 is acting on target and does not have any 
relevant off-targets up to 10 µM.  
 
3.3.3 Further validation of IMP366 as a tool inhibitor 
IMP366 is the first potent, specific and soluble compound targeting NMT in cells. However, before 
using it as a tool to study NMT inhibition in cancer cells, the compound required further 
investigation. The compound will be used in Chapter 4 in proteomics experiments for periods up to 
24 hours, and so the toxicity of the compound up to 1 day needed to be addressed, as well as its 
stability, translation in HeLa and ability to inhibit N-myristoylation of known NMT substrates. 
3.3.3.1 IMP366 is not toxic to HeLa cells after 1 day 
N-Myristoylation is a co-translational process and any inhibitors of protein synthesis or any excessive 
cell death due to inhibitor toxicity could impair YnC12 labelling. An experiment was carried out to 
confirm protein synthesis was not stopped upon NMT inhibition with IMP366 for 24 h (Figure 41). An 
azido-homoalanine (AHA) labelling experiment was performed in HeLa cells treated with different 
concentration of IMP366 (Figure 41 a, b, c, d).224 Protein synthesis was not affected at all the 
concentrations tested after 1 day of inhibition. A MTS assay was also carried out to check that the 
inhibitor was not toxic to the cells after 1 day treatment (Figure 41e). 
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3.3.3.2? Use of the inhibitor in combination with YnC12  
In the next Chapters (Chapter 4 and 5), IMP366 will be used in combination with YnC12 to carry 
various experiment, such as proteomics experiments to identify novel NMT substrates, or 
experiments to study the phenotype of NMT inhibition in cancer cells. YnC12 was shown to be not 
toxic to HeLa cells up to 3 days (Section 2.3.5.2) but an additional experiment was carried out to 
demonstrate YnC12 would not increase the toxicity of the inhibitor after 3 day treatment (Table 9). 
 
Figure 41. Inhibitor IMP366 does not inhibit protein synthesis and is not toxic to cells after 24 h treatment. 
a) Structure of L-azidohomoalaine (AHA). b) Dose-dependent labelling with AHA in HeLa. Cells were also 
treated with the highest concentration of AHA with cycloheximide (CHX), an inhibitor of protein synthesis, 
showing that AHA only labels newly synthesised proteins. c) AHA labelling with increasing amount of CHX. 
d) Cells were treated with AHA and DMSO or CHX or inhibitor IMP366. e) Metabolic activity in HeLa cells 
treated with inhibitor IMP366 for 24 h. The response corresponds to the% of metabolic activity compared to 
the control (cells treated with DMSO). The inhibitor concentration is in μM. The data was fitted to a dose-
response curve using GraFit 7.0 (IC50 replicate function).  
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As expected, the EC50 value of IMP366 in the presence of Myr or Ync12 was similar to the value 
obtained without any probe. The small differences may be attributed to experimental errors. 
 
Table 9. Cell cytotoxicity of IMP366 in the presence of Myr or YnC12 
IMP366 - + Myr (20 µM) + YnC12 (20 µM) 
EC50 (µM) 0.29 ± 0.03 0.34 ± 0.03 0.21 ± 0.03 
 
It would be right to compare IC50 and TC50 values only if IMP366 had the same binding affinity for 
the enzyme in the presence of MyrCoA and YnMyrCoA. A CPM assay was carried out, and as 
expected, the binding affinity of IMP366 was similar for HsNMT1 and HsNMT2 in the presence of 
MyrCoA and its alkyne-tagged analogue (Table 10). 
 
Table 10. IC50 values of IMP366 against HsNMT1 and HsNMT2 measured in the presence of MyrCoA (4 µM ~ 
KM) or YnMyrCoA (1 µM ~ KM) 
IC50 of IMP366 (nM) HsNMT1 HsNMT2 
With MyrCoA 17 ± 1 21 ± 1 
With YnMyrCoA 15 ± 1 15 ± 1 
 
 
3.3.3.3 Optimisation of the pre-incubation time 
In all the experiments described above, the cells were pre-fed for 1 h with the inhibitor before being 
labelled for 24 h with YnC12 in the presence of the inhibitor. An experiment was carried out to check 
that 1 h pre-feeding was sufficient (Figure 42).  
Interestingly, the same labelling pattern was observed for all the samples pre-fed with the inhibitor 
for 0-18 h. The background seems quite high on the gel, probably due to the use of only 1 µM of 
IMP366 and also to the use of a Tris-based buffer for cell lysis (Section  2.3.1). This result suggests 
that the inhibitor penetrates cells rapidly and that no pre-incubation time would be necessary. 
However, for the next experiments, 1 h pre-feeding was retained to ensure that all NMT was 
inhibited before the addition of YnC12 to the cells. 
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3.3.3.4? Inhibition of N-myristoylation of NMT substrates  
The decrease in tagging of three known N-myristoylated proteins, PSMC1, PRKACA, and c-SRC was 
also quantified, to assess if N-myristoylation of NMT substrates were dose-dependently affected by 
the inhibitor IMP366. HeLa cells were treated with several concentrations of inhibitor IMP366 and 
proteins were tagged with YnC12. After cell lysis and capture of the tagged proteins with AzTB, NMT 
substrates were enriched on streptavidin beads. Western blot analysis showed that PSMC1, PRKACA 
and c-SRC are dose-dependently less enriched when the inhibitor was added to the cells (Figure 
43a).  
The band intensities were quantified and plotted against the concentration of inhibitor (Figure 43b). 
The dose-dependent response of PRKACA is considerably different than the dose-dependent 
response of c-SRC and PSMC1. Estimation of the IC50 showed that half of PRKACA present in cells is 
not N-myristoylated with a concentration of inhibitor as little as 27 nM. However, to draw strong 
conclusions, the experiment would need to be repeated several times to take into account the error 
of the experiment. It would be better to use proteomics experiments to quantify accurately the 
decrease of enrichment of these proteins. This possibility will be discussed in Chapter 4. 
 
Figure 42. Results from bioorthogonal ligation experiment to optimise the pre-incubation time for inhibitor 
IMP366 HeLa cells. Cells were pre-fed with the inhibitor (1 μM) for 0-18h and labelled for a further 6 h with 
YnC12 (20 μM) in the presence of the inhibitor (20 μM). 
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This experiment confirms the observation made in Section ?3.3.1. We observed earlier that the TC50 
was different for the three major fluorescence bands, suggesting that NMT substrates will be 
differentially affected by an NMT inhibitor. The reason for this is currently not fully understood but 
will be discussed in Chapter 4. 
3.3.3.5? Translation in HeLa cells 
We observed that IMP366 has a relatively low translation from in vitro enzyme assay to in vitro 
cellular assays in HeLa cells, with an EC50 value approximately 10-fold higher than the IC50. This 
10-fold translation value was consistent with the inhibitors from the same series (Section ?3.3.2). As 
the compound was shown to highly bind to plasma,43 we suspected that the inhibitor might highly 
bind to serum in the culture media hence preventing the compounds getting into cells.  
 
Figure 43. Inhibition of N-myristoylation of PSMC1, PRKACA and c-SRC. a) In-gel fluorescence and Western 
blot (Western blot, bottom) analysis showing the decrease in tagging of PSMC1, PRKACA, c-SRC after 
enrichment. BPD = before pull-down and PD = pull down. Tubulin was used as a loading control. The equivalent 
of 4-fold more protein was loaded for the PD samples. b) Quantification of the bands observed in the PD 
samples for the 3 known substrates with ImageJ. The intensities of the bands was normalised to the intensity 
of the band in the sample without inhibitor for each protein. The abscissa is in log scale. c) IC50 values and 
slope factors determined by fitting the relative band intensities to an IC50 function in GraFit. 
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HeLa cells are normally grown in a culture media containing 10% of fetal bovine serum (FBS) but this 
amount can be decrease to 2% for a few hours without impairing the cell viability. A tagging 
experiment was carried out for 6 h with 10% or 2% or FBS (Figure 44). No difference in fluorescence 
labelling was observed, suggesting that the translation cannot be increased by changing the 
concentration of serum in the culture media. The translation of inhibitors is known to be highly 
dependent on the properties of the compounds, such as lipophilicity or pKa. Thus, it may not be 
possible to improve translation without changing the structure of the inhibitor IMP366. 
3.3.3.6? Stability of IMP366 
The stability of IMP366 in aqueous solution and at 37°C was assessed using an MTS assay. Dilutions 
of the inhibitors were prepared in the culture media, and half of each solution was incubated for 3 
days at 37°C. MTS assays were carried out in HeLa cells using these dilutions (pre-incubation and no 
pre-incubation) (Figure 45). The metabolic activity was highly similar between the two conditions, 
suggesting that the compounds would be stable for several days in the cell culture media at neutral 
pH. 
 
Figure 44. Effect of the serum concentration in the culture media on the uptake of IMP366 into HeLa cells. 
An YnC12-tagging experiment with cells treated with IMP366 in HeLa was carried out for 6 h. Cells were 
pre-treated for 1 h with the inhibitor. The culture media contained either 10% of Fetal Bovine Serum (FBS) or 
2% of FBS. 
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3.4? Screening of in-house NMT inhibitors 
The inhibitor described above (IMP366) is a good HsNMT inhibitor. However, alternate scaffolds are 
needed to improve target validation and provide multiple options for drug development. Several 
compounds prepared in-house were thus screened.  
In this Section, all the compounds assessed in vitro against recombinant HsNMT1 and HsNMT2 or in 
HeLa cells arose from a medicinal chemistry project carried out at Imperial College London. All the 
compounds tested were designed, synthesised and kindly donated by Dr. Jennie Hickin, Dr. Tayo 
Olaleye, Dr. Mark Rackham, Dr. Victor Goncalves, Dr. Zhiyong Yu and Andy Bell. These compounds 
were designed to inhibit parasite NMTs, including PfNMT, PvNMT, LmNMT (see Section ?1.2.3). In 
vitro potency of the inhibitors was usually assessed by the medicinal chemistry group members 
against recombinant parasite NMTs and HsNMT1. The best compounds were then tested in parasites 
and in a human liver cancer cell line, HepG2, in order to assess the ability of the compound to kill 
parasites without toxicity against human host cells. Potent inhibitors of HsNMT1 were assessed as 
potential inhibitor tools to study NMT inhibition in cancer cells. HsNMT isoforms and parasite NMTs 
have a relatively high sequence identity (Section 1.2.3) and any good parasite NMT inhibitor could 
potentially inhibit HsNMT as well.  
As discussed in Section ?3.1, the IC50s against both HsNMT isoforms, the cell toxicity, and the ability of 
the compounds to inhibit NMT in cells were all important features which were used to assess the 
quality of an inhibitor.  
 
Figure 45. Stability of IMP366 incubated at 37°C in the culture media. Inhibitor dilutions were incubated for 
0 day (No preincubation) or 3 days (Preincubation) in the warm culture media (37°C) and added to HeLa cells 
to carry out a 3-day MTS assay. The figure shows the remaining metabolic activity versus the concentration of 
inhibitor. 
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IMP366 was used as a reference compound and any future HsNMT inhibitor should have similar or 
improved properties. HsNMT inhibitor should have relatively low IC50 (<200 nM) and low EC50 (<10 
µM); if the IC50 is too high, high concentrations of inhibitor would be required to treat the cells to 
inhibit HsNMT and some off-target effects might come into play. Additionally, HsNMT inhibitors 
should inhibit NMT in cells (assessed with YnC12 labelling). For the cell viability assay, a 
dose-dependent decrease of the response and a plateau of residual metabolic activity at the highest 
concentrations should be observed when the concentration of inhibitor increases, as seen for 
IMP366.  
Design and synthesis of the inhibitors was not undertaken by the author of this thesis, and for 
intellectual property (IP) reasons inhibitor structures cannot be presented in this thesis. Compounds 
from the same series were sometimes tested for comparison, but the structure activity relationship 
will not be discussed. Inhibitors were separated in three groups. The first group corresponds to weak 
HsNMT inhibitors, and most unfortunately showed an off-target effect in cells and little on-target 
effect. The second group describes some weak inhibitors with a small selectivity for HsNMT1 over 
HsNMT2. The third group corresponds to some potent HsNMT inhibitors showing little off-target 
effect in cells. These compounds were tested in the last few months of the PhD project. Within each 
group, compounds are not ordered according to their respective series or structures similarity, but 
are ordered instead according to the order tested during this work.  
3.4.1 Non selective 
Many of inhibitors tested were found to have several issues that made them unsuitable as tools. 
First, some inhibitors had a low affinity for HsNMT1 and HsNMT2 
(IMP164/253/256/261/163/266/267, coloured in orange) and were not tested in cells. Secondly, 
some inhibitors were relatively potent against HsNMT1 and HsNMT2 but the cell cytotoxicity assay 
showed that the compounds had an off-target effect in cells (compounds IMP162/168, coloured in 
yellow). The slope factor was high (>4 for both inhibitors) and no plateau of metabolic activity was 
observed. A typical EC50 curve is presented in Figure 46. A YnC12 labelling experiment was carried 
out for IMP162 (Appendix D). However, even if IMP162 led to a decrease of the fluorescence on the 
gel, it was not appropriate to measure a TC50 value without confirming that these inhibitors do not 
inhibit protein synthesis or are not toxic to the cells after a few hours treatment. 
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The inhibitors shaded in green in Table 11 were more promising. The slope factor of the EC50 curve 
was closer to 1 and they inhibited NMT in cells dose-dependently (Appendix D). However, no plateau 
of metabolic activity was observed, suggesting that the inhibitors have an off-target effect in 
addition to NMT inhibition at the highest concentrations of inhibitor tested. Compound IMP329 was 
more interesting as it did not kill the cells even at 100 μM (Figure 47a and b). The translation was 
poor (>300) compared to IMP366 (translation~10). The TC50 value was determined and found to be 
4.9 μM ± 1 (Figure 47c and d). This value, determined with an YnC12 tagging experiment for 6 h, was 
lower than the EC50 value, suggesting that the compound might degrade over time. However, a 
similar experiment, as performed on compound IMP366 (Figure 45) was carried out to study the 
compound stability (Figure 48a). The compound appeared to be stable when incubated at 37°C for 
several days in the culture media. It is unclear why the TC50 is much lower than the EC50, but the 
same feature was observed for IMP366 and analogues (Section ?3.3.2). An AHA labelling experiment 
was carried out to check that the inhibitor did not inhibit protein synthesis (Figure 48b).  
 
Figure 46. Typical EC50 plot obtained with off-target inhibitors. The curve was obtained by measuring the 
metabolic activity of HeLa cells treated for 3 days with a concentration range of IMP162 (n= 3 biological 
replicates).  
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Table 11. Evaluation of HsNMT inhibitors. nd = not determined; n/a = not applicable. The IC50 was 
determined. When only an end-point assay was carried out, the residual activity is indicated at the 
concentration tested. The EC50 were determined and several features of the dose-dependent response 
are indicated. The translation was calculated by dividing the EC50 value by the average IC50 value. The 
“YnC12 tagging” column indicates if NMT inhibition in cells was assessed by YnC12 tagging (the gels can 
be seen in Appendix D or in Figure 47). IMP366 was added to the table for reference. 
 IC50 (nM)        
IMP NMT1  NMT2  
Selectivity 
NMT2/ 
NMT1 
EC50  
(µM) 
Slope 
factor 
EC50 
Residual % 
viability 
Transl
ation 
YnC12 
tagging 
366 17  ± 1 22  ± 3 1.3 221 ± 15 1.2 Plateau (19% at 10 µM) n/a 
TC50 = 
169 ±31 
µM 
164 >10  >10 n/a nd n/a n/a n/a nd 
253 73% at 5 µM 
78% at 
5 µM n/a nd n/a n/a n/a nd 
256 49% at 5 µM 
53% at 
5 µM n/a nd n/a n/a n/a nd 
261 87% at 5 µM 
86% at 
5 µM n/a nd n/a n/a n/a nd 
263 86% at 5 µM 
64% at 
5 µM n/a nd n/a n/a n/a nd 
266 76% at 5 µM 
80% at 
5 µM n/a nd n/a n/a n/a nd 
267 40% at 5 µM 
46% at 
5 µM n/a nd n/a n/a n/a nd 
162 68 ± 5 131 ± 20 1.9 8 ± 1.4 7.8 0% at 20 µM 53 Yes 
168 57  ± 20 91  ± 80 1.6 13  ± 2 4.7 4% at 100 µM 178 nd 
320 111 ± 8 162 ±13 1.5 31±13 1.2 0% at 20 µM 228 Yes 
918 82 ± 9 153 ±31 1.8 35±6 1.6 0% at 20 µM 299 Yes 
329  57 ± 6  86 ± 9  1.5 23.9 ±5 1.2 8.3% at 100 µM 336 Yes 
ETIII032 141 ± 16 183 ± 18 1.3 >100  1 
41% at 100 
µM n/a Yes 
BK14 31 ± 2  48 ± 3  1.5 22.9 ± 4.5 1 0% at 200 µM 587 nd 
BK16 91 ± 13  118 ± 18  1.3 >100  3.4 8% at 200 µM N/A nd 
BK17 73 ± 4  83 ± 4  1.1 33.5 ± 3.4 1.4 0% at 200 µM 429 nd 
BK19 2367 ± 653  
6891 ± 
7141  2.9 n/a n/a n/a n/a nd 
BK20 196 ± 17  276 ± 34  1.4 n/a n/a n/a n/a nd 
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Several analogues of this compound were produced by in collaboration with Boon Lee (BSc student, 
Tate group, Imperial College London ) (Table 11, compounds coloured in grey). Compound BK14 had 
similar enzyme affinity and cell toxicity than IMP329. All the other compounds tested had a lower 
enzyme affinity. Compound IMP329 was thus found to be the best HsNMT inhibitor tested. 
 
 
 
Figure 47. Evaluation of compound IMP329 in HeLa cells. A MTS assay was carried out starting from 
a) 100 μM or b) 200 μM (3-fold dilutions, n= 3 biological replicates, 72 h). c) YnC12 tagging experiment: 1 h 
pre-feeding with IMP329, followed by 6 h labelling with YnC12 in the presence of the inhibitor. d) TC50 plotted 
in GraFit. 
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3.4.2? Selective compound 
As in Section ?3.4.1, several inhibitors discovered during the medicinal chemistry project were tested. 
Compounds presented in Table 12 had > 2 fold selectivity for HsNMT1 over HsNMT2. The best 
compound could be used as a tool to study HsNMT1/HsNMT2 substrate selectivity in cells. 
Most of the compounds tested had a moderate affinity for the enzyme, and seem to have a 
substantial off-target effect in cells as observed with the high slope factors (>2) of the EC50 curves. 
One of the first compound tested, IMP475 (Table 12), was further examined. This inhibitor had been 
prepared by Dr. Tayo Olaleye (Tate group, Imperial College London), and has a relatively high affinity 
for the enzyme. However, when tested in cells, this compound did not inhibit NMT and was not toxic 
to the cells up to 100 μM. The compound is a peptidomimetic inhibitor and has two primary amines 
(Scheme 10). These amines would be charged in aqueous solution, and the hydrophilic compound is 
unlikely to penetrate the lipid cell membrane. 
 
Figure 48. Further evaluation of IMP329 as an HsNMT inhibitor. a) Stability of IMP329 incubated at 37°C in 
the culture media. Inhibitor dilutions were incubated for 0 day (No preincubation) or 3 days (preincubation) in 
the warm culture media (37°C) and added to HeLa cells to carry out a 3-day MTS assay. The figure shows the 
remaining metabolic activity versus the concentration of inhibitor. b) AHA labelling experiment carried out for 
24 h to check that the compound was not inhibiting protein synthesis. 
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Table 12. Enzyme affinity, cell cytotoxicity, tagging EC50s of several HsNMT1 selective inhibitors. Compounds 
difficult to dissolve at a concentration higher than 20 µM are indicated by #. They might have precipitated 
during the MTS assay and could result in a relatively low IC50. nd = not determined; N/A = not applicable. The 
IC50 and EC50 values were determined. Several features of the EC50 dose-dependent response are indicated. 
The translation was calculated by dividing the EC50 value by the average IC50 value. The “YnC12 tagging” 
column indicates if NMT inhibition in cells was assessed by YnC12 tagging (the gels can be seen in Appendix D). 
IMP366 was added to the table for reference. 
 IC50 (µM)       
 
IMP NMT1  NMT2  Selectivity NMT2/NMT1 
EC50  
(µM) 
Slope 
factor 
EC50 
Residual 
% viability Translation 
YnC12 
tagging 
366 17  ± 1 22  ± 3 1.3 221 ± 15 1.2 
Plateau 
(19% at 
10 µM) 
n/a 
TC50 = 
169 ±31 
µM 
475 52 ±5  149 ±24  2.9 >100 n/a n/a n/a Yes 
135 116 ±9  371 ± 35  3.2 nd n/a n/a n/a  nd 
476 701 ± 0.07 
1815 ± 
0.07 2.6 nd n/a n/a n/a  nd 
485 1517 ±28 
4351 ± 
410 2.9 nd n/a n/a n/a  nd 
489 697 ± 72 
1604 ± 
61 2.3 nd n/a n/a n/a  nd 
514 604 ± 47 
1480 ± 
76 2.5 nd n/a n/a n/a  nd 
166 496 ± 71 
1930± 
290 3.9 
25 ± 
1 4.4 0 21  nd 
621 87 ± 9 430 ± 69 4.9 
61 ± 
3 2.6 
21 at 50 
µM 238  Yes 
058 # 393 ± 67 
1764 ± 
622 4.5 
19 ± 
0.8 2.1 0 18  nd 
624 103 ±8 411 ± 68 4 
75 
±114 2.9 17 286  Yes 
625 125 ± 12 
692 ± 
83 5.5 
49 ± 
25 3 3 120  Yes 
626 74 ± 7 365 ± 56 4.9 
42 ± 
11 5.2 0 103  Yes 
623 25 ± 2 100 ± 7 4 56 ± 34 4.6 2 900 Yes 
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Scheme 10. Structure of IMP475. 
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It was envisioned that we could temporarily mask these charged amines by preparing a prodrug of 
this inhibitor.225 A prodrug is an analogue of a drug molecule that is enzymatically and/or chemically 
transformed in cells to release the active drug. Several strategies have been developed and are 
reviewed here.225 A prodrug based on a isobutanoyloxyethoxy carbamate protecting group appeared 
to be advantageous, since this group is cleaved in cells by esterases (Scheme 11). The reagent for the 
prodrug is prepared in two steps (Scheme 12), and this strategy has been successfully used to 
prepare a prodrug of gabapentin (Prodrug name Gabapentin enacarbil or XP13512), a drug used to 
treat restless leg syndrome and neuropathic pain).225 
 
 
The prodrug of IMP475 was prepared in four steps using standard solid phase peptide synthesis 
(Scheme 13).227 The prodrug reagent 57 was then coupled in one step to both primary amines of 
IMP475. Compound 62 was obtained in low yields. 
The prodrug 62 was then tested in HeLa cells. Unfortunately, compound 62 appeared to be toxic to 
HeLa cells. After 7 h treatment with 10 µM, cells started to have an abnormal shape and detached 
from the plate (Figure 49a). The toxicity at this concentration was confirmed by the MTS assay 
carried out for 3 days (Figure 49b). No plateau of residual activity could be observed and the slope 
factor was much higher than 1. The YnC12 tagging experiment showed a decrease in labelling when 
cells where treated with 5 and 10 µM of the prodrug 62 (Figure 49c). However, this decrease could 
be attributed to cell death and not NMT inhibition (Figure 49a). 
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Scheme 11. Mechanism of prodrug cleavage in cells by esterase enzymes. 
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Scheme 12. Synthesis of the prodrug reagent. i) Bu3N, 1-chloroethylchloroformate, Toluene. ii) isobutyric 
acid, KI, ZnO, Toluene. 226 
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Scheme 13. Synthesis of 61. i) a) Fmoc-Lys(Boc)-OH, DIPEA, DCM; b) Fmoc deprotection. ii) a) Fmoc-Ser(tBu)-
OH, DIPEA, HBTU; DMF b) Fmoc deprotection. iii) a) 9-(tert-butoxycarbonyl)aminodecanoic acid, DIPEA, HATU; 
DMF; b) 0.5% TFA, DCM. iv) a) 2-cyclohexylethanaminium acetate, HATU, DIPEA, DMF; b) 95% TFA, 2.5% TIS, 
2.5% H2O; v) 57, Tributylamine, dry THF. The synthesis route was adapted from Oaleye.
227. 
 
All these findings showed that the prodrug 62 appeared to be cell permeable, in contrast to IMP475. 
However, there is no strong evidence that the compound is inhibiting NMT in cells. The results in 
Figure 49 suggest that this compound has off-target effects, leading to rapid cell death at 
approximately 10 µM. 
It is also possible that the by-product of prodrug cleavage might be toxic in cells. However, this 
would be unexpected as this prodrug functionality is currently used for an FDA-approved drug 
(Gabapentin enacarbil).225 
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 Figure 49. 62 inhibition in HeLa cells. M = Myr. a) Pictures of HeLa treated with YnC12 and cells treated with 
inhibitor 62. b) MTS assay after 72 h in HeLa treated with 62. c) YnC12 tagging experiment with cells treated 
with IMP366 or 62.   
3.4.3? Promising inhibitors with no off-target effect 
In the last few months of this PhD project, four novel inhibitors were tested and were found to be 
promising (Table 13). The CPM and MTS assay results as well as the YnC12 tagging results are 
displayed in Appendix E. Compound IMP122/180/898 had a low affinity for the enzyme, relatively 
low EC50, and all showed a plateau of residual metabolic activity between 20-40%. The TC50 values 
were evaluated and were lower than the EC50 values, as observed before for other on-target 
inhibitors. 
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Table 13. Enzyme affinity, cell cytotoxicity, TC50s for inhibitors IMP122, IMP180, IMP898 and IMP917. 
IMP366 was added for reference. 
 
IC50 (µM)       
 
IMP NMT1 NMT2 EC50  (µM) 
Slope 
factor 
EC50 
Plateau-
Residual 
activity 
(%) 
Transl
ation 
TC50 
(µM) Comments  
366 17  ± 1 22  ± 3 221 ± 15 1.2 
19% at 
10 µM 11 
TC50 = 
169 ±31 
µM  
122 0.034 ±0.003 
0.040 
±0.002 
3.3 ± 
0.6 1.3 
27% at 
33 µM 89 1.01 
No remaining activity 
at 100 µM 
180 0.038 ±0.009 
0.098 
±0.011 
5.8 ± 
0.3 1.5 
35% at 
100 µM 85 1.97  
898 0.030 ±0.006 
0.064 
±0.007 
9.8 ± 
1.7 1.2 
21% at 
100 µM 209 1.44  
917 0.017± 0.001 
0.016 
±0.001 
0.78 
±0.03 2.1 
34% at 
11 µM 47 0.62 
No remaining activity 
at 100 µM 
 
Interestingly, IMP917 had a binding affinity to both HsNMT isoforms comparable to the best 
inhibitor tested so far, IMP366, in the low nM range. While the translation (47) is not as good as for 
IMP366 (~10), this compound has the best translation of all the in-house inhibitors tested, leading to 
an EC50 value lower than 1 µM). The TC50 value was is good correlation with the EC50. There was a 
plateau of residual activity, demonstrating that the compound did not have any off-target effect up 
to 10 µM. However, the slope factor of the EC50 curve is slightly high and further investigations 
would be required to understand why the slope factor is greater than 1. 
It would be interesting to further validate this compound as a tool to study NMT inhibition in cancer 
cells. This compound could also be used as a starting point to prepare more potent HsNMT 
inhibitors.
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3.5 Conclusions 
This chapter described the search for an HsNMT1/2 inhibitor which could be used as a tool to study 
NMT inhibition in cancer cells. Two previously reported HsNMT inhibitors were evaluated and found 
to be poor HsNMT inhibitors. HMA was poorly soluble while Tris DBA was shown to be a 
non-competitive inhibitor of NMT. In cell experiments demonstrated Tris DBA was toxic to cells but 
the toxicity was most likely not related to inhibition of HsNMT. 
A recently reported TbNMT inhibitor, referred to here as IMP366, was characterised. It was shown 
to be a potent inhibitor of both HsNMT isoforms. For the first time, specific NMT inhibition in cells 
was shown to lead to cell toxicity. Enzyme inhibition in cells was evaluated using a YnC12 tagging 
experiment and cytotoxicity was measured using the MTS assay after 3 days. Interestingly, cells were 
not all dead when treated at a concentration sufficient to inhibit >90% NMT in cells. Instead, a 
plateau of residual metabolic activity at 20-30% was observed. There could be several reasons for 
this phenomenon. First, the cells could stop dividing after a few hours or days. The second possible 
explanation is that only a population of the cells could be killed in the presence of the NMT inhibitor. 
These hypotheses will be addressed in Chapter 5.  
Interestingly, there was a good correlation between IC50s, EC50s and NMT inhibition from analogues 
of IMP366. This observation confirms that these compounds have no or little side-effect in cells. The 
translation of these compounds into HeLa cells was average (~10). However, it is important to note 
that when an excessive concentration of inhibitor IMP366 was used in cells (100 µM), the compound 
was toxic and cells were all dead after 3 days. This was attributed to off-target (non-mechanism 
based) effects. 
This compound allowed us to define the criteria for a good HsNMT inhibitor: 
 High enzyme affinity (< 200 nM). 
 Good translation giving a relatively low EC50 (< 20 µM). The slope of the EC50 curve should be 
close to 1 and if the compound does not have any off-target effect a plateau of residual 
metabolic activity should be observed, as shown in Figure 38.  
 Dose-dependent inhibition of NMT in cells. The TC50 value, the concentration of inhibitor 
required to inhibit half the myristoylation in cells, should correlate with the EC50 value. This 
underlines the importance of probes to validate a novel drug target or inhibitor. Without the 
YnC12 probe, it would be difficult to rapidly evaluate the on-target effect of an inhibitor. This 
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could only then be done by looking at the down-regulation of pathways where NMT targets are 
involved, which is also difficult given the many pathways affected. 
 Good correlation between IC50, EC50 and NMT inhibition from inhibitors in the same series. Poor 
inhibitors of HsNMT in vitro should not be toxic to the cells if they do not inhibit NMT in cells. 
A next logical step would be to carry out studies in mouse models of cancer, to determine whether 
these compounds could inhibit tumour growth in vivo. However, the focus in this thesis is on fully 
characterising the effect of NMT inhibition in cells, and this will be discussed further in Chapter 5. 
Several compounds issued from an in-house medicinal chemistry project were tested. The majority 
of the compounds showed significant off-target effects in cells. These off-target effects were mostly 
observed using the MTS cytotoxicity assay. The slope factors of the EC50 curves were generally very 
high and there was not a plateau of metabolic activity as expected for an inhibitor acting on-target. 
YnC12 experiments were carried out for key compounds. In some cases labelling was decreased, 
indicating that NMT was inhibited. However, in most cases, the loss of labelling did not correlate 
with cell toxicity and the TC50 values could not be measured accurately for these compounds. The 
loss of labelling might be caused by significant cell death at the highest concentration of these 
inhibitors. Inhibitor IMP329 emerged as one of the most promising inhibitor tested. The slope factor 
of the EC50 was close to 1 and there was a good correlation between the TC50 value and the EC50. 
Unfortunately, no plateau of metabolic activity was observed, potentially because off-target effects 
cause a phenotype before NMT is completely inhibited. This compound is currently used in the Tate 
group as an additional NMT inhibitor to study the phenotype of NMT inhibition in cells. 
In the last few months of this PhD, four inhibitors were tested and found to be good HsNMT 
inhibitors with no or little off-target effects. They had all the key characteristics of a good HsNMT 
inhibitor as describe above. The only issue is the translation which is still relatively high, however 
these compounds could be further optimised to improve their translation.  
Selectivity of the inhibitors for HsNMT1 or HsNMT2 was also considered as an interesting feature. 
One inhibitor was investigated but unfortunately showed an important off-target effect and could 
not be used as a tool to study HsNMT1/HsNMT2 selectivity in cells.  Several inhibitors were tested 
towards the end of this PhD work, such as IMP621, and could be promising. Some of these inhibitors 
are currently under further investigation within the Tate group.  
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Chapter 4 Detection of co-translational NMT 
substrates by mass spectrometry-based proteomics 
 
Target validation is a fundamental step in the target-based drug discovery pipeline. Failure to 
identify effective targets has been suggested to be the main cause for failure in drug discovery 
campaigns.1 The functional role of the molecular target must be clearly defined in the disease of 
interest, and to evaluate the potential of NMT as an anti-cancer drug target, chemical proteomic 
profiling of N-myristoylation is an important fundamental component. 
Previous work in the Tate group showed that myristate analogue YnC12 can be used in combination 
with the trifunctional capture reagent AzTB to detect known and putative NMT substrates in HeLa 
cells (Section  2.3).163 However, the number of known and putative substrates identified was low 
(<20) and some known substrates, such as the proto-oncogene tyrosine kinase c-SRC, were not 
detected. These results suggested that more NMT substrates could be identified by optimising the 
proteomics experiments. 
Several proteomics methods were employed in the current study to discover the myristoylated 
proteome in HeLa cells. Results were correlated with prediction of protein N-myristoylation obtained 
using two bioinformatic tools, MYR predictor 78 and Myristoylator.82 
First, non quantitative proteomics experiments and label-free quantification experiments 
(Section  1.11) were carried out. However, these experiments had significant limitations in the 
confident identification of N-myristoylated proteins.  
Secondly, double SILAC and spike-in SILAC (Section 1.11) quantitative proteomics experiments were 
employed in combination with the highly specific HsNMT inhibitor (IMP366) characterised in 
Chapter 3.  
The current Chapter also comments on the reliability of the YnC12 probe as a tool to identify NMT 
substrates in cells by chemical proteomics. YnC12 was shown to label NMT substrates (Section  2.3) 
but also labels other proteins such as palmitoylated proteins, in agreement with previous reports 
(Section  1.10.3).173 
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4.1 Previously reported NMT substrates and predictions of N-myristoylation 
4.1.1 Previously reported co-translationally N-myristoylated proteins 
As discussed in Section  1.5.1, many proteins have been reported to be N-myristoylated based on 
experiment evidence in the literature (see below). A non-exhaustive list of previously reported NMT 
substrates can be found in Appendix F. This list reports only NMT substrates expressed in HeLa cells, 
using the analysis of the HeLa cell proteome and transcriptome reported by Nagaraj et al. as a 
reference.207  
Various methods are typically employed to show that proteins are N-myristoylated in eukaryotes, as 
introduced in Section  1.10.1. They are here classified in three main categories. 
 Native. The method is referred to as “native” where an endogenous protein was shown to be 
N-myristoylated. Only six NMT substrates have been identified at a native level, typically by 
combining radiolabelling with [3H]myristate and immunoprecipitation (Annexin XIII,228 
MARCKS,105 c-SRC 204). Alternatively, the protein of interest has been purified from eukaryotic 
cells or tissue, digested and analysed by mass spectrometry (BASP1,161 Golgi-associated plant 
pathogenesis-related protein 1 (GLIPR2),229 and cAMP dependent protein kinase alpha subunit 
(PRKACA) 209).  
 Non native. The method is referred to as “non native” where the protein of interest was 
overexpressed in eukaryotic cells and N-myristoylated using endogenous NMT. In most cases, 
proteins were overexpressed, labelled with [3H]myristate and immunoprecipitated. 41 proteins 
have been previously identified as NMT substrates at a non native protein level. 
 Cell free. The method is referred to as “cell free” where the protein of interest and NMT were 
expressed in a cell free system (for example AIFM2 230 and protein Lunapark 230) or in E. coli (for 
example Tescalin/CHP3) 231. 21 proteins have been identified as NMT substrates using a cell free 
method. 
It is important to note that the level of confidence is different for these three categories. Proteins 
identified as NMT substrate at a native level can be considered as high confidence substrates (and 
will be referred to as “known”), whilst proteins falling into the non native and cell free categories 
can be considered as medium and low confidence substrates respectively. Sometimes a protein has 
been shown to be N-myristoylated using several different methods. In these cases, only the method 
with the highest confidence is considered (native > non native > cell free). 68 proteins were 
experimentally shown to be N-myristoylated using the three methods described above and will be 
referred to as “previously reported” or “experimentally shown” in this Chapter. 
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The table shown in Appendix F also indicates whether the proteins were identified by 
non-quantitative chemical proteomics experiments in Jurkat T-cells in two recent studies.173,224 These 
studies both used a metabolic tagging approach to label putative NMT substrates, but Wilson et al. 
used YnC12173 while Liu et al. used AzC12.224 Following capture and enrichment, tagged proteins 
were identified by mass spectrometry-based proteomics. Only proteins with an N-terminal MG 
motif, as required for NMT substrates (Section  1.4.2), will be discussed for these two studies. Wilson 
et al. 173 identified 23 putative NMT substrates, 21 of which were also expressed in HeLa cells. The 
two proteins not expressed in HeLa cells are HMGB1P1 and LCK. LCK has been shown to be 
N-myristoylated at a non native protein level.232 Liu et al. reported 13 putative NMT substrates. The 
list appears to be small but unfortunately the authors only reported proteins which had been 
annotated as N-myristoylated (known, “probable” or “by similarity”) in the Uniprot/KB database. 10 
proteins were found in both studies and in total 27 proteins bearing an N-terminal MG motif were 
labelled and enriched with myristic acid analogues in Jurkat T-cells. 16 of these 27 proteins have not 
been validated by any other experiments. These 16 proteins were considered as putative NMT 
substrates as there is no strong evidence that they are N-myristoylated. They have been added to 
Appendix F for comparison. 
As analogues of myristic acid are suspected also to label palmitoylated proteins, palmitoylation of 
proteins identified by chemical proteomics in the current study was also evaluated. The complete 
set of palmitoylated proteins in eukaryotes has yet to be identified. In the present study, proteins 
were considered to be palmitoylated when they were annotated in the UniProtKB/Swiss-Prot 
database or experimentally shown to be palmitoylated by mass spectrometry-based chemical 
proteomics.173 However, when a protein is palmitoylated, it does not imply that the protein is not 
N-myristoylated. Indeed, some NMT substrates, such as the tyrosine protein kinase FYN or GNAI1, 
are known to be dually-lipidated, carrying N-terminal N-myristoylation and S-palmitoyl cysteine.  
4.1.2 Prediction of N-myristoylation 
Two bioinformatic tools were used to predict protein N-myristoylation, MYR predictor (MP) 78 and 
Myristoylator (Myrist).82 However, these tools may not be completely reliable and may generate 
false positives or false negatives. These bioinformatics tools (which are based on neural network 
approaches) were trained on proteins annotated as N-myristoylated in public databases, and thus 
are based largely on non-native determinations of protein myristoylation, and on substrate proteins 
in non-mammalian systems (e.g. yeast). Furthermore, there are very few potential substrate 
proteins carrying an N-terminal MG motif experimentally proven to be non-myristoylated (out of the 
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ca. 3000 proteins with a MG motif in the human genome), presenting a very small negative control 
learning set for bioinformatic analysis. 
The N-terminal sequences of proteins listed in Appendix F (excluding proteins only identified by 
chemical proteomics) were analysed by these predictors (Figure 50). As suspected, some previously 
reported NMT substrates were not correctly annotated by the predictors. 22% and 9% of these 
proteins are not correctly predicted as NMT substrates by the MYR predictor and Myristoylator 
respectively and the predictors disagree on more than 35% of predictions. These results 
demonstrate that precautions need to be taken when using these predictors as they may not always 
be accurate. 
Another bioinformatic tool was tested to predict protein N-myristoylation: the TermiNator.83,84 This 
tool can provide a prediction for N-terminal methionine cleavage of a protein and various N-terminal 
 
Figure 50. N-myristoylation prediction for the 68 proteins reported to be N-myristoylated (Appendix F). 
Predictions a) by Myr predictor (MP) or b) by Myristoylator (Myrist) are shown for proteins identified at native 
or non native levels or in a cell-free system. 15 and 6 proteins could not be correctly predicted as NMT 
substrates by the MYR predictor and Myristoylator respectively. c) The predictions made by Myristoylator were 
compared to the predictions made by MYR predictor. 40 proteins predicted as reliable by MYR predictor were 
also predicted with the highest confidence by Myristoylator. 3 proteins were predicted not to be N-
myristoylated by both predictors. The predictors disagree on more than 25 predictions. Low and medium 
predictions made by Myristoylator were considered to be equivalent to twilight prediction by MYR predictor. 
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post-translational modifications including N-myristoylation. A prediction was made using the 
N-terminal sequence of c-SRC and the probability that the N-terminal methionine is retained was 
found to be 89%. This prediction suggests that the N-terminal methionine of c-SRC is not cleaved and 
is in contradiction with strong evidence showing that c-SRC is N-myristoylated. For other previously 
reported N-myristoylated proteins such as BASP1 and MARCKS, the prediction did not give any 
results. This prediction tool was therefore not used as a prediction tool in this study. 
4.1.3 Post-translational N-myristoylation 
Only a few proteins have been reported to be post-translationally N-myristoylated (Sections  1.5.2 
and  2.4). The focus of this Chapter is not on post-translationally myristoylated proteins; however, it 
proved useful to have a list of these proteins, to determine whether they were enriched in the 
proteomics experiments described in this Chapter. The list can be found in Appendix G and shows 
the nine post-translationally modified proteins known in eukaryotes.  
4.2 First experiment: YnC12/DMSO 
The low number of proteins identified as putative NMT substrates in previous studies (Section  4.1.1) 
suggests that in-depth coverage is lacking. A similar number of proteins were identified by 
Dr. Megan Wright in HeLa cells (17 previously reported and putative substrates),163 while 68 proteins 
expressed in this cell line have been experimentally shown to be N-myristoylated (at a native/non 
native level or in a cell free system, see Section  4.1.1). Several explanations could explain this low 
coverage. 
 Only a small amount of a given protein might be labelled with myristic acid analogues such as 
YnC12 and this level might be below the detection limit and therefore not be detected by mass 
spectrometry-based proteomics. N-myristoylation is a co-translational process and a few hours 
(4,224 6 163 or 8 h 173) might not be sufficient to label proteins with low turnover in cells. Low 
abundance proteins might also be poorly labelled and not identified with high confidence by 
proteomics. To overcome this problem, the labelling time could be increased to 24 h. As shown 
in Section  2.3.2, changing the YnC12 labelling time from 6 to 24 h dramatically improved the 
fluorescence labelling and the enrichment of known and putative NMT substrates. 
 The scale of experiments might have been too small. This problem is related to the previous 
problem. Low abundance proteins could be lost during the analysis by LC-MS/MS and increasing 
the scale of the experiment might improve the coverage.  
 Fractionation of the sample might be required to improve protein coverage. 
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 There might have been some issues associated with the sample preparation, such as on-bead 
digest with trypsin, or with the LC-MS/MS LC separation, such as the LC gradient or the 
sensitivity of the mass detector.  
These problems needed to be addressed to improve the quality and quantity of substrates 
identified. 
4.2.1 Experimental design 
An experiment was carried out to improve the coverage and number of identifications by increasing 
the labelling time to 24 h and increasing the scale of the experiment compared to previous 
experiment carried out in the Tate group (<1 mg lysate), starting from 3 mg of lysate for 
capture/enrichment/digest/LC-MS/MS analysis. HeLa cells were treated with YnC12 (20 µM, as 
optimised in Section  2.3.2) or with DMSO as a control. Only a single sample was prepared in the first 
instance, as such a large scale (3 mg of lysate) might not be required. While HeLa cells are easy to 
culture and milligrams of protein lysate can easily be prepared, reagents used for the sample 
processing are relatively expensive (capture reagent, trypsin, beads for the enrichment).  
While most previous proteomics experiments in the Tate group had been carried out with AzTB, a 
new reagent, prepared by Dr. Goska Broncel (Tate group) became available during the work 
described here. This reagent, referred to here as AzKTB 63 (Scheme 14) was similar to AzTB (Figure 
17), as it was also composed of an azido capture group, a TAMRA fluorophore and a biotin moiety. 
However, AzKTB had the additional feature of a trypsin cleavage site, which should allow the 
modified peptide to be released upon on-bead digest of the proteins with trypsin. Moreover, the 
modified peptide 64 comprises a charged lysine residue which is critical for MS ionisation. 
Preliminary experiments carried out by Dr. Goska Broncel showed that AzKTB performed very 
similarly to AzTB in experiments carried out with HeLa cell lysates labelled with YnC12. AzKTB gave a 
similar labelling profile by in-gel fluorescence and could also detect N-myristoylated proteins by 
mass spectrometry-based proteomics (data not shown). 
Due to the increased hydrophilicity of AzKTB compared to AzTB, protein precipitation following 
CuAAC ligation could not be carried out as usual, and the protocol was slightly modified by Dr. Goska 
Broncel (Section  8.3.4.2). The reagent has a tendency to stick to proteins and several careful washes 
of the protein pellet with methanol were required to ensure that no capture reagent remained with 
the protein. Any excess of AzKTB left would impair the pull-down as the reagent could bind to the 
streptavidin beads and prevent AzKTB-captured proteins from being pulled down. 
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A small scale capture/enrichment experiment was carried out to assess the new protocol and to test 
if a higher concentration of proteins could be used for the CuAAC reaction with AzKTB, as this would 
save some reagent, whose concentration would be kept constant (Figure 51a). A similar labelling 
profile was obtained by fluorescence when the proteins were captured with AzKTB at a protein 
lysate concentration of 1 or 2 mg/mL. This result confirms that the capture reagents (AzKTB, CuSO4, 
TCEP and TBTA) can be used in large excess in the standard protocol and that the capture reaction 
could be carried out at 2 mg/mL for the large scale proteomics experiment to prevent wasting too 
much capture reagent. 
For the proteomics experiment, Streptavidin-coated magnetic bead were switched for Neutravidin 
agarose beads as previous experiments carried out in the Tate group had shown that Neutravidin 
agarose beads were more stable during sample processing for proteomic analysis.163 The samples 
were processed using the protocol described in Section  8.3. After enrichment, gel-based analysis was 
carried out to check that the majority of the labelled proteins had been pulled-down onto the 
Neutravidin agarose beads (Figure 51b). Very little fluorescence was observed in the supernatant 
from the pull down, indicating that most labelled proteins were bound to the beads.  
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Scheme 14. Structure of AzKTB and of the modified peptide captured with AzKTB and digested with trypsin. 
X represents any amino acid except R and K. 
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The PNACL facility at the University of Leicester provided sample analysis (on-bead digest, LC-MS/MS 
and database searching).The totality of the sample (enrichment from 3 mg of lysate) was run on a 
LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific). It is difficult to evaluate the amount of 
protein digest injected. If 1% of the proteome is N-myristoylated but not all the NMT substrates are 
completely labelled with YnC12, the amount injected is estimated to be below 30 μg. Peptide 
identifications were assigned by Mascot and protein hits were provided as a Scaffold file 
(Appendix A). An example of sequence coverage and two assigned spectra (MS/MS) for the protein 
MARCKS are presented in Appendix H. More than 350 proteins with a confidence higher than 95% 
were identified in the YnC12 sample. Many of these proteins did not have an N-terminal glycine, as 
required for N-myristoylation. To reduce the number of false-negatives and false-positives, a first 
selection was made by keeping only proteins identified with the highest probability (>99.9%). Using 
these settings, 281 proteins were identified in total in the two samples (YnC12 and DMSO), 70 of 
which were common to both samples (Figure 52a and b). Proteins found in both DMSO and YnC12 
samples are probably the result of non-specific binding to the Neutravidin agarose beads. Consistent 
with this, some of these proteins are abundant proteins such as actin and tubulin. Other proteins are 
endogenously biotinylated (pyruvate carboxylase, methylcrotonoyl-CoA carboxylase subunit alpha, 
 
Figure 51. Capture and enrichment of YnC12-tagged proteins with AzKTB. BPB = Before pull down; PD = pull 
down, S = supernatant. a) 100 μg of lysate (HeLa treated with YnC12 for 24 h) were captured with AzKTB at a 
concentration of 1 or 2 mg/mL. Proteins were pulled-down onto streptavidin-coated magnetic beads. b) In-gel 
fluorescence of the DMSO and YnC12 samples processed for proteomics. The enrichment was carried out using 
Neutravidin agarose beads. A small amount of sample (ca. 10 μg of protein) was kept at each stage of the 
processing and analysed by in-gel fluorescence to ensure the pull down was efficient.  
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acetyl-CoA carboxylase 1) and are therefore likely to be pulled down onto the beads. 8 proteins were 
only identified in the DMSO control and mostly corresponded to keratin proteins, contaminants 
introduced by the operator during the sample preparation. 
92 proteins possessed an N-terminal MG motif, which is required for transfer of myristate to a 
protein by NMT (Figure 52c). 88 proteins were identified exclusively in the YnC12 sample and 
correspond to putative NMT substrates. The N-terminal sequences of these proteins were analysed 
with the two predictors described in Section ?4.1.2. To simplify the analysis, the results from the two 
predictors were combined (Section ?8.3.9). 64 of these substrates were predicted to be 
N-myristoylated with low, medium or high confidence, while 24 substrates were not predicted to be 
N-myristoylated (Figure 52d). However, as discussed in Section ?4.1.2., bioinformatics predictors are 
 
Figure 52. Non quantitative proteomics experiment (only 1 replicate). a) Only a few proteins were detected 
solely in the DMSO-treated sample; these are likely to be proteins that bound non-specifically to the beads. In 
the YnC12 treated sample, proteins detected correspond to YnC12 labelled proteins as well as proteins non-
specifically bound to the beads. b) 281 proteins were identified with a protein identification probability higher 
than 99.9% and 70 proteins were found in both samples. c) 92 proteins with an N-terminal MG motif, as 
required for N-myristoylation, were identified and 88 were exclusively found in the YnC12 sample. d) 203 
enriched proteins were identified only in the YnC12 sample. 88 of these proteins had an N-terminal MG motif. 
A prediction of N-myristoylation was performed by combining the result of the two online bioinformatic tools 
(Section ?8.3.9). Some proteins with no N-terminal MG motif are known to be palmitoylated or incorporate a 
GPI anchor. e) 88 proteins had an N-terminal MG motif and some had been experimentally shown to be 
N-myristoylated. They are classified according to the definitions described in Section 4.1.1. 
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not always reliable, and some of the 24 proteins not predicted might be N-myristoylated. Only one 
third of these 88 putative NMT substrates had been experimentally shown to be N-myristoylated 
(Figure 52e), implying that many NMT substrates remained to be identified. However, with the data 
provided by this proteomics experiment, it is difficult to identify substrates with high confidence; 
indeed, many of the proteins only identified in the YnC12 sample did not possess an N-terminal 
glycine. This suggests that some of the proteins with an N-terminal MG motif might also be the 
result of non-specific binding to the beads. Some of the proteins with no N-terminal MG motif are S-
palmitoylated and they could also be labelled with YnC12, by attachment of this analogue in place of 
palmitate (Sections  1.10.3 and  4.1.1 ). One solution to decrease the number of hits could be to 
exclude all the S-palmitoylated proteins from the list of identified proteins. However, dual-lipidated 
proteins such as FYN would be lost. Additionally, some of the proteins with no N-terminal MG motif 
are glycosylphosphatidylinositol (GPI)-anchored proteins, which incorporate palmitic acid 
(Section  1.10.3). It is probable that YnC12 also labels GPI-anchored proteins in humans, in the same 
way that YnC12 can replace palmitate in S-palmitoylation. For the following proteomics experiments 
proteins hits were screened for a predicted or known GPI-anchor.  
If YnC12 labels GPI-anchors and S-palmitoylated proteins, it would be via an ester or a thioester 
linkage respectively (Figure 19). As both functions are base-labile, it should be possible to remove 
YnC12 tagging of palmitoylated and GPI-anchored proteins by carrying out base-treatment after the 
CuAAC reaction. This possibility is discussed in Section  4.7.1. YnC12 could also be metabolised and 
incorporated into NMT non-substrate proteins. It is also possible that YnC12 might label a subset of 
proteins via other linkages. Indeed, N-myristate has recently been shown to be incorporated at 
lysine side-chains.233  
Although the experiment with AzKTB described above had some limitations, it represented a 
considerable improvement compared to previous experiments carried out in the Tate group with 
YnC12 treated cells. The number of putative substrates was greatly improved (from 17 to 88), and 
previously reported NMT substrates (Appendix F), which were not previously detected, such as 
c-SRC, were identified. The number of unique peptides, spectral counts (referred to in Scaffold as the 
number of assigned spectra) and percentages of sequence coverage were high (Appendix A and 
Appendix H). These numbers are important features as they reflect the confidence of the 
identification. The spectral count is the number of spectra assigned to a given protein and the 
sequence coverage corresponds to the percentage of all amino acid residues in a protein sequence 
detected in the sample. A protein with a high number of unique peptides and thus high sequence 
coverage will be identified with high confidence. The number of spectral counts reflects the 
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enrichment of a protein in a sample. Three proteins (ARF1, the proteasome subunit 26S protease 
regulatory subunit 4 (PSMC1) and Niban-like protein-1) were detected in the YnC12 sample with 
more than 100 spectral counts, suggesting that they were highly enriched. Interestingly, Niban-like 
protein-1 is not known to be myristoylated; further validation would be required to confirm that it is 
an NMT substrate. A traditional method to validate novel NMT substrates involves labelling cells 
with [3H]myristate or YnC12 followed by immunoprecipitation of the protein of interest 
(Section  1.10.1). However, it would be highly time-consuming, expensive and experimentally 
challenging to validate 53 putative NMT substrates by this approach (Figure 52).  
4.2.2 Modified peptides 
In the experiment presented in Section  4.1.1, proteins were captured with AzKTB, a reagent which 
allows the identification of proteins enriched with YnC12, but should also enable identification of the 
site of modification. N-terminal peptides of proteins which are N-myristoylated with YnC12 and 
captured with AzKTB will have a stable modification after trypsin digest (Scheme 14). The mass of 
this adduct was set as a stable modification of glycine and lysine residues for recognition by peptide 
identification software. The list of modified peptides can be found in Appendix H. An N-terminal 
modified peptide was identified for 25 proteins, identifying with high confidence these proteins as 
N-myristoylated. The raw data file was re-analysed with the search engine MaxQuant 185 (the 
previous analysis was carried out with Mascot). 34 modified peptides were identified with 
MaxQuant and 21 hits were common to both analyses, leading to a total of 38 modified peptides 
across the two analyses. Some of the proteins corresponding to these modified peptides were not 
identified in the original experiment; an example is ARF3. Only a few peptides are unique to ARF3 as 
the protein sequences of ARF1 and ARF3 are highly similar. Peptides shared by ARF1 and ARF3 had 
been assigned to ARF1 in the previous analysis.  
Interestingly, for three proteins enriched in the YnC12 sample, a unique peptide corresponding to 
the protein N-terminal sequence was detected, but no modification was detected. This suggests that 
these N-terminal peptides have not been labelled with YnC12 and these proteins are most likely not 
NMT substrates. These proteins, which might be palmitoylated, are: trafficking protein particle 
complex 3 (TRAPPC3), surfeit locus protein 4 (SURF4) and choline transporter-like protein 2 
(SLC44A2). 
17 proteins for which the modified peptide was identified had previously been reported to be 
N-myristoylated. It is important to note that the experiment presented here, with the identification 
of the site of modification at a native protein level allows the identification of NMT substrates with 
higher confidence that proteins previously identified at a non native level or in a cell free system 
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(Section  4.1.1 and Appendix F). This novel AzKTB reagent also allowed the high confidence 
identification of 22 new NMT substrates (Appendix H). However, even if this reagent is a powerful 
tool, it will not enable a comprehensive identification of all the NMT substrates in HeLa cells as it has 
two main limitations: 
 The N-terminal sequence requires at least 5 amino acids before the first arginine or lysine 
(trypsin cleavage site) to allow the identification with high confidence of the peptide and then 
the protein (it is difficult for example to identify one protein with a peptide composed of only a 
one or two amino acids as many proteins will share this peptide). Many known and putative 
NMT substrates, such as c-SRC (N-terminal sequence: GSNK) do not have 5 amino acids before 
the first cleavage site. 
 The N-terminal sequence has to be unique to a protein for that protein to be identified with high 
confidence. This is not always the case as for the protein Guanine nucleotide-binding protein G(i) 
subunit alpha-1 (GNAI1) and Guanine nucleotide-binding protein G(k) subunit alpha (GNAI3). The 
N-terminal sequences are the same, even after a potential missed cleavage site 
(GCTLSAEDKAAVER). 
4.2.3 Conclusions 
The experiment described in Sections  4.2.1 and  4.2.2 showed much promise for the identification of 
the myristoylated proteome in HeLa cells. Labelling the cells for 24 h and the large scale of the 
experiment allowed the protein coverage to be considerably enhanced. Some of the identified 
proteins are known/putative NMT substrates and for others the modified peptide was detected. 
However, more experiments are required to validate the other protein hits. However, some of the 
88 putative NMT substrates might be false positives. Therefore a label-free quantification 
experiment was carried out in order to help distinguish between NMT substrates and non-
specifically bound proteins (Section  4.4).  
A gel-based proteomic experiment was also carried out to map the NMT substrates onto an SDS-
PAGE gel (Section  4.3). Some proteins have an apparent molecular weight on-gel that is different 
from their molecular weight but it is valuable to know the apparent band size for the purposes of 
Western blot analysis. This experiment would also assess if fractionation could improve the coverage 
and thereby allow the scale of the experiment to be decreased. 
4.3 Gel-based proteomics 
For this experiment, AzTB was used as the capture reagent. YnC12 treated HeLa lysates (500 µg) 
were captured, enriched on Neutravidin agarose beads, and beads were washed according to the 
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standard protocol (Section ?8.3). Beads were boiled in the sample loading buffer and proteins were 
loaded on a SDS-PAGE gel. After the run, the gel was imaged by fluorescence and then cut into 7 
portions (Figure 53). Precautions were taken to prevent keratin contamination in the samples 
(pre-cast gel, clean container to run the gel, freshly opened buffer and reagents, clean scalpel to cut 
the gel slices, etc.).  
The PNACL facility at the University of Leicester provided sample analysis (in-gel digest, LC-MS/MS 
and database searching). Only proteins with an N-terminal MG motif and with a protein 
identification probability higher than 95.0% were kept and are shown Appendix H. The Scaffold file 
can be found in Appendix A and a summary is shown in Figure 53. 
The number of putative NMT substrates (N-terminal MG motif and enriched with YnC12) was lower 
than for the previous experiment. Most of the high molecular weight proteins (A-kinase anchor 
proteins, Formin-like protein 1/2, etc.) were missing, possibly due to protein aggregation or poor gel 
penetration.  
As expected some proteins had different apparent and predicted molecular weights. For example 
MARCKS was found in the gel slice 60-90 kDa while its predicted molecular weight was 32 kDa. This 
localisation of YnC12-tagged proteins on a SDS-PAGE gel proved useful for Western blot analysis 
(Section ?3.3.3.4).  
The number of unique peptides and spectral counts were similar to the numbers found in the 
previous experiment (Section ?4.2). However, approximately six fold less sample was analysed by 
LC-MS/MS. In the previous experiment, the proteins enriched from 3 mg of lysates were injected in 
 
Figure 53. Gel-based proteomics analysis. YnC12-tagged proteins bearing an N-terminal MG motif were 
identified by gel-based proteomics. This experiment allows the localisation of YnC12-tagged proteins on a SDS-
PAGE gel. The proteins were tagged with YnC12 in HeLa, captured, enriched and loaded on a SDS-PAGE gel. The 
picture shows the in-gel fluorescence image of the gel before it was cut in 7 portions for the gel based analysis. 
Blue lines show where the gel has been cut. Gene names of a few proteins identified are indicated. 
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the LC-MS/MS while in this experiment, the equivalent of 500 µg was analysed. This result 
suggested, as expected, that fractionation of the sample reduced its complexity and less sample was 
required to obtain the same coverage. 
4.4 Label-free quantification: DMSO/YnC12 (4 replicates) 
4.4.1 Experimental design 
A label free quantification (LFQ) experiment was carried out to assess if LFQ could be used to 
distinguish NMT substrates from non-specific background proteins. Due to limited availability of 
reagent AzKTB, the standard reagent AzTB was used, and four biological replicates were prepared 
for the YnC12 sample and four biological replicates for the myristic acid control sample. Samples 
were labelled, captured and enriched as for the first experiment (Section  4.2). However, they were 
digested in-house with trypsin and the peptide pellets sent to the proteomics facility at the 
University of Dundee for LC-MS/MS analysis. To ensure reproducibility of the samples 
(Section  1.11.2), samples were processed in parallel and analysed at the same time.  
The data were provided as a raw file and analysed with MaxQuant (see Section  1.11.2). The mass 
spectral peak intensities, referred to here as LFQ intensities, were obtained for each identified 
protein. They were used to quantify the relative amount of a protein in the YnC12 or myristic acid 
samples. The reproducibility between replicates of a given sample was particularly good, as seen on 
the multiple scatter plots displayed in Figure 54. 
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4.4.2? Results and discussions 
The data were further processed with Perseus,234 and more than 800 proteins were identified in the 
8 samples. To keep only the proteins identified with high confidence, the data were filtered to 
require at least 2 unique peptides and three (out of four) LFQ intensity values, referred to as ‘valid 
values’ across the four YnC12 replicates (Figure 55a). Proteins identified in the YnC12 sample were 
not always detected in the DMSO sample. However, Perseus does not permit missing values when 
carrying out statistical analyses and when calculating a relative enrichment between two samples. 
Missing values correspond to proteins not present, or present below the detection limit of 
LC-MS/MS. Missing values were thus imputed in Perseus with a value close to the detection limit. 
Log2 values of LFQ intensities typically follow a normal distribution across a large sample (Figure 
55b) and the detection limit corresponds to the left tail of this normal distribution (boxed in red in 
Figure 55b). Perseus was used to generate a valid value in this interval, close to the detection limit, 
for the missing values. 
 
 
Figure 54. Multiple scatter plots showing the excellent reproducibility between replicates in the label-free 
quantification experiment. The label-free quantification (LFQ) intensity for one replicate is plotted against the 
LFQ intensity of another replicate. The logarithm values (Log2) are indicated. The correlation coefficients are 
indicated. The four myristic acid biological replicates (a) are indicated as M1, M2, M3, M4 and the four YnC12 
biological replicates (b) as Y1, Y2, Y3, Y4. The correlation is shown before the imputation of the missing values. 
The proteins with an N-terminal MG motif are highlighted in red. 
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Proteins were then subjected to a two-sample test (Figure 56a) and only proteins at least four-fold 
enriched in the YnC12 samples versus the myristic acid sample were kept (Figure 55a). 257 proteins, 
including 108 proteins with an N-terminal MG motif, were significantly enriched in the YnC12 
samples (Figure 56b, Appendix A and Appendix H). The number of proteins with a N-terminal MG 
motif, which correspond to putative NMT substrates, was significantly increased compared to the 
previous experiment (Section ?4.2), probably due to the higher sensitivity of the LC-MS/MS platform 
and greater consistency in sample handling. Interestingly, the equivalent of only 0.2 mg of enriched 
protein was injected in the LC-MS/MS for each sample, which is 15 times less than for the previous 
experiment. This suggests that increasing the scale of the experiment might not improve protein 
coverage, and that the technology of the proteomics platform has a strong impact on sensitivity. 
 
 
Figure 55. Data processing for the LFQ experiment. a) The scheme summarises how the proteins selectively 
enriched in the YnC12 sample were selected. b) The graph represents the normal distribution followed by the 
Log2 (LFQ intensity) values. Proteins not detected in one replicate were given a value close to the detection 
limit after imputation by Perseus.  
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A large number of proteins with no N-terminal MG motif were significantly enriched in the YnC12 
samples (Figure 56b and c), suggesting that YnC12 was incorporated into these proteins in a non 
NMT-mediated manner. As before, some of these other proteins (78) are palmitoylated or 
GPI-anchored proteins, suggesting that they might incorporate YnC12 in place of palmitate. 
 
Figure 56. Label-free quantification. a) Two-sample test. To select the significantly enriched proteins in the 
YnC12 biological replicates, a two-sample test was carried out in Perseus (modified t-test (permutation-based 
FDR)) using the following criteria: 250 permutation; FDR 0.001; S0 = 1. The –log p value of the test was plotted 
against the difference of mean of the Myr replicates and YnC12 replicates (log2 values). The proteins shown in 
red were selected as significantly enriched in the YnMyr sample. b) Log2 LFQ enrichment was plotted for each 
protein significantly enriched in the YnMyr samples. Proteins shown in blue have an N-terminal MG motif and 
proteins shown in red do not have a N-terminal MG motif. c) 257 substrates were identified by label-free 
quantification (4 replicates) in HeLa cells. 108 proteins had an N-terminal MG motif, as required for 
myristoylation. Prediction of N-myristoylation was done by two online bioinformatic tools (the MYR predictor 
and the Myristoylator): H = high confidence; M = medium confidence; L= low confidence; N = not predicted. 78 
proteins with no N-terminal MG motif are known to be palmitoylated or incorporate a GPI anchor. d) 108 
proteins had an N-terminal MG motif and some had been experimentally shown to be N-myristoylated using 
the classification described in Section ?4.1.1. 
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Predictions of N-myristoylation revealed that 46 of the 108 proteins with an N-terminal MG motif 
were predicted with high confidence to be N-myristoylated (although, as explained in Section  4.1.2, 
these predictions are not always reliable). Seven additional known/putative NMT substrates were 
identified compared to the non-quantitative experiment (Figure 56d).  
The enrichment threshold (4 fold) could have been set to a higher value to decrease the number of 
proteins with no N-terminal MG motif. However, some previously reported NMT substrates 
(Appendix F), such as ankyrin repeat and IBR domain-containing protein 1 (ANKIB1, 4.8 fold 
enrichment), would have been lost as they are poorly enriched in the YnC12 samples. This might 
reflect the poor abundance of these proteins in HeLa cells or their slow turnover rate. Turnover of 
N-myristoylated proteins is discussed in Section  5.3.  
This LFQ experiment does not enable robust distinction of NMT substrates from proteins enriched 
for other reasons (S-palmitoylated, GPI-anchored, etc.). This suggested that a further improved 
method was required to identify NMT substrates in HeLa cells with high confidence. 
4.5 Double SILAC YnC12 +/- NMT inhibitor 
4.5.1 Experimental design 
Recently, two groups employed novel strategies to study protein palmitoylation in BW5147-derived 
mouse T-cell hybridoma cells 235 and in Plasmodium.236 Both strategies were based on the use of 
inhibitors of biological processes combined with stable-isotope labelling with amino acids in cell 
culture (SILAC) (Section  1.11.2). Martin et al. employed a serine thioesterase-selective inhibitor to 
identify palmitoylated proteins which are hydrolysed by serine thioesterases in cells.235 Jones et al. 
used 2-bromopalmitate, a non selective inhibitor of protein palmitoylation, to detect palmitoylated 
proteins in Plasmodium.236 
In the current study, a similar approach was applied in HeLa cells by combining SILAC quantitative 
proteomics with the highly specific NMT inhibitor IMP366 (characterised in Chapter 3), to identify 
NMT substrates. This approach should solve the problems encountered with the proteomic 
experiments described above. The YnC12 probe appears to label NMT substrates as well as 
palmitoylated proteins and possibly GPI-anchored proteins, but only labelling and enrichment of 
NMT substrates should be sensitive to an NMT inhibitor, and for these proteins a reduction in YnC12 
tagging should be observed upon NMT inhibition. This difference in YnC12 tagging can be evaluated 
using SILAC. The workflow of this experiment is presented in Figure 57. 
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Heavy isotope-labelled cells (R10K8 media, 13C615N4-Arginine and 13C615N2-Lysine) were treated with 
YnC12 while light isotope-labelled cells (R0K0 media, 12C614N4-Arginine and 12C614N2-Lysine) were 
treated with YnC12 and NMT inhibitor IMP366 at the same time. 5 μM of IMP366 was used, as this 
concentration was shown to be sufficient to inhibit N-myristoylation of most NMT substrates in cell 
without leading to toxicity (Chapter 3). After cell lysis, samples were mixed in a 1:1 ratio and the 
samples captured with AzTB, enriched on Neutravidin agarose beads and digested with trypsin as 
usual. For each protein, heavy/light ratios were assessed. A ratio close to 1 would indicate that the 
same amount of a given protein was tagged by YnC12 in both samples. A ratio significantly higher 
than 1 would show that tagging of a given protein was reduced in the light sample, and would 
strongly suggest that this protein is an NMT substrate. HeLa cells were treated with YnC12 and the 
inhibitor for 24 h as IMP366 was shown not to be toxic up to 24 h. 
4.5.2? Results and discussion 
Biological triplicates were prepared (4 mg total proteins (2 mg of light sample and 2 mg of heavy 
sample)) and the beads were sent to the PNACL facility at the University of Leicester for analysis 
(on-bead digest, LC-MS/MS). The data were provided as a raw file and analysed with MaxQuant. The 
coverage was disappointing as only 259 proteins were identified in total, including 78 proteins with 
 
Figure 57. Double SILAC quantitative proteomics strategy to identify NMT substrates. HeLa cells cultured in 
the light (R0K0) cell culture media were treated with YnC12 and 5 μM IMP366. Cells cultured in the heavy 
(R10K8) media (with Arginine and Lysine amino acids radiolabelled with 14C and 15N) were treated with YnC12 
and DMSO. Cells were lysed after 24 h, the lysates combined in a 1:1 ratio (heavy:light). The samples were 
captured with AzTB, affinity enriched, and analysed by LC-MS/MS. The data were analysed using MaxQuant 
and Perseus. 
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an N-terminal MG motif. When the data were filtered to require at least two quantified ratios (out of 
three) per protein, many proteins were lost. The remaining 174 proteins (54 MG) were analysed with 
Perseus (Appendix A). First, the reproducibility between the three biological replicates was assessed 
(Figure 58a). The correlation between the Log2 heavy/light ratios was good between replicates. 
Histograms showed that most ratios (Log2 values) followed a normal distribution centred 
approximately on zero (Figure 58b). Other proteins, mostly possessing an N-terminal MG motif) had 
a higher ratio (Log2 value between 2 and 6). These proteins are likely to be NMT substrates as their 
labelling is reduced by the inhibitor. 
A modified t-test was performed (FDR 0.2, side = right) to select proteins significantly depleted in the 
light sample treated with the NMT inhibitor. Only proteins with a Log2 heavy/light ratio higher than 
1 were kept. The list of the 44 proteins which were significantly depleted in the heavy sample is 
presented in Appendix H.  
33 proteins with an N-terminal glycine were significantly affected by the NMT inhibitor (Figure 59). 
However, 13 proteins did not have an N-terminal MG motif (Figure 59a and b). The twelfth most 
sensitive protein is proenkephalin-B (PDYN), a cysteine-rich protein. The N-terminal domain contains 
   
Figure 58. Distribution of the Log2 heavy/light (H/L; not inhibited/inhibited) ratios for the 174 proteins 
detected in the double SILAC experiment (n= 3 biological replicates). E1, E2 and E3 correspond to the three 
replicates. The data were filtered to have at least two valid values (out of 3) Proteins with an N-terminal MG 
motif are shown in red. a) Scatter plot showing the good correlations of the log2 H/L ratios between the 
triplicates. b) Histograms showing the repartition of the proteins according to their Log2 H/L ratios. Most 
proteins have Log2 H/L ratio close to 0, which means that the relative amount of the protein is the same in 
both samples and the protein is probably not an NMT substrate. 
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six conserved cysteine residues thought to be involved in disulfide bonding and/or processing. Whilst 
this protein could potentially be S-palmitoylated and tagged by YnC12, it should not be sensitive to 
the NMT inhibitor. Other sensitive proteins with no N-terminal MG motif include bromodomain-
containing protein 3 and 4 (BDR3 and BDR4), 26S protease regulatory subunit 7 (PSMC2) and 
Nesprin-1 (SYNE1). PSMC2 is a proteasome subunit and could have been pulled down with 26S 
protease regulatory subunit 7 (PSMC1), a previously reported NMT substrate, since the proteasome 
subunits are tightly associated.??????possibility is assessed in Section ?4.7.2. 
4.5.3? Conclusions 
Although only 33 proteins carrying an N-terminal MG motif were detected in this experiment, the 
number of proteins with no MG was notably reduced. In the LFQ experiment (Section ?4.4.2), almost 
 
Figure 59. Double SILAC +/- NMT inhibitor (n = 3 biological replicates). 44 substrates were identified using this 
strategy (3 biological replicates) in HeLa cells. a) Log2 ratio heavy/light (H/L) was plotted for each protein 
significantly depleted in the heavy sample. Proteins shown in blue have an N-terminal MG motif and proteins 
shown in red do not have an N-terminal MG motif. b) 70% of the proteins had an N-terminal MG motif, as 
required for protein N-myristoylation. Prediction of N-myristoylation was done by two online bioinformatic 
tools (the MYR predictor and the Myristoylator): H = high confidence; M = medium confidence; L= low 
confidence; N = not predicted. A few proteins with no N-terminal MG motif are known to be palmitoylated or 
incorporate a GPI anchor. c) 31 proteins had an N-terminal MG motif and some had been experimentally 
shown to be N-myristoylated. 
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60% of the enriched proteins did not have a MG motif, while in the SILAC experiment described in 
Section  4.5.2, this number had been reduced to 30%. 
The low coverage suggested that there were several issues with the experiment design and the 
sample processing. 
 The total number of proteins detected was relatively low. Without any sample filtering, only 78 
proteins with an N-terminal MG motif were detected across the three replicates. This number is 
much lower compared to the 135 proteins detected in the LFQ experiment after filtering the 
data to keep at least 3 valid values across the four YnC12 samples. This observation, together 
with later results, strongly suggests that the LC-MS/MS used at the PNACL facility at the 
University of Leicester had a much lower sensitivity than the other proteomics platforms used in 
this study. Moreover, the SILAC experiment was carried out on a large scale. As suggested in 
Section  4.4, a large scale experiment might not be necessary to get good protein coverage; 
indeed, this excess might instead have saturated the LC column and limited protein 
identification. 
 Log2 ratios higher than 4 are close to the dynamic range of any LC-MS/MS apparatus.235 Small 
quantities of YnC12 tagged proteins in the heavy sample might not have been detected. When 
cells are inhibited with 5 µM of IMP366, N-myristoylation should be nearly completely inhibited. 
MaxQuant should automatically impute a ratio value if one protein was found only in the light 
sample, but these ratios might not be accurate. It would be preferable to use a lower 
concentration of inhibitor to decrease the value of the ratios and move them away from the 
detection limit. 
It is unclear why several proteins with no N-terminal MG motif are less enriched in the presence of 
the NMT inhibitor. Several hypotheses were proposed and are discussed in Section  4.7. 
 Proteins might be enriched because they bind to NMT substrates. However, the interaction 
would need to be strong, possibly covalent, to be able to resist the highly denaturing conditions 
(2% SDS) during the sample processing for proteomics.  
 Proteins might have an internal protease cleavage site. Proteins can sometimes be processed 
outside the context of apoptosis,237 and any new N-terminal glycine could potentially be 
N-myristoylated. 
 Proteins that are tagged with YnC12 in a non NMT-mediated manner could be down regulated 
upon NMT inhibition; however this is unlikely as NMT inhibition has little effects on the cells 
after 24 h (Chapter 5). 
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 4.6 Spike-in SILAC with inhibitor 
4.6.1 Experimental design 
Spike-in SILAC quantitative proteomics has recently emerged as a straightforward method to 
quantitatively compare multiple samples.195 A heavy isotope labelled standard (referred to as the 
“spike-in standard”) is incorporated at the early stages of the proteomics workflow, preventing any 
bias due to sample processing (CuAAC, enrichment, LC-MS/MS) (Section  1.11.2). This method 
presents two major advantages compared to the double SILAC approach employed in Section  4.5. 
First, an arbitrary number of samples can be compared using this approach, while only two samples 
can be compared using the double SILAC approach. Secondly, for the spike-in SILAC methodology, 
samples to be compared can be prepared in any standard cell culture medium (DMEM and FBS for 
HeLa cells), while double SILAC experiments require the use of a defined media (R0K0/R10K8 
labelled DMEM, dialysed FBS). Cells grown in the R0K0 and R10K8 DMEM appeared to grow more 
slowly than cells grown in the standard media, probably due to the removal of low molecular weight 
nutrients (amino acids, hormones, etc.) in the dialysed FBS. This alteration of cell growth might alter 
the rate of YnC12 incorporation into NMT substrates.  
Heavy isotope-labelled cells (R10K8 media) were treated with YnC12 while cells grown in the 
standard DMEM media were treated with YnC12 and various concentrations (0, 0.08, 0.2, 0.4, 1 and 
5 µM) of NMT inhibitor IMP366 at the same time (Figure 60).  
The inhibitor supplemented at these concentrations to cell media was shown to give 
dose-dependent protein labelling by in-gel fluorescence (Section  3.3.3.4). 0.2 µM is close to the TC50 
value while 1 µM inhibited > 90% YnC12 labelling and 5 µM almost completely inhibited YnC12-
labelling in HeLa cells (Section  3.3.1). After cell lysis, the cell lysates treated with IMP366 were spiked 
with the heavy standard. The same ratio of proteins from “cells treated with IMP366”: “spike-in 
standard” was used for each sample, allowing them to be compared. The proteins were then 
captured with AzTB, enriched on Neutravidin agarose beads and digested with trypsin as usual. For 
each protein and each concentration of IMP366, “inhibited”/”spike-in” ratios (also referred to as 
light/heavy) were assessed. For a given protein, a dose-dependent decrease of the ratios would 
indicate that the protein is an NMT substrate. Additionally, this method could allow the 
determination of in-cell IC50 for each NMT substrate. 
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As explained in Section ?4.5, a heavy/light ratio higher than 4 (Log2 value) is close to or within the 
background noise and it is possible that some ratios, especially for the 5 μM sample, would not be 
determined accurately due to the low abundance of the light isotope labelled proteins. Mixing 
samples in a 2:1 ratio “sample treated with the inhibitor”: “spike-in” might overcome this problem 
as it would increase the relative abundance of light isotope labelled proteins. 
4.6.2? Data processing 
Four biological replicates and one technical replicate were prepared and analysed on a 
nanoLC-Q-Exactive platform at the mass spectrometry facility, Department of Chemistry, Imperial 
College London. The data were received as a ‘.raw’ file and analysed with MaxQuant and Perseus. 
The workflow used to process the data is presented in Figure 61. The data were first filtered to 
require at least three valid values across the 30 samples (5 replicates of 6 concentrations of IMP366). 
More than 600 proteins were identified in total, including 169 proteins with an N-terminal MG motif 
(Appendix A). For these 169 enriched proteins (or protein groups), 17,401 unique protein-derived 
peptide sequences were identified and quantified with high confidence, resulting in 20,084 spike-in 
SILAC ratios for which the response to inhibition was analysed.  
For each replicate, the ratios were normalised to the sample with 0 μM IMP366. For each protein, 
the ratio in the 0 μM IMP366 sample was taken as 1 whilst the ratios for all the other samples (0.08; 
 
Figure 60. Quantitative proteomics strategy to identify novel NMT substrates and calculate in-cell IC50s. HeLa 
cells cultured in the normal cell culture media were treated with YnC12 and different concentrations of 
inhibitors (x =0; 0.08; 0.2; 0.4; 1; 5 μM). Cells cultured in the heavy media (with Arginine and Lysine amino 
acids radiolabelled with 14C and 15N) were treated with YnC12 and DMSO. Cells were lysed after 24 h, the 
lysates combined in a 1:2 ratio (heavy:light). The samples were captured with AzTB, affinity enriched, and 
analysed by LC-MS/MS. The data were analysed using MaxQuant, Perseus and GraFit. 
138 
 
0.2, 0.4; 1 and 5 μM) were between 0 and 1. The closer the ratio to zero for a particular protein, the 
more depleted is N-myristoylation of that protein. 
Proteins were clustered to allow the rapid selection of NMT substrates versus non-substrates of 
NMT. The data were then manually inspected and divided up into four categories: 
?? N-myristoylated high confidence:  This group corresponds to proteins showing a dose-
dependent response to the NMT inhibitor with ratios reaching values lower than 0.3. 
?? N-myristoylated low confidence: This group corresponds to proteins fulfilling the previous 
criteria but which had a low number of unique peptide (0 or 1 unique peptides in the highest 
concentrations of inhibited samples) or to proteins with a minimum ratio value between 0.3 and 
0.6. 
?? Not N-myristoylated high confidence: This group corresponds to proteins for which the ratios 
do not drop below 0.6. 
 
Figure 61. Analysis of the spike-in SILAC experiment. Low number of razor+unique peptides refers to proteins 
having 0 or 1 razor+unique peptides in the highest concentrations of inhibited samples. 
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?? Not N-myristoylated low confidence: This group corresponds to proteins fulfilling the criteria for 
non-substrates of NMT but which had a low number of unique peptide (0 or 1 unique peptides in 
the highest concentrations of inhibited samples). 
4.6.3? Results: proteins with a N-terminal MG motif 
4.6.3.1? Identified proteins: sensitive or insensitive to inhibition 
70 proteins showed a robust dose-dependent response to increasing concentration of IMP366, and 
could thus be assigned with confidence as NMT substrates. Figure 62a shows the response for three 
previously reported NMT substrates, PSMC1, c-SRC and PRKACA. The experiment also allowed the 
identification of 54 non NMT substrates, as for example GOLIM4, CD81 and PTGFRN, displayed in 
Figure 62b. Interestingly, GOLIM4 was predicted to be N-myristoylated (Section ?4.1.2) whilst CD81 
and PTGFRN were highly enriched in the LFQ experiment (Section ?4.4). CD81 was detected in a non-
quantitative chemical proteomics experiment by Wilson et al. (Appendix F).173  
Most of the 54 non substrates were enriched in the LFQ experiment. Interestingly, one previously 
reported substrate, identified with a cell free method, serine incorporator 1 (SERINC1) was not 
sensitive to the NMT inhibitor. 
4.6.3.2? Proteins with N-terminal MG motif and sensitive to NMT inhibition: in-cell IC50 
An IC50 value could be determined for the 70 proteins for which enrichment is dose-dependently 
sensitive to NMT inhibition. Figure 63 displays the IC50 profiles of six NMT substrates plotted with 
GraFit 7.0. For most substrates, the error for the IC50 value was small and the slope factor was 
between 0.5 and 2, suggesting that sigmoidal curve fitting was excellent. While a wide range of IC50 
 
Figure 62. Identification of co-translational NMT substrates in HeLa cells. The response correspond to the 
ratios (spike-in SILAC ratios versus the concentration of IMP366) normalised to the 0 μM IMP366 sample (n= 4; 
error bars display the standard deviations). a) Shows the response obtained for three known/putative NMT 
substrates, PSMC1, SRC and PRKACA. b) Shows the response for three non NMT substrates, GOLIM4, CD81, 
PTGFRN. 
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values (from 2 to 762 nM) was obtained, the average IC50 value (168 ± 38 nM) correlated well with 
the TC50 value (169 ± 31 nM, Section  3.3.1). Plots showing the IC50 profiles of the 70 NMT substrates 
were generated by non-linear regression of IC50 values and slope factors to a standard dose-
response equation (GraFit 7.0) (Figure 64). 
 
 
Figure 63. Examples of IC50 profiles obtained with GraFit 7.0. The protein gene names are indicated. PRKACA, 
PSMC1, SRC were known/putative NMT substrates. LRRC57 and NOL3 were not known and poorly predicted to 
be N-myristoylated while HCCS was not known but predicted with high confidence to be N-myristoylated.  
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The diversity of in-cell IC50 values might reflect the affinity of a protein for HsNMT1/2. Indeed, a 
protein with a low affinity for HsNMT1/2 might be more sensitive to low concentrations of NMT 
inhibitor.  
4.6.3.3? N-myristoylated low confidence  
Using the spike-in SILAC approach described in this chapter, 27 proteins were defined as ‘low 
confidence’ NMT substrates as they were quantified from a smaller set of unique peptides or had an 
ambiguous dose response. Previous reports suggest that several of these ‘low confidence’ NMT 
substrates are likely to be N-myristoylated. 
?? Low number of unique peptides: 7 proteins: RING finger protein 11 (RNF11) has been shown to 
be N-myristoylated in a cell free system (Appendix F). Intriguingly, ADP-ribosylation factor-like 
protein 2 (ARL2) followed a nice dose-dependent response but had been previously reported not 
to be N-myristoylated.238
?? Ambiguous dose-response (do not drop below 0.3): Mitochondrial peptide methionine 
sulfoxide reductase (MSRA) had previously been shown to be N-myristoylated in a non-native 
context (Appendix F) whilst three other proteins had been shown to be N-myristoylated in a cell 
free system. YnC12-modified N-terminal protein sequence was identified with AzKTB for Opioid 
growth factor receptor-like protein 1 (OGFRL1) (Section ?4.2.2). Interestingly, platelet-activating 
factor acetylhydrolase 2, cytoplasmic (PAFAH2) had been labelled with an alkyne palmitate 
analogue and shown to be not sensitive to base-treatment, suggesting that it may be 
N-myristoylated (see Section ?4.7 for cross-talk between N-myristoylation and 
S-palmitoylation).175 
 
Figure 64. Dose-response for the 70 NMT substrates identified by quantitative chemical proteomics. The plot 
was generated by fitting the IC50 values and slope factors to the IC50 dose-response equation. 
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4.6.4? Conclusions 
This spike-in SILAC approach allowed the identification with high confidence of a large number of co-
translational NMT substrates as well as non-substrates. Seven newly identified NMT substrates were 
poorly predicted to be N-myristoylated whilst some proteins not sensitive to the NMT inhibitor had 
been predicted to be substrates (Figure 65). These results confirmed once again that the predictors 
are not always accurate.  
When proteins with no N-terminal MG motif were subjected to the same analysis (Figure 61), twelve 
proteins were found to be dose-dependently sensitive to NMT inhibition. Eleven were enriched in 
LFQ experiments (Section ?4.4) and possible explanations are discussed in Section ?4.7.2. 
4.7? Proteins tagged with YnC12 but not NMT substrates 
4.7.1? S-Palmitoylated proteins and GPI-anchored proteins 
In the current study, a substantial number of non-substrates of NMT were labelled with YnC12 and 
highly enriched in the YnC12-treated sample over the control (myristic acid or DMSO). As discussed 
in Section ?4.2, a large majority of these proteins do not have an N-terminal MG motif and might 
incorporate YnC12 in place of palmitate in S-palmitoylated proteins or GPI-anchored proteins.  
 
Figure 65. Identification of 70 NMT substrates in HeLa cells. Repartition of the alkyne-tagged proteins with a 
N-terminal MG motif : the proteins identified were either sensitive (NMT substrates) or not sensitive (not NMT 
substrates) to the NMT inhibitor. Proteins were predicted to be N-myristoylated with high confidence (H), 
medium confidence (M), low confidence (L) or not predicted (N) by the online predictors, the Myristoylator 
and the Myr predictor. 
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YnC12 is attached to the N-terminal glycine of NMT substrates via an amide linkage. If the YnC12 
probe labels S-palmitoylated proteins or GPI-anchored proteins, it would be via a thioester linkage 
(on side-chain of cysteine residues) or via an ester linkage to an inositol, respectively (Figure 19). It is 
possible to distinguish thioester and ester bonds from amide linkages by treating samples with 
hydroxylamine or base. Esters or thioesters would be hydrolysed by these reagents, and thus should 
no longer be enriched by pull-down, whilst amide bonds would be left untouched (Figure 66). 
Proteomics experiments carried out by Dr. Megan Wright (Tate group, Imperial College London) 
demonstrated that base-treatment of Plasmodium Falciparum lysates (labelled with YnC12) prior to 
the enrichment step could hydrolyse the YnC12-ester linkage within GPI-anchors, and result in a 
substantial decrease in enrichment of parasite GPI-anchored proteins.163  
A few examples have been reported in the literature showing that palmitate could be hydrolysed by 
treating the sample with sodium hydroxide.239,240 However, hydroxylamine-treatment of lysate has 
been preferred to hydrolyse thioester linkages as this method is chemically more efficient to 
hydrolyse thioester bonds and also milder. 
Hydroxylamine treatment has been widely employed to study the loss of enrichment of 
YnC16-tagged S-palmitoylated proteins by Western blot analyses, but it has rarely been used in 
combination with MS-based proteomics. However, Martin et al. treated human Jurkat T-cells with 
17-ODYA and noticed, using quantitative proteomics, the loss of enrichment upon treatment of the 
samples with hydroxylamine.175 After the CuAAC reaction, they boiled the samples for 5 min in the 
presence of neutralized hydroxylamine (2.5% final concentration) and diluted with PBS before being 
enriched on Streptavidin beads. However, this treatment resulted in visible smeared bands on the 
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Figure 66. Effect of hydroxylamine (NH2OH) or NaOH treatment on acylated proteins. Amide, thioester and 
ester linkages are typical of N-myristoylated, S-palmitoylated or GPI-anchored proteins respectively. Only 
amides are stable to hydroxylamine or base treatment. 
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gel, suggesting that proteins had been degraded. As protein degradation could falsify the 
identification of hits in the MS-based proteomics experiment, it was decided not to use the same 
protocol as Martin et al. 175 
4.7.1.1 Experimental design 
Hydroxylamine and base-treatments of HeLa cell lysates and Plasmodium samples had been 
previously optimised by Dr. Megan Wright (Tate group, Imperial College London). Treatment was 
typically carried out for 1 h, before the enrichment step; however, base/hydroxylamine cleavage of 
thioesters might not be complete after one hour and it might be preferable to use a quantitative 
approach to identify a set of proteins which were sensitive to the base-treatment. A spike-in SILAC 
approach appeared advantageous as it was shown in Section  4.6 to be highly reliable to quantify 
changes between samples. However, samples would preferably be base/hydroxylamine treated 
before the CuAAC reaction as it is preferable to mix the spike-in standard with the samples as early 
as possible in the proteomics workflow (Section  1.11.2). A fraction of YnC12-treated cell lysate was 
base/hydroxylamine treated and another fraction was treated with PBS buffer (to control for the 
salts added in the other samples). The two samples were then spiked with the same heavy standard 
employed in Section  4.6 (ratio 1:1). 
Experiments were required to optimise the base/hydroxylamine treatment before the CuAAC 
reaction. As it might be difficult to observe a reduction of YnC12 labelling following 
base/hydroxylamine treatment of the samples, optimisations were carried out using HeLa lysates 
labelled with YnC15, an alkyne analogue of palmitic acid prepared as described in Chapter 2. This 
analogue was used in the Tate group to study protein palmitoylation,163,174 and 50 µM YnC15 seemed 
optimal to label proteins in HeLa cells (Figure 67). Samples labelled with YnC12 were subjected to 
the same base/hydroxylamine treatment as the YnC15-labelled samples, to ensure fluorescence 
labelling was not completely lost and that proteins were not degraded. 
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As it was shown that hydroxylamine could inhibit the CuAAC reaction,163 proteins were precipitated 
directly after the base/hydroxylamine treatment (and thus before the CuAAC reaction) to remove 
excess hydroxylamine (Figure 68). As a control, samples were not precipitated before the CuAAC 
reaction. As expected, fluorescence signal was lost for the hydroxylamine treated samples without 
protein precipitation. When the samples were precipitated, a smear appeared on Coomassie, 
probably due to poor protein resuspension or protein degradation. Additionally, for the YnC12 
labelled proteins treated with hydroxylamine, the bands seen in fluorescence at 75 kDa and 20 kDa 
seemed weaker and all the sharp bands between 25 and 50 kDa were shifted and smeared (Figure 
68b). 
The sodium hydroxide treatment seemed to give better results, even if YnC15 labelling was not 
completely depleted. The YnC12 labelling pattern was similar in the treated and non-treated 
samples. Interestingly, protein molecular weight decreased upon prolonged treatment (proteins 
around 55 kDa boxed in red in Figure 68b), probably due to the conversion of Asn and Gln into Asp 
and Glu, known to occur upon base treatment. 241 These changes modify the charges of proteins and 
therefore might modify their motility on the gel.  
 
Figure 67. Optimisation of the YnC15 labelling in HeLa cells. Cells were labelled for 18 h with an increasing 
concentration of YnC15 or treated with DMSO (vehicle). 
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Base-mediated hydrolysis/removal of YnC15 labelling is incomplete after 2 hours as seen on the 
YnC15 gel. Increasing the base-treatment to 4 h helped to decrease the YnC15 labelling but at the 
same time, it also gave more protein degradation (smear on coomassie and smear of the proteins 
tagged with YnC12 observed in Figure 69). For the spike-in experiment, it was decided to treat the 
lysate with 0.2 M sodium hydroxide for 2 h and samples were not precipitated before the CuAAC 
reaction. Even if the ester and thioester bonds were not completely hydrolysed after 2 h treatment, 
quantitative proteomics should still identify the base/hydroxylamine sensitive proteins.  
 
Figure 68. Base and hydroxylamine treatment optimisation in HeLa cells. HeLa cells were treated with 
a) YnC15 (18 h, 50 μM) or b) YnC12 (18 h, 50 μM). Samples were treated for 1 or 2 h with PBS, 0.2 N NaOH, or 
0.2M freshly neutralised hydroxylamine. Samples were precipitated or not before CuAAC. Proteins shifted on 
the gel after the base-treatment boxed in red.  
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4.7.1.2? Base-treatment 
HeLa cells were labelled with YnC12 and four samples were prepared:  
?? Untreated sample + heavy spike-in  (1:1 ratio) (biological duplicates) 
?? 2 h base-treated sample + heavy spike-in (1:1 ratio) (biological duplicates). 
Samples were analysed by the mass spectrometry facility, Department of Chemistry, Imperial 
College London. The data were provided as raw files and analysed with MaxQuant. The data were 
filtered to keep only proteins with at least two valid values (out of four), resulting in a list of 421 
proteins (including 122 with an N-terminal MG motif). The reproducibility between duplicates of the 
non-base-treated sample was particularly good, as seen on the multiple scatter plots displayed in 
Figure 70a. However, the reproducibility between the base-treated samples was poor, and the 
reason is currently unclear (Figure 70b). 
Proteins were then subjected to a two-sample test (FDR 0.01, 250 permutations, S2) and only 
proteins with a t-test difference higher than 1 (Log2 scale) were kept (Figure 70c, Appendix A and 
Appendix H). 58 proteins, including 14 proteins with an N-terminal MG motif, were significantly 
 
Figure 69. 4 h base-treatment (0.2N NaOH). a) YnC15 and b) YnC12 labelling were compared. Samples were 
precipitated or not before CuAAC (after the base-treatment). 
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depleted in the base-treated samples, suggesting that they incorporate YnC12 via an ester or 
thioester bond (Figure 70d). 50 of these proteins were enriched in the YnC12 samples in the LFQ 
experiment (Section ?4.4). 
Some known S-palmitoylated proteins (as reported in the Uniprot/KB database), Calnexin and 
CKAP4, as well as two known GPI-anchored protein BST2 and CD59 were sensitive to the 
base-treatment. The three proteins carrying an N-terminal MG motif and not sensitive to the 
inhibitor shown in Figure 62b were base-sensitive. This result confirms that they are not NMT 
substrates but probably S-palmitoylated or GPI-anchored. 
Interestingly, a protein previously reported as NMT substrate,230 SERINC1, was highly sensitive to 
base-treatment. This protein was not dose-dependently affected by the increasing amount of NMT 
inhibitor (Section ?4.6.3). The fact that no dual-lipidated protein was significantly sensitive to base-
treatment suggested that SERINC1 is not N-myristoylated.  
 
Figure 70. Base-treatment. Correlation between the two biological replicates of the samples. a) Not base-
treated or b) base-treated. Proteins with an N-terminal MG motif are shown in red. c) A two sample test was 
used to select the proteins significantly affected by base-treatment. Proteins with an N-terminal MG motif are 
shown in red. d) Partition of the base-sensitive proteins. 14 proteins had an N-terminal glycine but only one 
protein was previously shown to be N-myristoylated. 
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4.7.1.3 Conclusions 
The experiment described in Section  4.7.1.2 showed much promise and explained why many 
proteins are tagged with YnC12 but are not NMT substrates; however, this experiment should be 
repeated to obtain a more comprehensive dataset. Probably more than 56 proteins labelled with 
YnC12 are S-palmitoylated or GPI-anchored. In particular, the number of replicates should be 
increased to increase the power of the statistical analysis and the conditions used for the 
base-treatment could be further optimised by varying the concentration of base. 
The specificity of YnC12 for palmitoylated proteins is currently unknown and YnC12 might be 
incorporated only into the most abundant palmitoylated proteins  
4.7.2 Proteins with no N-terminal MG motif but dose-dependently sensitive to NMT 
inhibition 
Twelve proteins with no N-terminal MG motif appeared to be sensitive to NMT inhibition 
(Section 1.6 and Appendix H). Eleven (all but Histone H2A.x) were significantly enriched in the YnC12 
sample in the LFQ experiment (Section  4.4). Six proteins are subunits of the 26S proteasome. The 
proteasome is a protein complex involved in the ATP-dependent degradation of ubiquitinated 
proteins. 26S proteasome regulatory subunit 4 (PSMC1) is a previously reported NMT substrate 208 
identified with high confidence in Section  4.6.3, and the six other subunits might be pulled down 
with PSMC1. It is also possible that these proteins are not specifically enriched and that their relative 
abundance decreases upon NMT inhibition. 
Experiments were carried out to verify these hypotheses. First, relative abundance of 26S protease 
regulatory subunit 7 (PSMC2), the most enriched protein in the LFQ experiment was studied. 
Western blot analysis showed that treatment of HeLa cells with an increasing amount of IMP366 did 
not decrease PSMC2 levels (Figure 71a). Secondly, PSMC1 and PSMC2 were immunoprecipitated 
from YnC12 or myristic acid treated lysates. Both samples were captured with AzTB to label 
alkyne-tagged proteins, and proteins were run on an SDS-PAGE gel (Figure 71b). For PSMC1, in-gel 
fluorescence revealed one band in the YnC12-treated sample, corresponding to PSMC1. Western 
blot analysis showed a non-specific band below 50 kDa, probably corresponding to the antibody 
heavy chains. For PSMC2, in gel fluorescence analysis showed several bands. The band observed at 
ca. 60 kDa (boxed in blue in Figure 71b) corresponded to a YnC12-tagged protein as it was present 
only in the YnC12 treated sample (and not in the myristic acid control). The molecular weight (MW) 
of this band did not match the apparent MW of PSMC2 (49 kDa) (Figure 71b). However, Western 
blot analysis in Figure 71b, could not confirm whether the band was PSMC2 due to the presence of 
non-specific bands on the Western blot at the same MW as that expected for PSMC2. The 
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non-specific bands below 50 kDa most likely corresponded to the antibody heavy chains. PSMC2 
antibody heavy and light chains probably corresponded to the extra bands observed by in-gel 
fluorescence. The capture reagent AzTB might bind non-specifically to the antibody released from 
the beads at the same time as the protein PSMC2. Attempts to decrease this background by 
precipitating the proteins before running the SDS-Page gel or by using milder conditions to elute the 
proteins from the beads were unsuccessful. More experiments are required to confirm that PSMC2 
is pulled down with PSMC1 in YnC12-labelled samples.  
Over the last decade, the structure of the 26S proteasome and the interactions between the 
different subunits have been well studied.242 The six regulatory subunits (PSMC1-6) have been 
shown to tightly interact via a coiled-coil domain present in the N-terminal region of these subunits 
(Figure 72).242,243 The N-terminal region of PSMD2 has also been shown to interact with PSMC1 and 
PSMC2. 242 
 
Figure 71. Possible explanation for the enrichment of PSMC2 in the YnC12 samples. a) PSMC2 levels do not 
decrease in HeLa cells treated with IMP3666 (μM) for 24 h. Tubulin was used as a loading control. 
b) Immunoprecipitation of PSMC1 or PSMC2 using Sepharose A beads, followed by capture on beads by AzTB. 
Proteins were released from the beads by boiling and the samples were run on a SDS-PAGE gel, analysed by in-
gel fluorescence and Western blot. A band is common to both YnC12 (Yn) treated samples (boxed in blue). 
Blue arrows indicate the heavy and light chains of the antibody seen by in-gel fluorescence. A green arrow 
indicates the band corresponding to PSMC1 on the Western blot and a red arrow indicates a band, probably 
corresponding to the antibody heavy chain. 
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None of the interactions between the 26S proteasome subunits are thought to be covalent, but they 
appeared to be highly stable as they were able to resist the highly denaturing conditions (2% SDS) 
during the sample processing for proteomics. 
Similarly, other proteins with no N-terminal MG motif form protein complexes with NMT substrates. 
Flotilin-1 (FLOT1, no MG motif) interacts with flotilin-2 (FLOT2, NMT substrate) 244 whilst 
serine/threonine-protein phosphatase 2B catalytic subunit alpha and beta isoforms also referred to 
as calcineurin A (PPP3CA and PPP3CB, no MG motif) interacts with calcineurin subunit B type 1 
(PPP3R1, NMT substrates) as they are tightly associated subunits of calcineurin.245 
No analogous interactions are known for the four other proteins without an N-terminal MG motif 
sensitive to NMT inhibition (BAG5, LANCL1, H2AFX; SERPINB6). These proteins might be 
post-translationally cleaved/processed and a new N-terminal glycine could be revealed and 
N-myristoylated. However, none is known to be post-translationally myristoylated (Appendix G) and 
none has been reported to have a cleavage site revealing an N-terminal glycine, in a proteolysis 
database (DegraBase).237 Immunoprecipitation experiments could be carried out to verify that these 
proteins are not tagged by YnC12 but instead pulled-down with another NMT substrate. 
4.7.3? Lysine side-chain myristoylation 
A few examples showing that myristate was not exclusively added to the N-terminal glycine of 
proteins have been described in the literature. Two proteins, tumour necrosis factor alpha 
(TNF-alpha) 246 and interleukin 1 alpha247 were suggested to be side-chain myristoylated on a lysine 
residue. Recently, the function of this post-translational modification has been explored and was 
Figure 72. Interaction map between the seven subunits of the 26S proteasome detected in the current 
study. PSMC1, the putative NMT substrate is shown in blue. Highly enriched proteins (LFQ ratio > 10) are 
shown in red and other subunits are shown in orange (6 <LFQ ratio ????. Adapted from Fu et al. 243. 
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found to be involved in the regulation of protein secretion.233 Jiang et al. showed that SIRT6, a sirtuin 
nicotinamide adenine dinucleotide (NAD)-dependent deacetylase enzyme, could hydrolyse the 
myristoyl moiety on Lys 19 and Lys 20 of TNF-alpha, which regulates the secretion of TNF-alpha from 
the cell membrane to the intracellular domain.233 However, little is known about the incorporation 
of myristate on lysine side-chain residues of proteins. As NMT is thought to transfer myristate to 
N-terminal glycine of proteins, it is probable that another enzyme is involved in this process. 
Any protein labelled with YnC12 but which is neither sensitive to NMT inhibition nor to 
base/hydroxylamine treatment might potentially incorporate myristate on a side-chain lysine 
residue. Work is on-going in the Tate group to identify these proteins.  
4.8 74 N-myristoylated proteins identified with high confidence in HeLa 
4.8.1 30 newly identified N-myristoylated proteins 
The spike-in SILAC inhibitor experiment (Section  4.6) allowed the identification with high confidence 
of 70 NMT substrates in HeLa cells. An additional four proteins had been identified in Section  4.2.2 
thanks to the identification of the YnC12-modified N-terminal peptide with AzKTB: coiled-coil-helix-
coiled-coil-helix domain-containing protein 6, mitochondrial (CHCHD6), opioid growth factor 
receptor-like protein 1 (OGFRL1), plasminogen receptor (KT) (PLGRKT) and the mitochondrial import 
receptor subunit TOM40B (TOMM40L).  
Out of these 74 proteins identified as NMT substrates in the current study, only five had been 
previously shown to be N-myristoylated in their native context in eukaryotes (no overexpression), 26 
in a non-native context in eukaryotes and 13 in non-eukaryotic cells (Figure 73). Interestingly, the 
current study allowed the identification of 30 novel substrates. Out of these 30 substrates, only 7 
had been identified previously in chemical proteomics experiments (Appendix F)173,224. However, in 
these previously reported proteomics experiments, the proteins were not directly proven to be 
either N-myristoylated or substrates of NMT. 
153 
 
4.8.2? N-myristoylated proteins function and localisation 
NMT substrates have various functions and localisation in-cells, and may eventually lead to cell 
death or dysfunction when not N-myristoylated (Figure 74). Many of these proteins are involved in 
protein transport (ARFs proteins, CHP, etc.), in redox processes (CYB5R3, NDUFB7, etc.) or are 
kinases (SRC, LYN, etc.). Several NMT substrates, previously reported as N-myristoylated, are 
involved in protein degradation through the ubiquitin pathway: a subunit of the 26S proteasome 
(PSMC1), and two E3 ubiquitin ligases (MGRN1 and ZNRF2) are N-myristoylated (Appendix H). 
4.8.3? Consensus 
Figure 75 displays the consensus sequence for N-myristoylation obtained from N-terminus of the 74 
proteins identified with high confidence in the current study. This consensus was compared to the 
consensus described in Section ?1.4.2. The latter stated that uncharged residues are preferred in 
position 3, any residues are allowed in positions 4 and 5, serine is preferred in position 6, but other 
 
Figure 73. Upper limit of prior evidence for the 74 NMT substrates identified in this study. 
 
 
Figure 74. Biological functions (a) and localisation (b) for the 74 NMT substrates identified in this study (GO 
annotations). 
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small uncharged residues are permitted, and residue is position 7 cannot be proline. The two 
consensuses are thus highly consistent. 
As expected, residues 9-20 were less conserved across the identified NMT substrates and no 
consensus could be generated. These residues do not bind to the enzyme active site. Residues 8-12 
are thought to interact with the enzyme surface while residues in positions 13-18 might act as a 
hydrophilic linker (Section ?1.4.2).  
4.8.4? Significance of the newly identified NMT substrates 
In this Section, only newly identified NMT substrates (proteins not previously shown to be 
N-myristoylated in a native, non native of cell free context, Appendix F)) will be discussed. 
4.8.4.1? Interaction with membranes 
Several new NMT substrates are of particular interest as they were previously shown to interact with 
membranes but the mechanism for this interaction had not been identified.  
Cytochrome c-type heme lyase (HCCS) is responsible for the attachment of heme to the apo-
cytochrome C and is known to localise in the mitochondrial intermembrane space.93,249,250 However, 
the association with the membrane is not well understood and was suggested to be peripheral. 251 In 
this study, HCCS was found to be N-myristoylated and myristate could therefore anchor the protein 
to the mitochondrial intermembrane.  
 
Figure 75. Sequence logo displaying the consensus for N-myristoylation. A consensus was generated from the 
N-terminal 20 amino acids of the NMT substrates identified with high confidence in the current study using 
MEME.248 The size of each letter is related to the probability of finding the particular amino acid in that 
position and the colours correspond to the type of amino acid (hydrophobic (blue), polar (green), acidic 
(magenta), positively charged (red), His (pink), Gly (orange), Pro (yellow), Tyr (turquoise)). 
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The mitochondrial amidoxime-reducing component 1, MARC1, is responsible for the reduction and 
activation of N-hydroxylated pro-drugs and also takes part in regulation of nitric oxide synthesis.252 
The N-terminus has recently been shown to target MARC1 into the outer mitochondrial 
membrane.253 The N-terminus is composed of two domains: a hydrophobic transmembrane helix 
domain (residues 21-40) and weak N-terminal mitochondrial targeting signal (1-20). The latter was 
shown to interact weakly with the mitochondria, and this weak interaction could be attributed to 
myristate, since this protein was detected as N-myristoylated in the present study (Section  4.6.3). 
MARC2, the second isoform of the mitochondrial amidoxime-reducing component, is another newly 
identified NMT substrate. It is also known to target outer mitochondrial membranes, and has similar 
functions in the cell 253 but its interaction with membranes has been less studied. 
LAMTOR1 is a subunit of the Ragulator complex, which is responsible with Rag GTPases for 
recruiting mTORC1 to lysosomes, where it can be activated. mTORC1 is a signalling complex involved 
in the MAPK pathway and which triggers cell growth in response to various stimuli.254 LAMTOR1 has 
been shown to be responsible for the association of the Ragulator complex to membrane in 
organelle like vesicles, a process essential for mTORC1 activation.255 The protein has putative 
N-myristoylation and palmitoylation sites but no experiment had been carried out to show that the 
protein was N-myristoylated. In the present study, LAMTOR1 was shown to be N-myristoylated and 
myristate could direct palmitoylation and attachment to membranes (Section  1.5.3). 
Disrupted in renal carcinoma 2 (DIRC2) is a lysosomal membrane protein that functions as an 
electrogenic metabolite transporter.256 DIRC2 has several transmembrane domains and an N-
terminal dileucine motif mediates its lysosomal targeting. It was suggested that N-myristoylation 
might also be involved in lysosomal targeting, but the protein had not been experimentally shown to 
be N-myristoylated.  
4.8.4.2 Proteins linked to diseases 
Some newly identified substrates are implicated in the progression of diseases. 
Battenin (CLN3), when mutated, is a protein responsible for Batten disease, a rare and fatal 
neurodegenerative disorder.257 The function of Battenin is not known but the protein has been 
suggested to be involved in transmembrane transport, lipid homeostasis and neuronal excitability 
and it was suggested that it could interact with ARF proteins.258  
Transmembrane protein 106B (TMEM106B) has been linked to frontotemporal lobar degeneration 
(FTLD), a fatal neurodegenerative disease causing presenile dementia.259 TMEM106B is localised to 
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late endosomes or lysosomes. In neurons from affected patients, TMEM106B is overexpressed and 
disrupts the endosomal–lysosomal pathway, resulting in an increased risk of developing FLTD.  
It would be interesting to study the role of N-myristoylation for these two proteins involved in 
neurodegenerative disorders.  
4.8.4.3 Proteins implicated in cancer 
Some proteins have been linked to cancer. While some proteins have an anti-apoptotic effect, 
others have a tumour suppressor role. Previously reported NMT substrates linked to cancer are 
discussed in Section  5.4. 
Nucleolar protein 3 (NOL3), also known as the apoptosis repressor with CARD or ARC, is an anti-
apoptotic protein, 260 has a cardio-protective effect 261 and also plays a key role in pulmonary 
hypertension.262 ARC is expressed in many cancer cell lines,263 and its overexpression is often 
associated with cancer cell resistance to apoptosis and cancer cell survival. 260,263,264 In clinical cases, 
low levels of ARC are usually associated with higher patient survival rates in acute myeloid 
leukemia.265 ARC inhibits the extrinsic apoptotic pathway in cancer cells via the inhibition of 
caspase 8,266 and was also shown to inhibit the intrinsic pathway in p53 deficient human colon 
cancer cells in the context of hypoxia.267 Regulation of ARC is not well understood but it has been 
proposed to be regulated by Ras, a protein which plays a critical role in the development and 
progression of many cancers.268 Overexpression of activated N-Ras or H-Ras induced the 
transcription of ARC in epithelial cancer and ARC degradation was also decreased.  
Flotilin-2 (FLOT2) is part of lipid rafts, microdomains of the plasma membrane that have high 
concentrations of cholesterol and glycosphingolipids.269 Flotilin-2 was overexpressed in various 
breast cancer cell lines and breast cancer tissues from several patients.270 High levels of flotilin-2 
were associated with low survival rates. Depletion of flotilin-2 in a mouse breast cancer model 
resulted in decreased lung metastases.271  
Plasminogen receptor (KT), Plg-RKT, (PLGRKT) has been well studied in macrophages, where it has 
been shown to regulate cell surface plasminogen activation, cell migration and inflammatory 
responses.272 Plasminogen is a protein that can bind to blood clots and is converted to plasmin, a 
serine-protease capable of dissolving fibrin blood clots. Plg-RKT is a trans-membrane protein and the 
N-terminus and C-terminus are exposed on the cell surface. It is unclear what could be the role of 
myristoylation for this protein, but it has been shown to be expressed in a wide range of tissues, 
including cancerous tissues, where it may have a different function.272 Plg-RKT has been suggested to 
have an anti-apoptotic function and inhibit TNFα-induced apoptosis.272  
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Protein Niban (FAM129A) positively regulates translation via the modulation of phosphorylation of 
several proteins involved in translation, including EIF2A, EIF4EBP1 and RPS6KB1.273 Interestingly, 
knockdown of Niban increased apoptosis in HeLa cells.273 Additionally, Niban modulates the ER 
stress response and Niban overexpression appears to protect cancer cells from genotoxic stress-
induced apoptosis via degradation of p53, a protein involved in the regulation of the cell cycle and 
induction of apoptosis.274 Niban is expressed in a wide range of cancer tissues.274 
Niban-like protein 1 (FAM129B), also known as Minerva, was identified using a phosphoproteomic 
approach as a downstream target/downstream effector of the MAP kinase (Erk1/2) signalling 
cascade in melanoma cells.275 Niban-like protein 1 enhances melanoma cell invasion upon its 
phosphorylation by B-Raf, a protein kinase often mutated in human melanomas. Mutations in B-Raf 
result in an elevated kinase activity and activation of the MAP kinase pathway. Interestingly, it was 
proposed that Niban-like protein 1 could enhance cell invasion by suppressing apoptosis.276 Indeed, 
repression of apoptosis is crucial to allow cancer cells to replicate and spread. Knockdown of 
Niban-like protein 1 promoted apoptosis upon apoptosis induction by various reagents. Additionally, 
the protein was quickly degraded upon apoptosis induction, and its degradation might have an anti-
apoptotic function.275 Niban-like protein 1 has variable localisation in cells: in growing and spreading 
cells it is mostly cytoplasmic, while in confluent cells it is localised at cell junctions.276 The mechanism 
of translocation is unknown but N-myristoylation could play a role. It has also been suggested that 
association of this protein to the plasma membrane might be modulated by C-terminal 
phosphorylation.275 Interestingly, Niban-like 1 was also shown to have an effect on cell motility and 
wound repair.277  
Coiled-coil-helix-coiled-coil-helix domain-containing protein 6, mitochondrial (CHCHD6) also referred 
as coiled coil helix cristae morphology 1 or CHCM1, is essential for cristae formation in the 
mitochondria.278 These cristae are responsible for the inner mitochondrial membrane organisation 
and are thus vital for the proper function of mitochondria. CHCM1 localises to the mitochondrial 
inner membrane, and has been suggested to be an oncogene as its overexpression in cancer cells 
enhances resistance while its down-regulation increased sensitivity to anti-cancer drugs. It has thus 
been proposed to be a new target for cancer therapeutics.278 CHCM1 has also been shown to 
interact with a putative N-myristoylated protein (see Appendix F), coiled-coil-helix-coiled-coil-helix 
domain-containing protein 3, mitochondrial (CHCHD3).279 
Cytospin-B (gene name SPECC1), also known as NSP5 3a3, is expressed in cancer cells originating 
from various tissues.280 It has been proposed as a new target for cancer therapeutics in head and 
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neck carcinoma, however, agonists of NSP5a3a are required to induce toxicity 280 as its 
overexpression triggers apoptosis through the TNFR-1 signalling pathway. 
4.8.4.4 Other newly identified NMT substrates less studied 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 4 (NDUFAF4), is part of a 
protein complex involved in NADH dehydrogenation and localised at the mitochondria.281 Another 
NMT substrate, NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7 (NDUFB7), is part 
of the same protein complex.  
Leucine-rich repeat-containing protein 57 (LRRC57) is a leucine rich protein with unknown function. 
Leucine rich domains are usually implicated in protein-protein interactions.282 
Cell division cycle-associated protein 3, (CDAC3) is a F-box-like protein which regulates the cell cycle 
and especially the entry into mitosis.283 CDAC3 is involved in E3 ligase complexes that regulate the 
ubiquitination and degradation of Wee1-like protein kinase (WEE1) at G2/M checkpoint. 
RING finger protein 141 (RNF141) has a RING finger motif, capable of binding two zinc cations.284 The 
function of RNF141 is not known but most RING finger proteins are involved in protein-DNA or 
protein-protein interactions, or ubiquitin ligases.284,285 
Golgi reassembly-stacking protein 2 (GRASP2) is essential for the structure of the Golgi apparatus.286 
Protein phosphatase 1G (PPM1G) has not been well studied in the literature. 
Protein-L-isoaspartate O-methyltransferase domain-containing protein 1 (PCMTD1), protein 
FAM49B (FAM49B), mitochondrial import receptor subunit TOM40B (TOMM40L) and Opioid growth 
factor receptor-like protein 1 (OGFRL1) have unknown functions. 
MARCKS-related protein (MARCKSL1), cAMP-dependent protein kinase catalytic subunit beta 
(PRKACB) and ARF3, ARF4, ARF5 were thought to be N-myristoylated but no strong evidence could 
be found in the literature. These two proteins have been well studied in the literature. MARCKSL1 is 
involved in various signalling events, for instance cell migration and adhesion 287 while ARF3 plays a 
role in protein transport.288  
4.8.5 Comments on previously known and putative NMT substrates not identified in the 
present study 
68 proteins expressed in HeLa cells had previously been experimentally shown to be N-myristoylated 
with varying levels of confidence (Section  4.6.2 and Appendix F)). 18 of these proteins were detected 
with high confidence in the spike-in SILAC experiment (Section  4.6.3.2) or thanks to the identification 
of the YnC12-modified N-terminal peptide with AzKTB (Section  4.2.2). 
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There could be several explanations: 
 Proteins could have been mis-assigned as NMT substrates, as for example serine incorporator-1 
(SERINC1) (Section  4.7.1).  
 Some proteins were identified with low confidence in the spike-in SILAC inhibitor experiment: 
mitochondrial peptide methionine sulfoxide reductase (MSRA), Formin-like protein 3 (FMNL3), 
RING finger protein 11 (RNF11) and Zinc finger ZZ-type and EF-hand domain-containing protein 1 
(ZZEF1). 
 Finally, some previously reported N-myristoylated proteins might be below the detection limit of 
the methods discussed in the current Chapter as they might be poorly abundant in HeLa cells.  
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4.9 Conclusions 
This Chapter has discussed the use of the YnC12 probe combined with several chemical proteomics 
approaches to identify previously reported and novel N-myristoylated proteins in HeLa cells at their 
native abundance (i.e. without the need for non-native overexpression). Non quantitative (gel-free 
and gel-based approaches) and label free quantification proteomics experiments were found to be 
less reliable than quantitative approaches as they gave more false-positive protein hits.  
A spike-in SILAC approach combining the YnC12 probe and a highly specific NMT inhibitor 
characterised in Chapter 3 (IMP366) was developed and found to be a powerful method to identify 
known/putative and novel NMT substrates. This method greatly improved the accuracy and 
sensitivity of YnC12–based proteomics, resulting in the detection of 70 NMT substrates in one 
experiment. Four additional substrates were identified with the capture reagent AzKTB.  
Only co-translational NMT substrates have been studied in this Chapter. It would be interesting to 
apply the same spike-in SILAC approach to identify post-translationally myristoylated proteins in the 
context of apoptosis (Sections  1.5.2 and  2.4). 
Mass spectrometry-based proteomics is a valuable tool to study N-myristoylated protein, but 
experiments can sometimes fail. During the process of identification of the 74 NMT substrates in 
HeLa cells, several proteomics experiments (not reported here) failed to identify a similar number of 
proteins. For example, one problem encountered was due to an issue during trypsin digest. A 
triethylammonium bicarbonate solution (pH 8.5), prepared from a concentrated stock solution, was 
used for washing the beads after the enrichment. However, an extremely low number of proteins 
were identified in this experiment, probably due to the change in pH of the triethylammonium 
bicarbonate stock solution on storage, resulting in an ineffective digest. The optimal pH of trypsin is 
pH8.289 Triethylammonium bicarbonate solution was thus replaced by freshly prepared ammonium 
bicarbonate pH 7.8. Quality of the data obtained for a proteomics experiment greatly depends on 
the protocol used for the sample preparation and the proteomics platform. Indeed, optimisation of 
the LC-gradient and sensitivity of the mass detector can have a massive impact on protein coverage. 
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Chapter 5 NMT inhibition: mode of action studies 
 
In Chapter 4, 74 NMT substrates were identified with high confidence by chemical proteomics. These 
substrates have various functions in cells and N-myristoylation has been shown to be essential for 
the localisation and function of some, such as c-SRC.104 These results suggested that 
N-myristoylation is critical for cells and NMT inhibition might cause toxicity. 
In Chapter 3, a potent HsNMT inhibitor was characterised, referred to in the current study as 
IMP366. This compound was shown to cause dose-dependent inhibition of NMT in HeLa cells. The 
compound acted exclusively on-target up to 10 µM and was shown to be toxic to HeLa cells after 
3 days. Interestingly, the cells were not completely killed after 3 days. A plateau of residual 
metabolic activity of 20-30% could be observed. 
In the current Chapter, experiments are described that shed light on the consequences of NMT 
inhibition in HeLa cells. Longer inhibition experiments (up to 7 days) were carried out in cells to show 
that cancer cells can be killed completely with this strategy. The mode of action of NMT inhibitor 
IMP366 is also addressed in HeLa cells.  
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5.1? Cell cycle arrest and cell death 
5.1.1? HeLa cells  
5.1.1.1? Cell cytotoxicity assays 
Cell metabolic assays carried out in Chapter 3 showed that IMP366 was not toxic to HeLa cells after 
1 day but showed a reduction of metabolic activity after 3 days. Assays were also performed after 2 
and 7 days to evaluate the toxicity of the inhibitor after different time points (Figure 76a and b). 
 
Figure 76. IMP366 inhibition in HeLa cells. For the 7 day experiment, the culture media was replaced after 3 
days with fresh media containing the inhibitor. a) Cell cytotoxicity assay (MTS) carried out for 1, 2, 3 and 7 
days. The error bars correspond to the standard deviation between replicates (n= 6 replicates). b) EC50 values 
and parameters of the EC50 curves determined with GraFit. c) YnC12 labelling experiment to assess NMT 
inhibition after 2, 3, 7, days. YnC12 was added to the cells 6 h before the end of the experiment. Loading on 
the gel was normalised to the protein concentration and the gel was stained with Coomassie as a loading 
control.  
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After 2 days of inhibition, a decrease of metabolic activity could be observed for cells treated with 
>0.1 µM IMP366. As seen after 3 days of treatment, a plateau of metabolic activity was observed, 
but the remaining metabolic activity was higher (66%). Interestingly, the EC50 values were 
comparable between 2, 3, and 7 days. The EC50 value after 2 days was slightly higher but the 
accuracy of this measurement was limited by the small range of the assay. The assays carried out for 
7 days showed for the first time that selective NMT inhibition could completely kill HeLa cells.  
The inhibitor was shown to be stable in aqueous media for 3 days (Section  3.3.3.6) and NMT should 
thus still be inhibited after several days. To check that the inhibitor was not metabolically hydrolysed 
in cells, an YnC12-tagging experiment was carried out during the final 6 hours of the viability assay 
(Figure 76c). This experiment confirmed that HsNMT was still inhibited dose-dependently in cells 
after 2, 3, and 7 days. The Coomassie had a different pattern for the cells treated with the highest 
concentrations of inhibitor, probably due to increasing levels of cell death. Upon NMT inhibition with 
>1 µM of IMP366, cells started to detach from the plate after 2 days. However, it is important to 
note that cells in suspension where always recovered and included in all the following experiments 
described in this Chapter. 
We hypothesised that the cells might stop dividing and then start to die after 2 days, paralleling the 
decrease in metabolic activity (Figure 76a and b).  
A simple experiment was performed to compare the number of cells in a plate treated with IMP366 
(1 µM) for 1, 2, 3 days or with DMSO as a control (Figure 77). Cells were counted with a 
hemocytometer. After 1 day of treatment, the same number of cells was present in both samples 
(control and inhibited cells), but after 2 and 3 days there was a noticeable decrease of the number of 
cells compared to control, suggesting that the cells stopped dividing and/or died. A cell cycle analysis 
was required to understand if the hypothesis was correct; observation of cell viability with trypan 
blue proved difficult due to limited colour differentiation between viable and non-viable cells, and 
therefore alternative methods were employed to assess cell viability after several days of treatment 
with the NMT inhibitor (Section  5.1.1.2.2 and Section  5.2.2.2 ). 
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Pictures of the cells were taken after 0, 1, 3, 7 days (Figure 78). After 1 day, cells treated with 1 μM 
of the inhibitor looked the same as at the beginning of the experiment. After 3 days, many 
rounded-up cells were present. After 7 days, cells were mostly rounded-up and appeared to be 
dead.  
 
 
5.1.1.2? Cell cycle analysis 
5.1.1.2.1? Introduction to flow cytometry and cell cycle analysis 
Flow cytometry is a process for simultaneously measuring and then analysing several physical 
characteristics of single particles, such as cells, as they flow through a beam of light in a fluid stream. 
Multiple properties can be measured thanks to the use of several lasers: the relative fluorescence 
intensity, the particle’s relative size, granularity or internal complexity.290 
 
Figure 77. Cell counts. HeLa cells were treated with inhibitor IMP366 for 24, 48, 72 h or with DMSO as a 
control. Cells were harvested and counted using a hemocytometer. The errors bars correspond to the standard 
deviation of three biological replicates. Different amount of cells were seeded for the 24, 48, 72 h, aiming to 
reach 80-90% confluence in the control. The number of cells can thus not be compared between different time 
points. 
 
 
Figure 78. Pictures of the cells after 0, 1, 3, or 7 day treatment with IMP366 (1 μM). 
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Flow cytometry can be used to carry out cell cycle analysis experiments.290 Cells are first fixed, killing 
the cell but leaving their shape and structure intact; however, the cellular membrane becomes 
permeable and reagents can be added to stain specific cell components. Propidium iodide (PI), a 
fluorescent compound which can intercalate into DNA, is commonly used to study the cell cycle 
(Figure 79a). Samples are usually supplemented with RNAse to digest RNA and ensure that only DNA 
is stained; the fluorescence intensity observed for a single cell is thus proportional to the amount of 
DNA. During the cell cycle, cells go through phases known as G1, S, G2 and M (mitosis) (Figure 79b). 
The amount of DNA is indicative of the cell cycle phase: in G1, cells have 2 copies of DNA, in S phase 
between 2 and 4 copies and in G2, just before mitosis, 4 copies. When cells are stained with PI, the 
fluorescence intensity of each individual cell can be measured by flow cytometry and the number of 
cells plotted against the relative fluorescence intensity (Figure 79c, non-treated HeLa cells). Two 
peaks are observed in Figure 79c, and the relative fluorescence intensity of the second peak (ca. 
100K RFU) is 2-fold higher than the fluorescence of the first peak (ca. 50K). The second peak 
corresponds to cells with 4 copies of their DNA (G2 phase, coloured in blue) while the first peak 
corresponds to cells with only 2 copies of their DNA (G1 phase, coloured in green), and between 
these peaks are cells in S phase (coloured in yellow). If cells have relative fluorescence intensity 
lower than cells in G1, they would correspond to a so-called subG0/G1 phase, and would be the 
apoptotic or dead cells present in the sample. The area under the curve can be integrated using 
FlowJo software to determine the relative proportion of cells in each state. 
For cell cycle analysis it is essential to measure the fluorescence intensity of single cells only, and 
thus samples are usually filtered prior to analysis to remove aggregates; however, this is often 
insufficient to generate a homogenous sample of single cells. The different physical characteristics of 
particles are therefore used to create cut off limits (gates) and define single particles: two voltage 
pulses are measured, the side-scatter pulse (SSC) which is related to the internal complexity of the 
particle, such as the shape of the nucleus, and the forward-scatter pulse (FSC), which depends on 
the cell volume. Each pulse has three characteristics: the height which measures the maximum 
fluorescence intensity, the width which corresponds to the transit time and the area which relates to 
the total fluorescence of the particle. Single cells have similar physical properties and gates can be 
created to select these cells for the cell cycle analysis (Section  5.1.1.2.2).  
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5.1.1.2.2? Cell cycle analysis after NMT inhibition 
HeLa cells were treated with various concentrations of inhibitor IMP366 and with DMSO as a control 
for 1, 3 or 7 days and subjected to cell cycle analysis; Figure 80 shows examples of the plots obtained 
at 1 μM IMP366. Single cells were selected by creating gates as mentioned above (Figure 80 a and b 
and Section ?5.1.1.2.1) and the number of single cells plotted against fluorescence intensity for 
different treatment conditions (Figure 80 c-f). After 3 days of treatment with 1 μM IMP366, a 
“shoulder” (boxed in red) can be observed on the G1 peak, characteristic of apoptotic cells. After a 
7 day treatment, a substantial population of dead cells (boxed in red) can be observed. These dead 
and apoptotic cells correspond to the subG0/G1 phase. 
 
Figure 79. Principle of the cell cycle analysis using propidium Iodide (PI) and flow cytometry. a) Structure of 
PI. b) Scheme of the cell cycle showing the different phases. c) Typical plot obtained with FlowJo for a cell cycle 
analysis experiment, obtained with non-treated HeLa cells. The number of cells is plotted against the 
fluorescence intensity (RFU). The area under the curve corresponding to each phase of the cell cycle and can 
be integrated using FlowJo. 
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Area under the curve was integrated using FlowJo (Figure 81a). 0.2 μM corresponds to the EC50 
value measured by MTS assay, whilst 1, 5 and 10 μM correspond to concentrations that inhibit >90% 
NMT in cells (Section ?3.3.1), and lead to the plateau of residual MTS signal observed after 3 days 
(Figure 76). At 5 and 10 μM, NMT is completely inhibited in cells (Figure 76 and Section 3.3.1). 
After 1 day, there were no more dead cells in samples treated with IMP366 than in the control 
(DMSO) (Figure 81). However, in samples treated with 1, 5, or 10 μM of the inhibitor, there is a small 
G1 accumulation. After 3 days, there is a substantial population of dead/apoptotic cells in the 
samples treated with >1 μM of inhibitor. In theory, the same partition of cells through the cell cycle 
 
Figure 80. Typical plots obtained for a cell cycle analysis experiment. a-c) were obtained from the same 
sample (cells treated with DMSO as a control). a) and b) show how the data were gated using different 
parameters (FSC-A, FSC-A, FSC-W and PI fluorescence intensity) to select single cells. Particles (single cells and 
cell aggregates) are shown as dots. The colour indicates the density of particles on the scatter plots (red = high 
density, blue = low density). Single cell population can be selected (as circled in black) in a) and plotted in b). 
b) Allows to further discriminate cell doublets. c) Shows the plot obtained after gating and doublet 
discrimination. d-f) Typical plots obtained after gating (the same gates as shown in a) and b) were used across 
all the samples). Cells were treated for d) 1 day, e) 3 days or f) 7 days with IMP366 (1 μM). The number of cells 
was plotted against the fluorescence intensity. Apoptotic cells can be seen after 3 days (circled in red) and an 
significant population of dead cells can be observed after 7 days (boxed in red). Cell cycle analysis was carried 
out on a BD LSRFortessa analyser and the data were analysed with FlowJo. SSC-A, FSC-A, FSC-W and PI 
fluorescence intensity are in RFU. 
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should be observed for samples treated with 5 and 10 μM inhibitor, as NMT is completely inhibited 
in both samples. However, it appears that more dead cells are present in the 10 μM sample, 
suggesting that there might be off-target effects of the inhibitor at this concentration or that the 
in-gel fluorescence assay is not sensitive enough. These results correlate well with the cell metabolic 
data (Figure 76). 
After 7 days of inhibition, cells were mostly dead/apoptotic (subG0/G1) in the samples treated with 
>1 μM of inhibitor. However, the integration of the curve obtained when the number of cells is 
plotted against relative fluorescence intensity is prone to error during high levels of cell death due to 
the overlap with G1 cells, (Figure 80f) and cells dead for more than 4 days are likely to be degraded 
into small particles that lie outside the gates used for the experiment (Figure 80 a and b). The 
number of dead/apoptotic cells is therefore likely to be significantly higher than measured here, as 
shown by the MTS assay since there was no viable cells left after 7 days in samples treated with 
>5 μM of inhibitor (Figure 76). Cells treated with 0.2 μM of inhibitor are not all dead after 7 days and 
this result correlates well with the MTS assay after 7 days (Figure 76). These findings suggest that 
upon NMT inhibition cells undergo a G1 arrest followed by cell death, possibly through apoptosis 
(Section ?5.2). NMT inhibition also appears to have a relatively slow onset of cytotoxicity, and this 
may be due to the time required to turn over existing N-myristoylated proteins in cells. The turnover 
of NMT substrates is studied further in Section ?5.3.  
 
Figure 81. HeLa cells treated with IMP366 for 1, 3, 7 days. For the 7 day experiment, the culture media was 
replaced after 3 days with fresh media containing the inhibitor. Cell cycle analysis showing the distribution of 
cells across subG0/G1 (dead + apoptotic cells), G1, S and G2 phases. Standard deviation (SD, n= 3 biological 
replicates) was <10%. The data were processed using the Dean-Jett-Fox integration option in FlowJo.  
169 
 
5.1.1.3? Regeneration of N-myristoylated proteins following NMT inhibition 
After 1 day inhibition, no dead cells were observed in the samples treated with a concentration 
sufficient to fully inhibit NMT in cells (Section ?5.1.1.2.2). To test whether cells can regenerate their 
complement of N-myristoylated proteins, cells were treated with inhibitor IMP366 (1 μM) or with 
DMSO as a control for 24 h (Figure 82a). Cells were then washed three times with PBS buffer and 
fresh media containing YnC12 was added to label NMT substrates. Interestingly, cells previously 
treated with the inhibitor or DMSO had similar labelling patterns and intensities, across all recovery 
time points. After 24 h inhibition, cells appeared to recover from inhibition and this result correlates 
well with the apparent lack of cytotoxicity after 1 day (Figure 76).  
5.1.2? Other cell lines 
Similar experiments as described in Section ?5.1.1 were performed in cancer cell lines originating 
from different tissues.  
5.1.2.1? Cell cytotoxicity assays 
MTS assays were carried out to study cytotoxicity of IMP366 in various cancer cell lines: 
MDA-MB-231 (breast cancer), HCT-116 (colon), MCF-7 (Breast), HepG2 (liver). Hek293, an 
immortalised human embryonic kidney cell line was also studied (Figure 83). 
 
Figure 82. Recovery from inhibition. Cells were treated for 1 day with IMP366 (1 μM) or DMSO, washed with 
PBS (3x) and allowed to recover in fresh culture media supplemented with YnC12 (20 μM) for several hours.  
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A similar pattern was obtained for HeLa, HepG2 and Hek293 cells. MDA-MB-231 and HCT-116 were 
not as strongly affected by NMT inhibition, and had residual metabolic activities of 51% and 73% 
respectively. MCF-7 also had a different pattern with a low EC50 value and a plateau of metabolic 
activity at 64%. It was decided to use MDA-MB-231, MCF-7 and HCT-116 for further investigations. 
Cells were counted after 3 days on inhibition with IMP366 (1 μM) (Figure 84). A decrease in the 
number of cells was observed compared to the control for the three cell lines tested, suggesting that 
the cells, like HeLa cells (Figure 77), stopped dividing or died upon IMP366 treatment.  
 
 
Figure 83. Cytotoxicity (MTS assay) in various cell lines treated with IMP366. a) Response (% metabolic 
activity) was plotted against inhibitor concentration for the 6 cell lines tested. Data were fitted to an IC50 
function in GraFit, error bars represent standard deviation (n = 3 biological replicates). b) EC50 values and 
parameters of the EC50 fit are indicated for the 6 cell lines tested. SD = standard deviation. 
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5.1.2.2? Flow cytometry 
Cell cycle analysis experiments were carried out in MDA-MB-231 to establish if a G1 accumulation 
could also be observed (Figure 86a). The cell cycle analysis was carried out after 1 and 3 day 
inhibition with various concentrations of IMP366. 
 
Figure 84. Cell counts after 3 day treatment with IMP366. HCT-116, MDA-MB-231 and MCF-7 were treated 
with inhibitor IMP366 for 72 h or with DMSO as a control. Cells were harvested and counted using a 
hemocytometer. The errors bars correspond to the standard deviation of three biological replicates.  
 
Figure 85. Effects of NMT inhibition on MDA-MB-231 cells. Cells were treated for 1 or 3 days with IMP366 or 
treated with DMSO as a control. M = Myr. a) Cell cycle analysis. SD <10%. b) YnC12 tagging experiment. Cells 
were inhibited for 24 h and Ync12 was added 6 h before the end of the experiment. The background on the gel 
was relatively high and samples were base-treated (0.2 M NaOH, 1 h) to determine whether the background 
corresponded to the incorporation of YnC12 into S-palmitoylated proteins. c) Pictures of the cells treated with 
DMSO or IMP366 (1 μM) after 3 days. 
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NMT inhibition in MDA-MB-231 resulted in a similar partition of the cells through the cell cycle as 
HeLa cells, and cells appeared to accumulate in G1 before dying. A YnC12-tagging experiment was 
also carried out after 3 days to check that the concentrations required to inhibit NMT in MDA-MB-
231 were similar to the ones required in HeLa (Figure 85b).  
Interestingly, MDA-MB-231 cells seemed to round and detached from the plate after 72 h treatment 
with 1 µM of inhibitor (data not shown). These cells were at first thought to be dead, but the cell 
cycle analysis showed that less than 30% of cells where in subG0/G1 in the sample, suggesting that 
the cells in suspension were not dead. Some NMT substrates, such as ARF6, are known to be 
necessary for cell adhesion and NMT inhibition might lead to a detachment of the cells when these 
substrates are not N-myristoylated.288 However, it has been suggested that some cells can undergo 
apoptosis when they are in suspension291,291 and there is clearly not a simple relationship between 
NMT inhibition and cell death in this cell line. The detachment of cells would make studies of NMT 
inhibition more difficult in MDA-MB-231.  
 
Similar experiments were carried out with HCT-116 and MCF-7 cells (Figure 86). Cells were treated 
for 1, 2 or 3 days with only one concentration of IMP366 (1 µM). Similarly to HeLa and MDA-MB-231, 
cells underwent a G1 accumulation after 1-2 days, followed by an increase in the number of dead 
cells after 3 days. The appearance of the cells changed after 2 days of treatment. Cells seemed to 
spread less on the plate but were instead growing in clusters (data not shown). YnC12 tagging 
experiments confirmed NMT inhibition was maintain from up to 3 days (data not shown). 
These results suggest that NMT inhibition might have a similar effect (G1 accumulation and 
increasing cell death over time) in a range of cancer cell lines. However, some cells appeared to be 
more sensitive than others to NMT inhibition (Figure 83). The sensitivity might be dependent on the 
NMT substrates expressed in these cell lines, the balance between NMT levels/activity, NMT 
substrate levels, and the particular importance of certain substrates to the specific cell line.  
For the four cancer cell lines studied, all the cell cycle plots after 3 day inhibition had a characteristic 
shoulder on the G1 peak as observed in Figure 80e, suggesting cell death by apoptosis. Experiments 
are described in Section  5.2 to assess this observation. 
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5.2? Apoptosis 
5.2.1? Introduction to apoptosis 
Apoptosis, also known as programmed cell death, corresponds to a cascade of events in cells leading 
to cell death.292 Apoptosis plays key roles in the early development of an organism, cellular 
responses to nutrient deprivation and diseases. Healthy cells can commit suicide when they are no 
longer needed by activating the apoptosis pathway, and apoptosis can also be triggered in cancer 
cells by many therapeutically relevant agents.292
Although the detailed mechanisms of apoptosis can be extremely complex and is not fully 
understood, programmed cell death is generally triggered through two main pathways:292 the 
intrinsic pathway, also referred as the mitochondrial pathway, and the extrinsic pathway, also 
known as the death receptor pathway; there is some crosstalk between these pathways. The 
extrinsic pathway usually involves the interaction of a ligand, such as TRAIL (TNF-related apoptosis-
inducing ligand), with death receptors, that causes activation of initiator caspase 8, followed by the 
activation of the execution pathway. The intrinsic pathway can be activated by several reagents or 
conditions such as radiation, hypoxia or DNA damaging agents. A cascade of signalling events results 
 
Figure 86. Cell cycle analysis of HCT-116 (a) and MCF-7 (b) treated with IMP366. The error bars represent the 
standard deviation from 3 biological replicates. The data were processed using the Dean-Jett-Fox integration 
option in FlowJo. 
 
174 
 
in the activation of initiator caspase 9, followed by initiation of the execution pathway. A third 
pathway, known as the perforin/granzyme pathway, is triggered by T-cells.292  
Apoptotic pathways are complex and can differ from one cell line to another. Each of the three 
pathways mentioned above result in the initiation of the executive pathway, which is mediated 
through cleavage and activation of caspase 3. This has several consequences in the cell, including 
degradation of cellular proteins, DNA fragmentation, development of apoptotic bodies and 
expression of proteins and lipids on the outer cellular membrane allowing phagocytes to recognise 
and degrade the apoptotic cell.  
Several characteristics of apoptotic cells allow their detection by analytical methods.292 
 Detection of caspase activation or cleaved substrates can be observed by fluorescence assays or 
Western Blot analysis. 
 Mitochondrial alterations have multiple effects, such as the release of cytochrome C from 
mitochondria. This change is observed only when the intrinsic pathway has been activated. 
Cytochrome C release can be visualised by several techniques, including western blot analysis.  
 Membrane alterations result in the redistribution of ligands such as phosphatidylserine to the 
outer surface of cell membranes. This ligand can be detected with fluorescently labelled 
Annexin-V by fluorescent microscopy or flow cytometry.  
 DNA fragmentation can be studied using the TUNEL (Terminal dUTP Nick End-Labelling) assay or 
DNA separation techniques.  
 Morphological changes characteristic of apopotosis (membrane blebbing, electron dense 
nucleus, etc.) can be observed for late-stage apoptotic cells using microscopy.  
It is important to note that cell death can also occur via other mechanisms, including necrosis 293 and 
autophagy.293 Necrosis is usually caused by unexpected and accidental cell damage, but many 
characteristics of apoptosis and necrosis overlap and multiple analyses must be carried out to 
distinguish between them.292 Autophagy has been suggested as another mechanism of programmed 
cell death, and involves degradation of cellular components through lysosomes.293 Low levels of 
autophagy are vital in cells to regulate protein and organelle turnover (Section  5.3.1), but high levels 
lead to cell death. Other mechanisms of cell death, such as mitotic catastrophe, have been reported 
but are controversial.294 
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5.2.2? Detection of caspase activation or cleaved substrates by Western blotting 
5.2.2.1 HeLa cells treated with staurosporine
As explained in Section ?5.2.1, apoptosis can be detected by observing the cleavage of caspases by 
Western blot analysis. Cleaved caspases become activated and allow the progression of apoptosis to 
the next step of the cascade pathway. Activated caspases can cleave proteins, such as BID or PARP.  
To establish a positive control for apoptosis, staurosporine (STS) was employed (Section ?2.4). STS 
binds to the ATP-binding site of many kinases in cells, blocking phosphate transfer and inducing 
apoptosis, probably through caspase 3 activation.295 4 h and 8 h after the addition of STS (1 μM) to 
HeLa cells, caspases 3 and 8 were cleaved (Figure 87). BID, a protein involved in the intrinsic 
pathway, and PARP, a late marker of apoptosis, were both cleaved.  
 
Tubulin was used as a loading control but the levels of tubulin decreased after 8 h. The protein 
loading on the Western blot was based on the total protein concentration, as determined with the 
DCTM protein assay (Bio-Rad). Since proteins are progressively degraded it is difficult to find a 
suitable loading control to study apoptotic cells.  
 
Figure 87. Western blot analysis showing the induction of apoptosis in HeLa via STS treatment. Cells were 
treated with STS (1μM) for 0, 4 or 8 h. Protein loading on the gel was normalised to the protein concentration 
and Tubulin was used as a loading control. 
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HsNMT1 and HsNMT2 were previously shown to be cleaved during apoptosis in an extensive study 
of proteolysis in the apoptotic proteome by mass-spectrometry based proteomics in Jurkat T-cells.91 
Here it was found that HsNMT1 was unambiguously cleaved in HeLa cells after 4 h and a 50 kDa 
fragment was released (Figure 88). HsNMT2 was also cleaved upon apoptosis induction, but Western 
blot analysis proved to be difficult with the HsNMT2 antibody available during this PhD project. 
Several antibodies were tested by Ute Brassat (Tate group, Imperial College London), but none gave 
a selective and strong signal in chemiluminescence. 
The HsNMT1 and HsNMT2 antibodies were tested against the four recombinant HsNMT enzymes 
available: the full length HsNMT1/2 and the HsNMT1/2 truncated at the N-terminus (Section ?2.2.2). 
The HsNMT1 antibody recognised full and short length HsNMT1 as well as HsNMT2. The HsNMT2 
antibody could only detect full length HsNMT2. This result was expected as the epitope of this 
antibody is based on the N-terminus of HsNMT2.  
 
Figure 88. NMT cleavage during apoptosis. a) HeLa cells were treated with STS for 0, 4, 8 or 16 h and a 
Western Blot analysis was carried out. PARP was used as a control for induction of apoptosis. Loading on the 
gel was normalised to the protein concentration and tubulin was used as a loading control. b) Western blot 
analysis of the recombinant HsNMT enzymes: full length HsNMT1 and HsNMT2 and amino-terminal truncated 
???????????????????????????????????-His6 western blot was used to confirm that the enzyme had a His-tag 
at the C-terminus. 
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Recently, Perinpanayagam et al. identified the cleavages site of both HsNMT isoforms.115 HsNMT1 
was shown to be cleaved at Asp-72 by caspase 3 and 8 while HsNMT2 was cleaved after Asp-25 by 
caspase 3. The activities of cleaved and full length HsNMTs were highly similar, suggesting that 
cleaved enzymes are still functional and can myristoylate NMT substrates post-translationally such 
as BID (see Sections  1.5.2 and  2.4). This is consistent with a previous observation. Rundle et al. 
suggested that the N-terminus of HsNMT was not essential for the catalytic activity.50  
Cleavage of HsNMT1 at Asp-73 results in the removal of the “K box motif”, known to be essential for 
ribosomal targeting of the enzyme (Section  1.6.2). As expected, Perinpanayagam et al. showed that 
NMT moved to the cytosol upon apoptosis induction. Interestingly, HsNMT2 was cleaved just before 
the “K box motif” and it was shown to shift from the cytosol to the membrane fraction upon 
apoptosis induction. It is unclear why full length HsNMT1 and HsNMT2 have different localisation in 
cells; although their sequences diverge mainly in the N-terminal region (Section  1.2.2), they both 
carry a polybasic region (“K box motif”) known to target proteins to the ribosome,21 and this 
phenomenon may merit further investigation due to its apparent role in apoptosis.  
5.2.2.2 HeLa cells treated with IMP366 
After confirming that we could detect apoptosis in HeLa using a selection of antibodies, we studied the 
potential induction of apoptosis in cells treated with IMP366 for 1, 3 or 7 days. STS was used as a 
control for apoptosis (Figure 89). Markers of apoptosis did not changed after 1 day inhibition, 
suggesting that the compound does not trigger apoptosis or induce toxicity after 1 day as previously 
indicated (Figure 76). However, at 3 days inhibition, PARP, BID, Caspase 3 and HsNMT1 were all 
cleaved to a substantial extent. Tubulin was used as a loading control. After 7 days inhibition, it 
proved difficult to detect full length or cleaved PARP, HsNMT1 and Caspase 3; it may be supposed 
that these proteins have been fully degraded in these cells.  
Interestingly, BID seemed to accumulate in cells after 7 days. It is possible that when BID is not 
N-myristoylated, it may be more resistant to proteolytic degradation, and may accumulate in the 
cytosol since it cannot relocate to the mitochondria.8  
These results suggested that HeLa cells were dying at least in part through apoptosis. However, as 
explained in Section  5.2.1, it can be difficult to distinguish between apoptosis and necrosis. It is thus 
necessary to perform several assays, based on different principles, to confirm apoptosis.  
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5.2.3? Flow cytometry (Annexin V/PI) 
An assay based on the detection of phosphatidylserine relocalised to the outer membrane of the 
cells by flow cytometry is a simple and reliable method for detecting dying cells 296,296 since 
phosphatidylserine can be detected by fluorescently-labelled Annexin V.296 However, Annexin V 
cannot distinguish necrotic and dead cells from apoptotic cells as phosphatidylserine moves to the 
outer surface of the cell membrane in all cases; Annexin V is therefore used in combination with PI 
(Section ?5.1.1.2.1), which only stains the nucleus of cells that have a permeable cell membrane, such 
as necrotic cells, late apoptotic cells or dead cells. Early/mid apoptotic cells will only be labelled by 
Annexin V (Figure 90a). 
Treatment of the cells with 1 or 5 μM IMP366 gave consistent results, and DMSO treatment was 
included as a negative control (PI negative, Annexin V negative) (Figure 90b). Early apoptotic cells 
appeared after 24 h treatment and a substantial population of dead cells could be observed after 
3 day treatment. The percentages of apoptotic cells (subG0/G1) differ from the cell cycle analysis; 
entry into subG1 phase is a later event than phosphatidylserine relocation, and it is therefore 
unsurprising that after 1 day treatment, around 14% of the cells are labelled with Annexin V whereas 
only 5% subG0/G1 cells were detected by cell cycle analysis. After 3 days, the percentage of cells 
undergoing early apoptosis plus dead cells correlates well with the number of cells in SubG0/G1 
detected by cell cycle analysis, and the percentage of cells in subG0/G1 was lower for cells treated 
with 1 μM than with 5 μM (ca. 35% and 50% respectively). 
 
Figure 89. Evaluation of IMP366 in HeLa cells. Western blot analysis after 1, 3, or 7 days of treatment with 
IMP366. Cells were treated with STS (1μM) for 4 h as a control for apoptosis. Loading on the gel was 
normalised to the protein concentration and tubulin was used as a loading control. 
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Cells all undergo apoptosis or are dead/necrotic after 7 days. The number of dead cells after 7 days 
can be underestimated as degraded cells can produce particles that fall outside the set gates 
(Section ?5.1.1.2.2). This result is consistent with the cell cycle analysis (Figure 81) and with the MTS 
assay (Figure 76).  
Figure 90. Annexin V/PI experiment to confirm that HeLa cells dies through apoptosis upon NMT inhibition. 
a) Scheme explaining where healthy, apoptotic and dead (as well as necrotic and late apoptotic) cells should 
appear when the PI-fluorescence is plotted against the Annexin V-fluorescence. b and c) HeLa cells were 
treated with DMSO or IMP366 (1 or 5 μM) for 1, 3 or 7 days and labelled with Annexin V/PI before being 
analysed by flow cytometry. Samples were analysed with FlowJo.  
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5.2.4 Comments on other possible mechanisms 
The Western blot analysis and the Annexin V/PI experiment confirmed that cells were dying through 
apoptosis, probably via a caspase-dependent pathway. However, this mechanism might not be 
exclusive. First, a caspase-independent pathway can also be involved in cell death.297 Secondly, other 
modes of cell death, such as autophagy can occur at the same time as apoptosis;298 cells in the top 
left corner of each analysis in Figure 90 may indicate the presence of autophagic cells.299 Moreover, 
different concentrations of a single reagent can also induce distinct mechanisms of cell death.300  
Apoptosis-resistant cell lines may be resistant to NMT inhibition if the mode of cell death is 
exclusively apoptotic.301 A better understanding of the mode of cell death could shed light on which 
(cancer) cell types are likely to be most sensitive to NMT inhibition. 
Several questions remain to be answered: 
 Is the mechanism of cell death only apoptotic? The evidence suggests a mix of necrosis and 
apoptosis. 
 Is the mechanism of apoptosis via the intrinsic or extrinsic pathways? Presumably, the intrinsic 
pathway is involved as the NMT inhibitor does not target the death receptors. However, as BID is 
usually cleaved upon activation of the extrinsic pathway, suggesting that there is some crosstalk 
between these pathways. 
 Would NMT inhibition delay apoptosis as some effectors proteins, such as BID,8 require 
N-myristoylation to induce the next step of the apoptotic cascade? This question is discussed in 
Section 5.2.5. 
 Is only a caspase-dependent pathway involved?  
 How is apoptosis initiated, and what are the key NMT substrates that lead to cell death when 
they are not myristoylated? This question is discussed in Section  5.4.1. 
 Which tissues/cancer cell types are more sensitive to NMT inhibition?  
 
5.2.5 Does NMT inhibition delay apoptosis? 
Cytochrome C release from the mitochondria is a key characteristic of the intrinsic apoptosis 
pathway.292 One of the requirements for cytochrome C release is the binding of BID to mitochondria. 
In early stages of apoptosis, BID is cleaved by caspase 8 and is N-myristoylated. N-myristoylation is 
known to be essential for cytochrome C release;8 when BID could not be N-myristoylated in 
Fas-activated (apoptotic) MCF-7 cells, cell viability significantly increased.8  
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It was hypothesised that cytochrome C might not be released upon induction of apoptosis with the 
NMT inhibitor IMP366. A positive control was first carried out with STS treatment followed by cell 
fractionation (Figure 91a), and calnexin was used as a control for the membrane fraction. While a 
small percentage of tubulin is associated with the mitochondria,302 most is cytoplasmic and hence 
serves as a good marker for this compartment. 
HeLa cells were then treated with NMT inhibitor for several days and changes in the subcellular 
localisation of cytochrome C were determined by Western blotting of fractionated cell lysates. Levels 
of cytochrome C appeared to decrease in the membrane fraction after 3 days, suggesting that 
cytochrome C was released from the mitochondria. However, the levels of cytochrome C in the 
cytosol did not increase. After 3 days, the control for the cell fractionation (tubulin and calnexin), 
were unreliable. Tubulin, the control for the cytosolic fraction relocated to the membrane fraction 
after 3 days. This relocation is probably an artefact due to the high number of apoptotic or dead 
cells. In the control experiment, few dead cells were observed and tubulin was cystoplasmic (Figure 
91a). Calnexin could not be detected in the membrane fraction after 3 days. 
From this experiment, it is difficult to conclude that cytochrome C is released from the mitochondria. 
The apparent decrease of cytochrome C in the membrane fraction might be caused by its 
degradation. An NMT substrate, HCCS, is required for the proper maturation of cytochrome C via the 
transfer of heme to cytochrome C (Section ?4.8.4.1).93,249 Recently, it was also demonstrated that 
HCCS regulates the import of cytochrome C into mitochondria.303 It is possible that upon NMT 
 
Figure 91. Cell fractionation experiments to study localisation of proteins upon apoptosis induction with STS 
or IMP366. a) HeLa cells were treated with DMSO or STS (1 μM) for 4 h. Cells were fractionated and the 
membrane and cytosolic fraction were analysed by Western blotting. b) HeLa cells were treated with IMP366 
(5 μM) for 0, 1, 3 or 7 days. Cells were fractionated and the membrane and cytosolic fractions were analysed 
by Western blotting. 
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inhibition, HCCS might not be able to import cytochrome C to the mitochondria and cytochrome C 
might be degraded. 
To determine if NMT inhibition could prevent or delay apoptosis, HeLa cells with treated with DMSO 
(8 h), STS (8 h), STS in the presence of IMP366 (8 h) and IMP366 (3 days) (Figure 92). Cleavage of 
caspase and effector proteins occurred in both STS-treated samples. These samples appeared 
morphologically similar, suggesting that IMP366 does not stop or delay apoptosis. However, STS is a 
non-selective kinase inhibitor and might induce apoptosis through several pathways 
simultaneously.295,304 
To test the hypothesis that NMT inhibition might delay apoptosis it would be advantageous to 
analyse a cell line highly dependent on the BID pathway or an apoptosis inducing agent triggering 
 
Figure 92. NMT inhibition does not delay apoptosis in HeLa. a) Western blot analysis of cells treated for 8 h 
with DMSO, or STS (1 μM) or STS (1 μM) in the presence of IMP366 (1 μM). after 1, 3, or 7 days of treatment 
with IMP366. Cells were treated with STS (1μM) for 4 h as a control for apoptosis. Loading on the gel was 
normalised to the protein concentration and tubulin was used as a loading control. In the last lane, the sample 
was treated with IMP366 (1 μM) for 2 days. b) Picture of a Western blot membrane stained with Ponceau S to 
control protein loading. 
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only the BID pathway. In preliminary experiments, Western blotting showed that MDA-MB-231 cells 
and HCT-116 were not highly dependent on BID cleavage as BID was not cleaved while PARP and 
some caspases were cleaved (data not shown). Two other apoptosis inducing agents (TRAIL305 and 
Oxaliplatin 306) have also been tested as they have been suggested to induce apoptosis through a 
BID-dependent pathway. However, these reagents did not induce BID cleavage even though 
apoptosis was triggered (data not shown). 
5.3 N-myristoylated proteins turnover 
NMT inhibition showed a slow apoptotic response in HeLa cells and as suggested in Section  5.1.1.2.2, 
this might be due to the turnover rate of N-myristoylated proteins. 
5.3.1 Introduction to protein turnover 
The levels of individual proteins in cells do not only depend on the rate of synthesis, but also on rate 
of degradation.307 Proteins are constantly degraded and synthesised to maintain cellular 
homeostasis, even when cells are not dividing. This dynamic state can be studied by evaluating the 
protein turnover rates, which are linked to protein half-lives. The turnover rates vary across each 
type of protein in a cell, between cell lines, and under different conditions. Proteins are degraded for 
two main reasons :307  
 Quality control: proteins which are damaged, denatured or misfolded can be degraded. 
 Regulation of biological pathways: some proteins can for example be degraded to allow the cells 
to enter the next phase of the cell cycle. Proteins degradation is also required for apoptosis or 
receptor mediated endocytosis. 
 
They are two known mechanisms for intracellular proteolysis.307 In lysosome-dependent 
degradation, lysosomes degrade extracellular proteins or intracellular components by autophagy. 
The other degradation mechanism is based on the ubiquitin-proteasome pathway in which proteins 
to be degraded are tagged with ubiquitin and digested by the proteasome, a proteolytic protein 
complex. Ubiquitin is covalently attached to the condemned protein by the successive action of 
three enzymes: E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme) and E3 
(ubiquitin-protein ligase). It has also been suggested that some proteins might be degraded by 
proteasomes without ubiquitination.308 
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5.3.2 Is it possible to predict protein turnover? 
It has been suggested that protein turnover could be highly dependent on the protein N-terminal 
sequence309,310 and some online predictors, such as ProtParam, 311 are available to predict protein 
turnover rates based on this hypothesis. It was also proposed that protein stability might depend on 
the protein molecular weight,312 isoelectric point,313 protein abundance314, or frequency of PEST 
motifs.314 However, all these results are controversial.314,315 Recently, it was suggested that proteins 
which are part of the same protein complex, such as the 26S proteasome, have similar turnover 
rates.315 
It was also shown that phosphorylation can control protein ubiquitylation 316 and thus regulates the 
protein turnover. Phosphorylated proteins have been shown to have a higher turnover rate, on 
average, than non-phosphorylated proteins.315  
5.3.3 Methods to study protein turnover 
The development of MS-based proteomics and the use of radiolabelled isotopes have made possible 
the high-throughput study of protein turnover. Protein half-life in HeLa cells was reported in two 
recent studies,314,315 however, they used two different methods, and they produced different results.  
In the first study (published by Cambridge et al. in 2011)315 protein turnover was studied in 
non-dividing cells. Cells were grown in a SILAC media (Section  4.5) containing a mixture of heavy and 
light isotopes (1:1 heavy : light (R10K8: R0K0)) for several passages. Cells were then kept highly 
confluent for more than 24 h and the media was replaced by heavy media (R10K8 DMEM) 
supplemented with only 2% FBS just before the beginning of the experiment.  
This method presents several advantages and drawbacks. Studying protein turnover in non-dividing 
cells would avoid labelled protein dilution arising from cell division.317,318 They assumed that the 
amount of each protein was kept constant, but the conditions used would also be expected to affect 
the turnover rate of specific proteins. Presumably, in non-dividing cells, the cell cycle is arrested and 
proteins required to be degraded for cell cycle progression such as cyclins might not be degraded, 
and thus have a lower turnover rate.319 However, they showed that some cyclin proteins still had a 
high turnover rate. The other advantage of their method is that they labelled the cells with a 1:1 
light : heavy isotope ratio., which allowed relative quantification of turnover of low abundance 
proteins even at time 0. However, the ratio of H/L might differ from one protein to the other at time 
0 and might not be 0.5.  
Protein half-life was determined for 43 out of the 74 NMT substrates identified in Section  4.8. The 
average half-life was 34.6 h, and ranged from 12.2 (for TMEM106B) to 56.1 h (for BASP1). More 
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recently, Boisvert et al. also studied the turnover of proteins in HeLa cells, incorporating 
fractionation of protein samples into cytoplasm, nucleus and nucleolus.314 A complex experiment 
was carried out to assess protein synthesis, degradation, and turnover rates within the same sample. 
Cells were labelled with medium isotopes (R6K4) and the media was replaced by a heavy media 
(R10K8) at time 0. Samples were chased for 0.5, 4, 7, 11, 27, and 48 h. To estimate the dilution 
effect, they estimated the doubling time of HeLa cells by counting them at different time points 
using a Cell Countess (Invitrogen). The cell counts were then fitted to an exponential growth 
curve (see below for more details). After cell lysis, the same amounts of lysate originating from 
cell grown in the light media (R0K0) were added and this light sample was used as an internal 
reference (similar to a “Spike-in” experiment, see Section ?4.6). Protein half-lives were determined 
for 40 out of the 74 NMT substrates identified in Section ?4.8. The average half-life was 17.5 h, and 
ranged from 8.8 (for DEGS1; value from Cambridge et al.315: 24 h) to 32.7 h (for CHCHD3; value from 
Cambridge et al 315: 54.9 h). These results are dramatically different from the analysis made by 
Cambridge et al. (Figure 93), and this divergence in protein half lives could be attributed to the 
different conditions (non-dividing or dividing cells, etc) used for the experiment. 
Thus, more experiments are required to accurately determine the half-lives of NMT substrates in 
dividing HeLa cells. Additionally, it would be interesting to evaluate protein turnover rates in the 
presence of NMT inhibition. NMT inhibition might lead to a new equilibrium in cells and proteins 
might be degraded more or less rapidly than they have been synthesised. 
 
Figure 93. Scatter plot showing the correlation between the protein half-life values determined by Boisvert 
et al. 314 and Cambridge et al. 315 Only 30 NMT substrates are common to both analysis and are shown here. 
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5.3.4? Experimental design and results 
For the purpose of determining which NMT substrate turnovers correlate with the apoptosis induced 
by NMT inhibition, it would be advantageous to focus specifically on the turnover of enriched 
N-myristoylated proteins as this is likely to enhance coverage.  All the proteomics experiments to 
study protein turnover reported in the literature have been carried out on the whole cell lysate. Cell 
fractionation was often required to increase coverage. However, in most cases, the low abundance 
proteins were lost during the analysis. For example, the turnover rate of c-SRC could not be 
quantified from the analyses of Cambridge et al.315 or Boisvert et al. 314. 
Two methods were tested to study the turnover rate of N-myristoylated proteins (Figure 94). First, 
as in the method used by Boisvert et al.,314 cells were labelled with the light isotope (R0K0), and the 
media replaced by heavy media (R10K8) at time 0 (Figure 94a). The light isotope was chased for 0, 2, 
6, 10 and 24 h. Cells were pre-tagged with YnC12 24 h before the beginning of the experiment and 
YnC12 was added to the heavy media during the chasing time. After cell lysis, N-myristoylated 
proteins could be enriched as described in Section ?4.2 and the ratio H/L was measured by LC-
MS/MS. The decrease of the light isotope should follow an exponential decay, and the relative 
isotope abundance (RIA) was measured for the light isotope (RIA (L) ) with the following Equation 
2.317,318 
 
 
 
Figure 94. Strategies to study NMT substrates turnover.
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Equation 2. The relative isotope abundance (RIA (L)) was measured for the light isotope for each time point. 
L and H represent the peak intensities detected for the light and heavy peptides respectively, for a given 
protein. The ratio L/H can directly be obtained from MaxQuant. 
??? (?) =  ?
? + ? =  
1
1 + ??
   
The ratios L/H were directly obtained from the proteomics analysis using MaxQuant (see 
Section 4.5). A dilution rate was calculated by fitting the cell number in the sample to an exponential 
decay curve (Figure 95). The dilution rate (kdil = 0.0277) correlated well with the dilution rate 
calculated based on the protein concentration in each sample (kdil = 0.0296). 
 
 
Missing values at time 0 were imputed with the median values of other NMT substrates (0.938). 
Many missing values were present at time 0 as no protein was labelled with the heavy isotope, but 
MaxQuant can often automatically determine a ratio close to the detection limit if the protein is 
found only in the light isotope; however, this was not the case for all the proteins. The data were 
fitted for each protein to an exponential curve fitting in Origin 8.0 (Equation 3) and a constant kloss 
was obtained. The real rate of degradation (kdeg) was determined by subtracting kdil to kloss.317 The 
protein half-lives were then determined according to Equation 4. 
 
Figure 95. Determination of the dilution rate based on the number of cells or the protein concentration in 
the samples. Both were normalised to time 0. Cells were counted (n=6) with a Hemocytometer and protein 
concentration was determined with the Bio-Rad DC protein assay (samples were lysed using the same volume 
of lysis buffer to be able to compare the concentrations). 
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Equation 3. The RIA (L) was fitted to an exponential fitting curve in Origin 8.0 with the following equation. Y0 
is the RIA (L) at time 0, t is the time in h and kloss is the rate of loss of the light isotope in h. 
??? (?) = ?? × ??? × ?loss 
 
Equation 4. Determination of the protein half-lives (t1/2). RIA (L) t1/2 is equal to 0.5 as 50% of the light isotope 
should be lost at the protein half-life. 
??/? =  
???(??? (?)??/?)
????
 
An average half-life of 38.3 h was found over 72 protein groups of NMT substrates (Figure 96 and 
Appendix I). This half-life value is highly comparable to the value obtained by Cambridge et al. 
(34.6 h).315 Only mitochondrial import receptor subunit TOM40B (TOMM40L) and tyrosine-protein 
kinase ABL1 were not detected in this experiment, and Battenin (gene name CLN3) could not be 
quantified.  
This method presents several potential issues.307 First, it was assumed that the protein synthesis and 
degradation follows a kinetic trend. To be valid, protein turnover needs to be independent of the 
protein concentration and follow a zero order rate law. Secondly, amino acids can be recycled, 
complicating later time points. In their study, Cambridge et al. showed that the incorporation of 
 
Figure 96. N-myristoylated proteins half-lives (h). Proteins with high and low turnover rates have been 
labelled. The average half-life is indicated in red. 
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internal amino acids (recycled amino acids) was negligible compared to the incorporation of external 
amino acids (from the media).315 They demonstrated that in the conditions they used, newly 
synthesised proteins preferentially incorporate heavy amino acids rather than recycled light amino 
acids. It would be important to check that this is the case in the experiment described above. Finally, 
there might be a delay in amino acid incorporation, and this delay, if not negligible, might also 
lengthen the apparent rate of degradation. 
To complement this half-life data, a second method was employed (Figure 94b). Proteins were 
pulsed with YnC12 for 6 h and chased for several days in the presence of myristic acid or inhibitor 
IMP366 (5 µM). Since N-myristoylation is believed to be mostly irreversible (Section  1.1), the amount 
of YnC12 label should decay as fast as proteins are degraded in cells. Each sample was then spiked-in 
after cell lysis with a heavy standard labelled together with YnC12 (Section  4.6), and following 
capture, enrichment and trypsin digest, samples were analysed by LC-MS/MS and processed with 
MaxQuant. As the same amount of heavy spike-in standard was added to each sample, L/H ratios 
directly reflected the relative incorporation of the light isotope (RIA (L)). As for the first strategy, L/H 
ratios were fitted to an exponential decay curve (Equation 3), and kdeg were determined by 
subtracting kdil to kloss. The NMT substrates turnover rates were found to be much higher than in the 
first approach, with an average half-life of 126 h and 263 h when YnC12 was chased with myristic 
acid or NMT inhibitor respectively (Appendix A and I). However, these values were determined on a 
smaller subset of proteins: the half-life could only be quantified for 44 proteins (myristic acid chase) 
or 33 proteins (inhibitor chase).  
5.3.5 Conclusions 
The results from the three experiments (light isotope chase experiment and both YnC12 chase 
experiments) were compared for each protein (Appendix I). Interestingly, some proteins, such as 
AIFM2 and Cytospin B (SPECC1), had highly similar half-lives. However, for most proteins, the 
half-life values were much higher for the YnC12 pulse-chase experiment. Strikingly, some proteins, 
such as BASP1, CYB5R3, FAM49B, had extremely high half-life. The difference in protein half-life 
between the three experiments suggests that they are flaws in the experiment design. The YnC12 
pulse-chase experiment would need further refinement and validation to generate meaningful data. 
It is possible that the 6 h YnC12 pulse does not reflect the turnover of the whole pool of NMT 
substrates in cells and that the strong condition changes during the YnC12 chase do not reveal the 
real protein turnover. Moreover, proteins with a low turnover rate and low abundance might be 
labelled poorly. Only half as many substrates were identified in the YnC12 pulse-chase experiment 
compared to the light isotope chase experiment.  
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However, the light isotope chase experiment is more promising, as half-life was determined for most 
NMT substrates identified in the current study and the values were consistent with a previous 
report.315 Interestingly, some proteins, such as MGRN1 had a very short half-life while some others, 
such as RP2 or PPM1B, were more resistant to proteolytic degradation (Figure 96). The relatively 
long half-life of NMT substrates is consistent with the slow phenotype observed upon NMT 
inhibition. These values might provide a key to understand which proteins are responsible for cell 
death upon NMT inhibition. However, there is unlikely to be a simple correlation between any one 
protein half-life and cytotoxicity.  
All these experiments were carried out on acylated NMT substrates. It might also be interesting to 
study what happens to the newly synthesised but not N-myristoylated NMT substrates. It has been 
suggested that turnover rates are different when protein are not myristoylated, for instance, non 
myristoylated LCK and c-SRC seem to be more stable.104,218 Padwardhan et al. hypothesised that 
membrane bound myristoylated c-SRC might have a different conformation than the non 
myristoylated protein, and might thus be more accessible to the ubiquitination machinery (Cbl and 
other E3 ubiquitin ligases). 
5.4 Effect of NMT inhibition on NMT substrates 
5.4.1 Hypothesis on key targets  
In Chapter 4, proteomics experiments allowed the identification of 74 NMT substrates in HeLa cells. 
Any of these substrates might be essential to cells and it is highly unlikely that a single critical 
substrates would be identified that leads to cell death when not N-myristoylated. Many substrate 
proteins are involved in protein transport (ARF proteins...) or are kinases or oncogenes. Several NMT 
substrates are involved in protein degradation through the ubiquitin pathway. PSMC1 is a 
proteasome subunit, and four E3 ubiquitin ligases are N-myristoylated: MGRN1, RNF125, ZNRF1 and 
ZNRF2 in Eukaryotes (see Appendix H). It is thus possible that NMT inhibition could result in a down 
regulation of protein degradation. 
Recently, loss of myristoylation of the 26S protease regulatory subunit 4 (PSMC1) was shown to 
result in a considerable growth defect in yeast.320 Proteasome assembly and peptidase activity were 
not affected by the loss of myristoylation but there was a localisation defect and major problems 
with protein aggregation and accumulation of poly-ubiquitinated proteins. A Western blot analysis 
was carried out to understand if NMT inhibition could result in the accumulation of 
poly-ubiquitinated proteins (Figure 97a). Epoxomicin, a selective proteasome inhibitor, was use as a 
control. Inhibition of HeLa cells with Epoxomicin led to a rapid accumulation of poly-ubiquitinated 
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proteins. NMT inhibition also resulted in an accumulation of poly-ubiquitinated proteins after 1 day 
but levels of poly-ubiquitinated proteins decreased after 3 days. This result is not surprising since 
several E3 Ubiquitin ligases are also NMT substrates and loss of N-myristoylation might impair their 
ability to transfer Ubiquitin to proteins, which could explain why the signal decreases again after 
3 days. However, cells have many ubiquitin ligases which could potentially compensate loss of 
activity of the ubiquitin ligases that are NMT substrates. It may be interesting in future to use a 
fluorometric assay based for example on an AMC (7-amino-4-methylcoumarin)-tagged peptide 
substrate which releases free, highly fluorescent AMC when the proteasome is functional, to study 
proteasome activity upon NMT inhibition.  
Myristoylation of PSMC1 was also shown to control proteasome localisation.320 The proteasome is 
mostly localised in the nucleus in yeast, but when PSMC1 was not N-myristoylated, the proteasome 
was mostly found in the cystoplasm. A similar experiment was carried out by Western blot analysis 
(Figure 97b). In HeLa cells, PSMC1 was localised in the cytosol in healthy cells and we observed that 
PSMC1 was re-localised to the nucleus upon NMT inhibition after 3 and 7 days. The proteasome 
localisation has been shown to be more complex in mammalian cells than in yeast, as it is distributed 
 
Figure 97. Possible key targets leading to cell death when they are not N-myristoylated. a) E= Epoxomycin. 
HeLa cells were treated with IMP366 (5 μM) for 0, 1 or 3 days, or with a proteasome inhibitor, Epoxomicin, for 
2 h (10 μM) as a control. b) HeLa cells were treated with IMP366 (5 μM) for 0, 1, 3 or 7 days. Cells were 
fractionated and the cytosolic and nuclear fractions were analysed by Western blot. c) Immunoprecipitation 
experiment and Western Blot analysis showing that c-SRC phosphorylation decreases upon NMT inhibition in 
HeLa cells. Cells were treated with IMP366 (5 μM) for 0, 1 or 3 days. 
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between the cytoplasm and nucleus.321,322 These results need to be replicated in a future study to be 
considered robust. Histone H3 (the control for the nuclear fraction) decreased after 3 and 7 days, 
probably due to cytotoxicity (Section  5.1.1). 
The proteasome subunit is a particularly interesting target as the proteasome is a known therapeutic 
target in cancer. One compound, bortezomib, was recently FDA-approved for the treatment of 
several cancers including multiple myeloma.323 Inhibition of the proteasome activity was shown to 
have varied effect in different cell lines;324,325 treatment of HeLa cells with MG132, a proteasome 
inhibitor, did not result in a G1 accumulation after 1 day.324 However, inhibition of the proteasome in 
MDA-MB-231 induced a G1 cell cycle arrest and caspase 3 independent apoptosis.326 Further 
experiments would be required to understand the importance of PSMC1 and E3 ubiquitin ligases in 
inducing cell toxicity upon NMT inhibition. 
 
c-SRC has been suggested to be a key target in cancer cells and is a known target for cancer 
therapy.327 High levels of c-SRC tyrosine kinase activity have been associated with cancer progression 
as they promote cell survival, proliferation and metastasis,328 and N-myristoylation is required for 
the autophosphorylation of c-SRC and, as a consequence, for its tyrosine kinase activity.104 Upon 
NMT inhibition with IMP366, we observed a decrease of phosphorylated c-SRC after 1 day and 
3 days, suggesting that c-SRC had a reduced protein kinase activity, while levels of total c-SRC 
remained constant (Figure 97). 
Interestingly, inhibition of MDA-MB-231 cells with Dasatinib, a FDA-approved SRC kinase inhibitor 
used for the treatment of chronic myelogenous leukemia, had some similarity with IMP366.329 
Inhibition with Dasatinib resulted in a decrease of cell growth, a G1 arrest but no apoptotic cells 
were present after 2 days. It would be interesting to study if IMP366 and Dasatinib have a synergic 
effect in cancer cells. No synergic effect would suggest that they both act mainly through inhibition 
of SRC (indirectly or directly). 
Another NMT substrate of interest is ARC (NOL3), the apoptosis repressor with caspase recruitment 
domain. ARC is an anti-apoptotic protein identified in the current study and discussed in Section 
 4.8.4.3. Interestingly, HeLa cells are resistant to Doxorubicin-mediated apoptosis, but it was shown 
that a knockdown of ARC promoted apoptosis. It would be interesting to study the effect of 
Doxorubicin combined with a NMT inhibitor in HeLa cells. Preliminary experiments (Section  5.3.4) 
suggested that the turnover rate of the protein is low in HeLa cells (around 60 h), compared to other 
NMT substrates. However, it could still play a role in apoptosis induction upon NMT inhibition.  
193 
 
A substantial number of other novel NMT substrates have an anti-apoptotic activity or have been 
associated with cancer progression (Section  4.8.4.3). It would be interesting to evaluate their role for 
the phenotype observed in cancer cells upon NMT inhibition.  
5.4.2 Tumour suppressors 
There is evidence that some NMT substrates are tumour suppressors, and inhibition of 
N-myristoylation of these substrates might lead to an unwanted effect; these include: 
 Guanine nucleotide-binding protein G(i) subunit alpha-1 (GNAI1), which can repress tumour cell 
migration.330 
 Protein phosphatase 1A (PPM1A) is a protein phosphatase which dephosphorylates RelA. 
Phosphorylated RelA has oncogenic activities.331 
 PPM1G is a protein phosphatase. Upon DNA damage, PPM1G is activated and dephosphorylates 
ubiquitin protease USP7S.332 USP7S, which is known to regulate the level of p53 in cells, then 
undergoes proteasomal degradation. As a consequence, levels of p53 decrease in cells, and 
there is an accumulation of unrepaired DNA damage as well as a p53-independent cell-cycle 
arrest in G1. 
 Calcineurin subunit B type 1 (PPP3R1) is a regulatory subunit of calcineurin, a protein 
phosphatase involved in the apoptosis pathway. When levels of calcium increase in the 
cytoplasm, calcineurin is activated by binding a regulatory subunit, PPP3R1 and calmodulin. As a 
consequence, Bad is released from 14-3-3 leading to Bax activation in the mitochondria and 
apoptosis.245 
 Brain acid soluble protein 1 (BASP1) is a transcriptional co-repressor which can interact with 
WT1, Wilms' tumour 1 protein (Section  1.2.2).54 WT1 is a transcriptional activator which is 
associated with cell growth and differentiation. Upon binding of WT1 with BASP1, WT1 is 
covered to a transcriptional repressor. Non N-myristoylated BASP1 cannot associate with WT1 
and WT1 cannot repress cell growth and differentiation. 
 Cytospin B (SPECC1) and Coiled-coil-helix-coiled-coil-helix domain-containing protein 6, 
mitochondrial (CHCHD6), both discussed is Section  4.8.4, are also tumour suppressors.  
More experiments would be required to understand the potential effect of NMT inhibition on these 
tumour suppressors, particularly in healthy tissues. 
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5.5 Conclusions  
This Chapter addressed one of the main questions of this PhD thesis: could NMT be a therapeutic 
target for cancer therapy? The phenotype of NMT inhibition in cancer cells was described and the 
difficulties faced in determining the mode of action of an NMT inhibitor were outlined. 
NMT inhibition was not toxic to cells after 1 day, probably due to the slow turnover of NMT 
substrates, and cell could recover from inhibition (Section  5.1.1.3). It would be interesting to 
determine whether cells could recover after a longer inhibition time.  
Turnover experiments would need to be repeated to confirm the half life-values using the light 
isotope pulse-chase experiment (Section  5.3). It would be interesting to see if similar values could be 
obtained by a heavy isotope pulse-chase experiment. It might also be advantageous to start the 
experiment with cells grown in 50 % heavy and 50 % light, as performed by Cambridge et al.315 as it 
would solve the issue of the missing values at time 0. 
Considering that many NMT substrates seem to be essential to the cells and that many have been 
linked with cancer progression, NMT inhibition would most likely have pleiotropic effects resulting in 
cancer cell death. Several data need to be combined to understand the mode of action of the NMT 
inhibitor in cancer cells: 
 In-cell IC50 values of the 74 NMT substrates (Chapter 4) 
 Half-lives of these substrates 
 Information (e.g. from other published studies) showing the importance of a substrate in cancer 
cells 
 Information on highly sensitive cells lines: if a particular pathway is upregulated in different cell 
lines sensitive to NMT inhibition, it would give clues as to the mode of action of the inhibitor.  
It would be interesting to study the effect of IMP366 on a normal cell line, to assess if NMT inhibition 
would lead to unwanted toxicity to patients. Interestingly, experiments showed that this inhibitor 
was well tolerated in mice in the context of parasite infection, suggesting the presence of a potential 
therapeutic window.43 
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Chapter 6 HsNMT1 and HsNMT2 selectivity 
 
Several methods were employed to study HsNMT isoform substrate specificity, both of recombinant 
enzymes and in cells.  
For in vitro studies, tagged MyrCoA substrate analogues were incorporated in the presence of 
recombinant NMT to the N-terminal glycine of peptide or protein substrates. The tag in this system 
enables a second extremely selective and high-yielding chemical ligation to any reporter of choice, 
for instance a dye label (Section  1.10.3 and Figure 18). 
First, in vitro myristoylation was tested in lysates from E. coli cells overexpressing Plasmodium 
falciparum ARF (PfARF). PfARF was shown to be a HsNMT substrate at the peptide level using the 
CPM assay (Dr. Victor Goncalves, Tate group Imperial College, London).145 Conditions required to 
label and detect NMT substrates were optimised and then applied to HeLa lysates obtained from 
cells subjected to NMT inhibition for a few hours. 
This Chapter also describes a method to prepare and screen peptide libraries in order to identify 
chemical differences in the protein binding pocket of HsNMT1 and HsNMT2. In this approach, 
libraries of peptides corresponding to the N-terminal sequences of known or putative NMT 
substrates were prepared on a cellulose membrane using the SPOT™ technology.150 Incubation of 
the library with either recombinant HsNMT1 or HsNMT2 would allow the identification of isoform 
substrate specificities. If peptide substrates specific to a NMT isoform could be identified, they may 
provide a basis for peptidomimetic inhibitors to assist in validating a specific NMT as a new 
therapeutic target for cancer. 
In-cell substrate specificity was also studied. HsNMT1 or HsNMT2 was knocked down using specific 
siRNA and YnC12 labelling could be used to identify the substrates of the remaining isoform. 
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6.1? In vitro studies using recombinant HsNMT1/2 
6.1.1? In vitro myristoylation in cell lysate 
6.1.1.1? Optimisation using PfARF overexpressed in E. coli   
To test if it was possible to N-myristoylate protein substrates in vitro, experiments were carried out 
in E. coli cells overexpressing Plasmodium falciparum ARF (PfARF) according to Heal et al.333 After cell 
lysis, lysates were subjected to in vitro myristoylation and capture reaction with YnTB or AzTB 
(Figure 17, Figure 98a). CaNMT was used as a positive control as it was employed by Heal et al. to 
myristoylate PfARF.333  
PfARF can be seen by in-gel fluorescence with a band at 20 kDa in lanes 1 and 2 (Figure 98a). PfARF 
appeared to be a better substrate of HsNMT1 than CaNMT. In Lane 3, a band was also observed by 
fluorescence and corresponds to background labelling probably due to high abundance of PfARF in 
the lysate. An extra band was observed in lane 1 at 60-70 kDa. This band might correspond to 
HsNMT1. A similar experiment was carried out to compare the in vitro myristoylation performed 
with HsNMT1 or HsNMT2 and also with YnC12CoA or AzC12CoA (Figure 98b). No labelling was 
 
Figure 98. In vitro myristoylation of PfARF overexpressed in E. coli lysates. Tagged-analogue of MyrCoA was 
incubated with HsNMT for 10 min and added to the cell lysate (1mg/mL, final concetration of enzyme of 
5 μg/mL and final concentration of MyrCoA analogues of 10 μM). The mixtures were incubated for 2 h at 37°C 
with constant agitation. Samples were then subjected to CuAAC (capture reaction) with AzTB or YnTB as 
described in Section ?2.3 and analysed by in-gel fluorescence. Coomassie was used as a loading control. a) In 
vitro myristoylation was carried out in the presence of AzC12CoA and HsNMT1 (Hs) or CaNMT (Ca) or no 
enzyme. Azido-tagged proteins were captured with YnTB. b) In vitro myristoylation was carried out in the 
presence of AzC12CoA or YnC12CoA and HsNMT1 or HsNMT2 or no enzyme. Tagged proteins were captured 
with AzTB or YnTB. Lanes 3, 6, 7 and 8 correspond to negative controls. 
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observed in the four negative controls (lane 3, 6, 7, 8), where no enzyme was used for the in vitro 
myristoylation step, suggesting that the experiment gave low background. A highly similar labelling 
pattern was obtained by using AzC12CoA or YnC12CoA, suggesting that both reagents could be used 
to carry out in vitro studies. The same extra band at 60-70 kDa was observed as in lane 1 in Figure 
98a in the presence of HsNMT1, but this band was not observed with HsNMT2. Fluorescence 
labelling of PfARF appeared to be stronger in the presence of HsNMT1 than HsNMT2. Several 
explanations are possible. PfARF might be a better substrate of one of the NMT isoforms, or 
HsNMT2 might be less stable or the final concentration of HsNMT might have been inaccurate for 
the in vitro myristoylation step.  
To check if the concentrations of HsNMT1 and HsNMT2 are the same, various concentrations were 
added to the E. coli lysate with overexpressed PfARF. The poly-His-tag present on both isoforms of 
recombinant HsNMT and PfARF was detected by chemiluminescence using enzyme coupled 
Neutravidin, Neutravidin-HRP (Horse Radish Peroxidase). Neutravidin is a deglycosylated form of 
avidin that has a high affinity for biotin with low non-specific binding. 334 The enzyme on Neutravidin 
is then detected selectively by a chemiluminescent substrate.  
The signal was highly similar for HsNMT1 and HsNMT2 at the different concentrations used, 
suggesting that the concentrations were similar. 
A time course experiment was carried out to optimise the in vitro myristoylation reaction time 
(Figure 100a). N-myristoylation seemed to be complete after 1h with HsNMT1 and was slower with 
HsNMT2. The experiment was repeated for HsNMT2 with the in vitro myristoylation time increased 
up to 4 h (Figure 100b). The reaction was complete after 2 h with HsNMT2. For the following 
experiments, the in vitro myristoylation step was carried out for 2 h. 
 
Figure 99. Verification of the enzyme concentration used for the in vitro myristoylation. HsNMT1/2 were 
added to E. coli lysate with overexpressed PfARF. Samples were separated on a SDS-Page gel. HsNMT1 and 2 
are both HIS-tagged at the N-terminus and the tag can be detected by Neutravidin HRP and revealed in 
chemiluminescence. PfARF is also HIS-tagged and was used as a loading control. 
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It would be interesting to understand why the reaction stopped after 1-2 h. It could be because all 
PfARF was consumed, or due to a low stability of the enzyme or the reagent. It is also possible that 
the concentration of the analogue of MyrCoA was too low, therefore this reagent was the limiting 
reagent. To check if all PfARF was myristoylated, a pull down experiment was carried out (Figure 
101). 
 
 
Figure 100. Optimisation of in vitro myristoylation time. A similar protocol as for Figure 98 was used. In vitro 
myristoylation was performed in the presence of AzC12CoA and a) HsNMT1/2 b) HsNMT2. CuAAC was carried 
out with YnTB. Coomassie was used as a loading control. 
 
Figure 101. Pull down experiment to check if all PfARF was N-myristoylated in vitro. Lysates were subjected 
to in vitro myristoylation with AzC12CoA in the presence of HsNMT1, HsNMT2 or no enzyme for 2 h. The 
capture reaction was performed in the presence of YnTB and the samples were enriched as described in 
Section ?2.3.4. 2 fold less protein was loaded for the supernatant samples compared to the samples before pull 
down (before PD) and pull down (PD). The strong band at 20 kDa seen by Coomassie corresponds to PfARF 
(overexpressed in E. coli lysate) and the band at 15 kDa in the PD samples corresponds to streptavidin released 
from the beads. 
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Not all PfARF was pulled down using these conditions, suggesting that not all PfARF was labelled and 
captured. It is probable that AzC12CoA was the limiting reagent of in vitro myristoylation.  
The extra band at 60-70 kDa was also pulled down, suggesting that AzC12 is covalently attached to 
this protein, which is presumably HsNMT1. AzC12 could have been transferred to a cysteine residue 
or it is also possible that HIS-tagged HsNMT1 might N-myristoylate itself. The N-terminal sequence of 
His-tagged HsNMT1 (GSSHHHHHH) was prepared and tested in the CPM assay but showed no 
activity against both recombinant HsNMT1 and HsNMT2. It is unclear why this extra band is 
observed with HsNMT1 but not with HsNMT2. 
To conclude, NMT substrates can be N-myristoylated in vitro in the presence of analogues of 
MyrCoA. Alkyne and azide analogues of MyrCoA gave similar results. The reaction seemed to be 
complete with both HsNMT isoforms after 2 h. N-myristoylated proteins can be detected by in-gel 
fluorescence, as previously described in Section  2.3 for HeLa cells labelled with YnC12. This method 
could be used to determine HsNMT1 and HsNMT2 substrate specificity in vitro in HeLa lysate. 
6.1.1.2 Test in vitro myristoylation in HeLa cells lysate 
In vitro myristoylation would be carried out in lysis buffer. It was preferable not to use detergent to 
lyse the cells as it could denature the enzyme and prevent in vitro myristoylation. A HEPES-based 
lysis buffer had been previously used in the group to perform in vitro enzymatic reactions and 
appeared suitable.335 An experiment was carried out to ensure that in vitro myristoylation could 
occur in these conditions. PfARF was purified from E. coli lysates (Figure 102a). HeLa cells were 
treated with IMP366 for 6 h, lysed in HEPES lysis buffer and purified PfARF was added to the lysate 
(Figure 102b). As seen in lane 7, PfARF could be N-myristoylated in HEPES buffer. However, the 
background was relatively high as seen with some extra bands in lanes 5 and 6. 
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In vitro myristoylation was tested again, without adding purified PfARF (Figure 103). The labelling 
obtained with HsNMT1 and YnC12CoA was compared to the labelling obtained with cells treated 
with YnC12 before lysis. Similar labelling patterns were observed for HeLa cells treated with YnC12 
(lane 2) and in vitro myristoylation in the presence of YnC12CoA and recombinant HsNMT1 (lane 4). 
However, the strong fluorescent band seen in lane 2 at 20 kDa, and probably corresponding to ARF 
proteins (Chapter 4), was weak in lane 4. Moreover, the background in lane 4 was relatively high, 
possibly due to the labelling of cysteine residues with YnC12. A highly similar labelling pattern was 
obtained by replacing HsNMT1 with HsNMT2 (data not shown). Preliminary optimisation 
experiments (data not shown) showed that decreasing the amount of DTT (1 mM in the HEPES lysis 
buffer) increased the background. However, a high quantity of DTT might also inhibit the CuAAC 
reaction (data not shown). More optimisation would be required to decrease the background 
labelling and to understand why the proteins at 20 kDa cannot be efficiently N-myristoylated in vitro. 
However, it appeared more accurate to carry out in-cell studies of the isoform substrate specificities 
(Section ?6.1.4) as this would reflect the in vivo substrate specificity of the two isoforms. 
 
 
Figure 102. In vitro myristoylation of PfARF in HEPES lysis buffer. a) PfARF was purified from E. coli  lysates. 
Top: Coomassie and Bottom: Western blot. An arrow indicates PfARF on the gel. b) M: Markers. E: E. coli lysate 
with overexpressed PfARF. H: HeLa cells lysate in HEPES lysis buffer. Cells were treated with IMP366 (1 μM) for 
6 h. Purified PfARF was added to some samples (final concentration 0.2 mg/mL) and in vitro myristoylation was 
performed for samples in lanes 1, 2, 5, 6, 7, with HsNMT1 or no enzyme. All samples were subjected to CuAAC 
with AzTB.  
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6.1.2? Spot synthesis 
6.1.2.1? Assay principle 
Several peptide libraries were prepared on cellulose membranes using an automated ResPep 
peptide synthesiser (Intavis). The membranes, purchased from Intavis, already contained a spacer 
(PEG linker, 10 PEG units) and were amino-functionalised. A cleavable linker was sometimes added 
before the peptide synthesis in order to perform post-synthesis cleavage of peptides. Two 
membranes of 600 individual peptides could be prepared simultaneously on the equipment available 
in the Tate group. After the synthesis, membranes were dried in a desiccator overnight to remove 
any residual solvent and cut into several units. After side-chain deprotection according to Intavis’ 
protocol, the membrane units were ready to be used for on-support assay or cleavage of the spots 
for further analysis (Figure 104).  
No assay had previously been developed to detect N-myristoylation on a solid support such as a 
cellulose membrane, therefore the assay conditions (concentration of reagents, time of the assay, 
method of detection, etc) required optimisation. The assay comprised three steps (Figure 104). First, 
the peptides were deprotected with a TFA mixture. The second step, later referred to as the 
N-myristoylation step, involved the incorporation of a myristic acid analogue to peptide substrates 
of HsNMT, using YnC12CoA or AzC12CoA. This step was carried out for 2 h in the presence of 
recombinant HsNMT1/2, as the analogous experiment in E. coli lysate (Section ?6.1.1.1) showed that 
the reaction was complete after 2 h. The concentration of enzyme was set to 500 ng/mL as this 
concentration was used in early optimisation experiments for the CPM assay. Analogues of MyrCoA 
 
Figure 103. In vitro myristoylation in HeLa lysates. HeLa cells were labelled with myristic acid or YnC12 for 6 h 
and/or treated with IMP366 for 6 h. In vitro myristoylation was carried out on one sample in the presence of 
YnC12CoA and HsNMT1. All lanes were subjected to CuAAC with AzTB. In-gel fluorescence allowed the 
visualisation of tagged proteins and Coomassie was used as a loading control. 
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were used at a concentration higher than KM (around 1 μM). After incubation for 2 h, the unbound 
tagged MyrCoA analogues could be washed away.  
 
Figure 104. Typical myristoylation assay on membrane. First step: peptide side-chains deprotection. Second 
step: in vitro myristoylation. Third step: capture reaction (CuAAC, “click” reaction) which allows to detect the 
tagged peptides in fluorescence or chemiluminescence. 
The third step corresponds to the capture reaction, where the tag (shown as an azido moiety in 
Figure 104) reacts selectively with a chemical reporter (the alkyne moiety in Figure 104) via 
bioorthogonal ligation. The chemical reporter carries an imaging probe, such as a fluorescent dye. 
Click chemistry was used as the bioorthogonal ligation in the assays. The reaction requires several 
reagents and the conditions were chosen according to conditions established previously for capture 
of YnC12-tagged proteins in HeLa cell lysate (0.1 mM capture reagent, 1 mM CuSO4, 1 mM TCEP and 
0.1 mM TBTA) (Section ?2.3). By considering the amount of amino acid added per spot and assuming 
100% yield, the amount of peptide was estimated at 0.1 μmol per spot. 30 mM Tris Buffer, 3.5 mM 
DTT pH 7.4 was chosen as the assay buffer as a similar buffer had been used in our group to study N-
myristoylation in vitro.154 For the capture reaction, DTT was not needed as the click ligation already 
requires the use of a reducing agent (TCEP).  
Several membranes were prepared in order to check the reliability of peptide synthesis on a 
cellulose membrane and the reliability of the detection method. Typically one membrane made of 
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several repeating units was prepared. The membrane was then cut to separate all the repeating 
units which were analysed separately to optimise the detection methods. The peptide sequences of 
the membranes prepared during this study, referred to here as membrane A-F, can be found in 
Appendix J.  
8 or 15 amino acid peptides corresponding to the N-terminus of putative N-myristoylated proteins 
(Section  1.4.2) were synthesised on the membrane and several controls were included: 
 Positive controls:  
-Known myristoylated proteins 
-CuAAC controls: an azido or alkyne moiety was added at the N-terminus of peptides 
synthesised on the membrane to control the efficiency of the CuAAC reaction. In early experiments, 
5-hexynoic acid and AzC12 were coupled at the peptides N-terminus. Later, AzC12 was replaced by 
4-azidobutyric acid 67 (Figure 105). This compound was prepared in two steps from the 
commercially available ethyl 4-azidobutyrate 65, according to the procedure employed to prepare 
AzC12 15 (Section  2.1.2). 
 Negative controls: 
-Non N-myristoylated proteins 
-G2A controls: known myristoylated protein where the N-terminal glycine was replaced by 
alanine. 
-Known myristoylated proteins acetylated at the N-terminus. 
-Cysteine and tryptophan rich sequences were added as controls, as these amino acids were 
suspected to give non-specific background in fluorescence. 
Furthermore, a few spots were low-loaded using a mixture of Fmoc:Boc 1:10 amino acid as the first 
coupled residue, and some peptides were only 8 amino acids long (instead of 15 amino acids). 
HO
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65 6766  
Figure 105. Preparation of 4-azidobutyric acid. Reagents and conditions: i) NaN3, DMSO, RT, 91%; ii) NaOH 
2N, MeOH, quantitative. 
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6.1.2.2 Optimisation of the synthesis 
6.1.2.2.1 Check membrane quality 
To check the membrane quality, a cleavable linker was added at the C-terminus of some peptides. 
This allowed these peptides to be cleaved from the membrane for analysis by MALDI or LC-MS. 
Membrane A (Appendix J) was prepared by first coupling a cleavable linker, 4-hydroxymethylbenzoic 
acid (HMB) 69, onto the membrane 68 (Figure 106). A similar experiment was described in the 
literature and comprised the use of TBTU (1.1 eq) and DIPEA (2 eq).336 TBTU was replaced by HBTU in 
the present work, which is a similar reagent. The coupling of the first amino acid, Fmoc-Gly-OH, via 
an esterification reaction is known to be difficult on cellulose membrane. Ay et al. improved this 
reaction by using 3 eq of CDI as activator in the reaction.337 15 amino acids were subsequently 
coupled by standard solid-phase peptide synthesis (SPPS). 
HMB is labile to nucleophilic attack. Several cleavage procedures were proposed in the literature 
including ammonia vapour to give the carboxamide,338 high pressure ammonia/THF vapour using a 
Schlenk line,339 1N NaOH,340 or methanolic ammonia.341 The two methods using ammonia vapour 
appeared to be less convenient and less safe than the other methods, and the use of 1N NaOH could 
be problematic for the analysis of the sample by LC-MS, due to high salt concentration in the sample. 
A mixture of ammonia in methanol was thus preferred.  
The spots were punched out in different wells of a 96-well plate and the peptides were cleaved 
overnight using 7N ammonia in MeOH. The mixture was allowed to evaporate and the peptides were 
dissolved in a mixture of H2O/MeOH. The amount of peptide for one spot was small (<1 µmol) and a 
pellet was usually not observed, thus it was difficult to check if the cleavage method was efficient. 
Attempts to analyse few cleaved peptides by LCMS were unsuccessful, as the amount of analyte was 
likely too small to be detected. MALDI analysis was more efficient as a few masses were detected; 
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Figure 106. Attachment of the HMB linker to the cellulose membrane before SPPS. Reagents: i) HBTU, DIPEA, 
NMP; ii) Fmoc-Gly-OH, CDI, NMP. 
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however, the masses corresponding to the full length peptides were not detected. It was proposed 
that the problem was due to an inefficient esterification reaction between the HMB linker and the 
first amino acid. To solve this problem, a linker composed of Fmoc-Gly-OH and HMB 69, was 
prepared in solution, prior to attachment to membranes (Compound 74, Figure 107). Two methods 
were proposed to prepare this cleavable linker from the commercially available HMB 69. The first 
one relies on the orthogonal protection of the acid 69, by a phenacyl protecting group, to prevent 
trans-esterification in the next step (Figure 107).342 Compound 72 was then coupled to Fmoc-Gly-OH 
via an esterification reaction mediated by DCC and DMAP. Subsequent removal of the phenacyl 
protecting group using zinc powder and AcOH gave the crude Fmoc-Gly-HMB-OH 74. Pure 74 was 
obtained after silica-gel purification with an overall yield of 71%.   
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Figure 107. Synthesis of Fmoc-Gly-HMB-OH. Reagents and conditions: i) 2-Bromoacetophenone, Et3N, EtOAc, 
RT, quantitative; ii) Fmoc-Gly-OH, DCC, DMAP, DCM, 91%; iii) Zn, AcOH, H2O, EtOAc, 78%  
 
The second method proposed to prepare the linker 74 relies on the direct coupling of the carboxylic 
acid 69 with Fmoc-Gly-OH 75, following the procedure of Ay et al.337 An excess of Fmoc-Gly-OH 
75(2 eq) was necessary to prevent trans-esterification of compound 69. Purification of the crude 
product by silica gel column chromatography gave 74 in relatively low yield (26%), thus the former 
method was preferred (71% overall yield), despite the longer reaction sequence. 
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Figure 108. Synthesis of Fmoc-Gly-HMB-OH in one step. Reagents and conditions: CDI, DMF, RT, 26% 
 
Membrane B was prepared using two different cleavable linkers (see Appendix J). The membrane 
was composed of 12 repeated units of 24 peptides. 6 units were prepared without any cleavable 
linker, 3 with the Fmoc-Gly-HMB-OH linker 74 and 3 with a rink amide linker 75 (Figure 109). The two 
linkers were coupled using HBTU/DIPEA, as normal amino acids in the sequence.  
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Rink amide linker is acid labile and can be cleaved by TFA during side chain deprotection. This linker 
is widely used in SPOTTM synthesis to check synthesis quality 159 and would be an additional control. 
However, it would not be possible to use the membrane unit bearing the rink linker to perform on-
membrane assays as side-chain deprotection with TFA is required prior to the assay. 
 
 
After the synthesis, peptides synthesised on a HMB linker-unit or on a rink amide linker-unit were 
cleaved in solution. The peptides on the HMB unit were cleaved after side-chain deprotection with 
TFA using 7N ammonia in MeOH as described above. Peptides on the rink amide unit were cleaved 
with a mixture of TFA:TIS:H2O:EDT 94:1:2.5:2.5. 
Most compounds characterised by MALDI were shown to be of the correct molecular weight and 
sufficient purity (only few other masses detected) to do on-support assays. Most of the spots 
contained contaminating shorter sequences but they should not be a problem for the assay since 
they are acetylated at the end and therefore cannot be myristoylated to give a signal in 
chemiluminescence. For a few peptides, such as low loading peptides or peptides with shorter 
sequence (8 amino acids), the expected molecular weight was not detected by MALDI. This may be 
due to a problem during analysis or isolation/synthesis. 
6.1.2.2.2 Check the relative amount of peptides  
Peptide synthesis on the membrane could be checked by staining the membrane with bromophenol 
blue or Ponceau S (Figure 110). However, the spot intensity varied with the sequences. The staining 
depends on the number of free amino groups since the reagents are acid/base indicators. For 
example, it was expected to see no spot on position A1, A2, D5 and E1 in Figure 110 c and d as the 
peptides have a no free amino group. Ponceau S and bromophenol blue gave similar results (Figure 
110 c and d). However, some spots have a weaker intensity and this might be due to a problem 
during the synthesis. Fmoc fluorescence might be a more efficient method of determining coupling 
efficiency. Before Fmoc-deprotection, the intensity of the spots should be identical if the synthesis 
was efficient.  
NHFmoc
H3COC O OH
O
COCH3
75  
Figure 109. Rink amide linker 
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6.1.2.3? Detection method 
6.1.2.3.1? Fluorescence: 
Various fluorescent reagents were tested on the membrane: AzTB, Yn-fluorescein, Yn-BODIPY. Only 
the CuAAC reaction was carried out and thus only the CuAAC controls should have given a signal in 
fluorescence. However, all these reagents gave high background in the negative controls, due to the 
auto-fluorescence of some peptides and probably because the capture reagent stuck unspecifically 
to the membrane and the peptides (data not shown). Copper used for the CuAAC reaction was 
suspected to give high background. However, the use of a strain promoted azide alkyne 
cycloaddition reagent (DABCO-TAMRA) 75 (Figure 111), available in the Tate group, did not reduce 
the background. Stringent washes for 1 h with NaOH 0.1 N or blocking the membrane for 1 h before 
the CuAAC did not decrease the background. Finally, membranes were captured with a DABCO-
biotin 76 reagent, blocked in 5% milk before being incubated with Streptavidin Alexa Fluor 647 (1/10 
000) in 5% milk and image in chemiluminescence. Using this method, a high background was also 
obtained. All these results suggested that fluorescence could not be used as a reliable detection 
method on cellulose membrane. This was confirmed by Mahrenholz et al.343 as they also showed 
that fluorescence gave high background on cellulose membranes. It seemed preferable to use 
chemiluminescence as a detection method. 
 
Figure 110. Membrane staining with bromophenol blue (a-c) or Ponceau S (d). The position with no peptide 
on the membrane is indicated by a black box. a) Membrane C. b) Membrane E. Membrane F is shown in c) and 
d). 
 
208 
 
6.1.2.3.2? Chemiluminescence 
The procedure using chemiluminescence was slightly different to the procedure using fluorescence. 
After the capture reaction using a biotinylated probe, the membrane was blocked with Bovine 
Serum Albumin (BSA) to prevent non-specific protein interactions. The bound capture reagent was 
probed with Neutravidin-HRP, and a series of controls were performed to determine whether 
chemiluminescence gave less background than fluorescence. 
??Control 1: no N-myristoylation - no capture reaction 
The membrane was probed in chemiluminescence directly after side chain deprotection of the 
peptides. The membrane was blocked, probed with Neutravidin-HRP and with the chemiluminescent 
reagent. Figure 112 demonstrates that there was no high non-specific background using this 
method. However, it should be noted that spot A4 (Figure 112a) appeared to have a small signal in 
chemiluminescence, probably due to low-level non-specific interaction. 
?
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Figure 111. Structure of DABCO-TAMRA 75 and DABCO-biotin 76. 
 
Figure 112. Background in chemiluminescence. Membranes B (a) and D (b) were probed in 
chemiluminescence, without prior N-myristoylation or CuAAC. a) Spot A4 (peptide sequence: azido-
GSNKSKPKDASQRRR, showed a small signal (exposure time 2 min). b) All peptides on the membrane have the 
following sequence: GGGX5GGG, where X5 represents a 5-fold repeat of any amino acid. Peptides showed a 
signal in chemiluminescence when X was R and K. 
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Mahrenholz et al.? suggested that some amino acids could also give high background in 
chemiluminescence.343 A membrane comprising peptides made of 5 repeating units of each amino 
acid was prepared. As suggested by Mahrenholz et al., Arg and Lys gave relatively high background.  
??Control 2: Only the capture reaction  
A second control on membrane B was performed to check that the capture reaction was possible on 
the solid support and to verify that it was specific. The capture reaction was performed after 
side-chain deprotection of the peptides and the membrane unit was probed in chemiluminescence. 
More spots than expected were detected, as can be seen in Figure 113. Only four spots, 
corresponding to the click controls, should be detected. These click controls have an azido moiety at 
the end of the peptide chain and should specifically react with YnTB when subjected to the CuAAC 
reaction.  
 
It was then proposed that this unexpected pattern could be caused by the non-specific interaction of 
copper with some peptides. As pyridine is known to be a good ligand for copper, the membrane was 
stripped and washed for 1 hour with pyridine. The membrane was then washed several times with 
DMF, DCM and EtOH to remove pyridine and probed again. Washing the membrane with a solution 
of EDTA gave similar results. Only three spots were unaffected by the washes, all corresponding to 
the click controls. One click control (E4,Figure 113) could not be detected, perhaps due to a problem 
during the synthesis. 
 
 
 
Figure 113: Image in chemiluminescence of membrane B after only the capture reaction (with YnTB). 
Subsequent wash with pyridine gave a different pattern. The click controls (azide) are outlined in red.  
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??Assay: membrane B 
A normal assay was then performed (Figure 114). As observed in Figure 113 , the background was 
high and the membrane was washed with pyridine. Interestingly, the same click controls as in Figure 
113  were detected, with three other spots corresponding to known myristoylated peptides. The 
peptide sequences of spots B1, C1, D1 are based on the N-terminal sequence of c-SRC. D1 has only 8 
amino acids while B1 and C1 are composed of 15 amino acids. The C1 SRC peptide has a low loading 
(10%) compared to B1. Chemiluminescence signal was highly similar for spots B1, C1, D1, suggesting 
that 8 amino acids are enough for enzyme recognition and that a smaller amount of peptide is 
required to obtain a maximum signal in chemiluminescence. Spots B2, C2, D2, based on the 
N-terminal sequence of ARF were expected to be myristoylated as well. The reason why they are not 
myristoylated is not yet clear, and tryptophan or cysteine rich sequences were not prone to high 
background. These results were promising but required further experimental validation. 
??Assay: reproducibility of the syntheses 
Membrane C was synthesised twice, at different time, to control for the reproducibility of the 
synthesis (Figure 115). A similar pattern was obtained in Figure 115 b and c, suggesting that the 
peptide synthesis and the assay were reproducible. 
 
Figure 114: Image in chemiluminescence of membrane B after N-myristoylation (with HsNMT1 and 
AzC12CoA) and capture reaction (with YnTB). a) Expected pattern. b) Subsequent wash with pyridine gave a 
different pattern. The CuAAC controls (azide) are outlined in red. The known myristoylated peptides are 
outlined in green. 
 
211 
 
??Assay: test different capture reagents 
The previous assays were all carried out with AzTB or YnTB via a CuAAC reaction and gave similar 
patterns. It appeared advantageous to use a copper free/strain promoted azide-alkyne cycloaddition 
(SPAAC) reagent, as this would not require a subsequent washing step with pyridine or EDTA. The 
strain promoted reagent 76 (Figure 111), was compared to AzTB (Figure 116). 
Interestingly, the two reagents, AzTB (CuAAC) and DABCO-TAMRA (SPAAC), gave similar results for 
both HsNMT isoforms. As expected, no signal was obtained for peptides reported or predicted not to 
Figure 115. Reproducibility of the synthesis and the assay. Units of membrane C (b and c) were synthesised 
and subjected to in vitro myristoylation (YnC12CoA and HsNMT1) and CuAAC (with AzTB) for comparison. The 
expected pattern is shown in a). 
 
Figure 116. Comparison of two capture reagents. Units of membrane E were subjected to in vitro 
myristoylation followed by CuAAC reaction with AzTB (1 μM) or SPAAC with DABCO-TAMRA (0.2 μM). Peptide 
sequences can be seen in Appendix J. 
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be N-myristoylated. A weak signal was obtained for the G2A controls. It is possible that G2A peptides 
might be low affinity substrates of HsNMT, even if an N-terminal glycine is known to be optimal for 
N-myristoylation (Chapter 1). Interestingly, a few peptides, such as peptide C3, seem to have a 
different pattern when a different HsNMT isoform was used. 
For validation of these results, a few of the labelled peptides were synthesised using standard SPPS 
techniques and tested with the CPM assay (Table 14). Interestingly, peptide C3 had a lower KM value 
with HsNMT1, which suggests (as seen in Figure 116) that it is a better substrate of HsNMT1. Further 
experimental analysis is required to validate these results. 
The ratio Kcat/KM , also referred as to the specificity constant, 344 can also be used to compared the 
enzyme-catalysed reaction efficiencies. Kcat is the catalytic constant, also referred to as the turnover 
number. It can be calculated by dividing Vmax by the enzyme concentration. The ratios Kcat/KM  were 
different for HsNMT1 and HsNMT2 for all the peptides shown in Table 14. It is unclear if this ratio is a 
good indication of the isoforms substrate specificity as this ratio has been suggested to have some 
limitations.345 
 
 
6.1.2.4 Screening of a small peptide library 
A small peptide library (141 peptides) was prepared on a cellulose membrane (2 repeating units, one 
for each HsNMT isoform, membrane G, Appendix J). The membrane units were screened against 
HsNMT1 and HsNMT2 using DABCO-biotin (Figure 117). The membrane was quite large, and difficult 
to fit in a dish without wasting reagents; this may have resulted in a problem during incubation of 
the membrane with HsNMT1, as no spots can be seen from positions 1 to 9. Future studies should 
consider screening a smaller membrane.  
Table 14. Kinetic parameters of peptides presented in Figure 116 evaluated with the CPM assay in the 
presence of a saturating amount of MyrCoA. Error  < 10%.  
  HsNMT1 HsNMT2 
Peptide 
KM 
(µM) 
Vmax 
(RFU/min) 
Kcat /KM (x10
5 
RFU/min/µM) 
KM 
(µM) 
Vmax 
(RFU/min) 
Kcat /KM (x10
5 
RFU/min/µM) 
A2 21.61 101388 9.3 9.01 21434 4.7 
A3 0.54 47774 174.7 0.51 11662 45.3 
C3 7.08 23653 6.6 63.3 15678 0.5 
C4 10.93 79674 14.4 9.74 17384 3.5 
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As expected, c-SRC (E20) was detected on both membranes. However, N-terminal sequences of 
proteins identified as substrates in Chapter 4, were not myristoylated, such as tescalin (A11) or 
NDUFB7 (A14). It is possible that these peptides have a lower affinity for the enzyme and that they 
require a higher concentration of YnC12CoA or enzyme to be in vitro myristoylated. 
Some differences could be observed between both membranes. Peptides outlined in red seemed to 
be better substrates of HsNMT1. Alignment of these peptide sequences did reveal a consensus, 
however, for potentially selective peptides (Figure 118). Only Gly in position 1 and Ser in position 5 
were common to the 8 peptides, and these two amino acids are often observed for NMT substrates 
(Section ?1.4.2). 
6.1.2.5? Conclusions SPOT synthesis and introduction to microarrays 
The peptide screening results are promising but require validation as the number of NMT substrates 
seems relatively low (30-40 out of the 141 peptides). It would be interesting to prepare a new 
membrane with only the NMT substrates identified with high confidence in Chapter 4. The main 
 
Figure 117. Assessment of 141 putative HsNMT substrates. Sequences can be found in Appendix J (Membrane 
G). Peptides circled in red seem to be better substrates of HsNMT1 over HsNMT2. 
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Figure 118. Sequence alignment of peptides outlined in red on Figure 117.The alignment was performed 
with Cluster omega.  
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disadvantages of SPOT synthesis are that the peptides might be of variable quality, fluorescence 
cannot be used as a detection method, and it is impossible to determine a KM value for the peptides. 
These problems could be solved using small molecule microarrays (SMM).346 A SMM is a 
miniaturized tool that allows screening many different compounds at once and is mainly used to 
discover protein-small molecule interactions.346,347 A library of chemically synthesised compounds is 
printed on a glass plate. The compounds bind covalently or via a strong interaction (biotin-avidin, 
thiol-alkene...) to the glass plate. Using this technique, it is possible to quantify the binding activities 
by printing different amount of compounds on the plate.151 Several groups have carried out SMM-
based enzyme assays and fingerprinting studies.347-349 The spots are smaller than the spots obtained 
with arrays on cellulose membrane, also referred to macroarrays (0.1-0.5 mm). The signal-to-
background ratio is usually high as the peptides are more accessible to be screened at planar 
surfaces and fluorescence can be used 350. However, this technique needs certain equipment and is 
also time consuming and expensive as all the compounds need to be prepared in solution or using 
SPPS before being printed on the glass plate.  
A small library of peptides bearing a PEG-biotin moiety at the C-terminus were prepared and spotted 
on a streptavidin functionalised microscope slide 151 by an OmniGrid Micro microarrayer (Digilab, UK) 
using 946MP2 pins (ArrayIt, USA) Microarrayer (in collaboration with Dr. Ali Salehi-Reyhani, 
Professor Paul French and Dr Mark Neil research groups, Imperial College London). 
As a control, AzTB was spotted on the glass plate but after several washes with PBS, no fluorescent 
signal could be detected using the Ettan Dige Imager (EDI, GE Healthcare) equipment generally used 
to image in-gel fluorescence, probably due to the low amount of fluorophore attached to the plate 
and the sensitivity limit of the EDI. Fluorescence was thus detected with a TIRF (total internal 
reflection fluorescence) microscope. The sensitivity was much higher than the EDI. However, the 
glass plate functionalisation was not perfect as small dust particles were stuck to the plate and some 
scratches could be observed with the microscope. Another procedure could have been used to 
improve functionalisation.351 However, the spotting on the glass plate was extremely laborious as 
the needle used to spot the solution had to be manually removed and washed each time the 
solution was changed. The software was not user friendly as each spot had to be set up manually 
with the coordinates on the plate. Moreover, for detection spots would need to be analysed one by 
one. It appeared extremely time consuming to optimise and screen a small library of peptides 
(around 100) using these equipments. However, this method holds promise if efficient automation 
and detection platforms were available. 
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6.1.3 ELISA assay 
A few peptides could not be characterised using the CPM assay for several reasons. Some peptides 
corresponding to the N-terminal sequences of NMT substrates, such as FYN and XRP2, contained a 
cysteine residue. This amino acid is not compatible with the CPM assay as it leads to high 
background (Section  2.2.2). Other peptides, such as HCCS were highly insoluble in the CPM assay 
buffer.  Preparing different lengths of HCCS (from 8 AA to 22 AA) did not improve the solubility. 
During the project described in this thesis, an ELISA assay was being developed in parallel by 
Dr. Antonio Konitsiotis (Tate group, Imperial College London) for an unrelated acyl transferase, and 
appeared attractive to solve the problems listed above. The peptides were synthesised with a biotin 
moiety at the C-terminus and bound to a streptavidin-coated 96-well plate (Figure 119). The 
peptides were incubated with recombinant HsNMT1/2 in the presence of YnC12CoA. After 1 h, the 
plate-bound peptides were washed and captured with an azido-FLAG peptide. After several washes, 
FLAG could be specifically recognised by a HRP-coupled FLAG antibody. The HRP substrate was 
revealed using a TMB (3,3’, 5,5’ tetramethyl benzidine) substrate (BD Biosciences) which 
allowed the detection of the antibody by absorbance. Absorbance should be proportional to the 
amount of alkyne-tagged peptides in the plates, and the assay differs from the CPM assay since it 
can only operate as an end-point assay (the CPM assay can be end-point or continuous). 
ELISA experiments were carried out with 15AA c-SRC biotinylated at the C-terminus. Conditions used 
in the assay (buffers, concentrations of reagents, incubation time) were optimised by Antonio 
Konitsiotis (Tate group, Imperial College London). All the other experiments described here have 
been carried out by the author.  
For the first experiment, 1 µM of peptide, 4 µM YnC12CoA and 500 ng/mL of enzyme were used. An 
acetylated c-SRC biotinylated peptide was prepared as a negative control (Figure 120). MyrCoA and 
no enzyme were also used as negative control. A similar absorbance signal was obtained for HsNMT1 
and HsNMT2 in the presence of YnC12CoA. A low signal was observed in all the controls and the Z 
factor was close to 1, suggesting that the background is relatively low for this assay.  
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The concentration of enzyme used in this ELISA assay was optimised across a range of several 
concentrations of HsNMT1/2 (0.16–????? ???????????? ?? ??? ????????? ???? ? ??? ???????? ?Figure 
121a). The absorbance signal was obtained by subtracting the signal from the no enzyme control. 
From 10 to 1000 ng/mL there is acceptable correlation between absorbance and concentration of 
enzyme. It was decided to use 300 ng/mL, the same concentration as in the CPM assay, to compare 
results between assays.  
 
Figure 119 ELISA NMT assay 
 
Figure 120. ELISA assay with 15AA biotinylated c-SRC. The error bars represent the standard deviation of two 
replicates. 15AA c-SRC and N-acetylated 15AA c-SRC (both biotinylated at the C-terminus) were incubated in 
the presence of YnC12CoA or MyrCoA (4 μM) and recombinant HsNMT1 or HsNMT2 (500 ng/mL) for 1 h in the 
streptavidin coated plate. After several washes, the plate-bound peptide was captured with Az-FLAG, and 
revealed using the TMB substrate reagent set (BD Biosciences). The Z factor of the assay was estimated for 
HsNMT1 (0.99) and HsNMT2 (0.98) in the presence of YnC12CoA and c-SRC (the background was the sample 
with the same conditions but no enzyme). 
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The KM of YnC12CoA and the KM of 15AA c-SRC were determined (Figure 121b). The values were 
similar to the values obtained with the CPM assay, confirming that the ELISA assay could be used to 
determine the kinetic parameters of peptides. 
 
The assay was then used to study the 15aa peptide derived from the N-terminus of HCCS, a highly 
insoluble peptide difficult to study with the CPM assay; addition of a PEG-biotin moiety coupled to 
the C-terminus greatly improved solubility in buffer. The background was slightly higher than with c-
SRC (Figure 122a). A KM value was determined with NMT1 and NMT2 and HCCS was found to have a 
good affinity for both isoforms, with KM values lower than 1 μM. The protein HCCS was identified 
with high confidence as a novel NMT substrate in Chapter 4 and these kinetic studies confirmed that 
the protein is an NMT substrate for the recombinant enzymes. 
 
 
Figure 121. Optimisation and validation of the ELISA NMT assay. a) The enzyme concentration was optimised 
by varying the concentration of HsNMT1 or HsNMT2 from 0.16 to 2500 ng/mL in the presence of 1 ???
YnC12CoA and 4 ??? ????????????? ????? ?-SRC. The background (absorbance value with no enzyme) was 
subtracted from each absorbance value. The error bars represent the standard deviation of two replicates. 
b) The KM of YnC12CoA or biotinylated 15AA c-SRC were determined in the presence of saturating amounts of 
biotinylated 15AA c-SRC (30 μM) or YnC12CoA (2 μM) respectively. The enzyme concentration was set to 
300 ng/mL. The values were compared to values obtained with the CPM assay. The error represents the 
standard deviation of two replicates. 
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An assay was then carried out with two cysteine-containing peptides, FYN and XRP2 (Figure 123 a 
and b). MyrCoA and no enzyme samples were used as negative controls. The background was 
relatively high for these peptides, and the assay buffer contained 1 mM DTT, which should be 
sufficient to prevent oxidation of cysteine residues. Optimisation experiments were carried out to 
decrease the background, including more stringent washes with a high salt buffer (1x PBS 
supplemented with 0.2% SDS and 0.5 M NaCl ) after the first step of the assay (myristoylation 
reaction) (Figure 123c). However, the absorbance signal was lost using these conditions, probably 
because the CuAAC reaction was inhibited. 
Washing peptides with hydroxylamine after the in vitro myristoylation step significantly decreased 
the background. However, it also decreased the window of the assay making it difficult to measure 
KM values accurately using these conditions. Further optimisation would be required to measure the 
affinity of cysteine containing peptides. The buffer used for in vitro myristoylation and for washes 
could be varied. 
In conclusion, this ELISA assay could be employed to assess the affinity of hydrophobic peptides 
poorly soluble in the CPM assay buffer but further optimisation would be required for cysteine 
containing peptides. The assay could also be used in the future as an inhibitor assay to test inhibitors 
containing an electrophilic moiety or atom such as oxygen or sulphur that would be incompatible 
with the CPM assay. 
 
 
Figure 122. ELISA NMT assay with HCCS. The error represents the standard deviation of two replicates. a) 
Absorbance values obtained for the assay carried out using various conditions. HsNMT1, HsNMT2 or no 
enzyme was added to the well in the presence of YnC12CoA or MyrCoA and biotinylated 15AA HCCS peptide 
(10 μM). b) The KM values of HCCS were determined in the presence of HsNMT1 or HsNMT2.  
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6.1.4? Conclusions on in vitro HsNMT1/2 selectivity 
Studies of the HsNMT isoform substrate specificities in vitro had not shed much light on whether the 
two isoforms have different substrate specificities in vivo. Additional studies were carried out with 
two peptides which were previously proposed to have a different selectivity in vivo: HIV-GAG and 
HIV-NEF. Kinetic studies using the CPM assay did not show any selectivity in vitro between these two 
peptides (Appendix K). If the peptide binding pockets of the two isoforms are highly similar, it would 
be difficult to design a selective HsNMT1 over HsNMT2 inhibitor.  
These concerns were confirmed when the crystal structure of HsNMT2 was obtained (Figure 39). Key 
residues in the active site superimpose remarkably well with the key residues in the HsNMT1 crystal 
structures (apo enzyme and enzyme bound to inhibitor IMP366). Moreover, when NMT inhibitors 
were tested (Chapter 3), no more than 3 to 4-fold selectivity could be achieved between the two 
isoforms. Recent high throughput screening of a diverse subset of the Pfizer corporate collection 
(ca. 150,000 compounds) showed that no more than 3-fold selectivity could be achieved between 
the recombinant isoforms, which is likely to be insufficient in a physiological context.352 
 
Figure 123. ELISA NMT assay with cysteine containing peptides. The error bars represent the standard 
deviation of two replicates. a) and b) Absorbance values obtained for the assay carried out using different 
conditions. NMT1, NMT2 or no enzyme was added to the well in the presence of YnC12CoA or MyrCoA and a) 
biotinylated 15AA FYN or b) biotinylated 15AA XRP2. c) An ELISA assay was carried out in the presence of 
HsNMT1, YnC12CoA and biotinylated 15 AA XRP2. Different washing conditions were used to try decreasing 
the background. After the in vitro myristoylation step, the plate-bound peptides were washed with PBS, a PBS 
buffer supplemented with 0.2% SDS 0.5 M NaCl (PBS high salt), or 0.3 M Hydroxylamine in PBS for 5 or 45 min. 
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However, siRNA experiments showed that selective knockdown of one isoform resulted in different 
substrate patterns, suggesting that selectivity could be achieved in vivo.28 The two isoform 
sequences mainly differ at the N-terminus, a region that has been shown to be essential for 
localisation of the enzymes in cells (Section  1.6.2), and recently the two isoforms were suggested to 
have different localisation.115 It is possible that isoform substrate specificity could arise from this 
different localisation and not from divergence in the isozyme active sites. As a consequence, It 
appeared more relevant to study the isoforms substrate specificity in cells by combining siRNA, 
YnC12 labelling and Proteomics. 
6.2 In-cell studies using siRNA 
To study HsNMT isoform substrate specificity in cells, expression of HsNMT1 or HsNMT2 was 
knocked down using specific siRNAs.28 HeLa cells were treated with HsNMT1 siRNA or HsNMT2 
siRNA, and a YnC12 labelling strategy combined with proteomics allowed detection of substrates of 
the isoform which was not knocked down. As it was unlikely that complete knockdown could be 
achieved, quantitative proteomics appeared to be an attractive method. In their study of the protein 
turnover in HeLa (Section  5.3), Cambridge et al. determined that the half lives of HsNMT1 and 
HsNMT2 was 50 and 58.8 h respectively,315 suggesting that at least a 2 day knockdown experiment 
would be required to decrease the level of one isoform by about 50%.  
The toxicity of several transfection reagents was assessed: Lipofectamine (Invitrogen), Lipofectamine 
2000 (Invitrogen) and RNAiMAX (Invitrogen). HeLa cells were seeded in a 6-well plate 24 h before 
treatment (50 000 or 100 000 cells per well). The transfection reagents were added (2 or 4 µL of 
Lipofectamine or RNAiMax, or 2.5 pr 5 µL of Lipofectamine 2000) according to the supplier’s 
protocol. 6 h after the beginning of the treatment, the media was replaced with fresh media. The 
cells were mostly dead after 48 h in wells where only 50 000 HeLa cells were seeded. In the other 
wells, less toxicity was obtained with Lipofectamine 2000 (2.5 or 5 µL).  
A siRNA knockdown experiment was carried out for 2 days using Lipofectamine 2000 (5 µL) and 
siRNA (2 µL of a 50 mM stock solution) (Figure 124a). The knockdown efficiency of a siRNAi 
experiment can be evaluated by Western Blotting, with a reduction in protein level. Unfortunately, 
no signal could be detected for HsNMT2 due to the poor quality of the antibody. The level of 
HsNMT1 decreased in the samples transfected with the siRNA against HsNMT1 and a combination of 
siRNA against both HsNMT isoforms.  
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A similar experiment was carried out to compare the efficiency of the knock down after 2 or 3 days. 
Cells were labelled with YnC12 6 h before cell lysis (Figure 124b). YnC12 labelling significantly 
decreased in the samples treated with siRNA against HsNMT1 or HsNMT2 but not in the samples 
treated with the control siRNA. Western blotting confirmed that HsNMT1 levels decreased in cells 
transfected with the siRNA against HsNMT1. Knockdown was similar after 2 or 3 days but it was 
decided to perform 3 day transfections for the next experiments. 
HsNMT1 knockdown was not complete after 3 days and it seemed more reliable to use quantitative 
proteomics to identify HsNMT1 or HsNMT2 substrates. Cell lysates were prepared by Dr. Ute Brassat 
(Tate group, Imperial College London) in view to perform iTRAQ quantitative proteomics 
experiments (Section ?1.11.2). The isotopic label would be introduced just before the analysis by LC-
MS/MS. This method would compare four samples: cells treated with the siRNA control, siRNA 
against HsNMT1, HsNMT2 or combination of HsNMT1 and HsNMT2 siRNA. Samples were captured 
and enriched as described in Chapter 4 (Figure 125). Interestingly, there is a noticeable difference in 
 
Figure 124. Optimisation of the siRNA transfection in HeLa. 100 000 HeLa cells were seeded (in a 6-well plate) 
in growth media containing 10% FBS (no antibiotic) 24 h before treatment. A complex of siRNA (2 μL of a 50 
mM stocksolution; control siRNA, siRNA against HsNMT1 or HsNMT2, or mix of siRNA against HsNMT1 and 
HsNMT2) with Lipofectamine 2000 (5 μL) was prepared in Opti-MEM media (Invitrogen), according to the 
supplier’s protocol. The mixture was added to the cells and incubated for 6 h. After this time, the growth 
media was changed (DMEM + 10%FBS) and the cells were allowed to grow for several hours. a) Cells were 
lysed 2 days post-treatment. Several controls were used: no treatment, cells only treated with Lipofeactimne 
2000 or cells treated with a non-targeting siRNA as a control. These controls checked that the conditions used 
for the cells were not toxic and determined the abundance of HsNMT1 in cells with no knockdown of HsNMT1 
by Western blotting. CDK2 was used as a loading control. b) Cells were lysed 2 or 3 days post-treatment. 6 h 
before cell lysis, cells were treated with YnC12. Myrsistoylated proteins were captured with AzTB and 
visualised by in-gel fluorescence. Western Blot analysis was performed to check the levels of HsNMT1 in cells 
and CDK2 was used as loading control. HsNMT2 antibody did not give a sufficient signal in chemiluinescnce. 
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the YnC12 labelling of HeLa cells treated with siRNA against HsNMT1 or HsNMT2. Unfortunately, 
technical issues prevented analysis of these samples within the timeframe of this thesis, but analysis 
of these samples by the optimised quantitative chemical proteomic workflow described in Chapter 4 
should be a priority for future work.  
 
 
Figure 125. siRNA treated samples for quantitative proteomics (ITRAQ). HeLa cells were treated for 3 days 
with siRNA (control, HsNMT1, HsNMT2 or HsNMT1+HsNMT2). Lysates were prepared by Dr. Ute Brassat (Tate 
group, Imperial College London). Samples were captured with AzTB and enriched on Neutravidin agarose 
beads. Sample before pull down (Before PD), pull down (PD) and the supernatant were loaded on the gel. The 
levels of HsNMT1 and HsNMT2 were checked by Western Blotting. Coomassie and CDK2 were used as loading 
controls for the gel and Western Blotting respectively.  
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6.3 Conclusions 
In this Chapter, different methods were assessed to identify HsNMT1 or HsNMT2 substrates in vitro 
or in cell. 
First, experiments carried out in E. coli lysates with overexpressed PfARF showed that an HsNMT 
substrate could be in vitro myristoylated in lysate, in the presence of analogues of MyrCoA and 
recombinant HsNMT1/2. The newly N-myristoylated PfARF could be captured by AzTB or YnTB and 
detected by in-gel fluorescence. This method was applied to HeLa lysates obtained from cells treated 
with an NMT inhibitor. Many HsNMT substrates could potentially be myristoylated in vitro. However, 
the labelling pattern seen by in-gel fluorescence was different from the labelling typically obtained 
with cells treated with only YnC12. Moreover, the background labelling was higher, suggesting that 
this experiment would require further optimisation. 
Secondly, small libraries of peptides were prepared on cellulose membrane and screened for activity 
against HsNMT1 and HsNMT2. If some of these peptides were selective for HsNMT1 over HsNMT2 
(or HsNMT2 over HsNMT1), they could be developed as peptidomimetic inhibitors and then 
employed in cells to study HsNMT1/2 protein substrates. Several experiments were carried out and 
showed that it was possible to myristoylate and detect HsNMT1/2 peptide substrates on a cellulose 
membrane. However, the use of cellulose membranes presented some limitations. Fluorescence, 
which provides a rapid readout, could not be used to detect the substrates on a cellulose membrane 
due to background problems. Moreover, peptides which were previously reported to be 
myristoylated were not always detected using this method, perhaps due to their lower affinity for 
the isoforms or synthesis issues on the membrane.  
Affinity of the peptides for HsNMT1 or HsNMT2 could be confirmed using the CPM assay for a few 
peptides. However, due to solubility issues or the presence of a nucleophile (a cysteine residue for 
example), kinetic parameters of some peptides could not be determined using the CPM assay. An 
ELISA end-point assay was developed. This assay was shown to be suitable to measure the KM of c-
SRC peptide as similar values were obtained with the CPM and ELISA assays. The KM values of a 
peptide poorly soluble in the CPM assay buffer could also be determined. However, further 
optimisation would be required to measure the kinetic parameters of peptides bearing a nucleophile 
as a high background was observed. 
To date, there is no strong evidence that the two HsNMT isoforms have different substrate 
specificities in vitro and it might be more reliable to carry out in-cell studies with specific siRNA 
against one isoform. The conditions of HsNMT1/2 knock down were optimised. Several proteomics 
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experiments were performed, using ITRAQ or triple SILAC, but were unsuccessful. Proteomics 
experiments will be repeated using the Spike-in SILAC method. 
In the last few years, a novel method has been developed to stably knock out a gene. A stop codon 
could be selectively introduced in the HsNMT1 and also in the HsNMT2 gene to stop expression of 
one of these two isoforms.353 Cas9 and a suitable RNA would need to be co-expressed in cells. 
Colonies could then be selected and sequenced to check that a hetero modification was obtained. By 
repeating the whole process, a homo modification could be achieved.353 It would be advantageous 
to study HsNMT1/2 substrate specificity in these engineered cell lines as a stable and complete 
knockdown of one of the isoform could potentially be obtained. 
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Chapter 7 Conclusions and future work 
This Chapter discusses the implications of this work for our understanding of protein 
N-myristoylation and for NMT as a cancer drug target and proposes future directions for this project. 
7.1 Conclusions 
7.1.1 Chemical tools to study N-myristoylation 
In the current study, several chemical tools were employed to study N-myristoylation in vitro and in 
cells. The synthesis of several chemical probes, YnC12, AzC12, YnC15, YnC12CoA, AzC12CoA and 
MyrCoA, was optimised (Chapter 2). These probes can now be prepared reliably in moderate yields. 
The work described in Chapter 2 confirmed that YnC12, an alkyne-tagged analogue of myristic acid is 
a useful probe to study N-myristoylation. YnC12 can be transferred, in place of the natural lipid 
substrate (Myr), co- or post- translationally to the N-terminal glycine of NMT protein substrates. The 
YnC12 probe first allowed assessment of the on-target activity of NMT inhibitors (Chapter 3) and was 
then successfully applied to identify co-translational NMT substrates by chemical proteomics in HeLa 
cells, a cervical cancer cell line (Chapter 4). YnC12 labelling was optimised in HeLa cells, by increasing 
the labelling time form 6 to 24 h, leading to an enhanced labelling of NMT substrates and the 
detection of low abundance substrates by chemical proteomics. It is important to note that YnC12 
does not only label NMT substrates but can also label S-palmitoylated proteins, GPI-anchored 
proteins and possibly other proteins, as described in Section  4.7. 
A novel approach, based on the combination of three assays (Chapter 3), was developed for the 
rapid evaluation (potency and on-target activity in cancer cells) of HsNMT inhibitors. Traditional 
methods to validate on-target activity of an inhibitor involve analysing the effect on downstream 
targets using biological assays or Western blotting. These methods can be laborious and do not 
always allow the rapid evaluation of potential off-target effects. In the current study, an in vitro 
enzyme assay, based on fluorogenic CPM readout, was employed to evaluate the potency of 
inhibitors against both HsNMT isoforms (IC50). Secondly, YnC12 labelling was used to assess 
on-target NMT inhibition in cells. A dose-dependent decrease of the fluorescence signal could be 
observed for compounds inhibiting NMT activity in cells and the in-cell tagging EC50s (TC50s) were 
determined. The third assay, the MTS metabolic activity assay, allowed the determination of EC50s. A 
good correlation between EC50 and TC50 indicated that the inhibitor was acting on-target and 
showed that the inhibitor had little or no side-effects in cells. HsNMT inhibitor IMP366 was 
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characterised and used as a chemical tool to identify new N-myristoylated proteins in HeLa cells 
(Chapter 4) and to study the phenotype of NMT inhibition (Chapter 5).  
7.1.2 Identification of N-myristoylated proteins in HeLa cells 
In Chapter 4, several chemical proteomics methods were studied for the identification of 
N-myristoylated proteins in HeLa cells, the cervical cancer cell line used in this study.  
Acylated proteins, such as N-myristoylated proteins and S-palmitoylated proteins, are typically 
identified using alkyne-tagged analogues of the fatty acid of interest combined with 
non-quantitative proteomics experiments (Section  4.2). Another approach, based on the use of 
double SILAC quantitative proteomics combined with an inhibitor (Section  4.5), has also recently 
been employed to study S-palmitoylated proteins.  
In the current study, these two approaches were applied to study protein N-myristoylation in HeLa 
cells and many putative NMT substrates were identified. However, both methods showed drawbacks 
as many proteins with no N-terminal MG motif were also detected. These proteins are most likely 
tagged with YnC12 in a non NMT-mediated manner, probably because these proteins are 
S-palmitoylated or GPI-anchored proteins.  
In the current study, a novel approach was developed to identify simultaneously and with high 
confidence a large number of N-myristoylated proteins (70 proteins) in HeLa cells. This method 
combined the spike-in SILAC approach, the YnC12 probe and the chemical genetic tool IMP366. This 
novel approach also allowed for the first time the evaluation of inhibition sensitivity (in-cell IC50s) for 
70 NMT substrates, demonstrating the specific in-cell on-target activity of IMP366. The significance 
of these in-cell IC50 values is discussed in the next session.  
An additional four substrates were identified using the AzKTB capture reagent which allowed the 
detection of the YnC12-modified peptide. 74 N-myristoylated proteins were identified with high 
confidence in HeLa cells; this is a huge improvement compared to previous proteomics experiments 
carried out to identify NMT substrates (typically around 20 proteins were detected).163,173,224 
7.1.3 NMT inhibition in cancer cells 
On-target inhibition of NMT in HeLa cells had a well-defined phenotype, arising from potential loss 
of function in >74 specific NMT substrates proteins. While NMT inhibition was not toxic to the cells 
after 1 day treatment, apoptosis and cell death were induced after 3 days and resulted in almost 
complete cell death after 7 days.  
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NMT substrates have key biological functions in cells, are all potentially essential and could lead to 
cell death when they are not N-myristoylated. Western blots and chemical proteomics experiments 
were carried out to assess the potential mode of action of NMT inhibitor IMP366. Loss of function of 
c-SRC and PSMC1 was evaluated by Western blot analysis. However, NMT inhibition is most likely to 
have a pleiotropic effect.  
The NMT inhibition/spike-in SILAC method described in Section ?4.6, allowed the determination of 
inhibition sensitivity (in-cell IC50s) for 70 NMT substrates. In-cell IC50 values might reflect the affinity 
of a protein for HsNMT1/2, and to date, it is unclear how in-cell IC50 could be used to identify the key 
NMT targets leading to cell death. These values might need to be correlated with protein function, 
importance of the protein for the cells, turnover rate and possibly abundance in cells. 
In-cell IC50 values were plotted against the protein half-lives determined in Chapter 5 (Figure 126) 
and with the protein abundance, determined using the sum of peptide intensities from the 
proteome analysis of HeLa cells.207 However, there was no obvious correlation between in-cell IC50s 
and protein half-life or protein abundance.  
The start of the phenotype could correlate with the depletion of N-myristoylation of NMT 
substrates. If toxicity starts after 2 days, key NMT substrates might have a half-life around 1.5 or 2 
days.  
Taken together, these results suggest that the relationship between NMT inhibition and cell death is 
likely to be complex, and that more experiments are required to understand the mode of action of 
NMT inhibitor IMP366 in HeLa cells. 
 
Figure 126. Plot of in-cell IC50 values with a) proteins half lives (t1/2) or protein abundance. Protein 
abundance corresponds to the protein copies per cell as reported by Nagaraj et al. 207 
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7.2 Future work 
7.2.1 N-myristoylation 
 NMT substrates in HeLa. While 74 NMT substrates were identified in HeLa cells in the current 
study, it is possible that a few substrates are missing. Indeed, more experiments need to be 
carried out to understand whether the NMT substrates identified with low confidence in 
Section  4.6.3 (27 proteins), are or not NMT substrates. It is difficult to predict how many 
substrates were missed in the current study. As it is thought that ca. 1% of the proteome in 
N-myristoylated (Section  1.1), ca. 100 proteins might be N-myristoylated in HeLa cells since 
Nagaraj et al. identified ca. 10 000 proteins in their study of HeLa cells proteome.207 
 NMT substrates in other cell lines or organisms or in vivo. The NMT inhibition/spike-in SILAC 
method developed in the current study (Section  4.6), could be applied to other cancer cell lines. 
As different cell lines express a different subset of proteins, the NMT substrates might differ 
from one cell line to another. 
 Post-translational NMT substrates in HeLa. While the main focus of the current work was on 
co-translational myristoylation, the NMT inhibition/spike-in SILAC approach could be applied to 
detect post-translationally N-myristoylated proteins in the context of apoptosis. HeLa cells 
could be treated using the conditions optimised in Section  2.4. 
 NMT1/2 localisation. The NMT isoforms are thought to be localised at the ribosome, but 
recently, Perinpanayagam et al. suggested that HsNMT2 was localised in the cytosol 
(Section  5.2.2.1.). More experiment need to be carried out to understand the localisation of the 
isoforms in cells and to understand the interaction of HsNMT1 (and HsNMT2) with the 
ribosome.  
 HsNMT1 and HsNMT2 selectivity. Experiments carried out in Chapter 6 have not confirmed 
that HsNMT isoforms have a different substrate specificity (Section  1.2). It is thus unclear 
whether HsNMT1-specific inhibitors might be effective anti-cancer agents, as suggested by 
Ducker et al.28 Quantitative chemical proteomics experiments, combining HsNMT1 or HsNMT2 
siRNA treatment and YnC12 labelling in HeLa cells, will need to be repeated to identify isoform 
substrate specificities (Section  6.2). If there is a different substrate specificity between the two 
isoforms, it would be interesting to correlate it with localisation and level of expression of the 
isoforms in a given cancer cell line. 
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 Methionine aminopeptidase (MetAP). MetAP removes the terminal methionine and exposes 
the N-terminal glycine, as required for N-myristoylation. Two isoforms have been identified in 
humans and specific inhibitors of HsMetAP1 354 and HsMetAP2 355 are available. YnC12 labelling 
experiments in cells could be performed to understand the impact of MetAP on myristoylation 
and to shed light on MetAP substrate specificity. These experiments will consist in feeding the 
cells first with MetAP1 and/or MetAP2 inhibitors and YnC12. Capture of the myristoylated 
proteins would allow visualisation by in-gel fluorescence and identification by proteomics.  
7.2.2 NMT as an anti-cancer drug target 
The work detailed here shows that NMT is essential in cancer cells and that its inhibition leads to cell 
death. However, several questions remain to be answered in order to validate NMT as an 
anti-cancer drug target. 
 NMT inhibitors. Four on-target NMT inhibitors, based on different scaffolds, were identified in 
Section  3.4.3 and could be further optimised into lead series for the future development of an 
anti-cancer drug candidate. Novel inhibitors can be characterised using the CPM assay, MTS 
assay and YnC12 labelling assay. 
 Identify tissues highly sensitive to NMT inhibition. The identification of cancer tissues highly 
sensitive to NMT inhibition could shed light on the mode of action of NMT inhibitors. One or 
several NMT inhibitors could be screened against a selection of cancer cell lines representing 
tissue type and genetic diversity of human cancers, such as the National Cancer Institute (NCI) 
NCI-60 cell lines. This selection comprises 59 cancer cell lines,356 all well characterised at the 
proteome and transcriptome levels. This selection has recently been used to study the mode of 
action of a drug,357 and could be employed to study NMT inhibition. 
 Identify the molecular pathways that lead to cell death using MS-based proteomics. Several 
methods can be used to identify the mechanism of action of a drug,358 such as transcriptome 
studies. Recently, mass spectrometry-based proteomics has emerged as a valuable tool for drug 
discovery and development,358-360 as allows one to study the global effects of an inhibitor on the 
proteome.361 Proteome studies are complementary (and potentially preferable) to 
transcriptome studies as they can take post-translational events or protein degradation into 
account.361 Recently, Sharma et al. used a SILAC-based approach to identify the molecular 
targets of Hsp90 and the proteins that were up/down-regulated upon Hsp90 inhibition. A 
similar approach could be applied to NMT inhibition to decipher the mode of action of NMT 
inhibitors.  
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 Identify N-myristoylated proteins in cancer cell lines highly sensitive to NMT inhibition. To 
understand the mode of action of an NMT inhibitor, it would be essential to identify all the 
N-myristoylated proteins in the cell line of interest. Correlation of the list of NMT substrates 
with sensitivity of the cell line to NMT inhibition could help to understand the role of some NMT 
substrates and help to identify the mode of action of NMT inhibitors. 
 Show that NMT inhibition is not toxic to non-cancerous cells and could reduce cancer growth 
in mouse models, such as human tumour xenografts. To validate NMT as a new cancer drug 
target, it would be important to show that NMT inhibition could decrease tumour growth in 
mouse models without increasing toxicity to healthy cells/tissues. NMT inhibition-mediated 
toxicity should be highly dependent on protein turnover, implying that slowly dividing cells (non 
cancerous cells) might be less sensitive to NMT inhibition.  
It is important to note that human tumour xenografts poorly predict the response of human 
cancers, and therefore, success of mouse-model experiments do not imply that a compound 
will be a safe clinical candidate able to decrease tumour growth in cancer patients.1 Recently, 
genetically engineered mouse tumour models (GEMM) have emerged as a more clinically 
relevant model to study human cancers.362 The tumours are initiated in a more natural 
environment (contrary to xenografts where human tumours are injected into mice) via the 
mutations of specific genes leading to the overexpression of oncogenes or depletion of tumour 
suppressors. However, it can be challenging to produce a GEMM to study the target of interest.1 
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Chapter 8 Materials and methods 
8.1 Chemical synthesis 
8.1.1 General methods 
All reagents and solvents were purchased from Sigma-Aldrich, NovaBiochem UK or National 
Diagnostics UK and used without further purification. Ultrapure water was obtained from MilliQ® 
Millipore water purification system. Moisture sensitive reactions were performed under nitrogen 
atmosphere using dried glassware and standard syringe/septa techniques. 
Thin Layer Chromatography was performed on Merck pre-coated Silica plates (Aluminum oxide 60 
F254, Merck). Spots were visualized by UV light (operating at 254 nm), and using the appropriate 
stain (iodine, potassium permanganate, ninhydrin or p-anisaldehyde stain). Silica gel column 
chromatography was carried either by hand-made columns with Merck Silica 60Å, or using an Isolera 
(Biotage, Uk) automated apparatus with fractions collector equipped with SNAP cartridges columns 
(Biotage, Uk). The freeze drying was carried out using a freeze dryer Alpha 2-4 LD plus, Christ 
(Germany). 
NMR spectra were recorded on 400MHz Bruker instruments and were referenced to TMS or residual 
solvent signals. Data are presented as follows: chemical shift, multiplicity (s = singlet, d = doublet, 
t = triplet, q = quartet, m = multiplet), coupling constant(s) in Hz and integration. NMR spectrometry 
was carried out at room temperature, except were indicated otherwise. 
Mass spectrometry characterisation was obtained from the Mass Spectrometry Service of 
Department of Chemistry, Imperial College London. 
Analytical and semi-preparative RP-HPLC were carried out on a Waters 2767 system equipped with a 
photodiode array, a mass spectrometer and an X-Bridge C18 column (5 μM, 4.6 mM × 100 mM).The 
following elution methods were used: Method A :(gradient of 25 mM ammonium carbonate pH 8 
and MeOH): 0 min 50% MeOH, 0-10 min up to 98% MeOH, 10-15 min 98% MeOH, 15-16 min 98 to 
5% MeOH, 16-20 min 5% MeOH; Method B (gradient of H2O and MeOH, supplemented with 0.1% 
formic acid): 0-10 min 5-98% MeOH, 10-12 min 98% MeOH, 12-13 min 98 to 5% MeOH, 13-17 min 
5% MeOH;  Method C (gradient of H2O and MeOH, supplemented with 0.1% formic acid): 0-10 min 
50-98% MeOH, 10-12 min 98% MeOH, 12-13 min 98 to 50% MeOH, 13-17 min 50% MeOH; Method 
D: (gradient of 25 mM ammonium carbonate pH 8 and MeOH), 0 min 2 % MeOH, 0-10 min 2-98% 
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MeOH, 10-15 min 98% MeOH, 15-16 min 98 to 5% MeOH, 16-20 min 5% MeOH;. The flow rate of 
1.2 mL/min was used for the analytical mode and 20 mL/min were used for the preparative mode.  
All peptide synthesis reagents and solvents were purchased from Sigma-Aldrich, Merck Chemicals or 
National Diagnostics and used without further purification. Peptides were synthesised manually or 
by automated solid phase peptide synthesis with a ResPep SL apparatus (Intavis, Germany) 
The following general methods were used for the manual peptide synthesis on resin: 
 Method 1: Fmoc deprotection. The resin was swelled in DMF for 1 h and Fmoc deprotected by 
treating it with 20% piperidine/DMF (3 × 3 mL) for 10 min per treatment. After the third 
treatment, the resin was washed with DMF (3 × 3 mL), DCM (3 × 3 mL) and swelled in DMF (3 × 
3 mL) for subsequent steps. 
 Method 2: General procedure for the manual coupling of amino acids or special acids to 
peptides on resins. The resin (typically 20 µmol) was swelled by addition of 1 mL DMF followed 
by shaking at room temperature for 1 h. DMF was removed by filtration. A mixture of the 
appropriate acid (5 eq of amino acid or 3 eq of special acid or amino acid) was pre-activated by 
the addition of the appropriate coupling reagent (5 eq HBTU for an amino acid or 3 eq of HATU 
for a special acid or amino acid) and DIPEA (10 eq if HBTU was used or 6 eq if HATU was used). 
After 5 min, the mixture was added to the resin bound peptide and shaken at room temperature 
for 2 h. The reagent mixture was removed by filtration and the coupling step was repeated. The 
reagent mixture was removed by filtration peptides washed with DMF (5 × 2 mL), DCM (3 × 
2 mL), MeOH (3 × 2 mL) and Et2O (3 × 2 mL) and left to dry in a desiccator. If another coupling 
was required, the resin was Fmoc-deprotected as explained in Method 1 before starting the 
second coupling. 
8.1.2 YnC12 synthesis  
I
O
OH
11  12-Iodododecanoic acid (29) 
To a solution of 12-Bromododecanoic acid (1.00 g, 3.58 mmols, 1 eq) in dry acetone (20 mL) was 
added NaI (1.61 g, 10.74 mmols, 3eq) in one portion. The mixture was stirred at room temperature 
overnight. Completion of the reaction was checked by 1H NMR. Water (200 mL) and DCM (100 mL) 
were added. The layers were separated and the aqueous layer was extracted with DCM (2 x 70 mL). 
The combined organic layers were washed with saturated aqueous sodium thiosulphate (100 mL), 
Brine (100 mL), dried over MgSO4 and concentrated under reduced pressure to yield a white solid 
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(1.05 g, 90 %). The crude product was used without further purification for the next reaction. 
1H NMR (400 MHz, CDCl3) δ = 3.17 (t, J=7.1, 2H), 2.33 (t, J=7.5, 2H), 1.84 – 1.75 (m, 2H), 1.64 – 1.56 
(m, 2H), 1.27 (m, 14H). 
O
OH
11 Tetradec-13-ynoic acid (YnC12, 16) 154 
Under nitrogen atmosphere, a solution of TMS-acetylene (1.12 mL, 7.82 mmol, 2.5 eq) in dry THF 
(8 mL) was cooled down to -78 °C using a bath of acetone and dry ice. A solution of n-BuLi in hexanes 
(3.8 mL, 2.5 M solution, 9.39 mmol, 3.0 eq) was added dropwise. The clear reaction mixture was 
allowed to warm to room temperature for 10 minutes and then cooled to -78 °C. DMPU (7.9 mL, 
21 eq) and a solution of 12-iodododecanoic acid 29 (1.02 g, 3.13 mmol, 1.0 eq) in dry THF (8 mL) 
were added dropwise. The yellow reaction mixture was allowed to warm to room temperature and 
stirred overnight. The reaction mixture was cooled to -78 °C and quenched by the dropwise addition 
of saturated NH4Cl (240mL). Et2O (100 mL) and water (50 mL) were added to the brown solution. 
The layers were separated and the aqueous layer was extracted with Et2O (2 x 50 mL). The 
combined organic layers were washed with water (100 mL), brine (100 mL), dried over sodium 
sulphate, filtered and concentrated under reduced pressure. The brown residue was purified by 
silica-gel chromatography (gradient chex: EtOAc: AcOH 99:0:1 to 95:4:1) to yield a white solid (500 
mg, 54 %). NMR analysis of the product showed that the product contained < 2 % of 12-
Iodododecanoic acid. 
To a suspension of TMS-protected alkyne (490 mg, 1 eq, 1.65 mmol) in MeOH (10 mL) was added 
K2CO3 (457 mg, 3.31 mmol, 2 eq). The reaction mixture was stirred at room temperature overnight 
to give a clear reaction mixture. The mixture was concentrated under reduced pressure. The residue 
was taken up in 2N HCl (50 mL) and Et2O (50 mL). The layers were separated and the aqueous layer 
was extracted with Et2O (2 x 50 mL). The combined organic layers were washed with water (50 mL), 
brine (50 mL), dried over sodium sulphate, filtered and concentrated under reduced pressure to 
yield an off-white solid (359 mg, 96 %). NMR analysis of the product showed that the product 
contained < 2 % of 12-Iodododecanoic acid.  
The white solid (YnMyr + < 2 % Iodododecanoic acid 29; 340 mg, 1.52 mmol) was dissolved in DMSO 
(500 µL) and ethanolamine (25 eq regarding 2 % impurity, 0.76 mmol, 46 µL) was added in one 
portion. The reaction mixture was heated to 120 ⁰C for 2 h and then allowed to cool down to room 
temperature. Et2O (100 mL) and 2N HCl (100mL) were added. The layers were separated and the 
aqueous layer was extracted with Et2O (50 mL). The combined organic layers were washed with 0.5N 
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HCl (50 mL), Brine (50mL), dried over MgSO4 and concentrated under reduced pressure to yield 16 
as a white solid (296 mg, 74%; overall yield = 37 %). 1H NMR (400 MHz, CDCl3) δ 2.33 (t, J = 7.5, 2H, 
CH2CO2H), 2.16 (dt, J = 7.1, 2.6, 2H, CH2C≡CH), 1.92 (t, J = 2.7, 1H, C≡CH), 1.65 – 1.55 (m, J = 7.3, 
14.8, 2H, CH2CH2CO2H), 1.54 – 1.45 (m, 2H, CH2CH2C≡CH), 1.41 – 1.19 (m, 14H, 7xCH2); 13C NMR 
(101 MHz, CDCl3) δ 179.69 (C=O), 85.03(C≡CH), 68.02 (C≡CH), 34.14, 29.49, 29.45, 29.40, 29.20, 
29.11, 29.00, 28.71, 28.50, 24.87, 18.60; HRMS (ESI, negative mode) found 223.1698 ([M - H]- 
requires 223.1699). The analysis was consistent with the NMR and MS analysis reported in the 
literature.154 
8.1.3 AzC12 synthesis 
Br
O
O
11  Methyl 12-bromododecanoate (31) 
To a solution of 12-bromododecanoic acid 27 (2.00 g, 7.16 mmol, 1 eq) in MeOH (20 mL) were added 
214 µL (30 µL/mmol) of concentrated H2SO4. The mixture was heated under reflux for 2 hours. The 
reaction mixture was allowed to cool down to room temperature and concentrated under reduced 
pressure. The residue was diluted in Et2O and washed with NaHCO3 sat. (1x), brine (1x). The organic 
layer was dried with sodium sulphate and concentrated under reduced pressure to yield 31 as a 
clear oil (1.96 g, 93%). The product was used without further purification for the next reaction. 1H 
NMR (400 MHz, CDCl3) δ 3.64 (3H, s, -CH3), 3.38 (t, 2H, J=7.0 Hz, CH2Br), 2.28 (t, 2H, CH2CO2Me), 
1.87 – 1.77 (m, 2H), 1.66 – 1.54 (m, 2H), 1.38 (d, J = 7.4, 2H), 1.25 (m, 12H); 13C NMR (101 MHz, 
CDCl3) δ 174.53 (-COOMe), 51.64, 34.31, 34.24, 33.03, 29.64, 29.59(2C), 29.43, 29.33, 28.94, 28.37, 
25.14; HRMS (ESI, positive mode) found 293.1114 ([M + H]+, requires 293.1116) 
N3
O
O
11 Methyl 12-azidododecanoate (32) 
To a solution of methyl 12-bromododecanoate 31 (1.95 g, 6.65 mmol, 1 eq) in DMSO (80 mL) was 
added dropwise sodium azide (520 mg, 7.98 mmol, 1.2 eq) and the clear reaction mixture stirred 
overnight at room temperature. The reaction mixture was then diluted with water (20 mL) and 
quenched with 1 N HCl (~15 mL) cautiously. Once cool, the mixture was extracted with ethyl acetate 
(3x) and the combined organic layers washed with water (3 x) then brine (2 x 50 mL), dried over 
sodium sulphate, filtered and concentrated under reduced pressure. A yellow oil was obtained and 
purified by silica gel column chromatography (hexanes: Et2O 9:1) to yield 32 as a clear oil (1.64 g, 
88%). Rf (hex: Et2O 9:1) = 0.2; 1H NMR (400 MHz, CDCl3) δ 3.64 (3H, s, CO2CH3), 3.23 (2H, t, J= 7.0Hz, 
CH2N3), 2.27 (2H, t, J= 7.5Hz, CH2CO2Me), 1.52-1.63 (4H, m, CH2CH2CO2H and CH2CH2N3), 1.37 – 
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1.21 (14H, m, (CH2)6); 13C NMR (101 MHz, CDCl3) δ 174.51 (-COOMe), 51.66, 51.62, 34.28, 29.62(2C), 
29.56, 29.41, 29.31 (2C), 29.02, 26.89, 25.12; HRMS (ESI, positive mode) found 228.2001 ([M + H – 
N2]+ requires 228.1947). 
N3
OH
O
11 12-azido-dodecanoic acid (AzC12, 15) 154 
Methyl 12-azidododecanoate 32 (1.5 g, 5.88 mmol, 1 eq) was suspended in 2N NaOH solution 
(5.9 mL, 11.76 mmol, 2.0 eq). 3ml of MeOH were added slowly to obtain a homogeneous solution. 
The mixture was stirred at room temperature for 24 hours, then MeOH was removed under reduced 
pressure. EtOAc (20mL) was added. The aqueous layer was acidified with 2N HCl. The two layers 
were separated and the aqueous layer was extracted with EtOAc (2 x 50 mL). The product was 
extracted with Et2O (4 x 100 ml), and the combined organic layers were dried over anhydrous 
sodium sulphate, filtered, and concentrated under reduced pressure to give the expected 
compound 15 as a white solid (1.32 g, 93%). The product did not require further purification. 
1H NMR (400 MHz, CDCl3) δ 3.23 (2H, t, J = 7.0 Hz, -CH2N3), 2.33 (2H, t, J = 7.5 Hz, CH2CO2H), 1.55–
1.72 (4H, m, CH2CH2CO2H and CH2CH2N3), 1.24–1.43 (14H, m, (CH2)6); 13C NMR (101 MHz, CDCl3) 
δ 179.71 (C=O), 51.70, 34.14, 29.64 (2C),  29.57, 29.41, 29.34, 29.24, 29.04, 26.91, 24.87; HRMS (ESI, 
negative mode) found 240.1719 ([M - H]- requires 240.1712). The analysis was consistent with the 
NMR and MS analysis reported in the literature.154 
8.1.4 YnC15 synthesis 
Br
OH
O
14 15-bromopentadecanoic acid (39) 
-1st method:198 15-hydroxypentadecanoic acid 34 (300 mg, 1.16 mmol, 1 eq) was dissolved in HBr 
33 % wt in AcOH (5 mL). The mixture was heated to 80 °C for 3h, allowed to cool down and 
partitioned between water (20 mL) and DCM (20 mL). The layers were separated and the aqueous 
layer was extracted with DCM (20 mL). The combined organic layers were washed withNaHCO3 
saturated aqueous solution (10 mL), brine (10 mL), dried over sodium sulphate and concentrated 
under reduced pressure. The crude product was purified by silica gel column chromatography (hex: 
Et2O: AcOH 9:1:0.1) to yield 39 as a white solid (142 mg, 38%). Rf (hex: Et2O: AcOH 9:1:0.1) = 0.33; 
1H NMR (400 MHz, CDCl3) δ 3.39 (t, J = 6.9, 2H), 2.33 (t, J = 7.5, 2H), 1.88 – 1.78 (m, 2H), 1.67 – 1.56 
(m, 2H), 1.46 – 1.35 (m, 2H), 1.24 (m, 18H). The analysis was consistent with the NMR analysis 
reported in the literature.363 
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-2nd method:199 To a suspension of 15-hydroxypentadecanoic acid 34 (150 mg, 0.58 mmol, 1 eq) was 
added PPh3 and CBr4 at 0°C. The mixture was stirred at room temperature overnight. The reaction 
mixture was filtered and the filtrate was concentrated under reduced pressure before being 
partitioned between water (20 mL) and DCM (20 mL). The layers were separated and the aqueous 
layer was extracted with DCM (20 mL). The combined organic layers were washed with NaHCO3 
saturated aqueous solution (10 mL), brine (10 mL), dried over sodium sulphate and concentrated 
under reduced pressure to give a yellow residue. The crude product was purified by silica gel column 
chromatography (hex: Et2O: AcOH 9:1:0.1) to yield 39 as a white solid (82 mg, 44%). The product was 
seen as one spot on TLC (hex: Et2O: AcOH 9:1:0.1, Rf=0.33) but according to the 1H NMR analysis, 
this product contained 40 % impurity seen with the following chemical shifts:1H NMR (400 MHz, 
CDCl3) δ 3.50 (t, J = 6.8, 2H), 2.33 (t, J = 7.5, 2H), 1.78 – 1.70 (m, 2H), 1.61 (m, 2H), 1.40 (m, 2H), 1.24 
(s, 18H).  
HO
O
O
14 Methyl 15-hydroxypentadecanoate (42) 
Same procedure as methyl 12-bromododecanoate 31 with slight modifications and starting from 
15-hydroxypentadecanioc acid (300 mg, 1.16 mmol, 1 eq). The reaction mixture was heated under 
reflux for 3 h, allowed to cool down and quenched by the addition of a saturated solution of NH4Cl 
(20 mL). The product was extracted with Et2O (3 x 20 mL). The combined organic layers were washed 
with brine, dried over sodium sulphate and concentrated under reduced pressure to give 42 as a 
white crystalline solid (480 mg, 91%). 1H NMR (400 MHz, CDCl3) δ 3.64 (s, 3H, CH3 -), 3.62 (br s, 2H, 
HO-CH2-), 2.28 (t, J = 7.6, 2H, -CH2-COOMe), 1.64 – 1.55 (m, 4H), 1.30-1.20 (m, 20H); HRMS (ESI, 
positive mode) found 273.2421 ([M – H + HCOO-]+ requires 273.2424). 
I
O
O
14 Methyl 15-iodopentadecanoate (44) 200 
To a solution of imidazole (318 mg, 4.68 mmol, 2.2 eq) and PPh3 (671 mg, 2.56 mmol, 1.2 eq) in DCM 
(10 mL) was added I2 dropwise at 0 °C. An orange/yellow solution was obtained and a solution of 
methyl 15-hydroxypentadecanoate 42 (580 mg, 2.12 mmol, 1eq) in DCM (5 mL) was added 
dropwise. The reaction mixture was stirred at room temperature (RT) for 3h and partitioned 
between DCM (50 mL) and H2O (50 mL). The layers were separated and the aqueous layer was 
extracted with DCM (2 x 50 mL). The combined organic layers were washed with brine (50 mL), dried 
over sodium sulphate and concentrated under reduced pressure to give a dark brown residue. The 
crude product was purified by silica gel column chromatography (gradient hex: EtOAc; %EtOAC 1 to 
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4%) to yield 44 as a yellow solid (518 mg, 64%). Rf (chex: EtOAc 9.5:0.5) = 0.22; 1H NMR (400 MHz, 
CDCl3) δ 3.65 (s, 3H, CH3 -), 3.17 (t, J = 7.1, 2H, I-CH2-), 2.28 (t, J = 7.6, 2H, -CH2-COOMe), 1.79 (dd, 
J = 7.2, 14.5, 2H), 1.60 (s, 2H), 1.41 – 1.32 (m, 2H), 1.32 – 1.19 (m, 18H). 
I
O
OH
14 15-Iodopentadecanoic acid (45) 
-1st method: Ester hydrolysis. To a solution of methyl 15-iodopentadecanoate 44 (500 mg, 1.3 mmol) 
in THF (15 mL) was added NaOH 4N (610 µL). The suspension was stirred at room temperature for 
2 days. The reaction mixture was concentrated under reduced pressure and the residue was 
partitioned between Et2O (50 mL) and 2N HCl (20 mL). The layers were separated and the aqueous 
layer was extracted with Et2O (2 x 50 mL). The combined organic layers were washed with brine 
(50 mL), dried over sodium sulphate and concentrated under reduced pressure to give a white solid. 
The crude product was purified by silica gel column chromatography (gradient hex: EtOAc : AcOH; 
9:1:0.1 to 7:3:0.1 ) to yield 45 as a yellow solid (337 mg, 70%).  
-2nd method: Pentadecanoline 46 (2.2 mL, 8.3 mmol, 1 eq) was added to a mixture of hydrogen 
iodide (57 % in H2O, 8 mL) and AcOH (4 mL). The reaction mixture was heated under reflux for 
3 hours. The brown reaction mixture was allowed to cool down to room temperature. A brown 
precipitate was obtained. The reaction mixture was quenched with a saturated solution of Na2SO7 
(50 mL) and DCM (50 mL) was added to dissolve the precipitate. The layers were separated. The 
aqueous layer was extracted with DCM (2 x 100 mL). The combined organic layers were washed with 
brine (1 x 100 mL), dried over sodium sulphate, filtered and concentrated under reduced pressure. 
The yellow residue was purified by silica-gel chromatography (gradient chex: EtOAc:AcOH 94:5:1 to 
74:25:1) to yield 45 as white crystals (2.28 mg, 75%).  
Rf (chex: EtOAc:AcOH 8:2:0.1) = 0.22; 1H NMR (400 MHz, CDCl3) δ 3.17 (t, J = 7.1, 2H, CH2CH2I), 2.33 
(t, J = 7.5, 2H, CH2CO2H), 1.80 (dt, J = 14.5, 7.1, 2H, CH2CH2I), 1.66 – 1.56 (m, 2H, , CH2CH2CO2H), 
1.41 – 1.21 (m, 20H, 10 x CH2); 13C NMR (101 MHz, CDCl3) δ 179.42 (C=O), 34.10, 33.79, 30.73, 29.80 
(3C), 29.75 (2C), 29.63 (2C), 29.45, 29.27, 28.76, 24.89, 7.60 (TMS); HRMS (ESI, negative mode) 
found 413.1188 ([M – H + HCOO-]- requires 413.1189). The analysis was consistent with the NMR 
and MS analysis reported in the literature.201 
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OOH
14
Si
TMS-protected Heptadec-16-ynoic acid (47) 
Under nitrogen atmosphere, a solution of TMS-acetylene (920 µL, 2.58 mmol, 2.5 eq) in dry THF 
(6 mL) was cooled down to -78 °C using a bath of acetone and dry ice. A solution of n-BuLi in hexanes 
(3.1 mL, 2.5 M solution, 3.0 eq) was added dropwise. The clear reaction mixture was allowed to 
warm to room temperature for 10 minutes and then cooled to -78 °C. DMPU (6.5 mL, 54 mmol, 
21 eq) and a solution of 15-iodopentadecanoic acid 45 (950 mg, 2.58 mmol, 1.0 eq) in dry THF (6 mL) 
were added dropwise. The yellow reaction mixture was allowed to warm to room temperature and 
stirred overnight. The reaction mixture was cooled to -78 °C and quenched by the dropwise addition 
of saturated NH4Cl (20 mL). Et2O (50 mL) and water (20 mL) were added to the brown solution. The 
layers were separated and the aqueous layer was extracted with Et2O (2 x 50 mL). The combined 
organic layers were washed with water (3 x 20 mL), brine (2 x 20 mL), dried over sodium sulphate, 
filtered and concentrated under reduced pressure. The brown residue was purified by silica-gel 
chromatography (gradient chex: EtOAc: AcOH 99:0:1 to 74:25:1) to yield 47 as a white solid (320 mg, 
37%). Rf (chex: EtOAc: AcOH 8:2:0.1) = 0.3; 1H NMR (400 MHz, CDCl3) δ 2.33 (t, J = 7.5, 2H, 
CH2CO2H), 2.19 (t, J = 7.2, 2H, -CH2-CC-TMS), 1.61 (dt, J = 14.9, 7.4, 2H, CH2CH2CO2H), 1.49 (m, 2H, 
CH2CH2-CC-TMS), 1.27 (d, J = 28.4, 20H), 0.13 (m, 9H, TMS); HRMS (ESI, negative mode) found 
265.2156 ([M – H –TMS) requires 265.2173 
Br OTHP
11 2-(11-Bromoundecoxy)tetrahydro-2H-pyran (48) 
To a solution of 11-bromoundecanol 38 (500 mg, 2.0 mmol, 1 eq) and p-TsOH (38 mg, 0.2 mmol, 
0.1 eq) in DCM (10 mL) was added DHP (266 mg, 3.0 mmol, 1.5 eq) at RT and the reaction mixture 
was stirred for 2h. The mixture was concentrated under reduced pressure and the crude product 
was purified by silica-gel chromatography (gradient chex: EtOAc 9:0.1 to 9:1) to yield 48 as a clear oil 
(410 mg, 62%). Rf (chex: EtOAc 20:1) = 0.28; 1H NMR (400 MHz, CDCl3) δ 4.57 – 4.52 (m, 1H, -O-CH-
O-), 3.89 – 3.80 (m, 1H, THP), 3.74 – 3.66 (m, 1H, -CH2-OTHP), 3.52 – 3.43 (m, 1H, THP),  3.38 (t, J = 
6.9, 2H, -CH2-Br), 3.36 – 3.31 (m, 1H, -CH2-OTHP), 1.87 – 1.76 (m, 3H, -CH2-CH2-OTHP+1H THP), 1.74 
– 1.63 (m, 1H, THP), 1.61 – 1.45 (m, 6H, 4H THP + 2H Br-CH2-CH2-), 1.32 (d, J = 55.9, 14H); 13C NMR 
(101 MHz, CDCl3) δ 99.08, 67.92, 62.58, 34.27, 33.05, 31.00, 29.96, 29.74, 29.67 (2C),, 29.62 , 28.97, 
28.39, 27.12, 26.44, 25.72. 
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OTHP
11  17-(tetrahydro-2H-pyran-2-yloxy)-heptadeca-5-yne (49) 197,364 
To a solution of 1-hexyne (151 µL, 1.3 mmol, 1.1 eq) in THF (3 mL) was added n-Buli dropwise at 
78 °C. The reaction mixture was allowed to warm to RT for 10 min. A solution of compound 48 
(400 mg, 1.2 mmol, 1 eq) in DMPU (3 mL) and dry THF (3 mL) was added dropwise at -78°C. The 
yellow solution was stirred at RT overnight. The reaction mixture was cooled to -78 °C and quenched 
by the dropwise addition of saturated NH4Cl (10 mL). Et2O (20 mL) and water (10 mL) were added 
The layers were separated and the aqueous layer was extracted with Et2O (2 x 10 mL). The 
combined organic layers were washed with brine (2 x 10 mL), dried over sodium sulphate, filtered 
and concentrated under reduced pressure. The yellow oil was purified by silica-gel chromatography 
(gradient chex: EtOAc 99:1 to 97:3) to yield 49 as a clear oil (252 mg, 63%). Rf (chex: EtOAc 9:1) = 0.5; 
1H NMR (400 MHz, CDCl3) δ 4.57 – 4.53 (m, 1H, -O-CH-O-), 3.90 – 3.80 (m, 1H, THP), 3.71 (dt, J = 9.6, 
6.9, 1H, -CH2-OTHP), 3.53 – 3.43 (m, 1H, THP), 3.36 (dt, J = 9.6, 6.9, 1H, -CH2-OTHP), 2.16 – 2.07 (m, 
4H, -CH2-C-C-CH2-), 1.86 – 1.75 (m, 1H), 1.74 – 1.64 (m,1H), 1.61 – 1.22 (m, 26H), 0.88 (t, J = 7.2, 3H); 
13C NMR (101 MHz, CDCl3) δ 99.06 (-O-CH-O-), 80.44 (-CH2-C-C-CH2-), 80.38 (-CH2-C-C-CH2-), 67.92, 
62.56, 31.49, 31.01, 29.98, 29.80, 29.77, 29.75, 29.71, 29.38, 29.08, 26.46, 25.73, 22.14, 19.92, 
18.97, 18.66; HRMS (ESI, positive mode) found 337.3097 [M + H ]+ requires 337.3107. 
OH
11  Heptadec-12-ynol (36) 
To a solution of compound 49 (100 mg, 0.3 mmol, 1 eq) in MeOH was added p-TsOH and the 
reaction mixture was heated under reflux overnight. The reaction mixture was concentrated under 
reduced pressure. The clear oil was taken up in Et2O (10 mL) and a saturated solution of NaHCO3 
(10 mL was added. The layers were separated and the aqueous layer was extracted with Et2O 
(10 mL). The combined organic layers were washed with brine, dried over sodium sulphate, filtered 
and concentrated under reduced pressure. The yellow oil was purified by silica-gel chromatography 
(gradient chex: EtOAc 9:1 to 6:4) to yield 36 as a white solid (60 mg, 78 %). Rf (chex: EtOAc 1:1) = 0.5; 
1H NMR (400 MHz, CDCl3) δ 3.62 (t, J = 6.6, 2H, -CH2-OH), 2.16 – 2.08 (m, 4H, -CH2-C-C-CH2-), 1.61 – 
1.50 (m, 2H), 1.49 – 1.19 (m, 20H), 0.88 (t, J = 7.2, 3H); 13C NMR (101 MHz, CDCl3) δ 80.43 (-CH2-C-C-
CH2-), 80.39 (-CH2-C-C-CH2-), 63.32, 33.03, 31.49, 29.81, 29.74, 29.64, 29.37, 29.07, 25.95, 22.14, 
18.97, 18.66, 13.85. 
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OH
15  Heptadec-16-ynol (35) 
NaH (150 mg, 6.2 mmol, 8eq) was washed with n-hexanes and added to 1.3-diaminopropane (4 mL). 
The suspension was stirred at 70 °C for 30 min under N2 atmosphere. The brown reaction mixture 
was allowed to cool down to RT and a solution of compound 36 (200 mg, 0.8 mmol, 1 eq) in 
1.3-diaminopropane (1 mL) was added dropwise at 70 °C . The reaction mixture was stirred 
overnight at 50 °C and allowed to cool down and then cool down to 0 °C. Water (20 mL) was added 
slowly followed by the addition of HCl 2N (20 mL). The product was extracted with Et2O (3x30 mL). 
The combined organic layers were washed with washed with brine, dried over sodium sulphate, 
filtered and concentrated under reduced pressure. The yellow residue was purified by silica-gel 
chromatography (gradient chex: EtOAc 9:1 to 6:4) to yield 35 as a yellowish solid (71mg, 36 %). 1H 
NMR (400 MHz, CDCl3) δ 3.62 (t, J = 6.6, 2H, -CH2-OH), 2.16 (td, J = 7.1, 2.6, 2H, CH2C≡CH), 1.92 (t, J 
= 2.6, 1H, CH2C≡CH), 1.53 (m, 2H, -CH2-CH2-OH), 1.23 (m, 22H); 13C NMR (101 MHz, CDCl3) δ 68.04, 
63.14, 32.84, 29.66 (2C), 29.63 (2C), 29.52, 29.45, 29.13 (2C), 28.79, 28.52, 25.76, 18.42; HRMS 
(ammonia CI, positive mode) found 270.2798 ([M+NH4]+ requires 270.2791).  
14
OH
O
 Heptadec-16-ynoic acid (24) 174 
-1st method: To a suspension of TMS-protected alkyne 47 (310 mg, 1 eq, 0.92 mmol) in MeOH 
(15 mL) was added K2CO3 (253 mg, 1.83 mmol, 2 eq). The reaction mixture was stirred at room 
temperature overnight to give a clear reaction mixture. The mixture was concentrated under 
reduced pressure. The residue was taken up in 2N HCl (20 mL) and Et2O (30 mL). The layers were 
separated and the aqueous layer was extracted with Et2O (2 x 30 mL). The combined organic layers 
were washed with water (20 mL), brine (20 mL), dried over sodium sulphate, filtered and 
concentrated under reduced pressure to yield 24 as an off-white solid (230 mg, 94%). The product 
did not require further purification.  
-2nd method: Jones reagent (2, 90 mL) was added dropwise to a solution of heptadec-16-ynol 35 
(70 mg, 0.28 mol) in acetone (10 mL) at 0 °C. The reaction mixture was stirred for 15 min at 0 °C and 
15 min at room temperature. The solution became orange and a precipitate started to form in the 
reaction mixture (Cr salt). The mixture was cooled down to 0 °C and isopropanol (20 mL) was added 
dropwise to quench the excess of Jones reagent. The reaction mixture was filtered to remove the 
chromium salt and concentrated under reduced pressure. The residue was taken up in EtOAC and 
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washed with 0.1N HCl (4 x 25 mL), brine, dried over sodium sulphate and concentrated under 
reduced pressure to yield 24 as a white solid (50 mg, 67%). 
1H NMR (400 MHz, CDCl3) δ 2.33 (t, J = 7.5, 2H, CH2CO2H), 2.16 (td, J = 7.1, 2.6, 2H, CH2C≡CH), 1.92 
(t, J = 2.6, 1H, C≡CH), 1.60 (dd, J = 7.3, 14.8, 2H, CH2CH2CO2H), 1.55 – 1.45 (m, 2H, CH2CH2C≡CH), 
1.30 (m, 20H, 10 x CH2); 13C NMR (101 MHz, CDCl3) δ 178.90 (C=O), 84.86 (C≡CH), 68.04 (C≡CH), 
33.84, 29.63 (4C), 29.52, 29.44, 29.25, 29.13, 29.07, 28.79, 28.52, 24.70, 18.42; HRMS (ESI, negative 
mode) found 265.2170 ([M - H]- requires 265.2168). The analysis was consistent with the NMR and 
MS analysis reported in the literature.174 
8.1.5 YnC12CoA synthesis (19) 
N
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To a suspension of tetradec-13-ynoic acid (16, 14.8 mg, 65 μmol, 2 eq) in dry THF (1.0 mL) was added 
a solution of 1,1’-carbonyl-diimidazole (12.7 mg, 78 μmol, 2.4 eq) in DCM (1.0 mL), under nitrogen 
atmosphere. The clear reaction mixture was stirred for 45 minutes at room temperature. The 
reaction mixture was concentrated under reduced pressure. The yellow residue was dissolved in dry 
THF (1.0 mL). Co-enzyme A hydrate from yeast (25 mg, 32.6 μmol, 1 eq) was dissolved in an aqueous 
solution of NaHCO3 (0.5 M, 3.4 mL) and added to the solution of activated acid. The reaction mixture 
was stirred at room temperature for 3 hours under nitrogen atmosphere. The THF was removed 
under reduced pressure. The product was precipitated by adding 20% perchloric acid dropwise 
(1 mL). The white solid was pelleted by centrifugation and washed with 1 % perchloric acid. The 
product was purified by preparative RP-HPLC over a gradient of 25 mM ammonium carbonate pH 8 
in MeOH (Method A). YnC12CoA 19 was obtained as a white lyophilised solid (22.2 mg, 66% yield). 
LC-MS: RT=10.04 min (Absorption wavelength = 258 nm; Method A), m/z (positive mode) = 974.94, 
m/z (negative mode) = 486.28 and 972.8, Purity > 98%; 1H NMR (400 MHz, D2O) δ 8.54 (s, 1H, Ar-H), 
8.24 (s, 1H, Ar-H), 6.14 (d, J = 6.6, 1H, CH(Pur)), 4.59 – 4.53 (m, 2H, 2 × Rib-CH), 4.23 – 4.18 (m, 3H, 
O-CH2 and Rib-CH), 4.01 (bs, 1H, C(O)CHOH), 3.84-3.79 (m, 1H, CH2C(CH3)2), 3.55-3.50 (m, 1H, 
CH2C(CH3)2), 3.42 (t, J = 6.6, 2H, SCH2CH2), 3.33 – 3.28 (m, 2H, C(O)CH2CH2NH), 2.99 – 2.94 (m, 2H, 
C(O)CH2CH2NH), 2.58-2.52 (t, J = 7.3, 2H, (CH2)2CH2C(O)NH), 2.40 (t, J = 6.7, 2H, SCH2), 2.30 (t, J = 
2.6, 1H, C≡CH), 2.15 (td, J = 2.6, 7.1, 2H, CH2C≡CH), 1.57-1.52 (m, 2H, CH2CH2CH2C(O)NH), 1.47 – 
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1.40 (m, 2H, CH2CH2C≡CH), 1.30 (bs, 2H, CH2 ), 1.18 (bs, 12H, 6xCH2), 0.86 (s, 3H, -CH3), 0.72 (s, 3H, -
CH3). The analysis was consistent with the NMR analysis reported in the literature.154 
8.1.6 MyrCoA synthesis (17) 
N
NN
N
NH2
O
OHO
HH
O
P O
O
HO
P
O
O
OP
O
O
O
OH
O
N
H
O
N
H
S
O
+3 NH4
 
A similar procedure as YnC12CoA 19 was used to prepare MyrCoA 17, replacing YnC12 16 by myristic 
acid 14 (65 μmol) (10.1 mg, 32 %). LC-MS: RT=12.80 min (Absorption wavelength = 258 nm; 
method A), m/z (positive mode) = 974.4, Purity > 98%; 1H NMR (400 MHz, D2O) δ 8.56 (s, 1H, Ar-H), 
8.26 (s, 1H, Ar-H), 6.17 (d, J = 6.4, 1H, Rib-CH), 4.60-4.57 (m, 2H, 2 × Rib-CH), 4.26-4.22 (m, 3H, O-CH2 
and Rib-CH), 4.04 (bs, 1H, C(O)CHOH), 3.87-3.82 (m, 1H, CH2C (CH3)2), 3.58-3.53 (m, 1H, 
CH2C(CH3)2), 3.45 (t, J = 6.7, 2H, SCH2CH2), 3.36-3.32 (m, 2H, C(O)CH2CH2NH), 2.99 (t, J = 6.3, 2H, 
C(O)CH2CH2NH), 2.60-2.55 (m, J = 7.3, 2H, (CH2)2CH2C(O)NH), 2.42 (t, J = 6.7, 2H, SCH2), 1.60-1.55 
(m, 2H, CH2CH2CH2C(O)NH), 1.1 (bs, 24H, 12 x CH2), 0.89 (s, 3H, -CH3), 0.84 (t, J = 6.9, 3H, CH3-
(CH2)12-), 0.75 (s, 3H, -CH3). 
8.1.7 AzC12CoA (18) 
+3 NH4
N
NN
N
NH2
O
OHO
HH
O
P O
O
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N
N
The same procedure as for YnC12CoA 19 was used (except using 12-azido-dodecanoic acid 15 
(15.7 mg, 65 μmol), and afforded AzC12CoA 18 as a white solid (10 mg, 30 % yield). LCMS: 
RT=10.54 min (Absorption wavelength = 258 nm; Method A), m/z (positive mode) = 991.4, 
Purity > 98%; 1H NMR (400 MHz, D2O) δ 8.43 (s, 1H, Ar-H), 8.24 (s, 1H, Ar-H), 6.14 (d, J = 7.0, 1H, Rib-
CH), 4.75-4.70 (m, 2H, 2×Rib-CH), 4.54 (bs, 1H, Rib-CH), 4.20 (bs, 2H, Rib-CH2), 4.00 (bs, 1H, 
C(O)CHOH), 3.83-3.78 (m, 1H, CH2C(CH3)2), 3.54-3.49 (m, 1H, CH2C(CH3)2), 3.42 (t, J = 6.6, 2H, 
SCH2CH2), 3.33-3.24 (m, 4H, CH2N3 and C(O)CH2CH2NH), 2.96 (t, J = 6.3, 2H, C(O)CH2CH2NH), 2.57-
2.53 (m, J = 7.3, 2H, (CH2)2CH2C(O)S), 2.39 (t, J = 6.6, 2H, SCH2), 1.60-1.50 (m, 4H, CH2CH2CH2C(O)S 
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and CH2CH2N3), 1.34 – 1.14 (m, 14H, 7 × CH2), 0.85 (s, 3H, -CH3), 0.71 (s, 3H, -CH3). The analysis was 
consistent with the NMR analysis reported in the literature.154 
8.1.8 Prodrug synthesis 
NO2
OO
O
Cl (1-chloroethyl)-(4-nitrophenyl)carbonate (56) 226 
To a suspension of 4-nitrophenol (55) in toluene (8 mL, 1 eq, 1.43 mmol) was added dropwise 
1-chloroethylchloroformate (200 µL, 1.3 eq, 1.85 mmol) and tributyl amine (442 µL, 1.3 eq, 
1.85 mmols). After few minutes, a clear brown solution was obtained. The reaction mixture was 
stirred at room temperature for 90 min. Completion of the reaction was followed by TLC (hex: EtOAc 
1:1 Rf product = 0.71; Rf 4- nitrophenol = 0.54.). The reaction mixture was washed with 1N HCl 
(40 mL), water (2 x 20 mL), brine (20 mL), dried over MgSO4 and filtered. The crude product 56 was 
directly used for the next step. 1H NMR (400 MHz, CDCl3) δ 8.32 – 8.25 (m, 2H, aromatic), 7.45 – 7.36 
(m, 2H, aromatic), 6.48 (q, J = 5.8, 1H, -CH-), 1.91 (d, J = 5.8, 3H, CH3); 13C NMR (101 MHz, CDCl3) δ 
155.15 (C=O), 150.66 (C-NO2), 145.92 (Caromatic-O), 125.65 (CH-C-NO2), 121.90 (CH-CH-C-NO2), 85.44 
(CH-CH3), 25.33 (CH3).  
 
NO2
OO
O
O
O
1-(((4-nitrophenoxy)carbonyl)oxy)ethyl 2-methyl propanoate (57) 226 
Zinc oxide, potassium iodide and isobutyric acid were added to 56 in one portion. The suspension 
was heated to 75 ⁰C for 2 h. Toluene was removed under reduced pressure to yield a brown oil. The 
oil was taken up in EtOAc, washed with a saturated solution of NaHCO3 (50 mL), brine (20 mL), dried 
over MgSO4 and concentrated under reduced pressure to give a brown oil. The crude product was 
purified by silica gel chromatography using hex: EtOAc 9:1 as eluent. (Rf product = 0.15). A yellow oil 
was obtained (420 mg). NMR showed that the product contained around 20 % of the intermediate. 
50 mg of the product was purified with a Sepak column (gradient 100% H2O-to 100% AcN). 12 mg of 
57 was obtained (9%). 1H NMR (400 MHz, CDCl3) δ 8.32 – 8.20 (m, 2H, aromatic), 7.43 – 7.32 (m, 2H, 
aromatic), 6.82 (q, J = 5.4, 1H, -O-CHMe-O-), 2.66 – 2.52 (m, 1H, -CH(CH3)2), 1.60 (d, J = 5.4, 3H), 1.19 
(dd, J = 7.0, 0.6, 6H); 13C NMR (101 MHz, CDCl3) δ 175.25 (CH-C(O)-O), 155.39 (O-C(O)-O), 150.73 (C-
NO2), 145.77 (Caromatic-O), 125.55 (CH-C-NO2), 121.96 (CH-CH-C-NO2), 92.55 (CH), , 34.01 (CH), 19.62 
(O-CH-CH3), 18.85(CH3-CH-CH3). 18.79 (CH3-CH-CH3). 
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9-(tert-butoxycarbonyl)aminodecanoic acid 77 
NH4OH (160 mL, 25% in H2O) was added to bromododecanoic acid (5.0 g, 20 mmol, 1 eq) and the 
brown suspension was stirred at RT for 24h. The mixture was concentrated under reduced pressure 
to give a brown solid, 8-aminooctanoic acid. To the crude product was added sodium hydroxide 
(840 mg, 21 mmol, 1.05 eq), H2O (18mL) and tert-butanol (9 mL). The solution was stirred at RT 
overnight. The solution was partitioned between Et2O (40 mL) and 1N HCl (30 mL). The layers were 
separated and the aqueous layer was extracted with Et2O (2 x 10 mL). The combined organic layers 
were concentrated under reduced pressure to give 77 as a brown solid (5.1 g, 88 %). 1H NMR 
(400 MHz, CDCl3) δ 4.50 (br s, 1H, -NHBoc), 3.08 (apparent q, J = 6.3, 2H, -CH2-NHBoc), 2.32 (t, J = 
7.5, 2H, -CH2-COOH), 1.61 (m, 2H, -CH2-CH2-NHBoc), 1.44 (m, 12H), 1.24 (apparent dd, J = 12.4, 5.7, 
9H, Boc). 
H
N
O
N
H
O
H
N
O
NH2
OH
H2N
(9-aminodecanoyl)-Ser-Lys-2-
cyclohexylethylamide (IMP475) 
Chlorotrityl resin was swelled in DCM for 1 h. Fmoc-Lys(Boc)-OH (514 mg, 1.10 mmol, 1.2 eq) and 
DIPEA (0.765mL, 4.4 mmol, 4.8 eq) were dissolved in dry DCM (7 mL) and added to the resin 
(750 mg, Loading: 1.22 mmol/g). The mixture was shaken for 2 h. The resin was drained and washed 
with DCM/MeOH/DIPEA (3 × 17:2:1) and with DMF (3x), DCM (3x), MeOH (3x), Et2O (3x) before 
being dried in a desiccator overnight. The resin was swelled in DMF for 1 h and Fmoc deprotected 
using method 1. Fmoc-Ser(t-Bu)-OH and 9-(tert-butoxycarbonyl)aminodecanoic acid 77 were 
coupled on the resin as explained in method 2 (HBTU and HATU were used as coupling reagents 
respectively). The peptide was cleaved off the resin by adding a mixture of triisopropylsilane (TIS, 
0.5%) and Trifluoroacetic acid (TFA, 0.5%) in DCM. The mixture was shaken for 2 h at RT and filtered. 
All volatiles were evaporated by flushing the mixture with N2. The brown oily residue was purified by 
preparative LC-MS (Method C). 80 mg of yellowish oil were obtained (yield 13 %) and directly used 
for the next step. To a solution of the product (0.13 mmol, 1 eq) in DMF (4 mL) was added 
HATU(144 mg, 0.38 mmol, 3eq), DIPEA (219 µL, 1.3 mmol, 10 eq) and 2-cyclohexylethanaminium 
acetate (49 mg, 0.38 mmol, 3eq, kindly donated by Tayo Olaleye, Imperial College London). The 
yellow solution was stirred at RT overnight. DCM (40 mL) was added and the organic layer was 
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washed with 1N HCl (100 mL), H2O (50 mL) and Brine (50 mL). The organic layer was concentrated 
under reduced pressure to give a brown oil. A mixture of TFA:TIS:H2O 95:2.5:2.5 (2 mL) was added to 
the residue and stirred at room temperature for 3 h. Completion of the deprotection (Boc and tBu) 
was checked by LC-MS (Method C). The mixture was flushed with N2 and dried in the desiccator 
overnight. The crude product was purified by preparative LC-MS (Method C) to give IMP475 as a 
yellowish oil (54 mg, overall yield 11%). 1H NMR (500 MHz, MeOD) δ ppm 8.52 (1H, s), 4.46 (t, J = 
6.0, 1H), 4.36-4.31 (m, 1H), 3.96 – 3.86 (m, 2H), 3.35-3.25 (m, 2H), 3.10 – 3.02 (4H, m), 2.40 (t, J = 
7.4, 2H), 1.99 – 1.87 (m, 1H), 1.76 – 1.60 (11H, m), 1.55 – 1.20 (19H, m), 1.03 – 0.91 (2H, m); Rt: 6.65 
min (Method C); HRMS (ESI, positive mode) found 512.4167 ([M + H]+ requires 512.4131). 
H
N
O
N
H
O
H
N
O
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OH
O
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O
O
O
O
Compound 62 
To a solution of (9-aminodecanoyl)-Ser-Lys-2-cyclohexylethylamide 61 (5 mg, 9.8 µmol, 1 eq) in dry 
THF (0.5 mL) was added 1-(((4-nitrophenoxy)carbonyl)oxy)ethyl-2-methyl propanoate 61 (6.6 mg, 
19.5 µmol, 2eq) and tributylamine ( 10.6 µL, 39 µmol, 4eq). The mixture was stirred at RT for 6 h and 
concentrated under reduce pressure. The crude product was purified by preparative LC-MS 
(Method C) to give 62 as a white solid (1.5 mg, 18%). Rt: 12.38 min (Method C). 1H NMR (500 MHz, 
DMSO) δ 7.95 (d, J = 8.2, 1H), 7.91 (d, J = 6.9, 1H), 7.87-7.82 (m, 1H), 7.72 (t, J = 5.4, 1H), 7.41-7.35 
(m, 2H), 6.63 (q, J = 5.4, 2H,2 x  -O-CHMe-O-), 4.87 (t, J = 5.5, 1H), 4.14--4.05 (m, 1H), 3.55-3.50 (m, 
2H), 3.10-2.98 (m, 2H), 2.96-2.86 (m, 4H), 2.63-2.61 (m, 1H), 2.37-2.34 (m, 1H), 2.13 (t, J = 7.4, 2H), 
2.02-1.96 (m, 1H), 1.68-1.59 (m, 6H, 2x CH3CH -prodrug), 1.50-1.42 (m, 4H), 1.40-1.33 (m, 8H), 1.3-
1.1 (m, 18H), 1.05 (dd, J = 7.0, 2.5, 12H, 2 x CH(CH3)2), 0.84 (m, 2H). HRMS (ES-ToF, positive mode) 
828.5347 expected 828.5328. 
8.1.9 4-azidobutyric acid  
O
O
N3
Ethyl 4-azidobutyrate (66) 
Same procedure as methyl 12-azidodecanoate, starting from Ethyl 4-bromobutyrate (2 g, 
10.3 mmols, 1 eq). A clear oil was obtained (1.27 g, 81 % yield).1H NMR (400 MHz, CDCl3) δ 4.12 (q, 
J = 7.1, 2H, -CH2-CH3), 3.33 (t, J = 6.7, 2H, -CH2-N3), 2.38 (t, J = 7.3, 2H, -CH2-COOEt), 1.89 (p, J = 7.0, 
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2H, -CH2-CH2-CH2-), 1.27 – 1.21 (t, J = 7.1, 3H, -CH3); 13C NMR (101 MHz, CDCl3) δ 172.91 (CO), 60.78 
(CH3-CH2-), 50.86 (-CH2-COOH), 31.39 (-CH2-N3), 24.47 (-CH2-CH2-CH2-), 14.41 (CH3). 
HO
O
N3
4-azidobutyric acid (67) 
Same procedure as 12-azidodecanoic acid, starting from ethyl 4-azidobutyrate 66 (1.2 g, 7.6 mmols, 
1 eq). A clear oil was obtained (1.0 g, quantitative).1H NMR (400 MHz, CDCl3) δ 3.36 (t, J = 6.7, 2H, -
CH2-N3), 2.46 (t, J = 7.2, 2H, -CH2-COOH), 1.90 (p, J = 7.0, 2H, -CH2-CH2-CH2-); 13C NMR (101 MHz, 
CDCl3) δ 179.07 (CO), 50.66 (-CH2-COOH), 31.07 (-CH2-N3), 24.14 (-CH2-CH2-CH2-); HRMS (CI, 
positive mode) found 147.0883 ([M + NH4]+ requires 147.0877). 
 
8.1.10 Linker for the spot synthesis 
 
 
Phenacyl-4-(hydroxymethyl)benzoate(72) 342 
To a suspension of 4-(hydroxymethyl)benzoic acid 69 (500 mg, 3.3 mmol, 1 eq) in EtOAc (30mL) was 
added 2-bromoacetophenone (726 mg, 3.63 mmol, 1.1 eq) and triethylamine (460 µL, 3.3 mmol, 
1 eq). The reaction mixture was stirred at room temperature overnight and concentrated under 
reduced pressure. The residue was purified by silica gel column chromatography (Hex:EtOAc 2:1) to 
yield 72 as a white powder (900 mg, quantitative). Rf (hex:EtOAc 1:1)= 0.45; 1H NMR (400 MHz, 
DMSO) δ 8.04 – 7.98 (m, 4H, -C6H4-CH2-OH), 7.74 – 7.69 (m, 1H, CH2-CO-C6H5), 7.59 (t, J = 7.7, 2H, 
CH2-CO-C6H5), 7.51 (d, J = 8.4, 2H, CH2-CO-C6H5), 5.75 (s, 2H, CH2-CO-C6H5), 5.42 (t, J = 5.7, 1H, -
C6H4-CH2-OH), 4.61 (d, J = 5.7, 2H, C6H4-CH2-OH); 13C NMR (101 MHz, DMSO) δ 193.30 (CH2-CO-
C6H5), 165.72 (-CO-C6H4-CH2-OH), 149.20 (-CH2-CO-C6H5), 134.52 (C6H4-CH2-OH), 134.36 (CH2-CO-
C6H5), 129.78 (Ar), 129.45 (Ar), 128.29 (Ar), 127.93 (Quaternary C, CH2-CO-C6H5), 126.87 (Ar), 67.53 
(-CH2-CO-C6H5), 62.84 (C6H4-CH2-OH). The analysis was consistent with the NMR and MS analysis 
reported in the literature.342 
 
 
 
O O
O
OH
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 Phenacyl-4-1-[[N-(9-fluorenylmethoxycarbonyl)-L-glycyl]oxy]- methyllbenzoate 
(73) 
 
To a solution of 73 (890 mg, 3.3 mmol, 1 eq), Fmoc-Gly-OH (921 mg, 3.3 mmol, 
1 eq) and DMAP (60.5 mg, 3.3 mmol, 1 eq) in DCM (15 mL) was added at 0 °C a solution of DCC 
(680.9 mg, 3.3 mmol, 1 eq) in DCM (5 mL). The suspension was stirred at 0 °C for 2 h and at room 
temperature overnight. The reaction mixture was filtered and concentrated under reduced pressure. 
The white residue was diluted in DCM and washed with NH4Cl (aq) 1N, brine, water, dried over 
sodium sulphate and concentrated under reduced pressure. The residue was purified by silica gel 
column chromatography (gradient: hex:EtOAc 3:1 to hex:EtOAc 1:1) to yield 73 as a white powder 
(1.65 g, 91%). Rf (hex:EtOAc 3:1)= 0.25; 1H NMR (400 MHz, DMSO) δ 8.03 – 7.98 (m, 4H, -C6H4-CH2-
OH), 7.89 (d, J = 7.5, 2H, Fmoc), 7.83 (t, J = 6.1, 1H, Fmoc), 7.74-7.67 (m, 3H, 1H of CH2-CO-C6H5+ 2H 
of Fmoc), 7.61 – 7.57 (m, 2H, CH2-CO-C6H5), 7.57-7.51 (m, 2H, CH2-CO-C6H5), 7.41 (t, J = 7.4, 2H, 
Fmoc), 7.31 (td, J = 6.5, 7.4, 2H, Fmoc), 5.74-5.76 (m, 2H, CH2-CO-C6H5), 5.19-5.26 (m, 2H, -C6H4-
CH2-OCO-CH2-NH-), 4.25-4.34  (m, J = 7.0, 2H, -NH-COO-CH2-), 4.12-4.25 (m, 1H, CH2-NH-Fmoc), 
3.78-3.90 (m, 2H, -C6H4-CH2-OCO-CH2-NH-); 13C NMR (101 MHz, DMSO) δ 192.71 (CH2-CO-C6H5), 
170.10 (-C(O)-CH2-NHFmoc), 164.99 (-CO-C6H4-CH2-), 156.59, 143.80, 141.77, 140.76, 134.07, 
133.88, 129.52, 128.99, 128.69, 127.86, 127.79, 127.66, 127.09, 125.18, 125.18, 120.16, 67.23, 
65.82, 65.17, 46.58, 42.26; HRMS (ESI, positive mode) found 550.2004 ([M + H]+ requires 550.1866). 
O OH
O
O
NHFmoc
 4-[N-(9-fluorenylmethoxycarbonyl)-L-glycyl]oxy]methyl]benzoic acid (74) 
-1st method: To as suspension of 73 (1.5 g, 2.73 mmol, 1 eq) in EtOAc (5.5 mL) and water (5.5 mL) 
were added AcOH (13.5 mL, 5 mL / mmol) and zinc powder (1.25 g, 19.11 mmol, 7 eq). The mixture 
was stirred at room temperature overnight. The mixture was filtered and the precipitate washed 
with DCM (5 mL) and MeOH (5 mL). The organic layer was concentrated under reduced pressure and 
the residue was taken up in DCM (20 mL). The organic layer was washed with NaHCO3 (aq) sat., 
brine, water, dried over sodium sulphate and concentrated under reduced pressure. The residue was 
purified by silica gel column chromatography (hex:EtOAc:AcOH 1:1:0.01) to afford 74 as a white 
powder (920 mg, 78%).  
O O
O
O
NHFmoc
O
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-2nd method: direct coupling. To a solution of Fmoc-Gly-OH 75 (977 mg, 3.29 mmol, 2 eq) in DMF was 
added CDI (533 mg, 3.29 mmol, 2 eq) in one portion. After stirring at room temperature for 30 min, a 
solution of 4-(hydroxymethyl)benzoic acid 69 (250 mg, 1.64 mmol, 1 eq) was added dropwise. The 
reaction mixture was stirred at room temperature for 3 h and concentrated under reduced pressure. 
The residue was purified by silica gel column chromatography (gradient DCM:EtOAc 9:5 to 
DCM:EtOAc:AcOH 9:5:0.01) to yield 74 as a white powder (220 mg, 26%). Rf (hex:EtOAc:AcOH 
1:1:0.01)= 0.5; 1H NMR (400 MHz, DMSO) δ 7.87-7.94 (m, 4H, HOOC-C6H4-CH2-), 7.83 (t, J = 6.1, 1H, 
Fmoc), 7.70 (d, J = 7.5, 2H, Fmoc), 7.47 (d, J = 8.2, 2H, Fmoc), 7.41 (t, J = 7.5, 2H, Fmoc), 7.32 (t, 
J = 7.0, 2H, Fmoc), 5.16-5.22 (m, 2H, C6H4-CH2-OCO-CH2-NH- ), 4.25-4.34 (m, 2H, -NH-COO-CH2), 
4.23 (t, J = 6.9, 1H CH2-NH-Fmoc), 3.78-3.88 (m, 2H, C6H4-CH2-OCO-CH2-NH-); 1H NMR (500 MHz, 
DMSO, 50°C) δ 7.90-7.93 (m, 2H, HOOC-C6H4-CH2-), 7.87 (d, J = 7.6, 2H, HOOC-C6H4-CH2-), 7.67-7.70 
(m, 1H, Fmoc), 7.46 (d, J = 8.2, 2H, Fmoc), 7.41 (t, J = 7.5, 2H, Fmoc), 7.32 (d, J = 7.4, 2H, Fmoc), 5.21 
(s, 2H, C6H4-CH2-OCO-CH2-NH-), 4.33 (d, J = 6.9, 2H, -NH-COO-CH2-), 4.23 (s, 1H, CH2-NH-Fmoc), 
3.86 (s, 2H, -C6H4-CH2-OCO-CH2-NH-); 13C NMR (101 MHz, DMSO) δ 170.10 (-C(O)-CH2-NHFmoc), 
156.56 (-COOH), 143.79, 140.83, 140.75, 129.42, 127.65, 127.60, 127.09, 125.18, 120.16, 65.79, 
65.24, 46.58, 42.23; HRMS (ESI, negative mode) found 430.1291 ([M - H]- requires 430.1291). 
8.1.11 Peptide synthesis 
8.1.11.1 Peptides on cellulose membranes (SPOTTM synthesis) 
The peptides were either pre-activated before the synthesis or pre-activated by the apparatus 
before each coupling. The peptides were synthesized either without any linker or with a cleavable 
linker (HMB, Fmoc-Gly-HMB-OH, or rink amide linker). The cleavable linker was coupled as a normal 
amino acid. 600 peptides were prepared on the same membrane (20 x 30 peptides). 
8.1.11.1.1 Pre-activated in the apparatus before each coupling 
Solutions of amino acids or linkers (0.5 M in NMP), HOBt (1.1 M in NMP), DIC (1.1 M in NMP) were 
prepared and placed in the apparatus. The membrane was swelled for 30 min in DMF and placed in 
the apparatus. The membrane was washed with EtOH (2 x 15 s) and dried by extraction (900 s). The 
reagents needed for the 1st step were automatically taken (2 coupling x number of peptide having 
this derivative in the sequence x (0.1 µL of derivative+0.05 µL of HOBt solution +0.5 µL DIC solution + 
0.001 µL NMP) and mixed in smaller vials. 0.22 µL of the pre-activated solution were added to each 
spot on the membrane and allowed to react for 10 minutes. The coupling step was repeated twice. 
Then, the membrane was extracted for 30 s and capped for 10 minutes with a 2% (v/v) Ac2O solution 
in NMP. The membrane was extracted (30 s), washed with DMF (8 x 5 s), EtOH (2 x 5 s) and extracted 
for 90 s. The N-terminal Fmoc group was cleaved using 20% piperidine (v/v) in DMF (2 x 5 min). The 
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membrane was extracted (30 s), washed with DMF (8 x 10 s), EtOH (2 x 10 s) and extracted for 900 s. 
The cycle of pre-activation, couplings, capping, washes, deprotection and washes was repeated for 
each amino acid in the peptide sequence. After the final amino acid coupling, the membrane was 
removed and dried in a vacuum desiccator overnight.  
8.1.11.1.2 Pre-activated before the synthesis 
Solutions comprising amino acids or linkers (0.5 M), HOBt (1.1 M), DIC (1.1 M) in NMP were 
prepared and mixed for 20 min at room temperature before being placed in the apparatus. Fresh 
solutions were prepared every 6 cycles (~24 h). The membrane was swelled for 30 min in DMF and 
placed in the apparatus. The membrane was washed with EtOH (2 x 15 s) and dried by extraction for 
900 s. 0.22 µL of the activated solutions were automatically taken, spotted on the membrane and 
allowed to react for 10 min (repeated twice). Then, the membrane was extracted, capped, washed, 
deprotected and washed as described for the previous method. The cycle of couplings, capping, 
washes, deprotection and washes was repeated for each amino acid in the peptide sequence. After 
the final amino acid coupling, the membrane was removed and dried overnight in the desiccator. 
The membrane was then cut in several units which were kept at -18 °C. 
8.1.11.1.3 Side chain deprotection: 
To a membrane, placed in a 15 mL Falcon tube, was added a solution of TFA 94%, water 2.5%, EDT 
2.5%, TIS 1%. The mixture was stirred at room temperature for one hour. The membrane was then 
washed with DCM (4 x 2 min), DMF (4 x 2 min) and EtOH (2 x 2 min) and dried under N2. The 
membrane was then ready to perform assays or to be cleaved in solution for subsequent analysis.  
8.1.11.1.4 Peptide cleavage in solution  
 HMB linker  
The spots were cut out and placed in different vials of a 96-well plate. A solution of ammonia 7 N in 
MeOH (100 µL) was added to each spot and the plate was shaken overnight at room temperature. 
The spot paper was removed and the solutions were heated at 60 °C for 2 hours to evaporate the 
solvent. Then, the residue was dissolved in MeOH: H2O (1:1) (20 µL) and analysed by MALDI. 
 Rink amide linker 
The spots were cut out and shaded with a pencil to give a much more visible grey pellet. The spots 
were cleaved using a solution of TFA 94%, H2O 2.5%, EDT 2.5%, TIS 1% (200 µL for each spot). After 
3 h, the spot paper was removed and the peptides were precipitated with tert-butylmethylether 
(TBME). The grey solid was pelleted by centrifugation and washed with TBME (2x). TBME was 
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removed and the peptides were allowed to dry for 2 hours at room temperature. The pellet was 
dissolved in MeOH: H2O (1:1) (20 µL) and analysed by MALDI. 
8.1.11.2 Solid Phase Peptide Synthesis (SPPS) 
Peptides bearing a C-teminal amino group were synthesised using Tentagel S RAM resin 
(substitution: 0.3 mmol/g). FLAG peptides (with an acid at the C-terminus were synthesised on a 
Wang resin pre-loaded with Lysine. Peptides bearing a biotin moiety at the C-terminus were 
synthesised using a Biotin-PEG NovaTag resin (Merck) 
The resin (20 μmol per well) was swelled in DMF for 30 min before deprotection of the N-terminal 
Fmoc protecting group with 20% piperidine (v/v) in DMF for 10 min (400 µL; 3 repeats). 
4.38 equivalents of the incoming N-Fmoc protected amino acid (as a 0.5 M solution in DMF; 
87.5 µmol) was activated in a separate vial with HBTU (0.5 M solution in DMF; 85 μmol, 4.25 eq), 
N-methyl pyrrolidinone (NMP) (5 μL) and N-methyl-morpholine (4 M; 52 μL; 208 μmol, 10.4 eq). The 
activated amino acid was added to the resin and allowed to couple for 35 min (repeated twice). The 
peptide was capped using a solution of 5% (v/v) acetic anhydride in NMP (400 μL). The resin was 
washed with DCM (2x) and DMF (6x) and the cycle of deprotection, DMF wash, amino acid couplings, 
capping and DMF wash was repeated for each amino acid in the peptide sequence. After the final 
amino acid coupling, the N-terminal Fmoc was cleaved using 20% piperidine (v/v) in DMF (400 μL, 
3× 10 min). The resin was placed in a 10 mL syringe equipped with a polyethylene frit and a syringe 
cap.  The resin bound peptide was then washed with DMF (3×), DCM (3×), MeOH (3×) and Et2O (3×) 
before being dried in a vacuum desiccator overnight. The peptide was deprotected and cleaved from 
the resin using a deprotection/cleavage mixture of 95% TFA, 2.5% water, 2.5% TIS. 6 mL of this 
mixture was added to the resin-bound peptide and it was shaken at room temperature for 3 h. For 
cysteine containing peptides, a different deprotection/cleavage mixture was used (88% TFA, 5% 
water, 2% TIS, 5% DTT).The liquid was filtered, and the resin washed with 2 mL of deprotection 
mixture. To the solution was added 10 mL cold tert-butylmethyl-ether (TBME) to precipitate the 
peptide. The mixture was centrifuged (4000 rpm, 4 °C, 15 min) and the solid washed with 10 mL 
TBME two more times. The peptide was then placed in a vacuum desiccator overnight before being 
purified by semi-preparative HPLC and freeze-dried. Characterisation data for these peptides is 
shown in Table 15. 
8.1.11.3 Manual coupling at the peptide N-terminus 
When an acid instead of an amino acid (myristic acid, YnC12, 5-pentynoic acid or azido-butyric acid) 
was coupled at the N-terminus of the peptide, the coupling was done manually to ensure a better 
yield. Following standard SPPS the peptide was transferred to a 5 mL syringe equipped with a 
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polyethylene frit and the coupling was carried out as described in Method 2. The peptide was 
deprotected as described in Section  8.1.11.2. Characterisation data for these peptides is shown in 
Table 15. 
8.1.12 Manual acetylation at the peptide N-terminus 
Following standard SPPS the peptide was transferred to a 5 mL syringe equipped with a polyethylene 
frit and the resin swelled by addition of 1 mL DMF followed by shaking at room temperature for 1 h. 
DMF was removed by filtration, and 1 mL acetylation mixture (10% acetic anhydride, 20% DIPEA in 
DMF (v/v)) added and shaken at room temperature for 1 h. The reagent mixture was removed by 
filtration and the peptides washed and deprotected as described in Section  8.1.11.2. 
Characterisation data for these peptides is shown in Table 15. 
8.1.13 Peptide characterisation 
The following peptides were prepared:  
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Table 15. Sequences, names, characterisation of the peptides prepared for the current study. Purif. = Purification method. 
Peptide  Sequence Purif. 
MW 
(g/mol) 
Exact mass 
(g/mol) ES+ peaks Rt 
Yield 
(%) 
Solvent  
stock  
c-SRC 15AA GSNKSKPKDASQRRR-NH2 B 1713.901 1712.940 858.13, 572.29, 429.57 0.98 15% DMSO 
c-SRC 8AA GSNKSKPK-NH2 B 843.964 843.482 844.92, 423.16 1.33 26% H2O 
BASP1 15AA GGKLSKKKKGYNVND-NH2 B 1634.88 1633.916 818.67; 546.13 1.18 16% DMSO 
ARF1 15AA GNIFEKLFKSLLGKK-NH2 C 1721.099 1720.029 861.59, 574.54 8.94 11% DMSO 
HIV Gag GARASVLSGGKLDAW-NH2 D 1486.675 1485.794 744.11 9.64 18% DMSO 
HIV Nef GKWSKSSIVGWPAV--NH2 B 1557.796 1556.835 780.08; 1558.45 9..58 32% DMSO 
Human sphingolipid delta GNSASRNDFEWVYTD-NH2 D 1759.788 1758.749 881.02 10.16 26% DMSO 
MARCKS GAQFSKTAAKGEAAA-NH2 B 1406.543 1405.720 704.23; 1407.22 0.95 21% DMSO 
SRC like adaptor 2 GSLPSRRKSLPSPSL-NH2 B 1580.832 1579.905 791.28 7.9 16% DMSO 
Annexin 13b GNRHSQSYTLSEGSQ-NH2 B 1649.678 1648.744 825.52 7.21 4% DMSO 
HIS-tag GSSHHHHHHS-NH2 B 1158.145 1157.486 579.99 0.88 26% DMSO 
CCHL 8AA GLSPSAPA-NH2 B 697.772 697.365 698.55 6.55 22% DMSO 
CCHL 12AA GLSPSAPAVAVQ-NH2 B 1095.246 1094.597 1095.70; 548.38 9.29 11% DMSO 
CCHL 15AA GLSPSAPAVAVQASN-NH2 B 1367.506 1366.709 1368.49; 684.60 10.54 8% DMSO 
CCHL 20AA GLSPSAPAVAVQASNASASP-NH2 B 1780.936 1779.900 891.54 9.3 6% DMSO 
c-SRC-biotin  GSNKSKPKDASQRRR-biotin B 2144.136 2142.514 537.48; 716.04 8.31 17% H2O 
YnC12-SRC-biotin  YnC12-GSNKSKPKDASQRRR-biotin B 2348.88 2347.38 471.04, 588.30, 784.4 10.37 20% H2O 
acetylated c-SRC-biotin  Ac-GSNKSKPKDASQRRR-biotin B 2186.17 2184.524 1093; 730.13 11.56 7% DMSO 
BASP1-biotin  GGKLSKKKKGYNVND-Biotin B 2064.25 2063.49 688.80; 517.55 1.22 24% DMSO 
acetylated BASP1-biotin  Ac-GGKLSKKKKGYNVND-Biotin B 2106.39 2105.50 703.24; 527.69 6.98 17% DMSO 
Fyn-biotin  GCIKSKENKSPAIKY-biotin B 2094.553 2093.141 1048.09; 699.40; 524.68 8.78 34% H2O 
XRP2-Biotin  GCFFSKRRKADKESR-biotin B 2243.667 2242.186 1122.65; 784.94; 562.18 0.8 26% H2O 
CCHL_biotin  GLSPSAPAVAVQASN-biotin B 1797.091 1795.953 899.35 10.59 7% H2O 
Yn-FLAG Yn-DYKDDDDK-COOH B 1107.094 1106.517 554.27 8.11 51% H2O 
Az-FLAG Az-DYKDDDDK-COOH B 1124.014 1123.437 562.82 8.77 31% H2O 
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8.2 Biological and biochemical methods 
8.2.1 General methods 
The capture reagents, AzTB and YnTB were prepared and kindly donated by Dr. Megan Wright 
(Imperial College London) as previously described.333 The capture reagent AzKTB was synthesised by 
Dr. Goska Broncel (Imperial College London). DABCO-TAMRA and DABCO-biotin were available in the 
Tate group (unknown suppliers). Azidohomoalanine (AHA) was purchased from Iris Biotech and 3,3'-
5,5' tetramethylbenzidine from Thermo scientific. 
In-gel fluorescence was recorded using an ETTAN Dige Imager (GE Healthcare). Chemiluminescence 
was recorded using a LAS-3000 Imaging System (Fujifilm). Absorbance in 96-well plates was 
measured using a SpectraMax M2/M2e Microplate Reader from Molecular devices. 
Culture media and reagents for HeLa cell culture were obtained from Sigma Aldrich, Gibco (Life 
technologies) and A&E Scientific (PAA).  
Microtiter plates pre-coated with streptavidin and pre-blocked were purchased from Thermo Fisher 
(Streptavidin Coated Plates (HBC), 8-well strips, clear, cat. no. 15501). The FLAG-HRP antibody used 
for the ELISA assay was obtained from Sigma-Aldrich (A8592). 
8.2.2 Enzymatic assay 
Kinetic studies and IC50 values determinations were carried out using a 7-diethylamine-3-
(4’maleimidylphenyl)-4-methylcoumarin (CPM) fluorescence assay, as described by Goncalves et al. 
145. The full length NMT1 and NMT2 enzymes were produced by Jim Brannigan, University of York, as 
described before 145. The enzymes were stored in the following buffer: 125 mM NaCl, 10 mM Tris-
HCl pH 8.5, 1mM EGTA, 1 mM EDTA, 25% glycerol. HsNMT1, HsNMT2, ΔHsNMT1 and ΔHsNMT2 were 
used at a final concentration of 300 ng/mL  
For kinetic studies, the initial rates values are the mean value of 3 initial rate values determined with 
Wallac EnVison Manager software. The data was fitted to the enzyme kinetics function in GraFit 7.0 
(Erithacus Software Ltd, UK). IC50 values are the mean value of two or more determinations and IC50 
values were determined using GraFit 7.0 (Erithacus Software Ltd, UK) by non-linear regression 
fitting. 
8.2.3 NMT ELISA assay 
The following assay buffer was freshly prepared: 1 mM DTT, 0.1 % BSA, 0.05 % Tween, 1 x PBS, 
pH 7.4 
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The plate was washed with PBS-T (3 X 200 µL) and with assay buffer (3 X 200 µL). YnC12CoA (4 µM 
final), peptide (4 µM final) and recombinant enzyme (300 ng/mL) were added to the plate and 
incubated at RT for 1 h on a shaker. The plate was washed with PBS-T (3 X 200 µL) and PBS 
(3 X 200 µL). Click mixture (94 µL PBS, 1 µL 10 mM N3FLAG, 2 µL 50 mM CuSO4, 2 µL 50 mM TCEP, 1 
µL 10 mM TBTA) was prepared and 100 µL  added to each well. After 1 h incubation at RT, the plate 
was washed with PBS-T (3 X 200 µL) and PBS (3 X 200 µL). A solution of anti-FLAG (1:20 000) in PBS 
was added to each well (100 µL) and the plate incubated at RT for 1 h. The plate was washed with 
PBS-T (3 X 200 µL) and PBS (3 X 200 µL). A mixture of 3,3'-5,5' tetramethylbenzidine (TMB) and H2O2 
(100 μl) was added to each well and the plate incubated at room temperature for 3 min. The 
reaction was stopped with addition of 50 μl of 1N H2SO4. The absorbance of each well was read at 
450 nm. 
8.2.4 Mammalian cancer cell culture 
HeLa, MDA-MB-231 and MCF-7 cells were grown in DMEM supplemented with 10% FBS and 1% 
penicillin/streptomycin. HCT 116 cells were grown in McCoy's 5a Medium Modified supplemented 
with 0.22 g/L Glutamine and with 10% FBS and 1% penicillin/streptomycin. All cells were grown in a 
humidified 10 % CO2 containing atmosphere at 37 oC. Cells were plated 24 h before treatments using 
the following cell concentrations (Table 16). 100 µL, 2 mL, 5 mL and 10 mL of culture media were 
used per well in 96-well plates, 6-well plates, 6-cm plates or 10-cm plates respectively. 
 
Table 16. Number of cells plated 24 h before the beginning of an experiment 
 
HeLa MDA-MB-231 HCT116 MCF7 
Treatment 
time (h) 6 24 48 72 168 6 24 48 72 168 6 24 48 72 168 6 24 48 72 168 
103 cells / mL 100 50 25 16 16 160 80 45 30 30 160 80 45 30 30 120 60 30 15 15 
 
8.2.4.1 YnC12 labelling and feeding cells with inhibitor in HeLa 
A solution of culture media containing the inhibitor was prepared in a Falcon tube and incubated at 
37oC for 5 min (typically for a 10 cm plate, final concentration 1 µM of inhibitor: 1 µL of a 10 mM 
stock solution was added to 10 mL of culture media and the solution was mixed). The culture media 
was aspirated and replaced by the medium containing the inhibitor. The cells were incubated for 1 h. 
The media of each plate was then removed and replaced by a solution containing the inhibitor and 
YnC12 (typically 20 µM) in the culture media. Cells were incubated for several hours (typically 24 h) 
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before cell lysis. The total amount of DMSO was normalised to the maximum amount of DMSO used 
in each plate (typically 0.05 %). 
8.2.4.2 Cell lysis  
8.2.4.2.1 Using detergents 
The culture media was aspirated and cells were washed with cold PBS (2 x). The plate was placed on 
ice and lysis buffer (PBS 1x, 0.1% SDS, 1% Triton X-100, 1 EDTA-free Complete protease inhibitor 
(Roche Diagnostics) was added to each plate (typically 0.3 mL for a 10 cm plate). To study c-SRC 
phosphorylation, the lysis buffer was supplemented with 1x phosphatase inhibitor cocktail set V 
(Millipore). Cells were scraped off the plates and the lysates transferred to microcentrifuge tubes 
and kept on ice for 20 min. The lysates were centrifuged at 17,000 ×g for 20 min to pellet insoluble 
material. Supernatants were collected and stored at -80 oC. Protein concentration was determined 
using the Bio-Rad DC Protein Assay. A calibration curve was prepared using BSA (bovine serum 
albumin) solutions in lysis buffer (0-4 mg/mL). The absorbance was measured using SpectraMax 
M2/M2e Microplate Reader from Molecular Devices. 
8.2.4.2.2 Cell lysis for in vitro myristoylation studies (no detergents) 
Cells were trypsinised and washed with PBS (2 x 1 mL). Cells were resuspended in lysis buffer 
(50 mM Hepes pH 7.2, 10 mM NaCl, 5 mM MgCl2, 1 mM DTT, 1x 1 EDTA-free Complete protease 
inhibitor (Roche Diagnostics) and mechanically lysed by passing the lysate through a 25 G needle 
(~ 20 times) using a 1 ml syringe. The lysates were kept on ice for 15 min and centrifuged at 17,000 
×g for 20 min to pellet insoluble material. The protein concentration was determined as described 
above and the samples were flash-frozen using liquid nitrogen and kept at -80 oC prior to analysis.  
8.2.4.2.3 Cell fractionation 
Cells were trypsinised and washed with PBS (2 x 1 mL). Cells were resuspended in  lysis buffer 
(250 mM Sucrose, 20 mM HEPES pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 
1 x protease inhibitor cocktail) and mechanically lysed by passing the lysate through a 25 G needle 
10 times using a 1 ml syringe. The lysates were kept on ice for 15 min and centrifuged at 720 ×g for 
5 min to pellet insoluble material. The supernatant (membrane + cytosolic fractions) was removed. 
200 µL of the lysis buffer were added to the pellet and the mixture was passed through a 25G needle 
(10 times), and centrifuged a 720 x g for 5 min. The supernatant was discarded and the pellet was 
resuspended in 2% SDS, 10 % glycerol. To help dissolving the pellet, the mixture was sonicated for 
5 s and passed through a 25 G needle again to break any aggregates. The membrane + cytosolic 
fractions were centrifuged at 10,000 xg for 10 min. The supernatant (cytosolic fraction) was 
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removed and the pellet (membrane fractions) was washed with lysis buffer (1x). The membrane 
fraction was resuspended in 2 % SDS in PBS.  
8.2.5 Gel electrophoresis  
Bis-Tris gels used for sample separation by gel electrophoresis were prepared using the following 
recipe: 
 
Table 17. Reagents to prepare 12 % Bis-Tris gels. Components of the recipe were mixed in the amounts given 
in Table 15 and cast in 1.0 mm glass plates (Bio-Rad).  
Component Volume (mL) for 25 mL resolving gel (12%) 
Volume (mL) for 7.5 mL 
stacking gel (4%) 
30 % acrylamide/bis-acrylamide  10 1 
1.25 M Bis-tris (pH 6.7)  9 2.7 
dH2O  5.8 3.8 
10 % w/v ammonium persulphate  0.2 0.037 
N,N,N′,N′-
Tetramethylethylenediamine  0.01 0.006 
 
8.2.6 CuAAC and in-gel fluorescence 
Lysates were thawed on ice. 100 µg of proteins was taken and diluted to 1 mg / mL using the lysis 
buffer. A click mixture was prepared by adding reagents in the following order and by vortexing 
between the addition of each reagent: the capture reagent (1 µL, stock solution 10 mM in DMSO, 
final concentration 0.1 mM), CuSO4  (2 µL, stock solution 50 mM in DMSO, final concentration 
1 mM), TCEP (2 µL, stock solution 50 mM in DMSO, final concentration 1 mM), TBTA (1 µL, stock 
solution 10 mM in DMSO, final concentration 0.1 mM). 6 µL of the click mixture was added to each 
sample. The samples were vortexed at RT for 1 h. Next, 1 mL ice cold MeOH and EDTA (final 
concentration 10 mM) were added to each sample. The samples were quickly vortexed and kept at -
80 oC overnight. The samples were centrifuged at 17,000 ×g for 30 min to pellet precipitated 
proteins. The pellets were washed with 1 mL ice-cold MeOH and dried. 75 µL 2 % SDS in PBS, 10 mM 
EDTA was added and the samples were vortexed. Once the proteins were completely dissolved, 
25 µL of 4 x SLB (Sample loading buffer prepared by mixing 4 x sample loading buffer (NuPAGE LDS 
sample buffer): β-mercaptoeptanol 5:1) was added (final concentration of proteins 1 mg/mL). The 
samples were boiled for 5 min, centrifuged at 1,000 ×g for 2 min and loaded on a SDS-PAGE gel. 
Typically, 10 µg of proteins were loaded on the gel. After the run, the gel was washed with MilliQ 
(3x) and soaked in fixing solution (40 % MeOH, 10 % acetic acid, 50 % water) for 20 min, washed with 
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MilliQ (3x). The fluorescence on the gel was detected using an Ettan DIGE Imager, GE Healthcare, 
and the protein loading was checked by Coomassie. The quantification of fluorescent bands to 
calculate in-cell tagging IC50 was carried out using ImageJ. The signal was measured by integrating 
the area under each band of interest using the ‘gel analyzer’ function and normalised relative to no 
inhibition (YnMyr). The signal was normalised to the total protein loading by integrating the gel 
stained with Coomassie. In-cell tagging IC50s (TC50s) were determined using GraFit 7.0 (Erithacus 
Software Ltd, UK) by non-linear regression fitting.   
8.2.7 Enrichment of myristoylated proteins  
For enrichment of myristoylated proteins, 100 µL of lysate was captured by CuAAC as described 
above. After protein precipitation, the pellet was resuspended in 2 % SDS in PBS, 10 mM EDTA 
(20 µL). Once the pellet was completely dissolved, 80 µL of PBS was added (final concentration 
1 mg/mL, 1 % SDS). 20 µL was reserved for the “before pull-down” sample. The remaining 80 µL was 
diluted to 0.2 % SDS and 0.5 mg/mL by the addition of 80 µL PBS. 15 µL Dynabeads® MyOne™ 
Streptavidin C1 were washed with 0.2 % SDS in PBS (3 × 250 µL). The sample was added to the beads 
and the beads were gently vortexed for 1h30. The supernatant was removed and the beads were 
washed with 0.2 % SDS (3 x 250 mL). 30 µL of 2 % SDS in PBS and 10 µL 4x SLB were added to the 
beads and the beads were boiled for 10 min. 7 µL SLB was added to the “before pull down” sample 
and 7 µL SLB was added to 20 µL of supernatant. Both samples were boiled for 5 min. Samples were 
centrifuged at 1,000 ×g for 2 min and loaded on a SDS-PAGE gel (“before pull down” sample: 10 µL 
(7.5 µg of proteins); supernatant: 10 µL (7.5 µg of proteins); pull down: 15 µL (30 µg of proteins).  
8.2.8 Western blot analysis 
Proteins were transferred to PVDF membranes (Millipore, Immobilon-PSQ membrane, pore size 
0.2 µM) or nitrocellulose membrane (GE Healthcare, Hybond ECL, pore size 0.45 µM) using a wet 
transfer set-up and a Tris-glycine transfer buffer supplemented with 0.1% SDS and 10 % MeOH. 
Membranes were washed with TBS-T (1 x TBS, 0.1 % Tween-20), blocked (5 % dried skimmed milk in 
TBS-T), washed with TBS-T (3x) then incubated with the appropriate primary antibody (Table 18) in 
blocking solution overnight, washed with TBS-T (4x 10 min), incubated with the appropriate 
secondary antibodies in blocking solution for 1 h (Mouse: HRP Goat anti Mouse, 1/20 000, BD 
Pharmingen, cat. no. 554002 or Rabbit: HRP Goat anti Rabbit, 1/5000, Invitrogen, cat. no. G-21234) 
washed with TBS-T (4x 10 min) and developed with Luminata Crescendo Western HRP substrate 
(Millipore) according to the manufacturer’s instructions and on a Fujifilm LAS 3000 imager. 
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Table 18. Antibodies used in the present study 
Protein  Supplier Cat. no. 
Dilution 
(Western 
blots) 
Secondary 
antibody /clonal Immunogen 
Apparent 
MW (if 
different 
from MW) 
BASP1 Abcam ab79349 1/1000 Rabbit Poly Synthetic peptide from the effector domain of Mouse BASP1 52 kDa 
BID Cell signaling technology 2002S 1/250 Rabbit Poly Residues surrounding the cleavage site of human BID   
Calnexin   Santa Cruz sc-23954 1/200 Mouse Mono 1-76 full length bovine ubiquitin   
Caspase3 Santa Cruz sc-13156 1/1000 Rabbit Poly Amino acids 1-277 representing full length procaspase-3 of human origin   
Caspase 8 Cell signaling technology 9746S 1/500 Mouse Mono 
Carboxy-terminal sequence of the p18 fragment of human 
caspase-8   
Cdk2 Santa Cruz sc-163 1/2000 Rabbit Poly C-terminus of Cdk2   
Cleaved caspase 3 Cell signaling technology 9664S 1/250 Rabbit Mono 
Amino-terminal residues adjacent to Asp175 of human 
caspase-3   
c-SRC Cell signaling technology 2123 1/500 Rabbit Mono Residues 1-110 of human SRC protein   
Cytochrome C Santa Cruz sc-13156 1/250 Mouse Mono Amino acids 1-104 of cytochrome c of equine origin   
HCCS Atlas HPA002946 1/500 Rabbit Poly Amino acids 63-203 of HCCS of human origin   
Histone H3 Santa Cruz Sc-10809 1/500 Rabbit Poly Amino acids 1-136 of Histone H3 of human origin   
HsNMT1 Sigma aldrich HPA022963 1/500 Rabbit Poly Amino acids 66-135   
HsNMT2 BD Biosciences 611310 1/125 Mouse Mono Human NMT-2 amino acids. 10-119   
PARP Santa Cruz sc8007 1/250 Mouse Mono Amino acids 764-1014    
PKA C-α  Cell signaling technology 5842S 1/500 Rabbit Mono Residues surrounding Ser326 of human PKA C-α protein.   
PSMC1 Atlas HPA000872 1/500 Rabbit Poly Amino acids 295-436of PSMC1 of human origin   
Phospho-Src 
(Tyr416) 
Cell signaling 
technology 2101S 1/500 Rabbit Poly 
Synthetic phosphopeptide corresponding to residues 
surrounding Tyr416 of human SRC   
MARCKS Cell signaling technology D88D11 1/500 Rabbit Mono Residues surrounding Ala245 of human MARCKS protein. 70-90kDa 
α-Tubulin Santa Cruz sc-53646  1/2000 Mouse Mono Full-length α Tubulin  (human)   
Ubiquitin Cell signaling technology 3936S 1/500 Mouse Mono 1-76 full length bovine ubiquitin   
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8.2.9? Immunoprecipitation and capture of myristoylated proteins 
200 μg of protein was ???????????????????????? ???????????????????????????????????????????????????
15 μL of Sepharose A beads (GE Healthcare, Fast Flow) pre-washed with 3 x PBS, were added and the 
s??????????????????????????????????????????????????? rotation wheel. The supernatant was discarded 
and the beads washed with ice-cold lysis buffer (2x) and 0.1% SDS in PBS (2x), and then resuspended 
in 47 ?L PBS for on-bead click labelling. Click reagents were premixed (TAMRA-capture reagent 
(0.5 μL of 10 mM stock), CuSO4 (1 μL of 50 mM stock), TCEP (1 μL of 50 mM stock) and TBTA (0.5 μL 
of 10 mM stock)) and added to each samples. The samples were incubated on ice for 1.5 h and 
gently vortexed occasionally. The supernatant was removed and the beads were washed with 0.1 % 
SDS in PBS (3 x). Beads were boiled in 1 x SLB (5 μL SLB + 15 μL 2 % SDS), except where indicated 
otherwise.  
8.2.10?Metabolic activity assay (MTS assay) 
HeLa cells were seeded in a 96-well plate 24 h before treatments. Cell suspensions were prepared by 
multiplying the cell concentrations reported in Table 16 by 2. 50 μL of cell suspension were 
transferred to wells B-G in columns 2-11 of a 96-well plate. 100 μL of growth media were added to 
the outer wells. 24 h after seeding, 50 μL of growth media containing DMSO (maximum amount of 
DMSO used for the inhibitor dilutions, typically 0.04%) were added to wells B-G in columns 2 and 11 
as a positive control. A solution of Puromycin (4 μg/mL, 50 μL, final concentration in the plate 
2 μg/mL) was used as a negative control and added to wells B-G in column 3. 7 concentrations of 
inhibitor were prepared (same final percentage of DMSO, dilution factor = 3, typically triple dilutions 
starting from 20 μM (final concentration in the plate starting from 10 μM) and 50 μL were added to 
the wells B-G in columns 4-10 (total volume of the wells = 100 μL).  
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24h, 48 h, 72 h or 164 h later  the MTS reagent (Promega) was prepared according to the supplier’s 
protocol and 20 µL of this reagent were added to each well of the 96-well plate. Absorbance was 
measured at 490 nm after 2 h. The average of absorbance values of the negative control (cells 
treated with Puromycin) was subtracted from each value. The metabolic activity was calculated as a 
percentage relative to the positive control. EC50s were calculated by fitting the data to the IC50 
function using GraFit 7.0 (Erithacus Software Ltd, UK). 
8.2.11 Cell cycle analysis 
For this experiment, 6 cm plates were typically used and cells were plated as described in Section 
 8.2.4. After treatment with the inhibitor or DMSO, both adherent and floating cells were harvested 
and washed with PBS (2 x 1 mL). Cell pellets were resuspended in 70 % EtOH and fixed overnight at 
4 ⁰C or for several days at -20 ⁰C. Fixed cells were washed with PBS (2 x 1 mL). Cell pellets were 
resuspended in 300 µL propidium iodide (PI) solution (50 µg/mL) and transferred to a 5 mL tube for 
flow cytometry analysis. 10 µL of RNAse was added to each tube. Samples were incubated at RT in 
the dark prior to analysis. Samples were diluted with PBS prior to analysis if necessary. Samples were 
processed using a BD LSRFortessa cell analyzer (BD Biosciences, UK). The distribution of cells in each 
phase of the cell cycle was calculated using FlowJo 7.6.5 software.  
8.2.12 Annexin V / PI analysis 
Dead and apoptotic cells were detected using FITC Annexin V Apoptosis Detection Kit I (BD 
Pharmingen™) as described by the supplier with some modifications. 
For this experiment, 6 cm plates were typically used and cells were plated as described Section  8.2.4. 
After treatment with the inhibitor or DMSO, both adherent and floating cells were harvested and 
washed with PBS (2 x 1 mL). Cell pellets were resuspended in 200 μl of 1X Binding Buffer 
(1 x 106 cells / mL). 100 μl of the solution were transferred to a 5 ml tube. 5 μl of FITC Annexin V and 
5 μl PI were added. The samples were vortexed and incubated for 15 min at RT in the dark. 400 μl of 
1X Binding Buffer were added to each tube prior to analysis by flow cytometry. Samples were 
analysed within 1 h following PI and Annexin V addition. Samples were processed using a BD LSR 
Fortessa cell analyzer (BD Biosciences, UK). Samples were compensated automatically using: 
untreated cells (unstained), apoptotic cells (1 uM STS treatment for 6 h, stained with Annexin V), 
dead cells (2 µg/mL Puromycin for 24 h, stained with PI). The distribution of apoptotic, dead, alive 
cells was calculated using FlowJo 7.6.5 software.  
8.2.13 SiRNA transfection 
The following SiRNA sequences were used: 28 
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siRNA NMT1: 5’ aatgaggaggacaacagctac 3’ mRNA 
siRNA NMT2: 5’ aaaaggttggactagtactac 3’  
100 000 HeLa cells/well were seeded in a 6-well plate and the growth medium (no PS) was replaced 
after 24 h. 5 µL of Lipofectamine 2000 (Invitrogen) was incubated at RT in DMEM without FBS and 
without PS (250 µL) for 5 min. 2 µL of SiRNA (50 mM) were mixed with 250 µL of DMEM media (no 
FBS, no PS). SiRNA mixture and Lipofectamine solution were combined and incubated at RT for 
25 min before addition to the corresponding well. The plates were gently mixed and incubated at 
37°C for 6 h. The media was replaced (DMEM + 10 % FBS) and the cells incubated at 37°C for 48 h or 
72 h. YnC12 (1.2 µL 50mM stock in DMSO, final conc. 20 µM) was added 6 h before cell lysis.  
8.2.14 Assays on cellulose membrane 
8.2.14.1 Preparation of the buffers 
The following buffers were prepared for the assays:  
Buffer A: 30 mM Tris, 3.5 mM DTT, pH 7.4  
Buffer B: 30 mM Tris, pH 7.4 
8.2.14.2 Myristoylation and click chemistry 
The membrane was placed in a 15 mL Falcon tube and soaked with buffer A. A mixture of MyrCoA 
analogue (YnC12CoA or AzC12CoA) and NMT in buffer A (3 mL) was incubated at 37°C for 5 min in 
another Falcon tube (Table 19). The membrane was added to this solution and the resulting mixture 
was incubated at 37°C for 2 h with constant shaking. The membrane was washed with buffer B (4 x 
2 min). 3 mL of buffer B and the following click chemistry reagents were added to the membrane 
(Table 20) 
Table 19.In vitro myristoylation on cellulose membranes 
 
Table 20. Capture reaction on cellulose membranes  
Compounds Final 
concentration 
Quantity Stock 
concentration 
Volume in µL 
Capture reagent 10 µM 30 nmol 10 mM 3 
CuSO4 40 µM 120 nmol 40 mM 3 
TCEP 40 µM 120 nmol 50 mM 2.4 
TBTA 4 µM 12 nmol 10 mM 1.2 
Compounds 
Final 
concentration 
Quantity 
Stock 
concentration 
Volume in µL 
Hs NMT 500 µg/mL 1.5 µg 9.8 mg /mL 0.15 
N3-Myr-CoA 1 µM 3 nmol 10 mM 3 
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The membrane was stirred at room temperature for 1 h and washed with buffer B (3 x 2 min). The 
membrane was directly imaged using an ETTAN Dige Imager (Fluorescein: Cy2 excitation/emission: 
492/520 nm; TAMRA: Cy3 excitation/emission: 550/570 nm) or probed in chemiluminescence. 
8.2.14.3 Chemiluminescence assay 
The membrane was washed with TBS-T (3x), blocked for 1 h (5% BSA in TBS-T) and washed with 
TBS-T (3x). A solution of Neutravidin HRP (Invitrogen, cat. no. A2664) (2.5 µL) in blocking solution (5 
mL) was prepared and added to the membrane. The membrane was stirred for 1h at room 
temperature and the membranes was washed with TBS-T (3 x) and developed with Luminata 
Crescendo Western HRP substrate (Millipore) according to the manufacturer’s instructions and 
imaged on a Fujifilm LAS 3000 imager. After imaging, the membrane was directly washed with TBS-T 
(2x) and kept in the fridge before stripping. 
8.2.14.4 Membrane stripping  
The membrane was washed with TBS-T (1x) and H2O (1x). 5 mL of a 1st stripping solution (62.5 mM 
Tris, pH 6.8, 100 mM β-mercaptoeptanol, 2% SDS) was prepared and added to the membrane. The 
membrane was incubated at 50°C for 30 min. The membrane was then washed with H2O (3x), TBS-T 
(3x) and H2O (2x). 5 mL of a 2nd stripping solution (50% EtOH, 10% acetic acid glacial, 40% H2O) was 
prepared and added to the membrane. The membrane was incubated at RT for 30 min with constant 
agitation. The membrane was then washed with H2O:EtOH 1:1 (1x) and TBS-T (4x). The membrane 
was then probed again directly or kept at -20°C. 
8.2.15 Protein expression in E. coli  
All manipulations of E. coli were carried out in an aseptic environment (flame-sterilized area) and 
kanamycin stock solution was filtered-sterilised. E. coli lysate co-expressing CaNMT and PfARF, and 
co-fed with or without AzC12 were kindly donated by Dr. William Heal (Imperial College London).  
Plasmids cloning the sequences used were the following: CaNMT1 into pET11c vector (Nde1/BamH1 
restriction site, ampicillin resistance) and P. falciparum ADP ribosylation factor 1 (PfARF1) into 
pET28a (Nco1/Xho1 restriction site, kanamycin resistance). 
8.2.15.1 Competent E. Coli transformation 
Lauria-Bertani (LB) broth media (10 g/L NaCl, 10 g/L tryptone, 5 g/L yeast extract, pH 7) and LB agar 
(10 g/L NaCl, 10 g/L tryptone, 5 g/L yeast extract, 20 g/L agar, pH 7) were prepared and autoclaved.  
An aliquot of chemically competent E. Coli (BL21(DE3) strain) were thawed on ice (chemically 
competent E. Coli were kindly donated by Chris Douse) 1µL of DNA (100ng) was added to 100 µL of 
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competent E. Coli. The mixture was mixed gently and left on ice. The cells were heat shocked by 
placing them in a water bath at 42°C for 1 min and then returned to ice for 2 min. 400 µL of warm LB 
media was added and the cells were incubated at 37°C for 1h with constant stirring. 100 µL of the 
cell suspension was plated onto LB agar plates containing the relevant antibiotics (50 µg/mL of 
Kanamycin), and the plates incubated at 37 °C for 18 h.  
8.2.15.2 PfARF1 expression 
In a 50 mL Falcon tube, 10 mL LB media containing 50 μg/mL kanamycin was inoculated with a single 
colony of BL21(DE3) cells containing the pET28a plasmid (including a His6-tag on the PfARF 
C-terminus) to form a starter culture. The mixture was incubated at 37 °C with constant oscillation 
overnight. 200 µL of the starter culture was added into 10 mL fresh LB media containing 50 μg/mL 
kanamycin, and the mixture was incubated at 37 °C with constant oscillation until optical density 
(OD600) measurements reached 0.5–0.6 AU (Absorbance unit). IPTG (10 µL of 1M stock solution, 
1 mM final concentration) was added and the tube was incubated at 37 °C for a further 4 h with 
constant oscillation. The culture was centrifuged (4000 rpm, 4 °C, 15 min), the supernatant removed, 
the cell pellet was washed with 2 x 1 mL PBS and frozen at −80 °C. 
The cell pellet was thawed on ice and 300 µL lysis buffer was added. The lysis buffer was prepared by 
mixing 9 mL of 50 mM Tris.HCl pH 8, 150 mM NaCl with 1 L of Bugbuster (Roche), and 1x Complete 
EDTA-free protease inhibitor tablet (Roche). The cells were resuspended in the lysis buffer by 
pipetting up and down (10 times) and transferred to an microcentrifuge tube. The cells were kept on 
ice for a further 20 min and centrifuged at 17,000 ×g for 30 min to pellet insoluble material. The 
supernatant (soluble fraction) was transferred to another microcentrifuge tube and the pellet 
(insoluble fraction) was retained. The protein concentration was determined using the Bio-Rad DC 
Protein Assay and the samples were kept at -80oC prior to analysis or purification.  
8.2.15.3 PfARF1 purification 
PfARF1 was expressed as described above, but with the following modifications: 1 L instead of 10 mL 
of culture was grown and the reagents were adjusted as required; the cells pellet was not frozen 
overnight before lysis but was lysed directly after the 4 h of cell growth. 
The following buffers were prepared: 
 Buffer C: 20mM Tris pH8 , 0.5M NaCl 
 Buffer D: 20mM Tris pH8 , 0.5M NaCl, 5mM imidazole, 6M urea 
 Buffer E: 20mM Tris pH8 , 0.5M NaCl, 40mM imidazole 
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The pellet was resuspended in 10 mL Buffer C. The pellet was kept on ice and sonicated 2 x 1 min 
(power 20). The sample was spun down at 3,000 x g for 10 min at 4 oC to give the soluble fraction 
(supernatant) and the insoluble fraction (pellet).  
The pellet was washed with 10 m buffer C and the supernatant was discarded. The pellet was 
resuspended in 10 ml buffer D by leaving the sample on a rotation wheel overnight at 4 oC. The 
sample was then spun down at 3,000 x g for 10 min and 4 oC. The supernatant was retained for in-gel 
analysis of the insoluble fraction. 
Chelating Sepharose Fast Flow (500 µL, GE Healthcare) beads were pre-equilibrated as follows. They 
were washed with MilliQ (2 x 2 mL), gently vortexed for 5 min at RT with a solution of 10mM NiSO4 
in MilliQ, spun down, washed with MilliQ (4 x 1ml) and buffer C (3 x 1 ml). The soluble fraction was 
added to the beads. The mixture was incubated for 45 min on a rotation wheel at 4 oC. The 
supernatant was discarded and the beads were washed with buffer C (3 x 15 mL). The beads were 
incubated with 500ul of buffer E for 5 min on a rotation wheel at RT. The sample was spun down and 
the supernatant was reserved (elution 1). The elution was repeated 2 times. The three elution 
samples were centrifuged at 17,000 x g for 10 min. A SDS-PAGE gel was run to confirm protein 
purity, and the elution fractions were  then dialysed overnight into storage buffer (50 mM Hepes, 10 
mM NaCl, 5 mM MgCl2) using a Slide-A-Lyzer 3500 MW dialysis cassette in 2 L buffer at 4 °C. Dialysis 
was performed twice more using the same conditions for 1 h each time. The protein concentration 
was determined using the Bio-Rad DC Protein Assay and the protein was flash frozen in liquid 
nitrogen.  
8.2.16 In vitro-myristoylation 
Mammalian cells were grown as described in Section  8.2.4, treated with inhibitor IMP366 for 24 h 
and lysed as described in Section  8.2.4.2.2. E. coli lysates were prepared as described in Section 
 8.2.15. 
In vitro myristoylation was carried out by incubating 50 µg of lysate (1 mg/mL final concentration) 
with AzC12CoA or YnC12CoA (10 µM final concentration) and the appropriate enzyme (HsNMT1, 
HsNMT2 or CaNMT, final concentration 5 µg/mL) for 2h at 37 oC with constant stirring. The capture 
reaction and in-gel fluorescence analysis were carried out as described in Section  8.2.6.  
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8.3 Chemical Proteomics 
8.3.1 General methods 
For quantitative proteomics (SILAC), R10K8 and R0K0 DMEM media was purchased from Dundee cell 
products. Cell dissociation buffer (enzyme free, PBS-based) obtained from Gibco (Life Technologies) 
was used instead of trypsin to detach the cells before splitting them. Dialysed FBS was obtained from 
Sigma-Aldrich. All buffers were filtered using a 0.2 µM filter to prevent any contamination. Low 
binding tubes (Protein LoBind tubes, Eppendorf) were used to carry out the enrichment of NMT 
substrate for MS-based proteomics and to freeze-dry the digested peptides. 
8.3.2 Lysate preparation 
Lysates for non quantitative proteomics experiments or label-free quantification were prepared as 
described in Section  8.2.4. 
8.3.2.1 Spike-in SILAC 
To prepare the Spike-in SILAC standard,195 cells were grown in a “heavy” growth medium. The heavy 
growth medium was composed of SILAC DMEM (containing 13C and 15N labelled arginine, and 13C and 
15N labelled lysine (R10K8)) supplemented with 10% dialysed FBS and 1% penicillin/streptomycin. 
Cells were grown for >10 passages in this growth medium before starting the experiment. The 
incorporation of the heavy label was determined by analysing 20 µg of cell lysate (from cells grown 
in the heavy media) by proteomics and found to be 97.7%.  
8.3.3 Base treatment of the lysate before CuAAC 
Lysates from cells treated for 24 h with YnC12 (20 µM) were used. 500 µg of lysate (200 µL, 
2.5 mg/mL) were base-treated with NaOH (50 µL 1 N NaOH; 0.2 M NaOH final; concentration of 
protein 2 mg/mL) for 2 h. The samples were then neutralised by the addition of HCl 1N. In the 
control sample, a neutralised mixture of NaOH and HCl was added (100 µL) to 500 µg of lysates. To 
both samples was added the spike-in standard (1:1 ratio sample:spike-in standard) and the samples 
diluted to 2 mg/mL with PBS (total amount of proteins: 1mg; volume: 500 µL).  
8.3.4 Capture and enrichment for MS-based proteomics 
8.3.4.1 Using AZTB 
Samples were subjected to CuAAC and affinity enrichment as before with the following 
modifications: CuAAC reaction was carried out with 2 mg/L of proteins. For Spike-in SILAC 
proteomics, the spike-in standard was mixed in a 2:1 sample:spike-in standard ratio before the 
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CuAAC reaction. For SILAC experiments, the samples were mixed in a 1:1 ratio heavy: light before 
the CuAAC reaction.  
For affinity enrichment, Dynabeads were replaced by NeutrAvidin agarose resin (Thermo Scientific). 
Typically 200 µL of bead slurry were used for 4 mg of lysate. The enrichment was carried out for 2 h 
and the protein concentration was 1 mg/mL (0.2 % SDS). The supernatant was removed and the 
beads were washed with 3x 1% SDS in PBS, 3x 4M urea in 50 mM ammonium bicarbonate (AMBIC), 
5x 50mM AMBIC. For each wash, 1 mL of washing solution was added to the beads, the beads were 
gently vortexed for 5 min, spun at 3,000 ×g for 3 min and the supernatant was carefully removed 
and discarded. Beads were stored in 50 mM AMBIC at 4°C. The efficiency of the enrichment was 
checked by in-gel fluorescence by loading the samples before enrichment and the supernatant from 
the pull down.  
8.3.4.2 Identification of the modified peptide with AzKTB.  
Proteins were captured by CuAAC as before with the following modifications: CuAAC reaction was 
carried out for 2 hours and with AzKTB in place of AzTB. Proteins were precipitated following CuAAC 
via a modified chloroform/methanol precipitation procedure: 4 volumes of MeOH, 1 vol. CHCl3, 
3 vol. H2O were added to the sample, which was centrifuged at 17,000 ×g for 5 min to pellet 
proteins at the interface. Both layers were then removed simultaneously, the pellet resuspended in 
0.2 % SDS/PBS to the original volume and the precipitation procedure repeated. The pellet was then 
washed twice with MeOH. Resuspension, affinity enrichment and preparation for LC-MS/MS were 
performed as before with the following modifications: beads were washed with 10 % ACN in TEAB 
following digest and this wash was combined with the supernatant from on-bead digest to improve 
recovery of modified peptides. The solutions were freeze dried overnight to give a white solid. The 
samples were kept at 4°C prior to analysis. 
8.3.5 On-bead reduction, alkylation and digest.  
All reagents and buffers were freshly prepared. Beads were spun at 3000 x g for 5 min and the 
excess liquid discarded. For a volume of beads of ~ 150 µL: samples were reduced (7.5 µL of 100 mM 
dithiothreitol in 50 mM AMBIC) at 60 °C for 30 minutes and allowed to cool to room temperature. 
The beads were washed with 2 x 50 mM AMBIC. Cysteines were alkylated (7.5 µL of 100 mM 
iodoacetamide in 50 mM AMBIC) at room temperature for 30 min in the dark. The beads were 
washed with 2 x 50 mM AMBIC. 15 µL of acetonitrile were added (~10% of total volume). Trypsin 
(6 µg Sequencing Grade Modified Trypsin (Promega) dissolved in 50 mM AMBIC) was added to the 
beads and samples were placed on a shaker and digested overnight at 37 °C. The samples were 
centrifuged and the supernatant was transferred into clean tubes. The beads were washed with 
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2 % FA, 10 % acetonitrile in water and these washes were combined with the supernatant removed 
after the addition of formic acid. The solutions were freeze dried overnight to give a white solid. 
The samples were kept at 4 °C prior to analysis. The solid was resuspended in 200 µL 2% acetonitrile, 
0.1 % FA in water; 50 µL / mg of lysate), vortexed for 5 min, sonicated for 25 min, vortexed again for 
5 min and spun down at 17000 x g for 10 min at 7 °C. The samples were transferred few hours 
before analysis to LC-MS vials.  
8.3.6 Gel-based proteomics: sample preparation, in-gel reduction, alkylation and digest 
For gel-based proteomics, 10 µL of 4x SLB (Sample loading buffer prepared by mixing 4x sample 
loading buffer (NuPAGE LDS sample buffer): β-mercaptoeptanol, 5:1) and 30 µL of 2 % SDS in PBS 
were added to the beads (~150 µL beads for 3 mg of lysate). The beads were boiled for 10 min, spun 
at 3,000 ×g for 5 min and the supernatant was loaded on a gel (NuPAGENovex 10 % Bis-Tris Gel, 
1.5 mm thick). Proteins were stained with Instant Blue (Expedeon) for 30 min, and the gel was cut in 
7 portions. The gel pieces were kept frozen in 50 mM TEAB before digest.  
In-gel reduction, alkylation and digestion were performed by the University of Leicester Proteomics 
Facility, the raw data files were obtained for each LC-MS/MS acquisition. 
For in-gel reduction, alkylation and digest, the following protocol was used: each slice was destained 
using 200 mM TEAB/20 % acetonitrile, followed by reduction (10 mM dithiothreitol) at 60 °C for 
30 minutes, alkylation (100 mM iodoacetamide) at room temperature for 30 minutes in the dark and 
enzymatic digestion (0.1 µg sequencing grade modified porcine trypsin) overnight at 37 °C. The liquid 
was evaporated to dryness and resuspended using 20 µL of a 10 fmol/µL yeast alcohol 
dehydrogenase tryptic digest standard (Waters, UK). 
8.3.7 LC-MS/MS runs.  
8.3.7.1 Proteomics facility, University of Leicester 
LC-MS/MS was carried out using an RSLCnano HPLC system (Dionex, UK) and an LTQ-Orbitrap-Velos 
mass spectrometer (Thermo Scientific). Samples were loaded at high flow rate onto a reverse-phase 
trap column (0.3 mm i.d. x 1 mm), containing 5 μm C18 300 Å Acclaim PepMap media (Dionex) 
maintained at a temperature of 37 °C. The loading buffer was 0.1 % formic acid / 0.05 % 
trifluoroacetic acid in water. Peptides were eluted from the trap column at a flow rate of 0.3 µl/min 
and through a reverse-phase capillary column (75 μm i.d. x 250 mm) containing Symmetry C18 100 Å 
media (Waters, UK) that was manufactured in-house using a high pressure packing device (Proxeon 
Biosystems, Denmark). The output from the column was sprayed directly into the nanospray ion 
source of an LTQ-Orbitrap-Velos mass spectrometer set to acquire a single microscan FTMS scan 
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event at 60000 resolution over the m/z range 350-1250 Da in positive ion mode. Accurate calibration 
of the FTMS scan was achieved using a background ion lock mass for polydimethylcyclosiloxane 
(445.120025 Da). Subsequently up to 10 data dependent HCD MS/MS were triggered from the FTMS 
scan and performed in the LTQ-Velos ion-trap. The isolation width was 2.0 Da, normalized collision 
energy 45.0, Activation time 0.1 ms. Dynamic exclusion was enabled. 
8.3.7.2 Proteomics facility, Imperial College London 
The analysis was performed using reverse phase Acclaim PepMap RSLC column 50 cm × 75 μm inner 
diameter (Thermo Fisher Scientific) using a 2 h acetonitrile gradient in 0.1 % formic acid at a flow 
rate of 250 nL/min.  Easy nLC-1000 was coupled to a Q Exactive mass spectrometer via an easy-spray 
source (all Thermo Fisher Scientific). The Q Exactive was operated in data-dependent mode with 
survey scans acquired at a resolution of 75 000 at m/z 200 (transient time 256 ms). Up to the top 10 
most abundant isotope patterns with charge +2 from the survey scan were selected with an isolation 
window of 3.0 m/z and fragmented by HCD with normalized collision energies of 25 W. The 
maximum ion injection times for the survey scan and the MS/MS scans (acquired with a resolution of 
17 500 at m/z 200) were 250 and 80 ms, respectively. The ion target value for MS was set to 106 and 
for MS/MS to 105.  
8.3.8 LC-MS/MS data analysis.  
8.3.8.1 Non quantitative proteomics (gel-based analysis) 
The .raw data file obtained from each LC-MS/MS acquisition was processed using the Raw2MSM 
application.365 The resulting .msm files were searched using Mascot (version 2.2.04, Matrix Science 
Ltd.)181 against a database containing the UniProtKB/Swissprot10 accessions for Homo sapiens. The 
peptide tolerance was set to 5 ppm and the MS/MS tolerance was set to 0.02 Da. Fixed 
modifications were set as carbamidomethyl cysteine with variable modifications as oxidised 
methionine. The enzyme was set to Trypsin/P and up to 3 missed cleavages were allowed. A decoy 
database search was performed. 
Data were further processed using Scaffold (version 3.6.02, Proteome Software).184 The Mascot .data 
files were imported and searched using X!Tandem (version 2006.9.15.4, The Global Proteome 
Machine Organization).183 PeptideProphet366 and ProteinProphet367 (Institute for Systems Biology) 
probability thresholds of 95 % were calculated from each of the Mascot and X!Tandem decoy 
searches and Scaffold was used to calculated an improved 95 % peptide and protein probability 
threshold based on the data from the two different search algorithms, resulting in a peptide false 
discovery rate of 0.0 %. Protein identifications were required to contain at least 2 peptides 
exceeding 95 % probability giving a calculated protein false discovery rate of 0.05 %. 
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8.3.8.2 Other proteomics data processing  
The data were processed with MaxQuant version 1.3.0.5, and the peptides were identified from the 
MS/MS spectra searched against the database using the Andromeda search engine. Cysteine 
carbamidomethylation was used as a fixed modification and methionine oxidation and protein 
N-terminal acetylation as variable modifications. For the identification, the false discovery rate was 
set to 0.01 for peptides, proteins and sites, the minimum peptide length allowed was five amino 
acids, and the minimum number of unique peptides allowed was set to one. Other parameters were 
used as pre-set in the software. “Unique and razor peptides” mode was selected; this calculates 
ratios from unique and razor peptides (Razor peptides are non-unique peptides assigned to the 
protein group with the most other peptides). Data were elaborated using Microsoft Office Excel 
2007, Perseus version 1.3.0.4, Origin 8.5 and GraFit 7.0.  
When the capture reagent AzKTB was used, N-terminal addition of 520.3373 (corresponding to the 
triazole adduct) was added as variable modification for the search.   
8.3.8.2.1 Label-free quantification 
Label free quantification experiments in MaxQuant was performed using the built in label free 
quantification algorithm,193,368 enabling the ‘Match between runs’ option (time window 2 minutes) 
and were analyzed with Perseus version 1.3.0.4. The experiment comprised 4 biological replicates 
treated with Myr and 4 biological replicates treated with YnC12. The label-free approach chosen was 
based on intensities of proteins calculated by MaxQuant from peak intensities and based on the ion 
currents carried by several peptides whose sequences match a specific protein to provide an 
approximation of abundance). 369. The replicates were grouped together.  
YnC12 protein group was filtered to require three valid values (three values out the four replicates) 
and in addition at least 2 peptides (unique and razor) were required. Label free intensities were 
logarithmised (base 2) and empty values were imputed with random numbers from a normal 
distribution, whose mean and standard deviation were chosen to best simulate low abundance 
values close to noise level ( imputation criteria: width 0.1 and down shift 1.8). A modified t-test with 
permutation based FDR statistics (Hubner et al., 2010; Tusher et al., 2001) was applied. We 
performed 250 permutations and required an FDR of 0.001. The parameter s0 was set to 1 to 
separate outliers from the background distribution. The data was further filtered by keeping only the 
proteins with an LFQ enrichment higher than 4. The LFQ enrichment was determine by first 
calculating the mean value of the LFQ intensities (non logarithmic values) of the Myr replicates and 
the mean value of the LFQ intensities (non logarithmic values) of the YnC12 replicates. The mean of 
YnC12 intensities was then divided by the mean of Myr intensities. 
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8.3.8.2.2 Spike-in SILAC.  
Ratios light/heavy (L/H, corresponding to amount of protein in the lysate with increasing amount of 
inhibitor/spike-in standard) found for each protein, each condition (concentration of inhibitor) and 
each replicate (four biological replicates 1 technical replicate in total) were determined by 
MaxQuant as explained above. The data was filtered to require three valid values per protein. For 
each replicate, the values were normalized to the sample with 0 µM of inhibitor, in order to 
normalize to the spike-in standard. The amount of protein in the 0 µM of inhibitor samples was then 
defined as 1. To compare the six conditions (six concentrations of inhibitor), an analysis of variance 
(ANOVA) was performed with Benjamini Hochberg correction at an FDR of 5 %. In addition, a 
hierarchical clustering was performed in Perseus. Proteins sensitive to NMT inhibition were 
clustered together while the insensitive proteins were in different clusters. The data was then 
manually inspected. In cell IC50 values were determined using the mean values of the ratios between 
the five replicates and determined using GraFit 7.0 (Erithacus Software Ltd, UK) by non-linear 
regression fitting (IC50 back corrected function).  
8.3.9 Bioinformatics 
Myristoylation predictions were carried out using two online predictors (Myr predictor 80 and 
Myristoylator 81. The Myr predictor shows three levels of confidence: R = reliable; T = twilight, 
N = not myristoylated and the Myristoylator has four levels of confidence: H = high probability, 
M = medium probability, L = low probability, N = not myristoylated. Four levels of Myristoylation 
confidence were defined by combining the results of the 2 predictors: N = not myristoylated, 
P = probable, L= low, M = medium, H =high. For example, if one protein had the probability R (Myr 
predictor) and H (Myristoylator), we reported this protein with a high probability to be myristoylated 
(H). If one protein had the probability R (Myr predictor) and M (Myristoylator), we reported this 
protein with a medium probability to be myristoylated (M). 
In the present study, proteins were described as palmitoylated when they were identified as 
palmitoylated in at least one proteomics experiments as reported by Wilson et al. 173(+: found in 
1 study, ++: found in 2 studies; +++: found in 3 studies; ++++: found in 4 studies) 173; or reported as 
palmitoylated in the UniProtKB/Swiss-Prot database (indicated as u in the dataset). GPI-anchored 
proteins are reported as found in the UniProtKB/Swiss-Prot database. 
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Appendix A: List of electronic files 
 
Website address to download the Scaffold viewer to open proteomics data files: 
http://www.proteomesoftware.com/Proteome_software_prod_Scaffold.html 
 
File name File 
type(s)  
Section Description 
Non 
quantitative_ 
AzKTB 
Scaffold 4.2 HeLa metabolic labelling with YnC12 or DMSO as a control 
(AzKTB, no quantification). 
Gel based 
analysis 
Scaffold 4.3 HeLa metabolic labelling with YnC12 (AzTB, no 
quantification). The gel was cut in 7 portions. 
Label free 
quantification 
Excel 4.4 HeLa metabolic labelling with YnC12 or Myr as a control 
(AzTB, 4 biological replicates, label-free quantification). 
Heavy label 
incorporation 
Excel + 
Scaffold 
4.5 Whole cell lysate from HeLa grown in the heavy media 
(R10K8) were analysed by LC-MS/MS to determine the 
average percentage of heavy label incorporation in 
proteins. 
Double SILAC 
inhibitor  
Excel 4.5 HeLa metabolic labelling with YnC12, in the presence or 
not of IMP366 (5 µM (AzTB, biological triplicate, spike-in 
SILAC quantification). 
Spike-in 
inhibitor 
Excel 4.6 HeLa metabolic labelling with YnC12, in the presence 
IMP366 (0-5 µM, 6 concentrations) (AzTB, 5 replicates, 
spike-in (heavy) SILAC quantification, Lysate:spike-in 2:1).  
Base Excel 4.7.1 HeLa metabolic labelling with YnC12, followed by base 
treatment with NaOH (AzTB, two biological replicates, 
spike-in SILAC quantification). 
Turnover Excel 5.3 Study of the turnover rate for the 74 NMT substrates 
identified with high confidence in Chapter 4. 
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Appendix B: Sequences of ∆HsNMT1 and ∆HsNMT2 
Sequence alignments of ∆HsNMT1 and ∆HsNMT2 using the program ClustalOmega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). 
The consensus is le following: * identical residues; : conserved substitutions;. semi-conserved substitutions; 
no sign:no match.  
 
∆HsNMT1 and ∆HsNMT2 were stored in the following buffer: 125 mM NaCl, 10 mM Tris-HCl pH 8.5, 
1 mM EGTA, 1 mM EDTA, 25% glycerol. 
∆HsNMT1          MGSSHHHHHHSSGLEVLFQGPHMEEASKRSYQFWDTQPVPKLGEVVNTHGPVEPDKDNIR  
∆HsNMT2          MGSSHHHHHHSSGLEVLFQGPHMDEAAKHRYQFWDTQPVPKLDEVITSHGAIEPDKDNVR  
                 ***********************:**:*: ************ **:.:** :******:* 
 
∆HsNMT1          QEPYTLPQGFTWDALDLGDRGVLKELYTLLNENYVEDDDNMFRFDYSPEFLLWALRPPGW  
∆HsNMT2          QEPYSLPQGFMWDTLDLSDAEVLKELYTLLNENYVEDDDNMFRFDYSPEFLLWALRPPGW 
                 ****:***** **:***.*  *************************************** 
 
∆HsNMT1          LPQWHCGVRVVSSRKLVGFISAIPANIHIYDTEKKMVEINFLCVHKKLRSKRVAPVLIRE 
∆HsNMT2          LLQWHCGVRVSSNKKLVGFISAIPANIRIYDSVKKMVEINFLCVHKKLRSKRVAPVLIRE 
                 * ******** *.:*************:***: *************************** 
 
∆HsNMT1          ITRRVHLEGIFQAVYTAGVVLPKPVGTCRYWHRSLNPRKLIEVKFSHLSRNMTMQRTMKL 
∆HsNMT2          ITRRVNLEGIFQAVYTAGVVLPKPIATCRYWHRSLNPKKLVEVKFSHLSRNMTLQRTMKL 
                 *****.******************:.***********:**:************:****** 
 
∆HsNMT1          YRLPETPKTAGLRPMETKDIPVVHQLLTRYLKQFHLTPVMSQEEVEHWFYPQENIIDTFV 
∆HsNMT2          YRLPDVTKTSGLRPMEPKDIKSVRELINTYLKQFHLAPVMDEEEVAHWFLPREHIIDTFV 
                 ****:. **:****** ***  *::*:. *******:***.:*** *** *:*.****** 
 
∆HsNMT1          VENANGEVTDFLSFYTLPSTIMNHPTHKSLKAAYSFYNVHTQTPLLDLMSDALVLAKMKG 
∆HsNMT2          VESPNGKLTDFLSFYTLPSTVMHHPAHKSLKAAYSFYNIHTETPLLDLMSDALILAKSKG 
                 **. **::************:*.**:************:**:***********:*** ** 
 
∆HsNMT1          FDVFNALDLMENKTFLEKLKFGIGDGNLQYYLYNWKCPSMGAEKVGLVLQ 
∆HsNMT2          FDVFNALDLMENKTFLEKLKFGIGDGNLQYYLYNWRCPGTDSEKVGLVLQ 
                 ***********************************:**.  :******** 
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Appendix C: TC50 inhibitor IMP-653/654/655 
Figure C1: YnC12 tagging assay and TC50 evaluation for inhibitors IMP653/654/655 (Section 3.3.2). 
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Appendix D: YnC12 labelling assay - non specific HsNMT 
inhibitor 
?? Figure D1: YnC12 tagging assay (Section 3.4.1). 
?? Figure D2: YnC12 tagging assay (Section 3.4.2). 
Figure D1: YnC12 tagging assay (Section 3.4.1). 
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Figure D2: YnC12 tagging assay (Section 3.4.2). 
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Appendix E: Best in-house HsNMT inhibitors 
?? Figure E1: CPM assay for the best in-house HsNMT inhibitors (Section 3.4.3). 
?? Figure E2: MTS assay results for the best in-house HsNMT inhibitors (Section 3.4.3). 
?? Figure E3: YnC12 tagging experiment for the best in-house HsNMT inhibitors (Section 3.4.3). 
Figure E1: CPM assay for the best in-house HsNMT inhibitors. 
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Figure E2: MTS assay results for the best in-house HsNMT inhibitors. 
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Figure E3: YnC12 tagging experiment for the best in-house HsNMT inhibitors 
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Appendix F: Previous studies of co-translationally 
N-myristoylated proteins  
 
Table F1: Previous studies of co-translationally N-myristoylated proteins expressed in HeLa cells. Proteins with an N-
terminal MG motif were experimentally shown to be N-myristoylated using a cell-free system or E. coli expression system 
(CF), a non native protein in eukaryotic cells (NN) or the native proteins in eukaryotic cells (Nat). Proteins identified by 
chemical proteomics (CP) are also reported.173,224 Only proteins expressed in HeLa are reported in this table.207 A column 
indicates if the proteins have been predicted to be N-myristoylated by online predictors (Myr predictor (MP): R= Reliable; 
T= twilight, N= No. Myristoylator (Myrist): H= high probability; M= medium probability; L= low probability; N= not 
myristoylated). A column shows if the protein is palmitoylated (+: found in 1 study, ++: found in 2 studies; +++: found in 3 
studies; ++++: found in 4 studies;173 u: reported as palmitoylated in the UniProtKB/Swiss-Prot database). A column 
indicates if the proteins have been detected in non quantitative proteomics experiments in Jurkat T-cell.173,224 
 
Method Protein name Gene name Protein IDs Ref Palm MP Myrist CP 
Nat 
Annexin XIII ANXA13 P27216 228  R H  
Brain acid soluble protein 1 BASP1 P80723 161  R H  
Golgi-associated plant pathogenesis-
related protein 1 GLIPR2 Q9H4G4 229  R H  
MARCKS MARCKS P29966 105  R H  
cAMP dependent protein kinase 
alpha subunit PRKACA P17612 209  R H +
173 
Tyrosine protein kinase Src SRC P12931 204
 
+ R H  
NN 
ABL1 ABL1 P00519 370  T N  
A-kinase anchor protein 12 AKAP12 Q02952 371  R H  
A-kinase anchor protein 7  AKAP7 O43687 372 u R H  
ADP ribosylation factor 1  ARF1 P84077 373
 
++ T H +
173,2
24 
ADP ribosylation factor 6 ARF6 P62330 374  R H  
ADP-ribosylation factor-like 5B ARL5B Q96KC2 375  N M  
Cyclin-Y CCNY Q8ND76 376 +++ R H  
Coiled-coil-helix-coiled-coil-helix 
domain-containing protein 3, 
mitochondrial 
CHCHD3 Q9NX63 
279
 
+ R H +
173,2
24 
Charged multivesicular body protein 
6 CHMP6 Q96FZ7 377  N H +
173 
Calcium and integrin-binding protein 1  CIB1 Q99828 378
  R H  
NADH cytochrome b5 reductase 3 CYB5R3 P00387 379 ++ R H +173 
Sphingolipid delta(4)-desaturase 
DES1 DEGS1 O15121 380  T H  
Dual specificity protein phosphatase 
22 DUSP22 Q9NRW4 381  N H  
Formin-like protein 1 FMNL1 O95466 382  T N  
Fibroblast growth factor receptor 
substrate 2 FRS2 FRS2 Q8WU20 383  R H  
Fibroblast growth factor receptor 
substrate 3 FRS3 FRS3 O43559 383  R H  
Tyrosine protein kinase Fyn FYN P06241 384
 
u; 
++ R H  
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Guanine nucleotide-binding protein 
G(i) subunit alpha-1  GNAI1 P63096 385 
u; 
++ R H  
Guanine nucleotide-binding protein 
G(i) subunit alpha-2  GNAI2 P04899 385
 
u; 
+++
+ 
R H +173 
Guanine nucleotide-binding protein 
G(k) subunit alpha GNAI3 P08754 385
 
u; 
+++
+ 
R H +
173,2
24 
Guanine nucleotide-binding protein 
G(o) subunit alpha GNAO1 P09471 385 
u; 
+++ R H +
173 
Guanine nucleotide-binding protein 
G(z) subunit alpha GNAZ P19086 385 u; + R H  
Neuron-specific calcium-binding 
protein hippocalcin HPCA P84074 160  R H  
Hippocalcin-like protein 1 HPCAL1 P37235 386  R H  
LanC-like protein 2 LANCL2 Q9NS86 387  N H  
Tyrosine protein kinase Lyn LYN P07948 388 u; + R H  
Mitochondrial peptide methionine 
sulfoxide reductase MSRA Q9UJ68 389  R H  
Neuronal calcium sensor 1 NCS1 P62166 160  R H  
Nephrocystin-3 NPHP3 Q7Z494 390  T H  
cGMP-dependent 3',5'-cyclic 
phosphodiesterase  PDE2A O00408 219 u N N  
Protein phosphatase 1A  PPM1A P35813 391  N H  
Protein phosphatase 1B PPM1B O75688 391  N M  
Calcineurin B type 1 PPP3R1 P63098 392  R H  
5'-AMP-activated protein kinase 
subunit beta-1 PRKAB1 Q9Y478 393  N N  
5'-AMP-activated protein kinase 
subunit beta-2 PRKAB2 O43741 394  N M  
26S protease regulatory subunit 4 PSMC1 P62191 208
 
++ R H +
173,2
24 
Raftlin RFTN1 Q14699 395 u N H  
Protein-associating with the carboxyl-
terminal domain of ezrin (PACE-1) SCYL3 Q8IZE3 396  R H  
TIR domain-containing adapter 
molecule 2 TICAM2 Q86XR7 397  R M  
Tyrosine protein kinase Yes YES1 P07946 398 u; ++ R H  
E3 ubiquitin-protein ligase ZNRF2 ZNRF2 Q8NHG8 399  R M  
 
 
 
 
 
 
 
 
 
 
CF 
Apoptosis-inducing factor 2 AIFM2 Q9BRQ8 230  R H  
Ankyrin repeat and IBR domain-
containing protein 1  ANKIB1 Q9P2G1 230  R H  
ADP ribosylation factor-like protein 1  ARL1 P40616 400
  R H  
BTB/POZ domain-containing protein 
7 BTBD7 Q9P203 230  R M  
Calcineurin B homologous protein 1 CHP1 Q99653 401  R H  
Calcineurin B homologous protein 3  CHP3 Q96BS2 231
  R H  
Dixin DIXDC1 Q155Q3 230  T N  
Dymeclin DYM Q7RTS9 402  R H  
Formin-like protein 2 FMNL2 Q96PY5 230  T H  
 Formin-like protein 3 (FMNL3) FMNL3 Q8IVF7 
230
  N M  
 
Golgi reassembly-stacking protein 1 
(GRASP65) GORASP1 Q9BQQ3 403  R H  
Uncharacterized protein KIAA1522 KIAA1522 Q9P206 230  N H  
TLD domain-containing protein 
KIAA1609 KIAA1609 Q6P9B6 230  T H  
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Protein Lunapark LNP Q9C0E8 230  T H  
E3 Ubiquitin-protein ligase MGRN1 MGRN1 O60291 230  R H  
NADH dehydrogenase [ubiquinone] 1 
beta subcomplex subunit 7 NDUFB7 P17568 404  N L  
Phosphoinositide 3-kinase regulatory 
subunit 4 (PIK3R4) PIK3R4 Q99570 405  T H  
 RING finger protein 11 RNF11 Q9Y3C5 
230
  N M  
 
Serine incorporator 1 SERINC1 Q9NRX5 230
  N N  
Tescalin   TESC Q96BS2 231
  R H  
 
Zinc finger ZZ-type and EF-hand 
domain-containing protein 1 ZZEF1 O43149 230
 
 R H  
CP 
ADP ribosylation factor 4 ARF4 P18085 
173,22
4 + R H + 
ADP ribosylation factor 5 ARF5 P84085 
173,22
4 + R H + 
CD81 antigen CD81 P60033 173 +++ N N + 
CD82 antigen CD82 P27701 173 + N N + 
ATP-dependent RNA helicase A DHX9 Q08211 173 + N N + 
Elongation factor 1-alpha 1 EEF1A1 P68104 173 ++ N N + 
Protein FAM49b FAM49B Q9NUQ9 
173,22
4  N M + 
Glyceraldehyde-3-phosphate 
dehydrogenase GAPDH P04406 173 +++ N M + 
Golgi reassembly-stacking protein 2  GORASP2 Q9H8Y8 224 u R H + 
High mobility group protein B1 HMGB1 P09429 173 + N N + 
Cation-independent mannose-6-
phosphate receptor IGF2R P11717 173 ++ N N + 
Ragulator complex protein LAMTOR1  LAMTOR1 Q6IAA8 173
  T H + 
MARCKS related protein  MARCKSL1 P49006 
173,22
4 + R H + 
Protein phosphatase 1G PPM1G O15355 
173,22
4 + R M + 
60S ribosomal protein L10 RPL10 P27635 173 ++ N N + 
40S ribosomal protein S8 RPS8 P62241 173 + N N + 
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Appendix G: Previous studies of post-translationally 
N-myristoylated proteins  
 
Table G1: Previously reported post-translationally N-myristoylated proteins. Proteins were shown to be 
post0translationally myristoylated at a native (Nat) or non native (NN) level in eukaryotic cells.  A column 
indicates if the new N-terminal sequences have been predicted to be N-myristoylated by online predictors: 
Myr predictor:  R= Reliable; T= twilight, N= No. Myristoylator: H= high probability; M= medium probability; L= 
low probability; N= not myristoylated). A column indicates if the protein is palmitoylated (+: found in 1 study, 
++: found in 2 studies; +++: found in 3 studies; ++++: found in 4 studies;173 u: reported as palmitoylated in the 
UniProtKB/Swiss-Prot database). 
 
 
 
Method Protein name Gene name 
Protein 
IDs 
Refer
ence 
New N-terminal 
sequence  
Cleavage 
site MP Myrist 
Nat BH3-interacting domain death agonist BID P55957 
8
 
GNRSSHSRLGRIE
ADSESQEDIIRNIA
RHL 
G60 R H 
NN 
Actin, cytoplasmic 1 
(β-actin) ACTB P60709 
406
 
GQVITIGNERFRC
PEALFQPSFLGME
SCGI 
G245 T N 
Cell division control 
protein 6 homolog CDC6 Q99741 
90
 
GNRMTLSQEGAQ
DSFPLQQKILVCS
LMLLI 
G443 R H 
Gelsolin GSN P06396 406 
GLGLSYLSSHIAN
VERVPFDAATLHT
STAM 
G404 R M 
Huntingtin HTT P42858 90 
GTQASSPISDSSQ
TTTEGPDSAVTPS
DSSE 
G551 R H 
Microtubule-actin 
cross-linking factor 1, 
isoforms 1/2/3/5 
MACF1 Q9UPN3 90 
GSDASQLLHQAE
VAQQEFLEVKQR
VNSGCV 
G5087 R H 
Induced myeloid 
leukemia cell 
differentiation protein  
MCL1 Q07820 90 
GSLPSTPPPAEEE
EDELYRQSLEIISR
YLR 
G158 R H 
p21-activated protein 
kinase-2 PAK2 Q13177 
407
 
GAAKSLDKQKKKT
KMTDEEIMEKLRTI
VSI 
G213 T H 
YTH domain family 
protein 2 
YTHD
F2 Q9Y5A9 
90
 
GNGVGQSQAGSG
STPSEPHPVLEKL
RSINN 
G367 R M 
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Appendix H: Proteomics data 
 Figure H1: Example of the sequence coverage and two assigned spectra (MS/MS) for the protein 
MARCKS for the proteomics experiment presented in Section 4.2. 
 Table H1: List of putative N-myristoylated proteins identified in Section 4.2.1. (non quantitative 
proteomic analysis with AzKTB).  
 Table H2: List of modified peptides identified with AzKTB (Section 4.2.2). 
 Table H3: Gel-based analysis. List of putative NMT substrates identified in the non-quantitative 
gel-based proteomics experiment. (Section 4.3). 
 Table H4: Label-free quantification (LFQ) of proteins enriched in the YnC12 treated samples 
compared to sample treated with myristic acid (Section 4.4.). 
 Table H5: Double SILAC +/- IMP366 (5 µM) (Section 4.5.). 
 Table H6: Spike-in SILAC with inhibitor IMP366 (High confidence NMT substrates) (Section 4.6). 
 Table H7: Spike-in SILAC with inhibitor IMP366 (Low confidence NMT substrates) (Section 4.6). 
 Table H8: Spike-in SILAC with inhibitor IMP366 (Protein with no MG motif sensitive to the NMT 
inhibitor IMP366) (Section 4.6). 
 Table H9: Base-treatment (Section 4.7). 
 Table H10: List of NMT substrates identified with high confidence in the current study 
(Section 4.8). 
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Figure H1: Example of the sequence coverage and two assigned spectra (MS/MS) for the protein MARCKS for 
the proteomics experiment presented in Section  4.2. a) Example of the sequence coverage and peptides 
identified for MARCKS resulting from YnC12 tagging of the N-terminus of MARCKS following capture with 
AzKTB and enrichment by pull down, followed by on-bead digestion with trypsin. Identified peptides are 
highlighted in yellow. Modified residues (with AzKTB) are highlighted in green. b) Example of MS/MS spectrum 
for peptide from the sequence (K)AAEEPSKVEEK(K), with assigned peaks. c) Example of MS/MS spectrum of a 
peptide modified with AzKTB, with the sequence (M)gAQFSK(T). All figures are directly exported from Scaffold. 
 
 Sequence coverage for MARCKS (59%) 
 
 Spectrum for peptide: (K)AAEEPSKVEEK(K)  
 
 Spectrum for the modified peptide: (M)gAQFSK(T) 
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Table H1: Non quantitative proteomics to compare DMSO and YnC12 treated HeLa cells captured with AzKTB. 
Spectral counts and unique peptides are given for YnC12 and DMSO samples. Only proteins bearing an N-terminal MG motif are reported in this table. The minimum protein identification 
probability was set to 99.9% and the minimum peptide identification probability was set to 95%. Four proteins were detected in both samples and are indicated with #. A column (“modified 
peptide”) shows if the modified peptide was detected (see Table H2) and a column (“PR”) indicates if the protein was previously reported to be N-myristoylated (see Table F1 in Appendix F) in 
a cell-free system (CF), using the native (Nat) or non native (NN) protein or using chemical proteomics experiments (CP) . For prediction of N-myristoylation, two online bioinformatics tools, 
the MYR predictor (MP) and Myristoylator (Myrist) were used. The MYR predictor shows three levels of confidence: R= reliable; T= twilight, N= not myristoylated and the Myristoylator has 
four levels of confidence: H= high probability, M=medium probability, L= low probability, N= not myristoylated. A column indicates if the protein is palmitoylated (+: found in 1 study, ++: 
found in 2 studies; +++: found in 3 studies; ++++: found in 4 studies; u: reported as palmitoylated in the UniProtKB/Swiss-Prot database) and a column shows if the protein is a GPI anchored 
protein (as reported in the UniProtKB/Swiss-Prot database).173 A star indicates if an N-terminal peptide was detected with no modification from the capture reagent AzKTB.  
   
Spectral 
count 
Unique 
peptide 
     
Protein name Gene name Protein ID YnC12 DMSO YnC12 DMSO PR MP Myrist GPI Palm 
Modified 
peptide 
ADP-ribosylation factor 1 ARF1 P84077 247 0 17 0 NN T H No ++ + 
Niban-like protein 1 FAM129B Q96TA1 130 0 35 0 
 
N H No 
 
+ 
26S protease regulatory subunit 4 PSMC1 P62191 112 0 28 0 NN R H No ++ + 
Protein phosphatase 1G PPM1G O15355 69 0 22 0 CP R M No + + 
cAMP-dependent protein kinase catalytic subunit alpha PRKACA P17612 69 0 20 0 N R H No - + 
NADH-cytochrome b5 reductase 3 CYB5R3 P00387 66 0 19 0 NN R H No ++ + 
Guanine nucleotide-binding protein G(i) subunit alpha-2 GNAI2 P04899 62 0 21 0 NN R H No  ++++ + 
Protein FAM49B FAM49B Q9NUQ9 59 0 18 0 CP N M No +++  
Annexin A2 # ANXA2 P07355 57 22 23 14 
 
N N No +  
Glyceraldehyde-3-phosphate dehydrogenase # GAPDH E7EUT4  49 14 12 6 CP N N No +++  
ADP-ribosylation factor 4 ARF4 P18085 49 0 7 0 CP R H No + + 
L-lactate dehydrogenase A chain # LDHA P00338 39 23 20 12 
 
N N No ++  
Cytochrome c-type heme lyase  HCCS P53701 38 0 16 0 
 
R L No 
 
+ 
ARF-like protein 1 ARL1 P40616 38 0 11 0 CF R H No 
 
 
A-kinase anchor protein 12 AKAP12 Q02952 37 0 22 0 NN R H No 
 
+ 
Apoptosis-inducing factor 2 AIFM2 Q9BRQ8 37 0 16 0 CF R H No 
 
 
Cytospin-B SPECC1 Q5M775 36 0 24 0 
 
T N No 
 
+ 
Elongation factor 1-alpha 1 # EEF1A1 P68104 35 25 14 11 CP N N No ++  
Hippocalcin-like protein 1 HPCAL1 P37235 34 0 13 0 NN R H No -  
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Golgi reassembly-stacking protein2 GORASP2 Q9H8Y8 33 0 15 0 CP R H No u + 
Guanine nucleotide-binding protein G(k) subunit alpha GNAI3 P08754 29 0 8 0 NN R H No 
u 
++++  
Flotillin-2 FLOT2 Q14254 28 0 18 0 
 
N N No +++  
ADP-ribosylation factor 6 ARF6 P62330 28 0 6 0 NN R H No 
 
 
Ragulator complex protein LAMTOR1 LAMTOR1 Q6IAA8 26 0 9 0 
 
T H No 
 
 
Myristoylated alanine-rich C-kinase substrate MARCKS P29966 25 0 12 0 N R H No 
 
+ 
Brain acid soluble protein 1 BASP1 P80723 23 0 11 0 N R H No 
 
 
Phosphoinositide 3-kinase regulatory subunit 4 PIK3R4 Q99570 23 0 18 0 CF T H No 
 
 
Tyrosine-protein kinase Yes YES1 P07947 22 0 11 0 NN R H No u ++  
Guanine nucleotide-binding protein G(i) subunit alpha-1 GNAI1 P63096 22 0 8 0 NN R H No u ++ + 
Protein phosphatase 1A PPM1A P35813 21 0 12 0 CF N H No 
 
+ 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex assembly factor 4 NDUFAF4 Q9P032 21 0 10 0 
 
N N No 
 
+ 
Tescalcin TESC Q96BS2 20 0 9 0 CF R H No 
 
+ 
Calcineurin B homologous protein1 CHP Q99653 20 0 8 0 
 
R H No -  
Coiled-coil-helix-coiled-coil-helix domain-containing 
protein 3, mitochondrial CHCHD3 C9JRZ6  20 0 8 0 NN R H No + + 
ADP-ribosylation factor 5 ARF5 P84085 19 0 8 0 CP R H No + + 
Prostaglandin F2 receptor negative regulator PTGFRN Q9P2B2 17 0 13 0 
 
N M No ++  
Calcineurin subunit B type 1 PPP3R1 D3YTA9 17 0 7 0 NN R H No - + 
Choline transporter-like protein 1 SLC44A1 Q8WWI5 16 0 7 0 
 
R M No +  
Mitochondrial import receptor subunit TOM40 homolog TOMM40 O96008 16 0 6 0 
 
T L No +  
Lysosome membrane protein 2 SCARB2 Q14108 15 0 6 0 
 
N N No ++  
MOSC domain-containing protein 1, mitochondrial MARC1 Q5VT66  14 0 9 0 
 
N H No 
 
+ 
Protein XRP2 RP2 O75695 14 0 7 0 
 
R H No u + 
Nucleolar protein 3 NOL3 O60936 14 0 5 0 
 
T L No 
 
+ 
Sphingolipid delta(4)-desaturase DEGS1 O15121 14 0 5 0 NN T H No 
 
 
Tyrosine-protein kinase Lyn LYN P07948 13 0 7 0 NN R H No u +  
cAMP-dependent protein kinase catalytic subunit beta PRKACB C9JK39  13 0 5 0 
 
R H No 
 
+ 
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Protein phosphatase 1B PPM1B O75688 12 0 7 0 
 
N M No 
 
 
High mobility group protein B1;Putative high mobility 
group protein B1-like 1 HMGB1 P09429  11 0 8 0 CP N N No +  
Leucine-rich repeat-containing protein 57 LRRC57 H3BSW0  11 0 7 0 
 
N N No 
 
+ 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 7 NDUFB7 P17568 11 0 6 0 CF N L No 
 
+ 
5-AMP-activated protein kinase subunit beta-1 PRKAB1 Q9Y478 11 0 5 0 NN N N No 
 
+ 
Plasminogen receptor (KT) PLGRKT Q9HBL7 11 0 5 0 
 
N H No 
 
+ 
Proto-oncogene tyrosine-protein kinase Src SRC P12931 11 0 5 0 N R H No +  
Protein lunapark LNP Q9C0E8 11 0 7 0 CF T H No 
 
+ 
CD81 antigen  CD81 A6NMH8  10 0 3 0 CP N N No +++  
Charged multivesicular body protein 6 CHMP6 Q96FZ7 10 0 6 0 NN R H No 
 
+ 
Monocarboxylate transporter 4 SLC16A3 O15427 9 0 5 0 
 
N N No +  
Serine incorporator 1 SERINC1 Q9NRX5 9 0 4 0 CF N N No -  
Surfeit locus protein 4 * SURF4 O15260 9 0 4 0 
 
N N No ++  
Golgi-associated plant pathogenesis-related protein 1 GLIPR2 Q9H4G4 9 0 7 0 N R H No -  
Golgi integral membrane protein 4 GOLIM4 O00461 9 0 5 0 
 
R H No +  
Neuronal calcium sensor 1 NCS1 P62166 9 0 5 0 NN R H No 
 
 
MOSC domain-containing protein 2, mitochondrial MARC2 Q969Z3 8 0 6 0 
 
N N No 
 
+ 
MARCKS-related protein MARCKSL1 P49006 8 0 4 0 
 
R H No + + 
TLD domain-containing protein KIAA1609 KIAA1609 F5GWS3  8 0 5 0 CF T H No 
 
 
6-phosphogluconate dehydrogenase, decarboxylating PGD B4DQJ8 7 0 6 0 
 
N N No -  
Opioid growth factor receptor-like protein 1 OGFRL1 Q5TC84 7 0 5 0 
 
N M No 
 
+ 
Choline transporter-like protein 2 * SLC44A2 E7ETY3 7 0 4 0 
 
N N No -  
Transforming acidic coiled-coil-containing protein 1 TACC1 G8JLK4  7 0 5 0 
 
R H No 
 
 
Dymeclin DYM Q7RTS9 7 0 4 0 
 
R H No 
 
 
Formin-like protein 2 FMNL2 Q96PY5 7 0 6 0 CF T H No 
 
 
Cell surface glycoprotein MUC18 MCAM P43121 6 0 6 0 
 
N N No +  
Scavenger receptor class B member 1 SCARB1 F8W8N0 6 0 3 0 
 
N N No +  
Serine incorporator 3 SERINC3 Q13530 6 0 3 0 
 
N N No 
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Guanine nucleotide-binding protein G(o) subunit alpha GNAO1 P09471-2 6 0 3 0 NN R H No u;+++  
Transmembrane protein 106B TMEM106B Q9NUM4 6 0 5 0 
 
T H No 
 
 
Trafficking protein particle complex subunit 3 * TRAPPC3 A6NDN0 5 0 4 0 
 
N N No u;++  
Glucose-6-phosphate 1-dehydrogenase G6PD P11413-3 5 0 4 0 
 
N H No 
 
 
ARF-like protein 5B ARL5B Q96KC2 5 0 3 0 NN N L No 
 
+ 
Elongation factor 1-beta EEF1B2 P24534 5 0 3 0 
 
N N No 
 
 
High affinity cationic amino acid transporter 1 SLC7A1 P30825 4 0 3 0 
 
N N No ++  
Platelet-activating factor acetylhydrolase 2, 
cytoplasmic PAFAH2 Q99487 4 0 3 0 
 
N N No 
 
 
RING finger protein 141 RNF141 E9PLX2 4 0 3 0 
 
N H No 
 
+ 
E3 ubiquitin-protein ligase ZNRF2 ZNRF2 Q8NHG8 4 0 4 0 
 
R M No 
 
 
Coiled-coil-helix-coiled-coil-helix domain-containing 
protein 6, mitochondrial CHCHD6 Q9BRQ6 4 0 3 0 
 
R H No 
 
+ 
Protein Niban FAM129A Q9BZQ8 4 0 3 0 
 
R H No 
 
 
Protein-L-isoaspartate O-methyltransferase domain-
containing protein 1 PCMTD1 Q96MG8 4 0 3 0 
 
R H No 
 
+ 
Formin-like protein 1 FMNL1 O95466 4 0 3 0 NN T N No 
 
 
Mitochondrial peptide methionine sulfoxide reductase MSRA Q9UJ68-5 3 0 3 0 NN R H No 
 
 
Zinc transporter 1 SLC30A1 Q9Y6M5 3 0 2 0 
 
N N No 
 
 
Cell division cycle-associated protein 3 CDCA3 Q99618 3 0 3 0 
 
R H No 
 
 
CD151 antigen CD151 E9PL82 2 0 2 0 
 
N N No +  
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Table H2: List of modified peptides identified with AzKTB. (Peptide identification probability >95%).UP = unique peptide. 
The modified peptides were listed in the Scaffold file (“non quantitative_AzKTB”, Appendix A) and the raw data file was 
re-analysed with MaxQuant. The number of unique peptides is indicated. Two unique peptides can be identified when the 
N-terminal peptide had a missed-cleavage site. 
 Identified Proteins  Gene name 
Accession 
Number 
Scaffold 
UP 
MaxQuant 
UP 
1 A-kinase anchor protein 12  AKAP12 Q02952 1 1 
2 ADP-ribosylation factor 1  ARF1 P84077 1 1 
3 ADP-ribosylation factor 3 ARF3 P61204   1 
4 ADP-ribosylation factor 4  ARF4 P18085 1 1 
5 ADP-ribosylation factor 5  ARF5 P84085 1 1 
6 ADP-ribosylation factor-like protein 5B ARL5B Q96KC2   1 
7 Coiled-coil-helix-coiled-coil-helix domain-containing protein 3, mitochondrial CHCHD3 C9JRZ6   1 
8 Coiled-coil-helix-coiled-coil-helix domain-containing protein 6, mitochondrial CHCHD6 Q9BRQ6   1 
9 Charged multivesicular body protein 6 CHMP6 Q96FZ7   1 
10 NADH-cytochrome b5 reductase 3 CYB5R3 P00387 1   
11 Niban-like protein 1 FAM129B Q96TA1 2 2 
12 Guanine nucleotide-binding protein G(i) subunit alpha-1 GNAI1 P63096 1 1 
13 Guanine nucleotide-binding protein G(i) subunit alpha-2  GNAI2 P04899 1   
14 Golgi reassembly-stacking protein 2  GORASP2 Q9H8Y8 1 1 
15 Cytochrome c-type heme lyase HCCS P53701 1 1 
16 Protein Lunapark LNP B7ZLA8 1 1 
17 Leucine-rich repeat-containing protein 57 (Fragment) LRRC57 H3BSW0   1 
18 MOSC domain-containing protein 1, mitochondrial MARC1 Q5VT66   1 
19 MOSC domain-containing protein 2, mitochondrial MARC2 Q969Z3 1 1 
20 Myristoylated alanine-rich C-kinase substrate MARCKS P29966 1 1 
21 MARCKS-related protein MARCKSL1 P49006   1 
22 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 4  NDUFAF4 Q9P032 1 1 
23 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7  NDUFB7 P17568 1 1 
24 Nucleolar protein 3 NOL3 B4DFL0   1 
25 Opioid growth factor receptor-like protein 1  OGFRL1 Q5TC84 1 1 
26 Protein-L-isoaspartate O-methyltransferase domain-containing protein 1 PCMTD1 Q96MG8   1 
27 Plasminogen receptor (KT)  PLGRKT Q9HBL7 1 1 
28 Protein phosphatase 1A  PPM1A P35813 1 1 
29 Protein phosphatase 1G  PPM1G O15355 1 1 
30 Calcineurin subunit B type 1  PPP3R1 D3YTA9 1 1 
31 5'-AMP-activated protein kinase subunit beta-1 PRKAB1 Q9Y478     
32 cAMP-dependent protein kinase catalytic subunit alpha  PRKACA P17612 1 1 
33 cAMP-dependent protein kinase catalytic subunit beta PRKACB B2RB89   1 
34 26S protease regulatory subunit 4  PSMC1 P62191 2 2 
35 RING finger protein 141 (Fragment)  RNF141 E9PLX2 1   
36 Protein XRP2 RP2 O75695   1 
37 Isoform 4 of Cytospin-B  SPECC1 Q5M775-4 1 1 
38 Calcineurin B homologous protein 3  TESC Q96BS2 1   
39 Mitochondrial import receptor subunit TOM40B TOMM40L Q969M   1 
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Table H3: Gel-based analysis. YnC12 tagged proteins were captured with AzTB, enriched and separated on a SDS-PAGE gel. The gel was cut in 7 portions. Only proteins possessing an 
N-terminal MG motif and identified with more than 2 unique peptides are shown in this table. The number of unique peptides and the number of assigned spectra are displayed for each 
protein and each gel slice. For each protein, the highest number on unique peptide or spectral count was shaded in dark blue, indicating that this protein was mainly found in this gel slice. 
When the same protein was also detected in other slices, it was shaded in light blue. 
    Number of unique peptides Number of assigned spectra (spectral counts) 
 Identified Proteins 
Accession 
Number 
Molecular 
Weight 
>90 
kDa 
60-
90 
kDa 
40-
60 
kDa 
30-
40 
kDa 
23-
30 
kDa 
18-
23 
kDa 
<18 
kDa 
>90 
kDa 
60-
90 
kDa 
40-
60 
kDa 
30-
40 
kDa 
23-
30 
kDa 
18-
23 
kDa 
<18 
kDa 
1 Prostaglandin F2 receptor negative regulator Q9P2B2 83 kDa 2 0 0 0 0 0 0 2 0 0 0 0 0 0 
2 Niban-like protein 1 Q96TA1 84 kDa 15 18 4 0 0 0 0 31 38 4 0 0 0 0 
3 Tyrosine-protein kinase Yes P07947 61 kDa 0 9 2 0 0 0 0 0 13 2 0 0 0 0 
4 Lysosome membrane protein 2 Q14108 54 kDa 0 8 0 0 0 0 0 0 15 0 0 0 0 0 
5 Proto-oncogene tyrosine-protein kinase Src P12931 60 kDa 0 5 0 0 0 0 0 0 7 0 0 0 0 0 
6 Choline transporter-like protein 2 E7ETY3 80 kDa 0 3 0 0 0 0 0 0 3 0 0 0 0 0 
7 Dymeclin Q7RTS9 76 kDa 0 3 0 0 0 0 0 0 5 0 0 0 0 0 
8 
Polypeptide N-
acetylgalactosaminyltransferase 1 
soluble form # 
F5GY99 57 kDa 0 3 0 0 0 0 0 0 3 0 0 0 0 0 
9 Scavenger receptor class B member 1 Q8WTV0 54 kDa 0 3 0 0 0 0 0 0 4 0 0 0 0 0 
10 Protein phosphatase 1G O15355 59 kDa 0 17 4 0 0 0 0 0 56 4 0 0 0 0 
11 Myristoylated alanine-rich C-kinase substrate P29966 32 kDa 0 10 5 2 0 0 0 0 24 6 3 0 0 0 
12 26S protease regulatory subunit 4 P62191 49 kDa 0 5 33 3 0 0 0 0 7 117 5 0 0 0 
13 Serine incorporator 1 Q9NRX5 50 kDa 0 2 3 0 0 0 0 0 2 4 0 0 0 0 
14 Choline transporter-like protein 1 Q8WWI5 73 kDa 0 0 4 0 0 0 0 0 0 5 0 0 0 0 
15 Isoform 2 of Tyrosine-protein kinase Lyn P07948-2 56 kDa 0 0 3 0 0 0 0 0 0 3 0 0 0 0 
16 Flotillin-2 Q14254 53 kDa 0 0 18 0 0 0 0 0 0 42 0 0 0 0 
17 Protein Lunapark Q9C0E8 51 kDa 0 0 6 0 0 0 0 0 0 12 0 0 0 0 
18 Brain acid soluble protein 1 P80723 23 kDa 0 0 14 0 0 0 0 0 0 47 0 0 0 0 
19 CD82 antigen # P27701 30 kDa 0 0 3 0 0 0 0 0 0 4 0 0 0 0 
20 Protein phosphatase 1B O75688 33 kDa 0 0 4 0 0 0 0 0 0 5 0 0 0 0 
21 
Protein-L-isoaspartate O-
methyltransferase domain-containing 
protein 1 
Q96MG8 32 kDa 0 0 2 0 0 0 0 0 0 3 0 0 0 0 
22 Protein phosphatase 1A P35813 42 kDa 0 0 11 0 0 0 0 0 0 21 0 0 0 0 
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23 TLD domain-containing protein KIAA1609 Q6P9B6 21 kDa 0 0 2 0 0 0 0 0 0 2 0 0 0 0 
24 cAMP-dependent protein kinase catalytic subunit alpha P17612 41 kDa 0 0 20 18 0 0 0 0 0 55 39 0 0 0 
25 cAMP-dependent protein kinase catalytic subunit beta C9JK39 41 kDa 0 0 5 4 0 0 0 0 0 9 8 0 0 0 
26 Transmembrane protein 106B Q9NUM4 31 kDa 0 0 3 2 0 0 0 0 0 4 2 0 0 0 
27 Elongation factor 1-alpha 1 # P68104 50 kDa 0 0 6 2 0 0 0 0 0 12 4 0 0 0 
28 Golgi reassembly-stacking protein 2 Q9H8Y8 42 kDa 0 0 7 0 3 0 0 0 0 10 0 4 0 0 
29 Monocarboxylate transporter 4 O15427 49 kDa 0 0 0 5 0 0 0 0 0 0 9 0 0 0 
30 Guanine nucleotide-binding protein G(i) subunit alpha-2 P04899 40 kDa 0 2 7 19 3 0 0 0 3 11 81 4 0 0 
31 Guanine nucleotide-binding protein G(k) subunit alpha P08754 41 kDa 0 0 2 7 0 0 0 0 0 3 21 0 0 0 
32 Guanine nucleotide-binding protein G(i) subunit alpha-1 P63096 40 kDa 0 0 0 7 0 0 0 0 0 0 14 0 0 0 
33 Isoform Alpha-2 of Guanine nucleotide-binding protein G(o) subunit alpha P09471-2 40 kDa 0 0 0 7 0 0 0 0 0 0 18 0 0 0 
34 Protein XRP2 O75695 40 kDa 0 0 0 10 0 0 0 0 0 0 21 0 0 0 
35 MOSC domain-containing protein 1, mitochondrial Q5VT66 38 kDa 0 0 0 4 0 0 0 0 0 0 5 0 0 0 
36 MOSC domain-containing protein 2, mitochondrial Q969Z3 38 kDa 0 0 0 6 0 0 0 0 0 0 11 0 0 0 
37 Sphingolipid delta(4)-desaturase O15121 38 kDa 0 0 0 5 0 0 0 0 0 0 11 0 0 0 
38 Apoptosis-inducing factor 2 Q9BRQ8 37 kDa 0 0 0 2 0 0 0 0 0 0 2 0 0 0 
39 Isoform 3 of L-lactate dehydrogenase A chain # P003383 37 kDa 0 0 0 12 0 0 0 0 0 0 20 0 0 0 
40 Protein FAM49B Q9NUQ9 37 kDa 0 0 0 14 0 0 0 0 0 0 59 0 0 0 
41 NADH-cytochrome b5 reductase 3 P00387 34 kDa 0 0 0 18 6 2 0 0 0 0 76 9 3 0 
42 Glyceraldehyde-3-phosphate dehydrogenase # P04406 32 kDa 0 0 0 9 0 0 0 0 0 0 23 0 0 0 
43 MARCKS-related protein P49006 20 kDa 0 0 0 3 0 0 0 0 0 0 6 0 0 0 
44 Cytochrome c-type heme lyase P53701 31 kDa 0 0 0 14 3 0 0 0 0 0 31 3 0 0 
45 Nucleolar protein 3 H3BM67 29 kDa 0 0 0 0 5 0 0 0 0 0 0 8 0 0 
46 Coiled-coil-helix-coiled-coil-helix domain -containing protein 3, mitochondrial Q9NX63 27 kDa 0 0 0 0 15 0 0 0 0 0 0 45 0 0 
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47 Ubiquitin domain-containing protein 2 # Q8WUN7 26 kDa 0 0 0 0 3 0 0 0 0 0 0 3 0 0 
48 E3 ubiquitin-protein ligase ZNRF2 Q8NHG8 24 kDa 0 0 0 0 3 0 0 0 0 0 0 6 0 0 
49 Charged multivesicular body protein 6 Q96FZ7 23 kDa 0 0 0 0 5 0 0 0 0 0 0 7 0 0 
50 Calcineurin B homologous protein 1 Q99653 22 kDa 0 0 0 0 3 0 0 0 0 0 0 4 0 0 
51 Calcineurin B homologous protein 3 Q96BS2 22 kDa 0 0 0 0 6 0 0 0 0 0 0 13 0 0 
52 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 4 Q9P032 20 kDa 0 0 0 0 8 0 0 0 0 0 0 15 0 0 
53 Neuronal calcium sensor 1 P62166 22 kDa 0 0 0 0 5 0 0 0 0 0 0 9 0 0 
54 RING finger protein 141 Q8WVD5 20 kDa 0 0 0 0 2 0 0 0 0 0 0 2 0 0 
55 Leucine-rich repeat-containing protein 57 Q8N9N7 16 kDa 0 0 0 0 8 0 0 0 0 0 0 15 0 0 
56 CD151 antigen P48509 15 kDa 0 0 0 0 2 0 0 0 0 0 0 4 0 0 
57 Hippocalcin-like protein 1 P37235 22 kDa 0 0 0 0 11 6 0 0 0 0 0 30 11 0 
58 CD81 antigen P60033 30 kDa 0 0 0 0 0 3 2 0 0 0 0 0 10 2 
59 ADP-ribosylation factor 1 P84077 21 kDa 2 3 3 4 5 13 6 2 6 4 8 6 211 28 
60 ADP-ribosylation factor 4 P18085 21 kDa 0 0 2 2 2 6 3 0 0 2 4 2 52 4 
61 ADP-ribosylation factor 5 P84085 21 kDa 0 0 0 0 0 6 0 0 0 0 0 0 25 0 
62 Calcineurin subunit B type 1 P63098 21 kDa 0 0 0 0 0 4 0 0 0 0 0 0 8 0 
63 ADP-ribosylation factor 6 P62330 20 kDa 0 0 0 0 0 4 0 0 0 0 0 0 20 0 
64 ADP-ribosylation factor-like protein 1 P40616 19 kDa 0 0 0 0 0 7 0 0 0 0 0 0 25 0 
65 Caveolin-2 # P51636 18 kDa 0 0 0 0 0 2 0 0 0 0 0 0 4 0 
66 Ragulator complex protein LAMTOR1 Q6IAA8 18 kDa 0 0 0 0 0 9 0 0 0 0 0 0 24 0 
67 Golgi-associated plant pathogenesis-related protein 1 Q9H4G4 17 kDa 0 0 0 0 0 5 0 0 0 0 0 0 10 0 
68 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7 P17568 16 kDa 0 0 0 0 0 6 0 0 0 0 0 0 13 0 
69 Plasminogen receptor (KT) Q9HBL7 17 kDa 0 0 0 0 0 0 5 0 0 0 0 0 0 14 
70 Trafficking protein particle complex 3, isoform CRA_a A6NDN0 15 kDa 0 0 0 0 0 0 3 0 0 0 0 0 0 4 
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Table H4: Label-free quantification (LFQ) of proteins enriched in the YnC12 treated samples (four biological replicates) 
compared to the sample treated with myristic acid (four biological replicates). The LFQ intensity, number of "razor + 
unique peptides", MS/MS count, sequence coverage are displayed for each replicate (n = 4 biological replicates) for the 
Myr and YnC12 samples. The enrichment (LFQ) was determined for each protein detected (LFQ = (intensity YnC12)/ 
(intensity Myr)). Only proteins significantly enriched in the YnC12 experiments (modified t-test FDR = 0.001 and s0 = 1; and 
with LFQ > 4) are reported. For prediction of N-myristoylation, two online bioinformatic tools, the MYR predictor (MP) and 
Myristoylator (Myrist) were used. The Myr predictor shows three levels of confidence: R= reliable; T= twilight, N= not 
myristoylated and the Myristoylator has four levels of confidence: H= high probability, M=medium probability, L= low 
probability, N= not myristoylated. When unique peptides could not be assigned to one unique protein but were assigned 
instead to a group of 2 or more proteins by MaxQuant, proteins were grouped and had the same number of unique 
peptides. A column indicates if the protein is palmitoylated (+: found in 1 study, ++: found in 2 studies; +++: found in 3 
studies; ++++: found in 4 studies; u: reported as palmitoylated in the UniProtKB/Swiss-Prot database) and a column 
indicates if the protein is a GPI anchored protein).  A column “PR” indicates if the protein was previously experimentally 
shown to be myristoylated (see Appendix F). Two columns show the results of the t-test (log2 values). 
 
Gene names Protein IDs LFQ  MG MP 
My
rist GPI Palm    PR 
 -Log 
t-test  
t-test 
diff 
1 ARF3;ARF1 P61204 2501 + T H No +;++ NN 6.74 11.48 
2 MARCKS P29966 1603.6 + R H No 
 
Nat 7.68 10.65 
3 PSMC1 P62191 1281.7 + R H No ++ NN 9.85 10.32 
4 CHCHD3 Q9NX63 821.73 + R H No + NN 10.87 9.68 
5 PRKACA P17612 738.85 + R H No 
 
Nat 7.74 9.50 
6 FAM49B Q9NUQ9 685.68 + N M No +++ CP 9.21 9.43 
7 MARCKSL1 P49006 683.48 + R H No + 
 
8.92 9.40 
8 ARF4 P18085 585.35 + R H No + CP 5.61 9.43 
9 BASP1 P80723 519.18 + R H No 
 
Nat 4.57 9.75 
10 HPCAL1;HPCA P37235 504.25 + R H No 
 
NN 8.81 8.99 
11 ARL1 P40616 499.1 + R H No 
 
CF 9.93 8.96 
12 PPM1G O15355 475.33 + R M No + CP 6.18 9.00 
13 TESC Q96BS2 458.36 + R H No 
  
5.57 8.65 
14 CYB5R3 P00387 456.54 + R H No ++ NN 4.64 9.47 
15 BST2 Q10589 413.73 
   
Pot 
  
9.60 8.70 
16 ARF6 P62330 389.49 + R H No 
 
NN 7.72 8.60 
17 ARF5 P84085 310.2 + R H No + CP 7.38 8.26 
18 HCCS P53701 305.91 + R L No 
  
7.74 8.23 
19 GORASP2 Q9H8Y8 265.35 + R H No u CP 9.48 8.06 
20 TFRC P02786 260.7 
   
No ++++ 
 
6.44 8.14 
21 NOL3 O60936 248.48 + T L No 
  
8.04 7.95 
22 PTGFRN Q9P2B2 226.35 + N M No ++ 
 
8.45 7.84 
23 GNAI3 P08754 221.47 + R H No u,++++ NN 3.92 8.41 
24 LAMTOR1 Q6IAA8 215.27 + T H No 
  
9.68 7.75 
25 SCAMP3 O14828 207.68 
   
No +++ 
 
6.91 7.64 
26 PLP2 Q04941 205.86 
   
No 
  
9.24 7.68 
27 PRKACB P22694 201.6 + R H No 
  
7.51 7.63 
28 FAM129B Q96TA1 195.94 + N H No 
  
3.74 8.46 
29 STOM P27105 190.15 
   
No +++ 
 
6.98 7.51 
30 AIFM2 Q9BRQ8 189.28 + R H No 
 
CF 8.40 7.58 
31 CKAP4 Q07065 183.94 
   
No +++ 
 
4.77 7.69 
32 DAGLB Q8NCG7 176.72 
   
No ++ 
 
6.46 7.39 
33 CD81 P60033 151.79 + N N No +++ CP 8.77 7.25 
34 CD44 P16070 149.09 
   
No + 
 
6.95 7.20 
35 LRRC57 Q8N9N7 143.79 + N N No 
  
9.74 7.17 
36 CD9 P21926 127.57 
   
No + 
 
7.12 6.98 
37 CD151 P48509 117.27 + N N No + 
 
6.06 6.79 
38 HADHB P55084 116.11 
   
No ++ 
 
7.68 6.85 
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39 CD59 P13987 114.87 + N N Yes 
  
6.34 6.76 
40 PPM1A P35813 114.72 + N H No 
 
NN 6.80 6.83 
41 SCARB2 Q14108 110.77 + N N No ++ 
 
6.78 6.74 
42 GNAI1 P63096 102.8 + R H No u, ++ NN 6.26 6.60 
43 CANX P27824 101.57 
   
No ++++ 
 
3.55 7.17 
44 DEGS1 O15121 99.003 + T H No 
 
NN 6.22 6.54 
45 SLC44A1 Q8WWI5 94.386 + R M No + 
 
5.62 6.44 
46 CHP Q99653 92.794 + R H No 
  
8.11 6.52 
47 CD55 P08174 92.22 
   
Yes 
  
6.39 6.48 
48 GLIPR2 Q9H4G4 92.204 + R H No 
 
Nat 4.90 6.29 
49 NDUFAF4 Q9P032 90.66 + N N No 
  
8.06 6.51 
50 SERINC1 Q9NRX5 85.129 + N N No 
 
CF 9.42 6.42 
51 FLOT2 Q14254 83.061 + N N No +++ 
 
3.58 7.05 
52 B4GALT1 P15291 82.705 
   
No 
  
7.24 6.38 
53 LYN P07948 79.472 + R H No u,  + NN 11.3 6.31 
54 TMX1 Q9H3N1 78.322 
   
No 
  
7.49 6.32 
55 GALNT2 Q10471 77.047 
   
No 
  
4.33 6.53 
56 LNP Q9C0E8 76.456 + T H No 
 
CF 6.98 6.22 
57 SRC P12931 71.615 + R H No + Nat 7.40 6.17 
58 CACNA2D1 P54289 71.325 
   
No 
  
6.94 6.19 
59 PSMC2 P35998 69.677 
   
No 
  
7.08 6.16 
60 GNAO1 P09471 67.517 + R H No u, +++ NN 8.99 6.08 
61 CD63 P08962 67.312 
   
No + 
 
6.34 6.02 
62 SERPINB6 P35237 65.566 
   
No 
  
8.75 6.04 
63 TMEM106B Q9NUM4 64.766 + T H No 
  
5.97 5.95 
64 SLC16A3 O15427 60.287 + N N No + 
 
7.42 5.90 
65 HLA-C P30508 59.972 
   
No + 
 
7.99 5.89 
66 SLC1A5 Q15758 59.873 
   
No +++ 
 
6.03 5.83 
67 YES1 P07947 59.637 + R H No u,++ NN 7.38 5.89 
68 ZNRF2 Q8NHG8 57.127 + R M No 
 
NN 8.96 5.84 
69 
IFITM3;IFITM2;IFIT
M1 Q01628 53.911 
   
No u 
 
7.10 5.75 
70 TSPAN3 O60637 49.346 + N N No 
  
7.27 5.64 
71 SPECC1 Q5M775 49.141 + T N No 
  
7.38 5.62 
72 TRIM23 P36406 47.786 
   
No 
  
7.67 5.59 
73 NPC1 O15118 46.981 
   
No 
  
6.19 5.56 
74 BAG5 Q9UL15 45.283 
   
No 
  
7.13 5.50 
75 SLC44A2 Q8IWA5 44.272 + N N No 
  
9.16 5.47 
76 PI4K2A Q9BTU6 44.059 
   
No +++ 
 
7.73 5.46 
77 MRPS36 P82909 43.587 
   
No 
  
9.06 5.44 
78 CHMP6 Q96FZ7 43.551 + R H No 
 
NN 6.31 5.43 
79 MARC2 Q969Z3 43.325 + N N No 
  
6.19 5.40 
80 NDUFB7 P17568 42.742 + N L No 
 
CF 7.06 5.44 
81 PIK3R4 Q99570 41.708 + T H No 
 
CF 5.56 5.30 
82 PPM1B O75688 40.525 + N M No 
 
NN 8.00 5.34 
83 PPP3R1 P63098 40.09 + R H No 
 
NN 4.99 5.21 
84 
UBC;UBB;RPS27A;
UBA52 P0CG48 39.625 
   
No + 
 
3.95 5.60 
85 MCAM P43121 39.458 + N N No + 
 
7.20 5.29 
86 RTN4 Q9NQC3 39.277 
   
No + 
 
9.05 5.30 
87 SLC25A3 Q00325 36.966 
   
No + 
 
7.57 5.21 
88 GNAI2 P04899 35.459 + R H No u,++++ NN 2.65 7.33 
89 CDCA3 Q99618 35.177 + R H No 
  
7.12 5.16 
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90 PLGRKT Q9HBL7 35.007 + N H No 
  
7.33 5.14 
91 CD276 Q5ZPR3 34.764 
   
No 
  
6.43 5.08 
92 SLC30A1 Q9Y6M5 34.261 + N N No 
  
7.60 5.09 
93 HLA-B P30464 33.246 
   
No + 
 
7.40 5.05 
94 CAV1 Q03135 33.014 
   
No + 
 
1.91 3.73 
95 RP2 O75695 31.418 + R H No u 
 
7.15 5.00 
96 TTYH3 Q9C0H2 29.556 
   
No ++ 
 
6.32 4.90 
97 MARC1 Q5VT66 28.937 + N H No 
  
6.49 4.83 
98 RNF141 Q8WVD5 28.772 + N H No 
  
6.81 4.87 
99 FMNL1 O95466 28.016 + T N No 
 
NN 5.60 4.73 
100 PRKAB2 O43741 27.522 + N M No 
 
NN 7.13 4.78 
101 SCARB1 Q8WTV0 26.723 + N N No + 
 
6.88 4.75 
102 SLC7A1 P30825 26.56 + N N No ++ 
 
6.10 4.74 
103 PLSCR1 O15162 25.97 
   
No + 
 
8.28 4.69 
104 PODXL O00592 25.747 
   
No 
  
9.61 4.69 
105 PPIB P23284 25.715 
   
No + 
 
7.41 4.68 
106 GOLIM4 O00461 25.293 + R H No + 
 
7.04 4.64 
107 TRAPPC3 O43617 25.221 
   
No u, ++ 
 
5.55 4.59 
108 RFTN1 Q14699 24.979 + N H No u NN 6.53 4.65 
109 LRRC15 Q8TF66 24.217 
   
No 
  
6.49 4.60 
110 PRKAB1 Q9Y478 24.185 + N N No 
 
NN 8.94 4.60 
111 IMMT Q16891 23.956 
   
No 
  
1.72 9.07 
112 FAM129A Q9BZQ8 23.466 + R H No 
  
4.54 4.41 
113 PRDX6 P30041 23.363 
   
No + 
 
5.07 4.45 
114 RPL22 P35268 22.911 
   
No 
  
7.46 4.51 
115 KIAA1609 Q6P9B6 22.851 + T H No 
 
CF 7.37 4.50 
116 RHOB P62745 22.599 
   
No u, ++ 
 
6.19 4.50 
117 L1CAM P32004 22.31 
   
No + 
 
6.61 4.46 
118 SVIP Q8NHG7 21.587 + N N No 
  
6.74 4.44 
119 PRNP P04156 21.538 
   
Pot 
  
6.52 4.42 
120 VAMP3 Q15836 21.275 
   
No +++ 
 
5.32 4.35 
121 SLC38A1 Q9H2H9 21.263 
   
No 
  
7.30 4.39 
122 DNAJC5 Q9H3Z4 20.957 
   
No u, ++ 
 
5.27 4.30 
123 SLC35B2 Q8TB61 20.848 
   
No + 
 
6.31 4.34 
124 GALNT1 Q10472 20.812 
   
No 
  
6.92 4.36 
125 SLC38A2 Q96QD8 20.808 
   
No ++ 
 
6.67 4.40 
126 DIRC2 Q96SL1 20.087 + R H No 
  
5.04 4.28 
127 PROCR Q9UNN8 20.06 
   
No + 
 
7.18 4.32 
128 ACAA2 P42765 19.769 
   
No 
  
6.05 4.33 
129 ECE1 P42892 19.706 
   
No + 
 
5.01 4.22 
130 SERINC3 Q13530 19.18 + N N No 
  
7.49 4.25 
131 RPL27 P61353 18.794 + N N No 
  
4.94 4.15 
132 NCS1 P62166 18.717 + R H No 
 
NN 5.90 4.22 
133 SCAMP2 O15127 18.14 
   
No ++ 
 
5.79 4.20 
134 CXADR P78310 17.716 
   
No + 
 
6.10 4.17 
135 PCMTD1 Q96MG8 17.647 + R H No 
  
6.48 4.13 
136 SNAP23 O00161 17.352 
   
No u,++++ 
 
5.07 4.14 
137 PPP3CA;PPP3CB Q08209 17.211 
   
No 
  
4.03 3.91 
138 VASN Q6EMK4 17.201 
   
No 
  
6.83 4.09 
139 LOH12CR1 Q969J3 17.05 + R H No 
  
6.46 4.09 
140 MAN1B1 Q9UKM7 16.516 
   
No 
  
6.97 4.04 
141 MGRN1 O60291 15.804 + R H No 
 
CF 7.30 4.00 
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142 AKAP12 Q02952 15.708 + R H No 
 
NN 1.70 5.90 
143 VDAC3 Q9Y277 15.665 
   
No + 
 
1.69 3.30 
144 MYOF Q9NZM1 15.063 
   
No 
  
4.40 3.80 
145 CDK1;CDK3;CDK2 P06493 14.845 + T N No 
  
3.90 3.75 
146 MDH1 P40925 14.44 
   
No 
  
4.76 3.79 
147 RAP2B;RAP2A P61225 13.863 
   
No +++ 
 
3.71 3.57 
148 GLG1 Q92896 13.76 
   
No + 
 
6.18 3.78 
149 SCYL3 Q8IZE3 13.714 + R H No 
 
NN 5.88 3.80 
150 VDAC2 P45880 13.701 
   
No + 
 
3.05 4.08 
151 GNB2 P62879 13.586 
   
No 
  
2.81 4.31 
152 PTTG1IP P53801 13.434 
   
No ++ 
 
4.12 3.71 
153 DYM Q7RTS9 12.679 + R H No 
  
3.11 3.76 
154 TACC1 O75410 12.653 + R H No 
  
4.85 3.59 
155 TSPAN4 O14817 12.63 
   
No 
  
6.12 3.63 
156 HADHA P40939 12.613 
   
No + 
 
6.80 3.66 
157 CLN3 Q13286 12.577 + T L No 
  
5.77 3.66 
158 CPD O75976 12.465 
   
No u, + 
 
4.72 3.57 
159 LANCL1 O43813 12.315 
   
No 
  
2.23 3.39 
160 OGFRL1 Q5TC84 12.003 + N M No 
  
3.67 3.38 
161 RPS25 P62851 11.671 
   
No 
  
6.69 3.53 
162 ERGIC3 Q9Y282 11.457 
   
No ++ 
 
5.92 3.53 
163 RPLP1 P05386 11.248 
   
No 
  
5.78 3.46 
164 PRAF2 O60831 10.966 
   
No + 
 
4.99 3.41 
165 DCAF11 Q8TEB1 10.815 + R H No 
  
5.78 3.44 
166 PAFAH2 Q99487 10.601 + N N No 
  
3.70 3.27 
167 STX12 Q86Y82 10.41 
   
No ++ 
 
5.73 3.38 
168 PSMD2 Q13200 10.356 
   
No 
  
3.26 3.55 
169 PSMA4 P25789 10.275 
   
No 
  
7.46 3.36 
170 VAMP7 P51809 10.202 
   
No + 
 
4.83 3.30 
171 C9orf169 A8MQ03 9.8717 
   
No 
  
4.03 3.21 
172 TMEM33 P57088 9.7879 
   
No 
  
4.76 3.25 
173 MGST3 O14880 9.7201 
   
No u 
 
6.98 3.29 
174 DSG2 Q14126 9.6557 
   
No + 
 
6.57 3.28 
175 TMX3 Q96JJ7 9.5515 
   
No 
  
4.52 3.17 
176 AUP1 Q9Y679 9.5354 
   
No ++ 
 
4.30 3.15 
177 HMGB1;HMGB1P1 P09429 9.3374 + N N No + CP 7.49 3.22 
178 PSMC3 P17980 9.3372 
   
No 
  
5.41 3.23 
179 PRSS21 Q9Y6M0 9.3314 + N N Pot 
  
5.45 3.22 
180 CPM P14384 9.0922 
   
Yes 
  
3.96 3.08 
181 NR3C1 P04150 8.961 
   
No 
  
3.53 3.00 
182 GPRC5A Q8NFJ5 8.9461 
   
No + 
 
5.87 3.16 
183 SURF4 O15260 8.8303 + N N No ++ 
 
5.91 3.14 
184 FMNL2 Q96PY5 8.7937 + T H No 
 
CF 2.16 2.62 
185 EFR3A Q14156 8.6959 
   
No + 
 
3.54 2.94 
186 STBD1 O95210 8.5918 + R M No 
  
5.19 3.08 
187 ALPL P05186 8.5734 
   
Pot 
  
2.11 5.07 
188 PCBP1 Q15365 8.4485 
   
No 
  
5.12 3.04 
189 BET1 O15155 8.4325 
   
No 
  
4.46 3.04 
190 TNFRSF10A O00220 8.2996 
   
No + 
 
4.08 2.99 
191 TECR Q9NZ01 8.2742 
   
No 
  
5.87 3.04 
192 ABL1 P00519 8.1698 + T N No 
 
NN 6.07 3.03 
193 TMEM106C Q9BVX2 8.1675 + R H No 
  
5.79 3.04 
311 
 
194 TMEM168 Q9H0V1 7.9593 
   
No 
  
3.02 2.83 
195 SLC25A6;SLC25A4 P12236 7.8278 + N N No +;++ 
 
2.94 3.18 
196 BCAP31 P51572 7.8258 + R H No 
  
3.12 3.05 
197 STX7 O15400 7.606 
   
No + 
 
4.57 2.91 
198 SEC61A1;SEC61A2 P61619 7.1242 + N N No 
  
5.54 2.83 
199 PVR P15151 7.1049 
   
No + 
 
6.31 2.82 
200 STEAP3 Q658P3 7.0554 
   
No 
  
5.85 2.80 
201 ITFG3 Q9H0X4 6.8538 
   
No 
  
6.83 2.77 
202 LNPEP Q9UIQ6 6.7584 
   
No +++ 
 
5.08 2.75 
203 FLOT1 O75955 6.7251 
   
No +++ 
 
1.79 3.32 
204 GORASP1 Q9BQQ3 6.6296 + R H No 
 
CF 6.83 2.73 
205 TSPAN6 O43657 6.57 
   
No 
  
5.38 2.73 
206 TMEM87A Q8NBN3 6.5601 
   
No 
  
5.10 2.68 
207 TRIP13 Q15645 6.555 
   
No 
  
4.25 2.67 
208 DDX39B;DDX39A Q13838 6.2994 
   
No 
  
5.16 2.66 
209 ANXA3 P12429 6.2925 
   
No 
  
3.82 2.58 
210 RAC2;RAC3;RAC1 P63000 6.2826 
   
No + 
 
4.55 2.68 
211 RPS20 P60866 6.0767 
   
No 
  
5.91 2.61 
212 SLCO3A1 Q9UIG8 6.0159 
   
No 
  
2.81 2.44 
213 KPNA2 P52292 5.9795 
   
No 
  
5.63 2.58 
214 RSPRY1 Q96DX4 5.9041 
   
No + 
 
4.03 2.51 
215 ABCB6 Q9NP58 5.8786 
   
No + 
 
4.53 2.56 
216 MTHFD1 P11586 5.8068 
   
No 
  
5.32 2.53 
217 CLPTM1L Q96KA5 5.7583 
   
No 
  
4.49 2.49 
218 TMEM63A O94886 5.7193 
   
No 
  
7.69 2.52 
219 ATP5J2 P56134 5.6876 
   
No 
  
2.57 2.82 
220 PSMC5 P62195 5.685 
   
No 
  
1.50 3.20 
221 PSMC6 P62333 5.657 
   
No 
  
2.57 2.90 
222 PARK7 Q99497 5.6448 
   
No 
  
2.82 2.33 
223 
RAB1A;RAB1B;RAB
1C P62820 5.5197 
   
No ++ 
 
5.10 2.49 
224 REEP5 Q00765 5.4723 
   
No + 
 
5.34 2.47 
225 PHB P35232 5.4565 
   
No + 
 
4.96 2.43 
226 SLC7A5 Q01650 5.4407 
   
No 
  
2.48 2.76 
227 UQCRC1 P31930 5.3865 
   
No 
  
7.72 2.43 
228 SLC39A10 Q9ULF5 5.2962 
   
No 
  
5.22 2.41 
229 MFSD12 Q6NUT3 5.2725 + N N No 
  
4.24 2.37 
230 USMG5 Q96IX5 5.0891 
   
No 
  
5.20 2.34 
231 TUBA4A P68366 5.0747 
   
No 
  
2.14 2.90 
232 ANXA5 P08758 5.0419 
   
No 
  
3.19 2.25 
233 SPAG1 Q07617 5.0051 
   
No 
  
4.69 2.34 
234 ANKIB1 Q9P2G1 4.9239 + R H No 
 
CF 4.68 2.26 
235 FH P07954; 4.8268 
   
No 
  
3.32 2.19 
236 CLIC1 O0029 4.8073 
   
No ++ 
 
2.19 2.84 
237 ERGIC2 Q96RQ1 4.7548 
   
No + 
 
4.04 2.24 
238 ELOVL1 Q9BW60 4.64 
   
No + 
 
4.16 2.22 
239 ATP9A O75110 4.6329 
   
No 
  
4.46 2.22 
240 DYNC1I2 Q13409 4.5737 
   
No 
  
4.24 2.16 
241 SFT2D3 Q587I9 4.5694 
   
No 
  
3.54 2.15 
242 STX6 O43752 4.5311 
   
No +++ 
 
3.54 2.12 
243 GOLGA7 Q7Z5G4 4.521 
   
No u,  ++ 
 
3.89 2.13 
244 PCMTD2 Q9NV79 4.5019 + R H No 
  
4.86 2.14 
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245 ZDHHC6 Q9H6R6 4.4669 + N H No + 
 
5.39 2.17 
246 YARS P54577 4.4423 + N M No 
  
3.12 2.05 
247 ITGA3 P26006 4.378 + N N No 
  
4.97 2.14 
248 PTRH2 Q9Y3E5 4.336 
   
No ++ 
 
3.86 2.09 
249 OXCT1 P55809 4.3333 
   
No 
  
2.13 2.51 
250 TUBB6 Q9BUF5 4.3067 
   
No + 
 
4.26 2.10 
251 USP32 Q8NFA0 4.2938 + N H No 
  
4.50 2.08 
252 SLC25A5 P05141 4.2928 
   
No ++ 
 
7.05 2.11 
253 LMAN2 Q12907 4.2921 
   
No 
  
4.29 2.09 
254 VDAC1 P21796 4.2822 
   
No + 
 
1.87 3.04 
255 NEGR1 Q7Z3B1 4.2161 
   
Pot 
  
3.95 2.13 
256 MLEC Q14165 4.1772 
   
No 
  
4.90 2.09 
257 MTDH Q86UE4 4.0372 
   
No +++ 
 
5.87 2.02 
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Table H5: Double SILAC +/- IMP366 (5 µM). (n= 3 biological replicates). Heavy (R10K8) HeLa cells were treated with DMSO and light (R0K0) HeLa cells were treated with IMP366 (5 µM) (both 
labelled with YnC12). Samples were mixed in 1:1 ratio. Only proteins significantly depleted in the inhibitor-treated sample (FDR = 0.2; S0=0; side = right) and log2 median H/L ratios higher 
than 1 were kept. MG = proteins with a N-terminal MG motif. PR = previously reported (Appendix F). For prediction of N-myristoylation, two online bioinformatic tools, the MYR predictor 
(MP) and Myristoylator (Myrist) were used. The Myr predictor shows three levels of confidence: R= reliable; T= twilight, N= not myristoylated and the Myristoylator has four levels of 
confidence: H= high probability, M=medium probability, L= low probability, N= not myristoylated. When unique peptides could not be assigned to one unique protein but were assigned 
instead to a group of 2 or more proteins by MaxQuant, proteins were grouped and had the same number of unique peptides. LFQ = LFQ enrichment as determined in Table H4. A column 
indicates if the protein is palmitoylated (+: found in 1 study, ++: found in 2 studies; +++: found in 3 studies; ++++: found in 4 studies; u: reported as palmitoylated in the UniProtKB/Swiss-Prot 
database) and a column indicates if the protein is a GPI anchored protein). Two columns show the results of the t-test (log2 values). 
Protein names 
Gene 
names 
Majority 
protein 
IDs Median MG PR MP Myrist LFQ Palm GPI  
-log t-
test p 
value 
t-test 
difference 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex assembly factor 4 NDUFAF4 Q9P032 5.36 +   N N 90   No 4.23 5.39 
ADP-ribosylation factor-like protein 1 ARL1 P40616 4.84 + CF R H 499   No 2.01 4.84 
Calcineurin subunit B type 1 PPP3R1 P63098 4.79 + NN R H 40 - No 1.36 4.79 
cAMP-dependent protein kinase catalytic subunit 
alpha PRKACA P17612; 4.70 + Nat R H 738 - No 2.20 4.47 
Cytochrome c-type heme lyase HCCS P53701 4.58 +   R L 305   No 2.34 4.70 
Hippocalcin-like protein 1 HPCAL1 P37235 4.42 + NN R H 504 - No 2.86 4.60 
Protein FAM49B FAM49B Q9NUQ9 4.35 + CP N M 685 +++ No 2.77 4.36 
NADH-cytochrome b5 reductase 3 CYB5R3 P00387 4.32 + NN R H 456 ++ No 2.11 4.74 
26S protease regulatory subunit 4 PSMC1 P62191 4.29 + NN R H 128 ++ No 3.32 4.29 
Coiled-coil-helix-coiled-coil-helix domain-
containing protein 3, mitochondrial CHCHD3 Q9NX63 4.24 + NN R H 821 + No 3.96 4.22 
Brain acid soluble protein 1 BASP1 P80723 4.15 + Nat R H 519   No 3.76 4.09 
Proenkephalin-B;Alpha-neoendorphin;Beta-
neoendorphin PDYN P01213 4.13             No 3.39 4.21 
ADP-ribosylation factor 5 ARF5 P84085 4.12 + CP R H 310 + No 2.81 4.03 
MARCKS-related protein MARCKSL1 P49006 4.05 +   R H 683 + No 4.06 4.11 
Guanine nucleotide-binding protein G(k) subunit 
alpha GNAI3 P08754 3.82 + NN R H 221 
u 
++++ No 1.93 3.82 
Niban-like protein 1 FAM129B Q96TA1 3.79 +   N H 195   No 2.14 3.57 
Guanine nucleotide-binding protein G(i) subunit 
alpha-2 GNAI2 P04899 3.75 + NN R H 35 
u+++
+ No 2.38 3.77 
Ragulator complex protein LAMTOR1 LAMTOR1 Q6IAA8 3.63 +   T H 215   No 1.50 3.63 
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Protein phosphatase 1G PPM1G O15355 3.57 + CP R M 475 + No 3.91 3.63 
A-kinase anchor protein 12 AKAP12 Q02952 3.46 + NN R H 15   No 1.52 3.05 
ADP-ribosylation factor 4 ARF4 P18085 3.44 + CP R H 585 + No 3.45 3.45 
ADP-ribosylation factor 3;ADP-ribosylation factor 1 ARF3;ARF1 P61204 3.38 + NN T H 2501 +;++ No 2.90 3.27 
Leucine-rich repeat-containing protein 57 LRRC57 Q8N9N7 3.36 +   N N 143   No 1.57 3.36 
ADP-ribosylation factor 6 ARF6 P62330 3.34 + NN R H 389   No 1.57 3.34 
Bromodomain-containing protein 4;Bromodomain-
containing protein 3 BRD4;BRD3 O60885 3.30             No 1.71 3.30 
Guanine nucleotide-binding protein G(i) subunit 
alpha-1 GNAI1 P63096 3.29 + NN R H 102 u++ No 1.33 3.29 
Golgi reassembly-stacking protein 2 GORASP2 Q9H8Y8 3.23 + CP R H 265 u No 3.59 3.20 
Nucleolar protein 3 NOL3 O60936 3.11 +   T L 248   No 2.15 3.26 
Calcium-binding protein p22 CHP Q99653 2.94 +   R H 92 - No 2.26 3.26 
26S protease regulatory subunit 7 PSMC2 P35998 2.90         69 - No 1.68 2.90 
Nesprin-1 SYNE1 Q8NF91 2.88             No 1.47 2.88 
Myristoylated alanine-rich C-kinase substrate MARCKS P29966 2.63 + Nat R H 160   No 3.41 2.60 
E3 ubiquitin-protein ligase MGRN1 MGRN1 O60291 2.51 + CF R H 15   No 1.77 2.51 
Cysteine-rich and transmembrane domain-
containing protein 1 CYSTM1 Q9H1C7 1.76             No 1.16 1.76 
Tyrosine-protein kinase Yes YES1 P07947 1.71 + NN R H 59 u++ No 1.30 1.71 
Calnexin CANX P27824 1.66         101 ++++ No 2.39 1.55 
Transmembrane 4 L6 family member 1 TM4SF1 P30408 1.62             No 2.59 1.59 
Polypeptide N-acetylgalactosaminyltransferase 2 GALNT2 Q10471 1.48         77   No 2.28 1.37 
Coxsackievirus and adenovirus receptor CXADR P78310 1.35         17 u ++ No 1.24 1.58 
Podocalyxin PODXL O00592 1.34         25   No 1.50 1.34 
CD9 antigen CD9 P21926 1.21         127 + No 2.45 1.20 
CD59 glycoprotein CD59 P13987 1.20 +   N N 114   Yes 2.20 1.14 
Adenosylhomocysteinase AHCY P23526 1.10           - No 1.18 1.10 
Complement decay-accelerating factor CD55 P08174 1.06         92   Yes 1.44 0.95 
Secretory carrier-associated membrane protein 3 SCAMP3 O14828 1.06         207 +++ No 1.65 1.14 
 
315 
 
Table H6-8: Spike-in SILAC with inhibitor IMP366. Table H6: High confidence NMT substrates. Table H7: Low confidence NMT substrates. Table H8: Protein with no MG motif sensitive to 
the NMT inhibitor IMP366. (n = 5 replicates). Proteins are ordered by alphabetical order of gene names. The ratios of “lysate treated with inhibitor”/ "spike-in standard” (L/H = light/heavy) 
were determined for each unique +razor peptide detected. The same spike-in standard was used for each replicate, across the 6 samples with different concentrations of inhibitor. The ratios 
L/H were normalised to the 0 µM concentration sample for each replicate to allow the comparison between all the samples. When unique peptides could not be assigned to one unique 
protein but were assigned instead to a group of 2 or more proteins by MaxQuant, proteins were grouped. The number of “razor + unique peptide” and the ratio counts are indicated for each 
replicate and each concentration of inhibitor. The mean value is indicated for each inhibitor concentration, for each protein. The median, standard deviation, the number of “razor + unique” 
peptides, spectral counts and sequence coverage can be found in Appendix A (Spike-in inhibitor). The IC50 values, errors and slope factors were determined with GraFit 7.0 (back-corrected 
IC50) using the mean values for each concentration of inhibitor (N=4). Proteins sensitive to NMT inhibition dose dependently are classified as "N-myristoylated-high confidence". When the 
number of "razor + unique peptide" was low or when the dose-response was ambiguous (more than 30 % residual protein in the sample treated with the highest concentration of inhibitor), 
the proteins were classified as "N-myristoylated-low confidence". For each identified protein, myristoylation prediction (Myr predictor and Myristoylator), palmitoylation, GPI anchor, and LFQ 
ratio (see Table H4) are shown. When proteins were not sensitive to the NMT inhibitor, they were labelled "not N-myristoylated-high confidence". If the numbers of "razor + unique peptide" 
were low, the proteins were classified as "not N-myristoylated-low confidence". A column indicates if the protein has been detected before in a chemical proteomics experiments.173,224 
 
Table H6: Spike-in SILAC (High confidence NMT substrates) Mean Ratio L/H  IC50 (µM) 
      
CP 
 
Protein names 
Gene 
names 
Protein 
IDs 0 0.08 0.2 0.4 1 5 IC50  Error  Slope  MP 
Myri
st Pred PR Palm GPI Hang  
Yao 
SQ LFQ 
Tyrosine-protein kinase ABL1 ABL1 P00519 1 1.19 0.38 0.21 0.31 0.07 0.15 0.25 1.26 T N L CF 
 
No 
  
8 
Apoptosis-inducing factor 2 AIFM2 Q9BRQ8 1 0.63 0.35 0.19 0.09 0.23 0.11 0.05 0.96 R H H CF 
 
No 
  
189 
A-kinase anchor protein 12 AKAP12 Q02952 1 0.87 0.54 0.29 0.14 0.04 0.23 0.02 1.48 R H H NN 
 
No 
  
16 
Ankyrin repeat and IBR domain-
containing protein 1 ANKIB1 Q9P2G1 1 0.94 0.81 0.38 0.12 NaN 0.34 0.03 2.3 R H H CF 
 
No 
  
5 
ADP-ribosylation factor 1 ARF1 P84077 1 0.70 0.38 0.22 0.11 0.04 0.15 0.01 1.22 T H M NN ++ No + + 2501 
ADP-ribosylation factor 3 ARF3 P61204 1 0.67 0.36 0.21 0.11 0.04 0.14 0.01 1.2 T H M 
 
+ No 
  
2501 
ADP-ribosylation factor 4 ARF4 P18085 1 0.95 0.61 0.40 0.21 0.07 0.3 0.05 1.33 R H H CP + No + + 585 
ADP-ribosylation factor 5 ARF5 P84085 1 0.71 0.40 0.23 0.11 0.06 0.15 0.04 1.22 R H H CP + No + + 310 
ADP-ribosylation factor 6 ARF6 P62330 1 0.68 0.42 0.24 0.12 0.06 0.15 0.01 1.11 R H H NN 
 
No 
  
389 
ADP-ribosylation factor-like protein 1 ARL1 P40616 1 0.46 0.22 0.14 0.07 0.03 0.07 0.01 1.05 R H H CF 
 
No 
  
499 
ADP-ribosylation factor-like protein5B ARL5B Q96KC2 1 0.68 0.28 0.22 NaN 0.02 0.12 0.02 1.4 N M L NN 
 
No 
   Brain acid soluble protein 1 BASP1 P80723 1 0.79 0.52 0.32 0.16 0.04 0.22 0.01 1.2 R H H Nat 
 
No 
  
519 
Cyclin-Y;Cyclin-Y-like protein 1 CCNY;CCNYL1 Q8ND76 1 1.10 1.17 0.74 0.43 0.12 0.76 0.21 1.76 R H H NN +++ No 
   Cell division cycle-associated protein3 CDCA3 Q99618 1 0.56 0.29 0.16 0.08 0.09 0.09 0.02 1.08 R H H 
  
No 
  
35 
Coiled-coil-helix-coiled-coil-helix domain-
containing protein3,mitochondrial CHCHD3 Q9NX63 1 0.92 0.61 0.34 0.16 0.04 0.27 0.02 1.53 R H H NN + No + + 822 
Charged multivesicular body protein 6 CHMP6 Q96FZ7 1 0.58 0.31 0.14 0.09 0.08 0.1 0.02 1.16 R H H NN 
 
No 
 
+ 44 
Calcium-binding protein p22 CHP Q99653 1 1.09 0.75 0.45 0.20 0.07 0.36 0.06 1.72 R H H CF 
 
No 
  
93 
Battenin CLN3 Q13286 1 1.01 0.37 0.27 0.29 0.37 0.23 0.31 0.69 T L L 
  
No 
  
13 
NADH-cytochrome b5 reductase 3 CYB5R3 P00387 1 0.16 0.08 0.04 0.03 0.03 0.01 0 0.83 R H H NN ++ No 
 
+ 457 
Sphingolipid delta(4)-desaturaseDES1 DEGS1 O15121 1 0.39 0.17 0.14 0.05 0.04 0.05 0.01 0.96 T H M NN 
 
No 
  
99 
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Disrupted in renal carcinoma protein 2 DIRC2 Q96SL1 1 0.47 0.31 0.16 0.13 0.18 0.05 0.03 0.57 R H H 
  
No 
  
20 
Dymeclin DYM Q7RTS9 1 0.76 0.40 0.21 0.10 0.05 0.16 0.01 1.43 R H H CF 
 
No 
  
13 
Protein Niban FAM129A Q9BZQ8 1 0.68 0.42 0.31 0.16 0.14 0.16 0.06 0.83 R H H 
  
No 
  
23 
Niban-like protein 1 FAM129B Q96TA1 1 0.49 0.23 0.13 0.06 0.04 0.08 0.01 1.16 N H M 
  
No 
  
196 
Protein FAM49B FAM49B Q9NUQ9 1 0.23 0.10 0.06 0.03 0.03 0.02 0 1 N M L CP +++ No + + 686 
Flotillin-2 FLOT2 Q14254 1 0.72 0.42 0.23 0.15 0.28 0.15 0.1 0.74 N N N 
 
+++ No 
  
83 
Formin-like protein 1 FMNL1 O95466 1 0.46 0.20 0.15 0.10 0.07 0.06 0.01 0.91 T N L NN 
 
No 
  
28 
Formin-like protein 2 FMNL2 Q96PY5 1 0.83 0.43 0.47 0.19 NaN 0.25 0.09 0.99 T H M CF 
 
No 
  
9 
Golgi-associated plant pathogenesis-
related protein 1 GLIPR2 Q9H4G4 1 0.40 0.19 0.10 0.16 0.02 0.04 0.02 0.78 R H H Nat 
 
No 
  
92 
Guanine nucleotide-binding protein G(i) 
subunit alpha-1 GNAI1 P63096 1 0.76 0.46 0.25 0.12 0.05 0.18 0.01 1.28 R H H NN u, ++ No 
  
103 
Guanine nucleotide-binding protein G(i) 
subunit alpha-2 GNAI2 P04899 1 0.69 0.41 0.22 0.11 0.04 0.15 0.01 1.2 R H H NN ++++ No + 
 
35 
Guanine nucleotide-binding protein G(k) 
subunit alpha GNAI3 P08754 1 0.73 0.43 0.23 0.11 0.04 0.17 
0.00
3 1.29 R H H NN ++++ No + + 221 
Guanine nucleotide-binding protein G(o) 
subunit alpha GNAO1 P09471 1 0.63 0.33 0.16 0.08 0.02 0.12 0.01 1.31 R H H NN u, +++ No + 
 
68 
Golgi reassembly-stacking protein 2 GORASP2 Q9H8Y8 1 0.86 0.57 0.33 0.17 0.07 0.25 0.03 1.32 R H H CP 
 
No 
 
+ 265 
Cytochrome c-type heme lyase HCCS P53701 1 0.45 0.20 0.12 0.06 0.05 0.06 0.01 1.08 R L M 
  
No 
  
306 
Hippocalcin-like protein 1;Neuron-specific 
calcium-binding protein hippocalcin 
HPCAL1;H
PCA 
P37235;P84
074 1 0.40 0.18 0.09 0.04 0.02 0.06 0 1.15 R H H NN 
 
No 
  
504 
TLD domain-containing protein KIAA1609 KIAA1609 Q6P9B6 1 0.52 0.27 0.17 NaN NaN 0.08 0.01 1.05 T H M CF 
 
No 
  
23 
Ragulator complex protein LAMTOR1 LAMTOR1 Q6IAA8 1 0.93 0.55 0.32 0.15 0.07 0.24 0.04 1.54 T H M 
  
No + 
 
215 
Protein lunapark LNP Q9C0E8 1 0.83 0.44 0.26 0.19 0.14 0.19 0.05 1.2 T H M CF 
 
No 
  
76 
Leucine-rich repeat-containing protein 57 LRRC57 Q8N9N7 1 0.43 0.20 0.11 0.05 0.06 0.06 0.01 1.11 N N N 
  
No 
  
144 
Tyrosine-protein kinase Lyn LYN P07948 1 0.56 0.28 0.15 0.08 0.13 0.09 0.02 1.08 R H H NN u, + No 
  
79 
MOSC domain-containing protein 1, 
mitochondrial MARC1 Q5VT66 1 0.36 0.13 0.10 0.05 0.03 0.05 0.01 1.1 N H M 
  
No 
  
29 
MOSC domain-containing protein 2, 
mitochondrial MARC2 Q969Z3 1 0.53 0.18 0.12 0.06 NaN 0.08 0.01 1.47 N N N 
  
No 
  
43 
Myristoylated alanine-rich C-kinase 
substrate MARCKS P29966 1 1.15 0.96 0.65 0.37 0.11 0.61 0.14 1.52 R H H Nat 
 
No 
  
1604 
MARCKS-related protein MARCKSL1 P49006 1 0.84 0.54 0.30 0.14 0.04 0.23 0.01 1.4 R H H 
 
+ No + + 683 
E3 ubiquitin-protein ligase MGRN1 MGRN1 O60291 1 1.16 0.83 0.62 0.31 0.13 0.53 0.14 1.43 R H H CF 
 
No 
  
16 
Neuronal calcium sensor 1 NCS1 P62166 1 0.83 0.52 0.28 0.14 0.04 0.22 0.02 1.4 R H H NN 
 
No 
  
19 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex assembly factor 4 NDUFAF4 Q9P032 1 0.12 0.05 0.06 0.05 0.13 
0.00
2 0.01 0.56 N N N 
  
No 
  
91 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 7 NDUFB7 P17568 1 0.69 0.46 0.25 0.10 0.09 0.16 0.02 1.13 N L N CF 
 
No 
  
43 
317 
 
Nucleolar protein 3 NOL3 O60936 1 0.55 0.28 0.14 0.08 0.06 0.09 0.01 1.17 T L L 
  
No 
  
248 
Protein-L-isoaspartate O-methyl 
transferase domain-containing protein 1 PCMTD1 Q96MG8 1 0.28 0.16 0.08 0.07 NaN 0.02 0.05 0.79 R H H 
  
No 
  
18 
Phosphoinositide 3-kinase regulatory subunit 4 PIK3R4 Q99570 1 1.10 0.77 0.56 0.20 0.14 0.42 0.1 1.62 T H M CF 
 
No 
  
42 
Protein phosphatase 1A PPM1A P35813 1 0.98 0.70 0.44 0.22 0.10 0.35 0.06 1.37 N H M NN 
 
No 
  
115 
Protein phosphatase 1B PPM1B O75688 1 1.23 0.87 0.47 0.22 0.06 0.37 0.08 1.95 N M L NN 
 
No 
  
41 
Protein phosphatase 1G PPM1G O15355 1 0.95 0.62 0.37 0.17 0.06 0.29 0.04 1.5 R M M CP + No + + 475 
Calcineurin subunit B type 1 PPP3R1 P63098 1 0.65 0.33 0.17 0.07 0.05 0.12 0.01 1.34 R H H NN 
 
No 
  
40 
cAMP-dependent protein kinase catalytic 
subunit alpha PRKACA P17612; 1 0.28 0.13 0.07 0.03 0.02 0.03 0 0.98 R H H Nat 
 
No 
 
+ 739 
cAMP-dependent protein kinase catalytic 
subunit beta PRKACB P22694 1 0.42 0.20 0.11 0.06 0.05 0.06 0.01 1.05 R H H 
  
No 
  
202 
5-AMP-activated protein kinase subunit 
beta-1 PRKAB1 Q9Y478 1 0.33 NaN NaN NaN NaN 0.07 0.01 3.52 N N N NN 
 
No 
   26S protease regulatory subunit 4 PSMC1 P62191 1 0.88 0.54 0.31 0.15 0.06 0.24 0.03 1.45 R H H NN ++ No + + 1282 
Raftlin RFTN1 Q14699 1 0.45 0.07 0.21 0.16 0.57 0.04 0.03 0.75 N H M NN u No 
  
25 
RING finger protein 141 RNF141 Q8WVD5 1 0.29 0.14 0.10 NaN 0.24 
0.00
2 0 0.3 N H M 
  
No 
  
29 
Protein XRP2 RP2 O75695 1 1.06 0.88 0.62 0.28 0.10 0.53 0.07 1.59 R H H 
 
u No 
  
31 
Protein-associating with the carboxyl-
terminal domain of ezrin SCYL3 Q8IZE3 1 0.28 0.22 NaN 0.13 0.03 0.01 0.01 0.44 R H H NN 
 
No 
   Cytospin-B SPECC1 Q5M775; 1 0.70 0.21 0.14 0.06 0.05 0.12 0.01 1.94 T N L 
  
No 
  
49 
Proto-oncogene tyrosine-protein kinase 
Src SRC P12931 1 0.65 0.37 0.17 0.09 0.01 0.13 0.01 1.27 R H H Nat + No 
  
72 
Tescalcin TESC Q96BS2 1 0.78 0.47 0.24 0.12 0.05 0.19 0.02 1.37 R H H CF 
 
No 
  
458 
Transmembrane protein 106B TMEM106B Q9NUM4 1 0.41 0.20 0.15 0.07 0.07 0.05 0.01 0.83 T H M 
  
No 
  
65 
Tyrosine-protein kinase Yes YES1 P07947 1 0.63 0.26 0.15 0.08 NaN 0.11 0.01 1.44 R H H NN u,++ No 
  
60 
E3 ubiquitin-protein ligase ZNRF2 ZNRF2 Q8NHG8 1 0.27 0.13 0.09 0.17 0.15 
0.00
2 0 0.33 R M M NN 
 
No 
  
57 
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Table H7: Spike-in SILAC (Low confidence NMT substrates).  Mean Ratio L/H IC50 (µM) 
       
Protein names 
Gene 
names Protein IDs 0 0.08 0.2 0.4 1 5 IC50 Error Slope MP 
Myr 
ist Pred PR Palm GPI LFQ 
N-myristoylated proteins- Low confidence (low number of razor+unique peptides) 
            ADP-ribosylation factor-like protein 2 ARL2 P36404 1 0.65 0.42 0.27 0.1 NaN 0.15 0.01 1.06 N N N 
  
No 21.6 
Transmembrane protein C9orf123 C9orf123 Q96GE9 1 0.07 NaN NaN 0.16 NaN 0 0 0.59 R H H 
  
No 
 DDB1- and CUL4-associated factor 11 DCAF11 Q8TEB1 1 0.19 NaN NaN 0.03 NaN 0.01 0 0.84 R H H 
  
No 
 cAMP-dependent protein kinase catalytic 
subunit gamma PRKACG P22612 1 0.31 0.13 0.07 0.02 0.02 0.04 0 1.15 R H H 
  
No 24.2 
RING finger protein 11 RNF11 Q9Y3C5 1 NaN NaN 0.22 0.24 NaN 0.05 0.1 0.53 N M L CF 
 
No 6.63 
Small VCP/p97-interacting protein SVIP Q8NHG7 1 0.15 0.2 0.12 NaN NaN 0.01 0 0.32 N N N 
  
No 6.63 
Ubiquitin carboxyl-terminal hydrolase 32 USP32 Q8NFA0 1 0.58 0.17 0.08 NaN 0.09 0.09 0.01 1.96 N H M 
  
No 4.29 
N-myristoylated proteins- Low confidence (ambiguous dose response , ratios do not drop below 0.3) 
Abelson tyrosine-protein kinase 2 ABL2 P42684 1 0.35 NaN 0.4 NaN NaN 0.03 0.06 0.3 T M M 
  
No 13.7 
DCN1-like protein 3 DCUN1D3 Q8IWE4 1 1.11 1 0.85 0.51 NaN N/A N/A N/A R M M 
 
+ No 
 DDXX46 DDX46 Q7L014 1 0.99 0.82 0.72 0.57 0.6 N/A N/A N/A N N N 
  
No 
 F-box only protein 17 FBXO17 Q96EF6 1 0.39 0.36 NaN NaN NaN 0.99 0.11 1.21 T H M 
  
No 
 Formin-like protein 3 FMNL3 Q8IVF7 1 0.81 NaN NaN NaN NaN N/A N/A N/A T M M CF 
 
No 
 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-3 GNB3 P62873 1 0.71 0.66 0.34 0.37 0.32 N/A N/A N/A N N N 
  
No 
 Golgi reassembly-stacking protein 1 GORASP1 Q9BQQ3 1 0.12 NaN NaN 0.51 NaN N/A N/A N/A R H H CF 
 
No 10.8 
L-lactate dehydrogenase A chain LDHA P00338 1 0.93 0.77 0.59 0.54 0.55 N/A N/A N/A N N N 
 
++ No 
 Mitochondrial peptide methionine sulfoxide 
reductase MSRA Q9UJ68  1 1.48 1.13 0.73 NaN NaN N/A N/A N/A R H H NN 
 
No 
 Monofunctional C1-tetrahydrofolate 
synthase, mitochondrial MTHFD1L Q6UB35 1 0.76 NaN NaN NaN NaN N/A N/A N/A N N N 
  
No 
 Opioid growth factor receptor-like protein 1 OGFRL1 Q5TC84 1 0.54 0.74 0.63 NaN NaN N/A N/A N/A N M L 
  
No 12 
Platelet-activating factor acetylhydrolase 2 PAFAH2 Q99487 1 0.6 0.31 NaN NaN 0.39 N/A N/A N/A N N N 
  
No 10.6 
Testisin PRSS21 Q9Y6M0 1 0.74 0.69 0.46 0.45 0.47 N/A N/A N/A N N N 
  
Pot 9.33 
Inactive tyrosine-protein kinase 7 PTK7 Q13308 1 1.09 0.68 0.62 0.78 0.59 N/A N/A N/A N N N 
 
+ No 
 Serine incorporator 3 SERINC3 Q13530 1 0.78 0.65 0.54 0.49 0.6 N/A N/A N/A N N N 
  
No 19.2 
ADP/ATP translocase 3 SLC25A6 P12236 1 0.87 0.7 0.57 0.55 0.57 N/A N/A N/A N N N 
 
+;++ No 7.83 
Choline transporter-like protein 1 SLC44A1 Q8WWI5 1 0.52 0.51 0.39 0.37 0.41 N/A N/A N/A R M M 
 
+ No 94.4 
TOM40 homolog TOMM40 O96008 1 0.69 0.75 0.66 0.41 0.46 N/A N/A N/A T L L 
 
+ No 
 Probable palmitoyltransferase ZDHHC6 ZDHHC6 Q9H6R6 1 NaN NaN 0.42 0.53 NaN 0.47 0.55 0.65 N H M 
 
+ No 
 ZZEF1  ZZEF1 O43149 1 1.45 1.16 0.67 0.44 0.45 N/A N/A N/A R H H CF 
 
No 
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Table H8: Spike-in SILAC, protein with no MG motif sensitive to the NMT inhibitor IMP366. 
   
Mean Ratio L/H  
   
Protein name Gene name Uniprot ID 0 0.1 0.2 0.4 1 5 Palm GPI LFQ 
BAG family molecular chaperone regulator 5 BAG5 Q9UL15 1 0.55 0.24 0.16 0.06 0.07 
 
No 45 
Flotillin-1 FLOT1 O75955 1 0.65 0.42 0.34 0.30 0.17 +++ No 6 
Histone H2A.x;Histone H2A type 1-B/E;Histone 
H2A type 1;Histone H2A type 1-D;Histone H2A 
type 3;Histone H2A type 1-C;Histone 
H2A.J;Histone H2A type 1-H;Histone H2A type 1-
J;Histone H2A type 1-A;Histone H2A type 2-B 
H2AFX;HIST1H2AB;HIST1
H2AG;HIST1H2AD;HIST3
H2A;HIST1H2AC;H2AFJ;H
IST1H2AH;HIST1H2AJ;HI
ST1H2AA;HIST2H2AB 
P16104;P04908;P0C0S8;P20671;Q7L7
L0;Q93077;Q9BTM1;Q96KK5;Q99878;
Q9BTM1-2;Q96QV6;Q8IUE6 1 0.24 0.14 0.28 0.14 0.11 
   LanC-like protein 1 LANCL1 O43813 1 0.86 0.97 0.59 0.41 0.16 
 
No 12 
Serine/threonine-protein phosphatase 2B catalytic 
subunit alpha isoform;Serine/threonine-protein 
phosphatase 2B catalytic subunit beta isoform PPP3CA;PPP3CB 
Q08209;Q08209-2;Q08209-3;P16298-
4;P16298;P16298-3;P16298-2 1 0.69 0.45 0.25 0.17 0.14 
 
No 17 
26S protease regulatory subunit 7 PSMC2 P35998 1 0.83 0.47 0.28 0.16 0.09 
 
No 70 
26S protease regulatory subunit 6A PSMC3 P17980 1 0.90 0.60 0.43 0.33 0.28 
 
No 9 
26S protease regulatory subunit 6B PSMC4 P43686;P43686-2 1 0.90 0.65 0.42 0.26 0.17 
   26S protease regulatory subunit 8 PSMC5 P62195 1 0.90 0.55 0.40 0.20 0.12 
 
No 6 
26S protease regulatory subunit 10B PSMC6 P62333 1 0.87 0.60 0.36 0.23 0.16 
 
No 6 
26S proteasome non-ATPase regulatory subunit 2 PSMD2 Q13200 1 0.83 0.57 0.33 0.26 0.20 
 
No 10 
Serpin B6 SERPINB6 P35237 1 1.04 0.83 0.64 0.36 0.19 
 
No 66 
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Table H9: Base-treatment.  
(n= 2 biological replicates). When unique peptides could not be assigned to one unique protein but were assigned instead 
to a group of 2 or more proteins by MaxQuant, proteins were grouped and had the same number of unique peptides. 
Heavy (R10K8) YnC12-treated HeLa lysates were not treated and light (grown in the standard media) YnC12-treated HeLa 
lysates were treated with 0.2M NaOH (both labelled with YnC12). Samples were mixed in 1:1 ratio after the 
base-treatment. Only proteins significantly depleted in the base-treated sample are shown (FRD 0.01, 250 permutations, 
S2). Two columns show the results of the t-test (log2 values). MG = proteins with a N-terminal MG motif. PR = previously 
reported (Appendix F). Pred= combined predictions of MYR predictor and Myristoylator (Section  8.3.9). A column indicates 
if the protein is palmitoylated (+: found in 1 study, ++: found in 2 studies; +++: found in 3 studies; ++++: found in 4 studies; 
u: reported as palmitoylated in the UniProtKB/Swiss-Prot database) and a column indicates if the protein is a GPI anchored 
protein). LFQ = LFQ enrichment as determined in Table H4. 
Protein names 
Gene 
names Protein IDs 
ratio 
base/no 
base 
-Log t-
test p 
value 
t-test 
Differ
ence MG PR 
Pre
d Palm GPI LFQ 
CD59 glycoprotein CD59 P13987 17.8 0.7 -22.7 + 
 
N 
 
Yes 
 CD44 antigen CD44 P16070 7.9 0.5 -11.8 
   
+ No 115 
Complement decay-accelerating 
factor CD55 P08174 8.8 2.6 -11.2 
    
Yes 149 
Voltage-dependent anion-
selective channel protein 2 VDAC2 P45880 9.0 0.6 -11.1 
   
+ No 92.2 
Transferrin receptor protein 1 TFRC P02786 6.9 2.1 -10.6 
   
++++ No 13.7 
Beta-1,4-galactosyltransferase1 B4GALT1 P15291 8.3 1.4 -10.2 
    
No 261 
Calnexin CANX P27824 3.8 2.8 -9.5 
   
++++ No 82.7 
CD276 antigen CD276 Q5ZPR3 5.9 1.3 -9.0 
    
No 102 
Endothelial protein C receptor PROCR Q9UNN8 5.7 3.0 -7.8 
   
+ No 34.8 
CD151 antigen CD151 P48509 4.9 3.7 -6.4 + 
 
N + No 20.1 
Golgi integral membrane protein 
4 GOLIM4 O00461 3.3 1.4 -5.8 + 
 
H + No 117 
Podocalyxin PODXL O00592 2.5 1.7 -5.8 
    
No 25.3 
Prostaglandin F2 receptor 
negative regulator PTGFRN Q9P2B2 4.4 1.1 -5.5 + 
 
L ++ No 25.7 
Lysosome membrane protein 2 SCARB2 Q14108 4.9 4.1 -5.5 + 
 
N ++ No 226 
Voltage-dependent calcium 
channel subunit alpha-2/delta-1 CACNA2D1 P54289 5.3 1.5 -5.3 
    
No 111 
Choline transporter-like protein 
2 SLC44A2 Q8IWA5 3.2 1.5 -5.3 + 
 
N 
 
No 71.3 
Polypeptide N-
acetylgalactosaminyltransferase 
1 GALNT1 Q10472 3.8 1.3 -5.2 
    
No 44.3 
Poliovirus receptor PVR P15151 3.4 2.3 -5.1 
   
+ No 20.8 
CD81 antigen CD81 P60033 4.9 1.1 -5.0 + CP N +++ No 7.1 
Cysteine-rich and 
transmembrane domain-
containing protein 1 CYSTM1 Q9H1C7 4.3 2.5 -4.9 
    
No 152 
Niemann-Pick C1 protein NPC1 O15118 3.6 1.5 -4.9 
    
No 
 CD63 antigen CD63 P08962 4.3 3.0 -4.7 
   
+ No 47 
Cytoskeleton-associated protein 
4 CKAP4 Q07065 3.5 1.5 -4.6 
   
+++ No 67.3 
Erythrocyte band 7 integral 
membrane protein STOM P27105 4.6 4.8 -4.6 
   
+++ No 184 
Serine incorporator 1 SERINC1 Q9NRX5 4.8 2.5 -4.5 + CF N 
 
No 190 
Bone marrow stromal antigen 2 BST2 Q10589 4.4 2.2 -4.3 
    
Pot 85.1 
DnaJ homolog subfamily C 
member 5 DNAJC5 Q9H3Z4 3.9 2.0 -4.3 
   
++ No 414 
CD9 antigen CD9 P21926 3.0 2.5 -4.2 
   
+ No 21 
Neutral amino acid transporter 
B(0) SLC1A5 Q15758 3.7 2.5 -4.2 
   
+++ No 128 
Transmembrane protein 63B TMEM63B Q5T3F8 2.6 0.8 -4.1 
   
++ No 59.9 
Adenosine 3-phospho 5-
phosphosulfate transporter 1 SLC35B2 Q8TB61 2.8 1.0 -3.8 
   
+ No 
 Carboxypeptidase D CPD O75976 2.5 0.8 -3.8 
   
+ No 20.8 
Caveolin-1 CAV1 Q03135 2.7 2.4 -3.8 
   
+ No 12.5 
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Leucyl-cystinyl 
aminopeptidase;Leucyl-cystinyl 
aminopeptidase, pregnancy 
serum form LNPEP Q9UIQ6 3.8 1.6 -3.8 
   
+++ No 33 
Zinc transporter 1 SLC30A1 Q9Y6M5 3.0 1.8 -3.7 + 
 
N - No 6.76 
Vasorin VASN Q6EMK4 1.5 0.5 -3.7 
    
No 34.3 
Phosphatidylinositol 4-kinase 
type 2-alpha PI4K2A Q9BTU6 3.2 3.0 -3.6 
   
+++ No 17.2 
Neural cell adhesion molecule 
L1 L1CAM P32004 3.3 0.8 -3.6 
   
+ No 44.1 
Rho-related GTP-binding 
protein RhoB RHOB P62745 2.6 0.8 -3.5 
   
++ No 22.3 
Alkaline phosphatase, tissue-
nonspecific isozyme ALPL P05186 3.5 2.5 -3.5 
    
Prob 22.6 
Serine/arginine repetitive matrix 
protein 2 SRRM2 Q9UQ35 8.4 4.6 -3.3 
    
No 8.57 
CD82 antigen CD82 P27701 4.8 1.9 -3.1 + CP N + No 
 Sn1-specific diacylglycerol 
lipase beta DAGLB Q8NCG7 3.2 1.9 -3.1 
   
++ No 
 Leucine-rich repeat-containing 
protein 15 LRRC15 Q8TF66 3.4 1.6 -2.9 
    
No 177 
Secretory carrier-associated 
membrane protein 3 SCAMP3 O14828 2.2 1.4 -2.8 
   
+++ No 24.2 
Myoferlin MYOF Q9NZM1 3.5 1.3 -2.7 
    
No 208 
Probable phospholipid-
transporting ATPase IIA ATP9A O75110 1.9 2.2 -2.6 
    
No 15.1 
Endothelin-converting enzyme 1 ECE1 P42892 2.2 1.9 -2.4 
   
+ No 4.63 
Thioredoxin-related 
transmembrane protein 1 TMX1 Q9H3N1 1.9 1.7 -2.3 
    
No 19.7 
60S ribosomal protein L18 RPL18 Q07020 4.2 2.5 -2.2 + 
 
N 
 
No 78.3 
Polypeptide N-
acetylgalactosaminyltransferase 
2 GALNT2 Q10471 2.1 1.2 -2.2 
    
No 
 Serine incorporator 3 SERINC3 Q13530 2.5 1.7 -2.1 + 
 
N 
 
No 77 
Endoplasmic reticulum 
mannosyl-oligosaccharide 1,2-
alpha-mannosidase MAN1B1 Q9UKM7 2.3 1.5 -2.1 
    
No 19.2 
Tetraspanin-6 TSPAN6 O43657 2.5 2.1 -1.9 
    
No 16.5 
60S ribosomal protein L28 RPL28 P46779 3.7 1.5 -1.8 
    
No 6.57 
 
322 
 
Table H10: List of NMT substrates identified with high confidence in the current study with GO annotations (localisation, biological process and molecular function).  Pred= combined 
predictions of MYR predictor and Myristoylator (Section  4.8). PR= previously reported to as NMT substrates (Appendix F). 
 
Gene 
names Protein IDs 
In cell 
IC50 
(µM) 
Mod 
pep Localisation Biological process Molecular function Pred PR 
ABL1 P00519 0.147  
Cytoskeleton; Membrane; 
Mitochondrion; Nucleus; 
Cytoplasm 
DNA repair; Autophagy; Cell adhesion; 
DNA damage; Endocytosis;Apoptosis 
Tyrosine-protein kinase; 
Transferase;Kinase L CF 
AIFM2 Q9BRQ8 0.114  
Cytoplasm, , Mitochondrion 
outer membrane Apoptosis, chromosome condensation Oxidoreductase, DNA binding H CF 
AKAP12 Q02952 0.227 + Cytoplasm, Cytoskeleton 
G-protein coupled receptor signaling 
pathway, positive regulation of cAMP 
biosynthetic process, positive regulation of 
protein kinase A signaling cascade, protein 
targeting 
Protein kinase A binding H NN 
ANKIB1 Q9P2G1 0.344  Unknown Unknown Zinc ion binding H CF 
ARF1 P84077 0.146 + 
Cytoplasm, Golgi apparatus ER-Golgi transport, Protein transport GTP binding, GTPase activity, receptor signaling protein activity 
M NN 
ARF3 P61204 0.135 + M   
ARF4 P18085 0.301 + H CP 
ARF5 P84085 0.153 + H CP 
ARF6 P62330 0.151  H NN 
ARL1 P40616 0.067  Golgi apparatus, Membrane 
Golgi organization, Golgi vesicle transport, 
activation of phospholipase D activity, 
protein localization to Golgi apparatus, 
retrograde transport 
GTP binding, GTPase activity, enzyme 
activator activity, metal ion binding H CF 
ARL5B Q96KC2 0.123 + Intracellular Small GTPase mediated signal transduction GTP binding L NN 
BASP1 P80723 0.219  Cell membrane, cell projection 
Diaphragm development, glomerular 
visceral epithelial cell differentiation, gonad 
development 
Transcription corepressor activity, 
transcription regulatory region DNA 
binding 
H N 
CCNY;CC
NYL1 Q8ND76 0.762  Cell membrane, nucleus 
 Cell division; Wnt signaling pathway;Cell 
cycle 
Cyclin-dependent protein 
serine/threonine kinase regulator 
activity 
H NN 
CDCA3 Q99618 0.094  Cytoplasm 
 Cell division; Mitosis; Ubl conjugation 
pathway;Cell cycle   H   
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CHCHD3 Q9NX63 0.273 + Cytoplasm, Mitochondrion inner membrane, Nucleus 
Transcription regulation, inner 
mitochondrial membrane organization, 
mitochondrial fusion 
negative regulation of transcription, 
phosphatase binding, protein complex 
scaffold 
H NN 
CHCHD6 Q9NX64 N/A + Mitochondrial inner membrane Cristae formation, response to DNA damage stimulus   H   
CHMP6 Q96FZ7 0.101 + Endosome, Membrane Protein transport Unknown H NN 
CHP Q99653 0.361  
Cell membrane, Cytoplasm, 
Cytoskeleton, Endoplasmic 
reticulum, Nucleus 
Protein transport Protein kinase inhibitor H CF 
CLN3 Q1328 0.231  
Endosome, Lysosome, 
Membrane 
Transport of late endosomes and 
lysosomes Unfolded protein binding L   
CYB5R3 P00387 0.011 + 
Cytoplasm, Endoplasmic 
reticulum, Mitochondrion outer 
membrane 
Cholesterol, lipid, steroid, sterol 
biosynthesis and metabolism, blood 
circulation 
Oxidoreductase H NN 
DEGS1 O15121 0.049  
Endoplasmic reticulum, 
Membrane, Mitochondrion Lipid biosynthesis and metabolism Oxidoreductase M NN 
DIRC2 Q96SL1 0.050  Lysosome, membrane Electrogenic metabolite transporter. Transport H   
DYM Q7RTS9 0.160  Cytoplasm, Golgi apparatus Golgi organisation, bone development Unknown H CF 
FAM129A Q9BZQ8 0.160  Cytoplasm  Translation regulation;Stress response 
Regulates phosphorylation of proteins 
involved in translation regulation H   
FAM129B Q96TA1 0.076 + Cytoplasm, cell junction Negative regulation of apoptosis process phospholipid binding M   
FAM49B Q9NUQ9 0.023  Cilium Unknown Unknown L CP 
FLOT2 Q14254 0.150  Cell membrane, endosome Cell adhesion Unknown N   
FMNL1 O95466 0.060  
 Cell projection; Cytoplasm; 
Cytoplasmic vesicle; Cell 
membrane 
Cortical actin cytoskeleton organization; 
regulation of cell shape; substrate-
dependent cell migration 
 Actin filament binding; Rac GTPase 
binding;GTPase activating protein 
binding 
L NN 
FMNL2 Q96PY5 0.246  Cytoplasm 
Regulation of cell morphology and 
cytoskeletal organization Unknown M CF 
GLIPR2 Q9H4G4 0.042  Membrane, Golgi apparatus Unknown Unknown H N 
GNAI1 P63096 0.179 + 
Cell membrane, Cytoplasm, 
Cytoskeleton, Membrane Cell cycle, cell division 
Transducer, GTP binding, GTPase 
activity, metal ion binding, G-protein 
beta/gamma-subunit complex binding, 
G-protein coupled serotonin receptor 
binding 
H NN 
GNAI2 P04899 0.149 + H NN 
GNAI3 P08754 0.165  H NN 
GNAO1 P09471 0.118  
 neuron 
projection;heterotrimeric G-
protein complex 
Adenylate cyclase-modulating G-protein 
coupled receptor signaling pathway Transducer H NN 
GORASP
2 Q9H8Y8 0.248 + Golgi apparatus, Membrane Organelle organisation Unknown H CP 
HCCS P53701 0.063 + Mitochondrion inner membrane 
Organ morphogenesis, oxidation-reduction 
process 
Lyase, holocytochrome-c synthase 
activity M   
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HPCAL1;
HPCA P37235 0.055  Unknown Inner ear development Calcium ion binding, actin binding H NN 
KIAA1609 Q6P9B6 0.085  Unknown Unknown Unknown M CF 
LAMTOR1 Q6IAA8 0.242  
Cell membrane, endosome, 
Lysosome 
Cell growth, cellular protein localisation, 
cellular response to amino acid stimulus, 
cholesterol homeostasis, endosome 
localization 
Unknown M   
LNP Q9C0E8 0.191 + Cytoplasm 
Blood coagulation, embryonic digit 
morphogenesis, embryonic forelimb 
morphogenesis, limb development 
Developmental protein M CF 
LRRC57 Q8N9N7 0.060 + Unknown Unknown Unknown N   
LYN P07948 0.092  
Cell membrane, Cytoplasm, 
Golgi apparatus, Membrane, 
Nucleus 
Adaptive immunity, Host-virus interaction, 
Immunity, Inflammatory response, Innate 
immunity 
Tyrosine-protein kinase H NN 
MARC1 Q5VT66 0.046 + Mitochondrion outer membrane 
 nitrate metabolic process;detoxification of 
nitrogen compound Oxidoreductase M   
MARC2 Q969Z3 0.084 +  Miitochondrion outer membrane  nitrate metabolic process Oxidoreductase N   
MARCKS P29966 0.612 + Cytoplasm, cytoskeleton 
Energy reserve metabolic process, 
regulation of insulin secretion, small 
molecule metabolic process 
Actin filament binding, calmodulin 
binding H N 
MARCKS
L1 P49006 0.229 + Cell membrane, cytoplasm 
Controls cell movement by regulating actin 
cytoskeleton homeostasis and filopodium 
and lamellipodium formation; Positive 
regulation of cell proliferation 
Unknown H   
MGRN1 O60291 0.527  
Cytoplasm; Endosome; 
Membrane; Nucleus; Cell 
membrane 
Ubl conjugation pathway Ligase H CF 
NCS1 P62166 0.216  
Cell junction, Cell membrane, 
Cytoplasm, Golgi apparatus, 
Membrane, Postsynaptic cell 
membrane, Synapse 
phosphatidylinositol-mediated signaling, 
positive regulation of exocytosis, regulation 
of neuron projection development 
Calcium ion binding, voltage-gated 
calcium channel activity H NN 
NDUFAF4 Q9P032 0.002 + Mitochondrion mitochondrial respiratory chain complex I assembly 
Involved in the assembly of 
mitochondrial NADH:ubiquinone 
oxidoreductase complex (complex I). 
N   
NDUFB7 P17568 0.163 + 
Membrane, Mitochondrion, 
Mitochondrion inner 
membrane 
Electron transport, Respiratory chain, 
Transport 
NADH dehydrogenase (ubiquinone) 
activity N CF 
NOL3 O60936 0.093 + Cytoplasm, nucleus 
Negative regulation of apoptosis, mRNA 
processing, mRNA splicing, response to 
hypoxia 
RNA binding L   
OGFRL1 Q5TC84 N/A + Membrane Unknown Receptor protein L   
325 
 
PCMTD1 Q96MG8 0.024 + Cytoplasm Unknown Protein-L-isoaspartate (D-aspartate) O-methyltransferase activity H   
PIK3R4 Q99570 0.420  Endosome 
Innate immune response, insulin receptor 
signaling pathway, phosphatidylinositol 
biosynthetic process, small molecule 
metabolic process 
Serine/threonine-protein kinase, 
transferase M CF 
PLGRKT Q9HBL7 N/A + Integral to plasma membrane, mitochondrion 
Chemotaxis ,Inflammatory 
response,Plasminogen activation   M   
PPM1A P35813 0.354 + Nucleus 
Wnt receptor signaling pathway, cell cycle 
arrest, insulin receptor signaling pathway, 
negative regulation of SMAD protein 
complex assembly, negative regulation of 
transcription  
Hydrolase, Protein phosphatase, metal 
ion binding M NN 
PPM1B O75688 0.373  Cytosoplasm 
cytokine-mediated signaling pathway, 
peptidyl-threonine dephosphorylation 
Hydrolase, Protein phosphatase, metal 
ion binding L NN 
PPM1G O15355 0.285 + Cytoplasm, nucleus Cell cycle arrest, peptidyl-threonine dephosphorylation 
Hydrolase, Protein phosphatase, metal 
ion binding M CP 
PPP3R1 P63098 0.123 + Cytoplasm Apoptosis 
Calcium ion binding protein, calcium-
dependent protein serine/threonine 
phosphatase activity, calmodulin 
binding protein 
H NN 
PRKAB1 Q9Y478 0.066  Cytoplasm, Nucleus 
Lipid biosynthesis and metabolism, cell 
cycle arrest, insulin receptor signaling 
pathway, positive regulation of gene 
expression 
Protein kinase activity N NN 
PRKACA P17612 0.030 + 
Cell membrane, Cytoplasm, 
Membrane, Mitochondrion, 
Nucleus 
Cell proliferation,cell cycle regulation,  
blood coagulation, transmembrane 
transport 
Serine/threonine-protein kinase, 
Transferase H N 
PRKACB P22694 0.057 + Cell membrane, Cytoplasm, Nucleus 
Cell proliferation,cell cycle regulation,  
differentiation and regulation of microtubule 
dynamics, chromatin condensation and 
decondensation 
Serine/threonine-protein kinase, 
Transferase H   
PSMC1 P62191 0.236 + Cytoplasm, Nucleus, Proteasome Degradation of ubiquitinated proteins ATP binding, ATPase activity H NN 
RFTN1 Q14699 0.042  Membrane, cell membrane Unknown Unknown M NN 
RNF141 Q8WVD5 0.002 + Unknown Regulation of transcription, DNA-dependent DNA binding, Zinc ion binding M   
RP2 O75695 0.535 + Cell membrane, Cell projection, Cilium, Membrane Protein transport 
GTP binding, GTPase activity, ATP 
binding, nucleoside diphosphate kinase 
activity, unfolded protein binding 
H   
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SCYL3 Q8IZE3 0.010  
 Cytoplasm; Golgi 
apparatus;Cell projection Protein phosphorylation;cell migration 
Transferase activity, transferring 
phosphorus-containing groups;ATP 
binding 
H NN 
SPECC1 Q5M775 0.117 + Nucleus Unknown Unknown L   
SRC P12931 0.129  
Cell membrane, Mitochondrion 
inner membrane, Nucleus 
Cell adhesion, Cell cycle, Host-virus 
interaction, Immunity Transferase, Tyrosine-protein kinase H N 
TESC Q96BS2 0.185 + 
Cell membrane, Cell 
projection, Cytoplasm, 
Membrane, Nucleus 
Protein transport, differentiation Protein kinase inhibitor H CF 
TMEM106
B Q9NUM4 0.048  
Endosome, Lysosome, 
Membrane Unknown Unknown M   
TOMM40L Q969M1 N/A + Mitochondrial outer membrane, pore complex Ion transport, protein transport Porin activity M   
YES1 P07947 0.108  
 Cytoplasm; Cytoskeleton; 
Membrane;Cell membrane Unknown 
 Transferase; Tyrosine-protein 
kinase;Kinase H NN 
ZNRF2 Q8NHG8 0.002  
Cell junction, Cell membrane, 
Endosome, Lysosome, 
Membrane, Synapse 
Protein ubiquitination Ligase M NN 
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Appendix I: Turnover experiments 
Table I1: Protein half life (t1/2) of the 74 NMT substrates identified with high confidence in Chapter 4 (Section 5.3). L/H = 
chase of the light isotope. T = YnC12 pulse chase and TI = YnC12 pulse chase in the presence of NMT inhibitor IMP366. Two 
columns indicate the half-lives determined by Cambridge et al.315 and Boisvert et al. 314. A star indicates proteins identified 
as NMT substrates using AzKTB (identification of the modified peptide). All the other proteins were identified in the 
spike-in inhibitor experiment described in Section 4.6. 
 
Gene name L/H t1/2 (h) T t1/2 (h) TI t1/2 (h) 
Turnover 
(h)_Cambridge 
et al. 
Turnover 
(h)_Boisvert 
et al. 
ABL1 N/A N/A N/A N/A N/A 
AIFM2 22.1 15.6 18.5 26.7 N/A 
AKAP12 13.9 48.5 65.5 36.2 5.2 
ANKIB1 25.1 N/A N/A N/A N/A 
ARF1 34.7 63.2 116.3 29.9 18.8 
ARF3 N/A 10.8 
ARF4 34.5 40.2 68.9 33.3 19.1 
ARF5 36.0 63.3 128.9 29.4 20.2 
ARF6 31.1 59.6 83.7 35.1 18.6 
ARL1 59.2 182.3 256.1 33.1 21.1 
ARL5B 6.5 N/A N/A N/A N/A 
BASP1 54.1 398.2 2976.6 56.1 20.6 
CCNY 18.8 N/A N/A N/A N/A 
CCNYL1 32.3 N/A N/A N/A N/A 
CDCA3 6.8 N/A N/A N/A N/A 
CHCHD3 68.1 134.8 N/A 54.9 32.7 
CHCHD6* 20.2 N/A N/A N/A N/A 
CHMP6 34.8 71.2 N/A N/A 21.2 
CHP 22.7 14.4 27.3 23.7 N/A 
CLN3 N/A N/A N/A 18.0 N/A 
CYB5R3 49.6 280.3 2520.3 51.7 22.6 
DEGS1 26.1 16.5 N/A 24.0 3.9 
DIRC2 16.8 N/A N/A N/A N/A 
DYM 49.5 56.4 45.9 23.8 N/A 
FAM129A 58.5 N/A N/A 45.5 16.5 
FAM129B 38.8 77.2 66.8 36.3 20.8 
FAM49B 44.7 599.3 890.2 53.9 25.9 
FLOT2 32.6 189.8 N/A 48.8 11.5 
FMNL1 30.2 N/A N/A 26.1 10.1 
FMNL2 36.5 N/A N/A N/A 16.6 
GLIPR2 22.9 N/A N/A N/A N/A 
GNAI1 34.2 24.3 40.5 28.2 7.9 
GNAI2 27.1 55.2 71.9 33.6 14.7 
GNAI3 22.5 36.0 52.9 27.6 13.9 
GNAO1 61.7 732.7 N/A 32.2 N/A 
GORASP2 53.5 632.8 165.6 53.0 21.2 
HCCS 38.5 37.2 33.8 23.6 18.2 
HPCAL1;HPCA 42.3 423.3 N/A 50.6 24.2 
KIAA1609 21.0 N/A N/A N/A N/A 
328 
 
KIAA1715;LNP 87.1 N/A N/A N/A N/A 
LAMTOR1 39.5 25.6 39.7 43.3 N/A 
LRRC57 35.9 42.8 53.5 36.6 N/A 
LYN 26.7 50.8 N/A 27.4 N/A 
MARC1 7.0 N/A N/A N/A N/A 
MARC2 48.5 38.1 N/A N/A N/A 
MARCKS 36.8 60.9 60.3 25.5 15.2 
MARCKSL1 31.1 N/A 55.5 N/A 17.9 
MGRN1 4.2 N/A N/A N/A N/A 
NCS1 19.1 N/A N/A 28.4 N/A 
NDUFAF4 25.9 19.0 N/A N/A 25.1 
NDUFB7 7.6 10.4 67.5 N/A 9.6 
NOL3 62.1 182.8 N/A N/A 24.9 
OGFRL1* 21.0 N/A N/A N/A N/A 
PCMTD1 29.6 N/A N/A 16.0 N/A 
PIK3R4 26.0 18.5 28.1 22.4 7.9 
PLGRKT* 85.8 N/A N/A N/A N/A 
PPM1A 63.8 156.0 146.5 33.1 N/A 
PPM1B 130.8 N/A N/A 33.1 N/A 
PPM1G 56.9 68.8 79.8 29.8 20.1 
PPP3R1 46.6 119.1 154.4 N/A 17.2 
PRKAB1 57.2 N/A N/A 51.8 17.7 
PRKACA 31.7 63.7 83.4 35.6 18.0 
PRKACB 42.5 59.9 104.1 54.6 N/A 
PSMC1 67.1 87.4 93.5 38.4 24.9 
RFTN1 24.3 N/A N/A N/A N/A 
RNF141 22.0 N/A N/A N/A N/A 
RP2 130.8 N/A N/A 37.7 8.5 
SCYL3 35.4 N/A N/A N/A 16.7 
SPECC1 28.0 28.1 29.2 N/A N/A 
SRC 41.1 117.3 55.0 N/A 16.1 
TESC 16.0 12.6 15.5 N/A N/A 
TMEM106B 10.8 6.7 N/A 12.2 N/A 
TOMM40L* N/A N/A N/A N/A 27.7 
YES1 33.6 138.6 N/A 27.4 14.5 
ZNRF2 56.4 N/A N/A N/A N/A 
Average 38.0 126.4 263.5 34.6 17.5 
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Appendix J: Membrane-bound peptide sequences prepared 
using the SPOTTM technology 
?? Membrane A  
 
?
-Small letter: low loading (20% Fmoc-AA+ 80% Boc-AA) 
-Az: AzC12 incorporated at the N-terminus 
-Yn: 5-Hexynoic acid incorporated at the N-terminus 
-Peg: Fmoc-NH-PEG3-COOH incorporated as the first amino 
acid  
?
?
?
?
?
?
?
?
? ?
??? ??????????????????
??? ??????????????????
??? ??????????????????
??? ??????????????????
??? ???????????????????????
??? ???
??? ????????????????
??? ????????????????
??? ????????????????
??? ????????????????
???? ???
???? ???????????????????
???? ???????????????????
???? ????????????????
???? ????????????????
???? ????????????????
???? ???????????????????
???? ???????????????????
???? ??????
???? ??????????????????
??? ??????????????????
??? ????????????????
??? ????????????????
??? ????????????????
??? ????????????????
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?? Membrane B  
?
 
 
-Small letter: low loading (20% Fmoc-AA+ 80% Boc-AA) 
-Az: AzC12 incorporated at the N-terminus 
-Yn: 5-Hexynoic acid incorporated at the N-terminus 
-Peg: Fmoc-NH-PEG3-COOH incorporated as the first amino 
acid  
?
?
?
?
?
?
?
?
?
?
?
??? ??????????????????
??? ??????????????????
??? ??????????????????
???? ??????????????????
??? ???????????????????????
???? ????????????????
??? ????????????????
??? ????????????????
???? ????????????????
??? ????????????????
???? ????????????????
???? ????????????????
???? ????????????????
???? ????????????????
???? ????????????????
???? ?????????
???? ?????????
???? ?????????
???? ?????????
???? ????????????????
???? ?????????????????
??? ??????????????????
??? ???
???? ???
?? ?????
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?? Membrane C  
?
?????????????????????????????????????????????????????
??????????????????????????????????????????
????????????????????????????????????????????????????
?
?
?
?
??? ?????????????????
???????
??? ?????????????????
??? ??????????
??? ??????????
??? ?????????????????
??? ?????????????????
???????
??? ?????????????????
??? ??????????
??? ??????????
??? ??????????????????
???? ?????????????????
???????
???? ?????????????????
???? ??????????
???? ??????????
???? ?????????????????
???? ??????????????????? ????????????????
???? ???????????????????
???? ???????????????? ??????????????????????
???? ?????????????????
???? ??????????????????????? ?????????????????????
??? ??????????????????? ????????????????
??? ???????????????????
??? ????????????????? ???????????????????
??? ?????????????????
??? ????????? ??
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 Membrane D  
A1 GGGAAAAAGGG  
A2 GGGRRRRRGGG  
A3 GGGNNNNNGGG  
A4 GGGDDDDDGGG  
B1 GGGCCCCCGGG  
B2 GGGEEEEEGGG  
B3 GGGQQQQQGGG  
B4 GGGGGGGGGGG  
C1 GGGHHHHHGGG  
C2 GGGIIIIIGGG 
C3 GGGLLLLLGGG 
C4 GGGKKKKKGGG  
D1 GGGMMMMMGGG  
D2 GGGFFFFFGGG  
D3 GGGPPPPPGGG  
D4 GGGSSSSSGGG  
E1 GGGTTTTTGGG  
E2 GGGWWWWWGGG  
E3 GGGYYYYYGGG  
E4 GGGVVVVVGGG 
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?? Membrane E  
?
?
?
?
?
?
?
?
?
?
?
?
?
??? ???????????????? ??????
????????? ????
??? ???????????????? ????????
?? ??????????????? ??????????????????
??? ???????????????? ???????
??? ???????????????? ????????????????????????
??? ???????????????? ??????????
??? ???????????????? ??????????????????????
??? ????????????????? ?????????????
??? ???????????????? ???????
??? ???????????????? ???????????????
??? ???????????????? ????
??????????
??????????
??? ???????????????? ????
??? ???????????????? ?????????????????????????????
??? ???????????????? ???????????????????
??? ???????????????? ???????????? ???????????????
??? ???????????????? ????????????
??????????????
??? ???????????????? ??????????
??? ???????????????? ??????????????
??? ???????????????? ???????????????????
??? ???????????????? ??????????
?? ???????????????
?????? ????????????? ????????????????
??? ????????????????
????????? ????????????????
??? ?????? ?? ??
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?? Membrane F  
?
??? ???????????????
?
??? ???????????????
??? ??????????????????????????????
??? ??????????????????????????????
???
??? ??????????????????????????????
??????
??? ?????????????????????????????????????
??? ????????????????
??? ???????????????????????
??? ????????????????????????????????
??? ??????????????????????????????
??????
??? ??????????????????????????????
??? ????????????????
??? ????????????????
??? ??????????????????????????????
??? ???????????? ????????????? ??? ?????????????????????
??? ???????????? ????????????? ???
??? ?????????????????????????????? ?????????
???????????? ??????????????????????????????
??? ???????????????????????????
??? ??????????????????????????? ??????
???????????? ?????????????????????????????????
??? ?????????????????????????????????
??????
??? ?????????????????????????????????
??? ?????????????????????????????????
335 
 
 Membrane G 
Position Accession Uniprot entry name Sequence 
A10 Q6X4W1 NELF_HUMAN GAAASRRRALRSEAM 
A11 Q96BS2 TESC_HUMAN GAAHSASEEVRELEG 
A12 P11488 GNAT1_HUMAN GAGASAEEKHSRELE 
A13 Q6ICN9 Q6ICN9_HUMAN  GAHLVRRYLGDASVE 
A14 P17568 NDUB7_HUMAN GAHLVRRYLGDASVEP 
A15 Q8NHG8 ZNRF2_HUMAN GAKQSGPAAANGRTR  
A16 P29966 MARCS_HUMAN GAQFSKTAAKGEAAA  
A17 P00387 NB5R3_HUMAN GAQLSTLGHMVLFPV 
A18 
O75896 TUSC2_HUMAN 
GASGSKARGLWPFAS 
B2R4Y9 B2R4Y9_HUMAN  
A19 Q9CB01  RABF1_ARATH GCASSLPDRNSGTLS 
A20 P00568 KAD1_HUMAN GCCSSSDPRREDDLR 
A21 O75695 XRP2_HUMAN GCFFSKRRKADKESR 
A22 P06239 LCK_HUMAN GCGCSSHPEDDWMEN 
A23 Q8WXS3 BAALC_HUMAN GCGGSRADAIEPRYY 
A24 Q14699 RFTN1_HUMAN GCGLNKLEKRDEKRP 
A25 
Q52LD8 RFTN2_HUMAN 
GCGLRKLEDPDDSSP 
Q14DH4 Q14DH4_HUMAN  
A26 P11801 KPSH1_HUMAN GCGTSKVLPEPPKDV 
A27 P07947 YES_HUMAN GCIKSKENKSPAIKY 
A28 P07948 LYN_HUMAN GCIKSKGKDSLSDDG 
A29 P08631-2 HCK_HUMAN  GCMKSKFLQVGGNTF 
A30 Q9BSF0 CB088_HUMAN GCMKSKQTFPFPTIY 
B1 A6NI79 CCD69_HUMAN GCRHSRLSSCKPPKK 
B2 
B2R6C1 B2R6C1_HUMAN  
GCRQSSEEKEAARRS 
P19086 GNAZ_HUMAN 
B3 
P63096 GNAI1_HUMAN 
GCTLSAEDKAAVERS 
P08754 GNAI3_HUMAN 
Q5TZX1 Q5TZX1_HUMAN  
A8KA88 A8KA88_HUMAN  
B4 P09471 GNAO_HUMAN GCTLSAEERAALERS 
B5 A6NGG8 CB071_HUMAN GCTPSHSDLVNSVAK 
B6 P04899 GNAI2_HUMAN GCTVSAEDKAAAERS 
B7 P09769  FGR_HUMAN GCVFCKKLEPVATAK 
B8 
P06241 FYN_HUMAN 
GCVQCKDKEATKLTE 
B5BU57 B5BU57_HUMAN  
B9 Q9NS86 LANC2_HUMAN GETMSKRLKLHLGGE 
B10 P63117 GFC1_HUMAN  GGAQSKIDPKTPLGC 
B11 Q96MG8 PCMD1_HUMAN GGAVSAGEDNDDLID 
B12 Q9NV79 PCMD2_HUMAN GGAVSAGEDNDELID 
B13 
P40616 ARL1_HUMAN 
GGFFSSIFSSLFGTR 
Q53XB1 Q53XB1_HUMAN  
B14 Q9NZU7 CABP1_HUMAN GGGDGAAFKRPGDGA  
B15 P80723 BASP1_HUMAN GGKLSKKKKGYNVND 
B16 Q8ND25 ZNRF1_HUMAN GGKQSTAARSRGPFP 
 
 
336 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Position Accession Uniprot entry Sequence 
B19 
Q99828 CIB1_HUMAN 
GGSGSRLSKELLAEY 
B5BU40 B5BU40_HUMAN 
B20 O75716 STK16_HUMAN GHALCVCSRGTVIID 
B21 Q86XR7 TCAM2_HUMAN GIGKSKINSCPLSLS 
B22 
Q9Y689 ARL5A_HUMAN 
GILFTRIWRLFNHQE 
Q580I5 Q580I5_HUMAN  
B23 Q17RS7  GEN_HUMAN GIQGLAKLIADVAPS 
B24 B2RC39 B2RC39_HUMAN  
GKLHSKPAAVCKRRE 
B25 Q969G9 NKD1_HUMAN 
B26 Q969F2 NKD2_HUMAN GKLQSKHAAAARKRR 
B27 P62760 VISL1_HUMAN GKQNSKLAPEVMEDL 
B28 
P84074 HPCA_HUMAN 
GKQNSKLRPEMLQDL 
B2R9T3 B2R9T3_HUMAN  
B29 
Q6FGY1 Q6FGY1_HUMAN  
GKQNSKLRPEVLQDL 
P37235 HPCL1_HUMAN 
B30 
P61601 NCALD_HUMAN 
GKQNSKLRPEVMQDL 
B2RB70 B2RB70_HUMAN  
C1 Q9H4G4 GAPR1_HUMAN GKSASKQFHNEVLKA 
C2 P62166 NCS1_HUMAN GKSNSKLKPEVVEEL 
C3 
Q9UM19 HPCL4_HUMAN 
GKTNSKLAPEVLEDL  
B2R5U2 B2R5U2_HUMAN  
C4 
P62330 ARF6_HUMAN 
GKVLSKIFGNKEMRI 
Q6FGZ2 Q6FGZ2_HUMAN  
C5 
Q9Y3E7 CHMP3_HUMAN 
GLFGKTQEKPPKELV 
Q3ZTS9 Q3ZTS9_HUMAN  
C6 
B3KWC8 B3KWC8_HUMAN 
GLGVSAEQPAGGAEG 
Q9BQQ3 GORS1_HUMAN 
C7 
Q96KC2 ARL5B_HUMAN 
GLIFAKLWSLFCNQE 
B0YIW9 B0YIW9_HUMAN 
C8 
Q9H0F7 ARL6_HUMAN 
GLLDRLSVLLGLKKK 
A8KA93 A8KA93_HUMAN  
C9 P22694-3 KAPCB_HUMAN  GLLKEFLAKAKEDFL 
C10 P36405 ARL3_HUMAN GLLSILRKLKSAPDQ 
C11 
P36404 ARL2_HUMAN 
GLLTILKKMKQKERE 
Q53YD8 Q53YD8_HUMAN 
C12 P22694-7 KAPCB_HUMAN  GLSRKSSDASACSSS 
C13 P18085 ARF4_HUMAN GLTISSLFSRLFGKK 
C14 
P84085 ARF5_HUMAN 
GLTVSALFSRIFGKK 
A4D0Z3 A4D0Z3_HUMAN  
C15 
P51451 BLK_HUMAN 
GLVSSKKPDKEKPIK 
Q96IN1 Q96IN1_HUMAN  
C16 Q9NR22 ANM8_HUMAN GMKHSSRCLLLRRKM 
C17 P17612 KAPCA_HUMAN GNAAAAKKGSEQESV 
C17 
P22694 KAPCB_HUMAN 
GNAATAKKGSEVESV P22694-8 KAPCB_HUMAN  
B2RB89 B2RB89_HUMAN  
C18 Q13009 TIAM1_HUMAN GNAESQHVEHEFYGE 
C19 P22612 KAPCG_HUMAN GNAPAKKDTEQEESV 
C20 Q9NPB3 CABP2_HUMAN GNCAKRPWRRGPKDP 
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Position Accession Uniprot entry name Sequence 
C21 Q9NZU7-2 CABP1_HUMAN GNCVKYPLRNLSRKD 
C22 Q9NZU7-1 CABP1_HUMAN GNCVKYPLRNLSRKM 
C23 Q96LZ3 CANB2_HUMAN GNEASYPAEMCSHFD 
C24 P63098 CANB1_HUMAN GNEASYPLEMCSHFD 
 
C25 
B2RC10 B2RC10_HUMAN   
GNEVSLEGGAGDGPL Q9UPA5 BSN_HUMAN 
C26 P29728 OAS2_HUMAN GNGESQLSSVPAQKL 
C27 O95843 GUC1C_HUMAN GNGKSIAGDQKAVPT 
C28 P40617 ARL4A_HUMAN GNGLSDQTSILSNLP 
C29 Q13976  KGP1_HUMAN GNGSVKPKHSKHPDG 
C30 P49703 ARL4D_HUMAN GNHLTEMAPTASSFL 
 
D1 
B2RC59 B2RC59_HUMAN  
GNIFANLFKGLFGKK P84077 ARF1_HUMAN 
D2 Q8IVW1 ARL17_HUMAN GNIFEKLFKSLLGKK 
D3 P61204 ARF3_HUMAN GNIFGNLLKSLIGKK 
 
D4 
A8K6G8 A8K6G8_HUMAN   
GNIPPKAKTPLRCIL Q9NRZ4 GAW2_HUMAN  
D5 P56559 ARL4C_HUMAN GNISSNISAFQSLHI 
 
D6 
Q53R10 Q53R10_HUMAN  
 
GNLFGRKKQSRVTEQ Q4A519 Q4A519_HUMAN  
Q96FZ7 CHMP6_HUMAN 
D7 Q548C1 Q548C1_HUMAN  GNLKSVAQEPGPPCG 
D8 P29474 NOS3_HUMAN GNLKSVAQEPGPPCG 
D9 P63118 GAH2_HUMAN  GNLPPSIPPSSPLAC 
 
D10 
Q8N8A4 GAH6_HUMAN  
GNQLAGIAPSQILSV Q99570 PI3R4_HUMAN 
D11 P42526 HATB_DICDI GNRAFKAHNGHYLSA 
D12 P13231 HATA_DICDI GNRAFKSHHGHFLSA 
D13 P27216 ANX13_HUMAN GNRHAKASSPQGFDV 
D14 P27216-2 ANX13_HUMAN  GNRHSQSYTLSEGSQ 
D15 Q6QHC5 DEGS2_HUMAN GNSASRNDFEWVYTD 
D16 Q8IVF5 TIAM2_HUMAN GNSDSQYTLQGSKNH 
D17 P35243 RECO_HUMAN GNSKSGALSKEILEE 
 
D18 
Q53XL0 Q53XL0_HUMAN   
GNSMKSTPAPAERPL Q13239 SLAP1_HUMAN 
 
D19 
Q6FI01 Q6FI01_HUMAN   
GNTSSERAALERHGG Q9Y478 AAKB1_HUMAN 
D20 Q8ND76 CCNY_HUMAN GNTTSCCVSSSPKLR 
D21 O43741  AAKB2_HUMAN GNTTSDRVSGERHGA 
D22 P43080 GUC1A_HUMAN GNVMEGKSVEELSST 
 
D23 
B3KWT4 B3KWT4_HUMAN  
GQALGIKSCDFQAAR P16452 EPB42_HUMAN 
 
D24 
Q4VB97 Q4VB97_HUMAN  
GQDQTKQQIEKGLQL Q13702 RAPSN_HUMAN 
D25 Q9UMX6 GUC1B_HUMAN GQEFSWEEAEAAGEI 
D26 Q7KYS9  Q7KYS9_HUMAN GQFLSSTFLEGSPAT 
D27 P16452-2 EPB42_HUMAN GQGEPSQRSTGLAGL 
D28 Q6BDI9 REP15_HUMAN GQKASQQLALKDSKE 
D29 O43687 AKA7A_HUMAN GQLCCFPFSRDEGKI 
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Position Accession Uniprot entry name Sequence 
D30 A6NH57 ARL5C_HUMAN GQLIAKLMSIFGNQE 
E1 P00519 ABL1_HUMAN GQQPGKVLGDQRRPS 
E2 P42684 ABL2_HUMAN GQQVGRVGEAPGLQQ 
E3 Q9BZ96 TTY14_HUMAN  GQSFSCSLHQRRVGE 
E4 
P62191 PRS4_HUMAN 
GQSQSGGHGPGGGKK 
Q53XL8 Q53XL8_HUMAN  
E5 
P62690 GAK18_HUMAN  
GQTESKYASYLSFIK 
P62691 GAK19_HUMAN  
E6 P62688 GAK15_HUMAN  GQTKSKIKSKYASHL 
E7 P62683 GAK1_HUMAN GQTKSKIKSKYASYL 
E8 Q9HDB9 GAK8_HUMAN GQTKSKTKSKYASYL 
E9 Q96PI4 GAK7_HUMAN  GQTKTKSKYASYLSF 
E10 Q86UY6 NAA40_HUMAN GRKSSKAKEKKQKRL  
E11 Q59EY7 Q59EY7_HUMAN  GRPIDPREGPGRPPL 
E12 O43559 FRS3_HUMAN GSCCSCLNRDSVPDN 
E13 Q8WU20 FRS2_HUMAN GSCCSCPDKDTVPDN 
E14 Q8IZE3 PACE1_HUMAN GSENSALKSYTLREP 
E15 
P19087 GNAT2_HUMAN 
GSGASAEDKELAKRS 
Q5T697 Q5T697_HUMAN  
E16 
A8MTJ3 GNAT3_HUMAN 
GSGISSESKESAKRS 
B9EJG5 B9EJG5_HUMAN  
E17 P98073 ENTK_HUMAN GSKRGISSRHHSLSS 
E18 Q8N4G2 ARL14_HUMAN GSLGSKNPQTKQAQV 
E19 
Q9H6Q3 SLAP2_HUMAN 
GSLPSRRKSLPSPSL  
A8K648 A8K648_HUMAN  
E20 P12931 SRC_HUMAN GSNKSKPKDASQRRR 
E21 Q7RTS9 DYM_HUMAN GSNSSRIGDLPKNEY 
E22 P49006 MRP_HUMAN GSQSSKAPRGDVTAE 
E23 Q99653 CHP1_HUMAN GSRASTLLRDEELEE 
E24 
O43745 CHP2_HUMAN 
GSRSSHAAVIPDGDS 
A8K2I8 A8K2I8_HUMAN  
E25 
Q9H8Y8 GORS2_HUMAN 
GSSQSVEIPGGGTEG 
Q53TE3 Q53TE3_HUMAN  
E26 Q96EQ8 RN125_HUMAN GSVLSTDSGKSAPAS 
E27 Q969Q4 ARL11_HUMAN GSVNSRGHKAEAQVV 
E28 Q9Y250 LZTS1_HUMAN GSVSSLISGHSFHSK 
E29 Q9ULE6 PALD_HUMAN GTTASTAQQTVSAGTP 
E30 Q5XKD4  Q5XKD4_HUMAN GTVLSLSPASSAKGR 
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Appendix K: Kinetic studies of HIV Gag and HIV Nef 
The kinetic parameters of HIV Gag and HIV Nef were determined with the CPM assay, in the 
presence of saturation amount of MyrCoA (30 or 40 µM) or 4 µM of MyrCoA. The IC50s of IMP366 
was also determined in the presence of both peptides at concentration close to KM.  
 
 HIV Gag (sequence: G A R A S V L S G G K L D A W) 
 
  HsNMT1 HsNMT2 
30 µM MyrCoA  
KM (µM) 70.7 ± 3.9  44.8 ± 2.6  
Vmax  100364 ± 2966  80115 ± 2131  
4 µM MyrCoA  
KM (µM) 37.6 ± 10.5  17.7 ± 1.2  
Vmax  48476 ± 5967  32429 ± 766  
10 µM HIV GAG IC50 of IMP366 (nM) 14.1 ± 2.5 12.5 ± 2.2  
 
 
 
 HIV Nef (sequence: G G K W S K S S I V G W P A V) 
  HsNMT1 HsNMT2 
50 µM MyrCoA  
KM (µM) 0.42  ±  0.06  0.34  ± 0.03  
Vmax  36666  ± 2075  30338  ± 830  
30 µM MyrCoA  
KM (µM) 0.31  ± 0.06  0.30  ± 0.08  
Vmax  45285  ± 2875  32721  ± 3049  
4 µM MyrCoA  
KM (µM) 0.34  ± 0.06  0.23  ±  0.03  
Vmax  21269  ±  1401  19013  ±  813  
0.3 µM HIV Nef IC50 of IMP366 (nM) 22.8 ± 1.3 15.2  ± 1.2  
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